# Patent

## Title
Fused-ring compounds and use thereof as drugs

## Abstract

The present invention provides a fused ring compound of the following formula [I]





 

wherein each symbol is as defined in the specification, a pharmaceutically acceptable salt thereof, and a therapeutic agent for hepatitis C, which contains this compound. The compound of the present invention shows an anti-hepatitis C virus (HCV) action based on the HCV polymerase inhibitory activity, and is useful as a therapeutic agent or prophylactic agent for hepatitis C.

## Background
This is a continuation in part of U.S. patent application Ser. No. 09/939,374 filed on Aug. 24, 2001, which is a continuation in part of PCT/JP00/09181 filed on Dec. 22, 2000.


TECHNICAL FIELD
The present invention relates to a novel fused ring compound and a pharmaceutically acceptable salt thereof useful as a therapeutic agent for hepatitis C, and to an intermediate compound for the synthesis thereof. The present invention also relates to a novel use of a certain fused ring compound or a pharmaceutically acceptable salt thereof as a therapeutic agent for hepatitis C. More particularly, the present invention relates to a therapeutic agent for hepatitis C, which contains a novel fused ring compound or a pharmaceutically acceptable salt thereof, which is effective for the prophylaxis or treatment of hepatitis C and which shows anti-hepatitis C virus (HCV) activity, particularly anti-HCV activity based on an RNA-dependent RNA polymerase inhibitory activity.
BACKGROUND ART
In 1989, a main causative virus of non-A non-B posttransfusion hepatitis was found and named hepatitis C virus (HCV). Since then, several types of hepatitis viruses have been found besides type A, type B and type C, wherein hepatitis caused by HCV is called hepatitis C.
The patients infected with HCV are considered to involve several percent of the world population, and the infection with HCV characteristically becomes chronic.
HCV is an envelope RNA virus, wherein the genome is a single strand plus-strand RNA, and belongs to the genus Hepacivirus of Flavivirus (from The International Committee on Taxonomy of Viruses, International Union of Microbiological Societies). Of the same hepatitis viruses, for example, hepatitis B virus (HBV), which is a DNA virus, is eliminated by the immune system and the infection with this virus ends in an acute infection except for neonates and infants having yet immature immunological competence. In contrast, HCV somehow avoids the immune system of the host due to an unknown mechanism. Once infected with this virus, even an adult having a mature immune system frequently develops persistent infection.
When chronic hepatitis is associated with the persistent infection with HCV, it advances to cirrhosis or hepatic cancer in a high rate. Enucleation of tumor by operation does not help much, because the patient often develops recurrent hepatic cancer due to the sequela inflammation in non-cancerous parts. In addition, there is a report on the involvement of HCV infection in dermatosis such as chronic urticaria, lichen planus, cryoglobulinemic purpura and the like (The Japanese Journal of Dermatology, 111(7), 1075-81, 2001).
Thus, an effective therapeutic method of hepatitis C is desired. Apart from the symptomatic therapy to suppress inflammation with an anti-inflammatory agent, the development of a therapeutic agent that reduces HCV to a low level free from inflammation and that eradicates HCV has been strongly demanded.
At present, a treatment with interferon is the only effective method known for the eradication of HCV. However, interferon can eradicate the virus only in about one-third of the patient population. For the rest of the patients, it has no effect or provides only a temporary effect. Therefore, an anti-HCV drug to be used in the place of or concurrently with interferon is awaited in great expectation.
In recent years, Ribavirin (1-β-D-ribofuranosyl-1H-1,2,4-triazole-3-carboxamide) has become commercially available as a therapeutic agent for hepatitis C, which is to be used concurrently with interferon. It enhances the efficacy of interferon but only to a low efficacy rate, and a different novel therapeutic agent for hepatitis C is desired.
Also, an attempt has been made to potentiate the immunocompetence of the patient with an interferon agonist, an interleukin-12 agonist and the like, thereby to eradicate the virus, but an effective pharmaceutical agent has not been found yet.
In addition, the inhibition of HCV growth, wherein HCV-specific protein is targeted, has been drawing attention these days.
The gene of HCV encodes a protein such as serine protease, RNA helicase, RNA-dependent RNA polymerase and the like. These proteins function as a specific protein essential for the growth of HCV.
One of the specific proteins, RNA-dependent RNA polymerase (hereinafter to be also briefly referred to as an HCV polymerase), is an enzyme essential for the growth of the virus. The gene replication of HCV having a plus-strand RNA gene is considered to involve synthesis of a complementary minus-strand RNA by the use of the plus-strand RNA as a template, and, using the obtained minus-strand RNA as a template, amplifying the plus-strand RNA. The portion called NS5B of a protein precursor, that HCV codes for, has been found to show an RNA-dependent RNA polymerase activity (EMBO J., 15, 12-22, 1996), and is considered to play a central role in the HCV gene replication.
Therefore, an HCV polymerase inhibitor can be a target in the development of an anti-HCV drug, and the development thereof is eagerly awaited. However, an effective HCV polymerase inhibitor has not been developed yet, like in other attempts to develop an anti-HCV drug based on other action mechanisms. As the situation stands, no pharmaceutical agent can treat hepatitis C satisfactorily.
The following discloses known compounds relatively similar to the compound of the present invention.
The therapeutic agents for hepatitis C, which have a benzimidazole skeleton, are known from JP-A-2001-247550 (WO01/47883, EP1162196A1) and WO02/04425.
These publications disclose the following β-ketoamide compounds J etc. and K etc., respectively, as anti-HIV agents having an integrase inhibitory activity:





 

Note that the earliest publication dates of these publications are Jul. 5, 2001 (WO01/47883) and Jan. 17, 2002 (WO02/04425), and the priority date of the present application is Jun. 26, 2001, antedating these publication dates.
In addition, a known therapeutic agent for hepatitis C having a benzimidazole skeleton is also disclosed in WO97/36866, Japanese Patent Application under PCT laid-open under kohyo No. 2000-511899 (EP906097) and WO99/51619.
WO97/36866 discloses the following compound D and the like, and HCV helicase inhibitory activity of the compounds.
Japanese Patent Application under PCT laid-open under kohyo No. 2000-511899 (EP906097) discloses the following compound E and the like, and WO99/51619 discloses the following compound F and the like, in both of which a possibility of these compounds being effective as an HCV inhibitor is mentioned.
However, these publications do not include the compound disclosed in the present specification, or a disclosure suggestive thereof.





 

A known anti-hepatitis virus agent having a benzimidazole skeleton is disclosed in Japanese Patent Application under PCT laid-open under kohyo No. 2000-503017 (WO97/25316) and Japanese Patent Application under PCT laid-open under kohyo No. 10-505092 (WO96/7646).
WO97/25316 discloses the following compound A and the like, wherein the use thereof is for a treatment of viral infection. The target virus is a DNA virus such as hepatitis B virus and the like. However, this publication does not include the compound disclosed in the present specification or a description regarding or suggestive of HCV.
Japanese Patent Application under PCT laid-open under kohyo No. 10-505092 discloses the following compound B and the like, wherein the use thereof is for a treatment of viral infection. The target virus is a DNA virus such as herpesvirus and hepatitis B virus. However, this publication does not include the compound disclosed in the present specification or a description regarding or suggestive of HCV.





 

The benzimidazole derivatives having an antiviral activity have been disclosed in JP-A-3-31264, U.S. Pat. No. 3,644,382 and U.S. Pat. No. 3,778,504. In addition, WO98/37072 discloses, as a production inhibitor of tumor necrosis factor (TNF) and cyclic AMP, a benzimidazole derivative for the use as an anti-human immunodeficiency virus (HIV) agent and an anti-inflammation agent. WO98/05327 discloses, as a reverse transcriptase inhibitor, a benzimidazole derivative for the use as an anti-HIV agent. J. Med. Chem. (13(4), 697-704, 1970) discloses, as a neuraminidase inhibitor, a benzimidazole derivative for the use as an anti-influenza virus agent.
However, none of these publications includes the compound of the present invention or a description regarding or suggestive of an anti-HCV effect.
Known benzimidazole derivatives having a pharmaceutical use other than as an antiviral agent are disclosed in JP-A-8-501318 (U.S. Pat. No. 5,814,651) and JP-A-8-134073 (U.S. Pat. No. 5,563,143). These publications disclose the following compound C and the like as a catechol diether compound, and the use thereof as an anti-inflammation agent. However, neither of the publications includes the compound of the present invention, and as the action mechanism, the former discloses phosphodiesterase IV and the latter discloses TNF. These publications do not include a description regarding or suggestive of an anti-HCV effect.
Japanese Patent Application under PCT laid-open under kohyo No. 2000-159749 (EP882718) discloses the following compound G and the like, and the use thereof for the treatment of bronchitis, glomerulonephritis and the like. However, this publication does not include the compound of the present invention, but discloses only a phosphodiesterase IV inhibitory and hypoglycemic action. This publication does not include a description regarding or suggestive of an anti-HCV effect.
U.S. Pat. No. 6,211,177 discloses the following compound H and the like with their use as antitumor agents. However, this publication does not encompass the compound of the present invention, and does not disclose or suggest an anti-HCV effect.





 

WO98/50029, WO98/50030 and WO98/50031 disclose benzimidazole derivatives as an antitumor agent having a protein isoprenyl transferase action. While this publication discloses a wide scope of the claims, at least it does not include a compound analogous to the compound of the present invention or a description regarding or suggestive of an anti-HCV effect.
JP-A-8-109169 (EP694535) discloses the application of a tachykinin receptor antagonist to treat an inflammatory disease, and WO96/35713 discloses the application thereof as a growth hormone release promoter to treat a growth hormone-related disease such as osteoporosis and the like. However, none of these publications includes a description regarding or suggestive of an anti-HCV effect.
WO2001/21634 discloses the following compound I in a chemical library. However, this publication does not encompass the compound of the present invention. While it discloses an antimicrobial activity of certain compounds, this publication does not teach or suggest an anti-HCV effect.





 

JP-A-53-14735 discloses a benzimidazole derivative as a brightener besides its pharmaceutical use, but this publication does not include the compound of the present invention.
SUMMARY OF THE INVENTION
Based on the findings from the preceding studies, it has been elucidated that a pharmaceutical agent having an anti-HCV activity is effective for the prophylaxis and treatment of hepatitis C, and particularly an anti-HCV agent having an inhibitory activity on RNA-dependent RNA polymerase of HCV can be a prophylactic and therapeutic agent effective against hepatitis C and a prophylactic and therapeutic agent for the disease caused by hepatitis C.
Accordingly, the present invention provides a pharmaceutical agent having an anti-HCV activity, particularly a pharmaceutical agent having an RNA-dependent RNA polymerase inhibitory activity.
The present inventors have made an in-depth study of compounds having an anti-HCV activity, particularly RNA-dependent RNA polymerase inhibitory activity, and completed the present invention.
Thus, the present invention provides the following (1) to (88).
(1) A therapeutic agent for hepatitis C, which comprises a fused ring compound of the following formula [I] or a pharmaceutically acceptable salt thereof as an active ingredient:





 
wherein


    a broken line is a single bond or a double bond,
    G1 is C(—R1) or a nitrogen atom,
    G2 is C(—R2) or a nitrogen atom,
    G3 is C(—R3) or a nitrogen atom,
    G4 is C(—R4) or a nitrogen atom,
    G5, G6, G8 and G9 are each independently a carbon atom or a nitrogen atom,
    G7 is C(—R7), an oxygen atom, a sulfur atom, or a nitrogen atom optionally substituted by R8,

wherein R1, R2, R3 and R4 are each independently,
    
        (1) hydrogen atom,
        (2) C1-6 alkanoyl,
        (3) carboxyl,
        (4) cyano,
        (5) nitro,
        (6) C1-6 alkyl optionally substituted by 1 to 3 substituent(s) selected from the following group A, group A; halogen atom, hydroxyl group, carboxyl, amino, C1-6 alkoxy, C1-6 alkoxy C1-6 alkoxy, C1-6 alkoxycarbonyl and C1-6 alkylamino,
        (7) —COORa1 
        
            wherein Ra1 is optionally substituted C1-6 alkyl (as defined above), C6-14 aryl C1-6 alkyl optionally substituted by 1 to 5 substituent(s) selected from the following group B or glucuronic acid residue, group B; halogen atom, cyano, nitro, C16 alkyl, halogenated C1-6 alkyl, C1-6 alkanoyl, —(CH2)r—COORb1, —(CH2)r—CONRb1Rb2, —(CH2)r—NRb1Rb2, —(CH2)r—NRb1—CORb2, —(CH2)r—NHSO2Rb1, —(CH2)r—ORb1, —(CH2)r—SRb1, —(CH2)r—SO2Rb1 and —(CH2)r—SO2NRb1Rb2 wherein Rb1 and Rb2 are each independently hydrogen atom or C1-6 alkyl and r is 0 or an integer of 1 to 6,
        
        
        (8) —CONRa2Ra3 
        
            wherein Ra2 and Ra3 are each independently hydrogen atom, C1-6 alkoxy or optionally substituted C1-6 alkyl (as defined above),
        
        
        (9) —C(═NRa4)NH2 
        
            wherein Ra4 is hydrogen atom or hydroxyl group,
        
        
        (10) —NHRa5 
        
            wherein Ra5 is hydrogen atom, C1-6 alkanoyl or C1-6 alkylsulfonyl,
        
        
        (11) —ORa6 wherein R1-6 is hydrogen atom or optionally substituted C1-6 alkyl (as defined above),
        (12) —SO2Ra7 
        
            wherein Ra7 is hydroxyl group, amino, C1-6 alkyl or C1-6 alkylamino,
        
        
        (13) —P(═O)(ORa31)2 
        
            wherein Ra31 is hydrogen atom, optionally substituted C1-6 alkyl (as defined above) or C6-14 aryl C1-6 alkyl optionally substituted by 1 to 5 substituent(s) selected from the above group B

or

        
        
        (14) heterocyclic group having 1 to 4 heteroatom(s) selected from an oxygen atom, a nitrogen atom and a sulfur atom, and
        R7 and R8 are each hydrogen atom or optionally substituted C1-6 alkyl (as defined above),

ring Cy is

        (1) C3-8 cycloalkyl optionally substituted by 1 to 5 substituent(s) selected from the following group C, group C; hydroxyl group, halogen atom, C1-6 alkyl and C1-6 alkoxy,
        (2) C3-8 cycloalkenyl optionally substituted by 1 to 5 substituent(s) selected from the above group C, or





 

        wherein u and v are each independently an integer of 1 to 3,
    
    


ring A

    
    
        (1) C6-14 aryl,
        (2) C3-8 cycloalky,
        (3) C3-8 cycloalkenyl or
        (4) heterocyclic group having 1 to 4 heteroatom (s) selected from an oxygen atom, a nitrogen atom and a sulfur atom,
    
    


R5 and R6 are each independently

    
    
        (1) hydrogen atom,
        (2) halogen atom,
        (3) optionally substituted C1-6 alkyl (as defined above) or
        (4) —ORa8 wherein Ra8 is hydrogen atom, C1-6 alkyl or C6-14 aryl C1-6 alkyl, and
        
            is
        
        
        (1) hydrogen atom,
        (2) halogen atom,
        (3) cyano,
        (4) nitro,
        (5) amino, C1-6 alkanoylamino,
        (6) C1-6 alkylsulfonyl,
        (7) optionally substituted C1-6 alkyl (as defined above),
        (8) C2-6 alkenyl optionally substitutd by 1 to 3 substituent (s) selected from the above group A,
        (9) —COORa9 
        
            wherein Ra9 is hydrogen atom or C1-6 alkyl,
        
        
        (10) —CONH—(CH2)1—Ra10 
        
            wherein Ra10 is optionally substituted C1-6 alkyl (as defined above), C1-6 alkoxycarbonyl or C1-6 alkanoylamino and 1 is 0 or an integer of 1 to 6,
        
        
        (11) —ORa11 
        
            wherein Ra11 is hydrogen atom or optionally substituted C1-6 alkyl (as defined above)

or





 

wherein

        
        
        ring B is
        
            (1′) C6-14 aryl,
            (2′) C3-8 cycloalkyl or
            (3′) heterocyclic group (as defined above),
        
        
        each Z is independently
        
            (1′) a group selected from the following group D,
            (2′) C6-14 aryl optionally substituted by 1 to 5 substituent(s) selected from the following group D,
            (3′) C3-8 cycloalkyl optionally substituted by 1 to 5 substituent(s) selected from the following group D,
            (4′) C6-14 aryl C1-6 alkyl optionally substituted by 1 to 5 substituent(s) selected from the following group D,
            (5′) heterocyclic group optionally substituted by 1 to 5 substituent(s) selected from the following group D,
            wherein the heterocyclic group has 1 to 4 heteroatom(s) selected from an oxygen atom, a nitrogen atom and a sulfur atom, or
            (6′) heterocycle C1-6 alkyl optionally substituted by 1 to 5 substituent(s) selected from the following group D,
            wherein the heterocycle C1-6 alkyl is C1-6 alkyl substituted by heterocyclic group optionally substituted by 1 to 5 substituent(s) selected from the group D, as defined above,

group D:
            
                (a) hydrogen atom,
                (b) halogen atom,
                (c) cyano,
                (d) nitro,
                (e) optionally substituted C1-6 alkyl (as defined above),
                (f) —(CH2)t—CORa18, (hereinafter each t means independently 0 or an integer of 1 to 6),

wherein Ra18 is
                
                    (1′′) optionally substituted C1-6 alkyl (as defined above),
                    (2′′) C6-14 aryl optionally substituted by 1 to 5 substituent(s) selected from the above group B or
                    (3′′) heterocyclic group optionally substituted by 1 to 5 substituent(s) selected from the above group B wherein the heterocyclic group has 1 to 4 heteroatom(s) selected from an oxygen atom, a nitrogen atom and a sulfur atom,
                
                
                (g) —(CH2)t—COORa19 
                
                    wherein Ra19 is hydrogen atom, optionally substituted C1-6 alkyl (as defined above) or C6-14 aryl C1-6 alkyl optionally substituted by 1 to 5 substituent(s) selected from the above group B,
                
                
                (h) —(CH2)t—CONRa27Ra28 
                
                    wherein Ra27 and Ra28 are each independently,
                    (1′′) hydrogen atom,
                    (2′′) optionally substituted C1-6 alkyl (as defined above),
                    (3′′) C6-14 aryl optionally substituted by 1 to 5 substituent(s) selected from the above group B,
                    (4′′) C6-14 aryl C1-6 alkyl optionally substituted by 1 to 5 substituent(s) selected from the above group B,
                    (5′′) heterocyclic group optionally substituted by 1 to 5 substituent(s) selected from the above group B,
                    (6′′) heterocycle C1-6 alkyl optionally substituted by 1 to 5 substituent(s) selected from the above group B,
                    wherein the heterocycle C1-6 alkyl is C1-6 alkyl substituted by heterocyclic group optionally substituted by 1 to 5 substituent(s) selected from the above group B, as defined above,
                    (7′′) C3-8 cycloalkyl optionally substituted by 1 to 5 substituent(s) selected from the above group B,
                    (8′′) C3-8 cycloalkyl C1-6 alkyl optionally substituted by 1 to 5 substituent(s) selected from the above group B,
                    (9′′) hydroxyl group or
                    (10′′) C1-6 alkoxy,
                
                
                (i) —(CH2)t—C(═NRa33)NH2 
                
                    wherein Ra33 is hydrogen atom, C1-6 alkyl, hydroxyl group or C1-6 alkoxy,
                
                
                (j) —(CH2)t—ORa20 
                
                    wherein Ra20 is
                    (1′′) hydrogen atom,
                    (2′′) optionally substituted C1-6 alkyl (as defined above),
                    (3′′) optionally substituted C2-6 alkenyl (as defined above),
                    (4′′) C2-6 alkynyl optionally substituted by 1 to 3 substituent(s) selected from the above group A,
                    (5′′) C6-14 aryl optionally substituted by 1 to 5 substituent(s) selected from the above group B,
                    (6′′) C6-14 aryl C1-6 alkyl optionally substituted by 1 to 5 substituent(s) selected from the above group B,
                    (7′′) heterocyclic group optionally substituted by 1 to 5 substituent(s) selected from the above group B,
                    (8′′) heterocycle C1-6 alkyl optionally substituted by 1 to 5 substituent(s) selected from the above group B,
                    (9′′) C3-8 cycloalkyl optionally substituted by 1 to 5 substituent(s) selected from the above group B, or
                    (10′′) C3-8 cycloalkyl C1-6 alkyl optionally substituted by 1 to 5 substituent(s) selected from the above group B,
                
                
                (k) —(CH2)t—O—(CH2)p—CORa21 
                
                    wherein Ra21 is amino, C1-6 alkylamino or heterocyclic group optionally substituted by 1 to 5 substituent(s) selected from the above group B, and p is 0 or an integer of 1 to 6,
                
                
                (l) —(CH2)t—NRa22Ra23 
                
                    wherein Ra22 and Ra23 are each independently
                    (1′′) hydrogen atom,
                    (2′′) optionally substituted C1-6 alkyl (as defined above),
                    (3′′) C6-14 aryl optionally substituted by 1 to 5 substituent(s) selected from the above group B,
                    (4′′) C6-14 aryl C1-6 alkyl optionally substituted by 1 to 5 substituent(s) selected from the above group B,
                    (5′′) heterocycle C1-6 alkyl optionally substituted by 1 to 5 substituent(s) selected from the above group B or
                    (6′′) heterocyclic group optionally substituted by 1 to 5 substituent(s) selected from the above group B,
                
                
                (m) —(CH2)t—NRa29CO—Ra24 
                
                    wherein Ra29 is hydrogen atom, C1-6 alkyl or C1-6 alkanoyl, and Ra24 is
                    (1′′) amino,
                    (2′′) C1-6 alkylamino,
                    (3′′) optionally substituted C1-6 alkyl (as defined above),
                    (4′′) C6-14 aryl optionally substituted by 1 to 5 substituent(s) selected from the above group B,
                    (5′′) heterocyclic group optionally substituted by 1 to 5 substituent(s) selected from the above group B or
                    (6′′) heterocycle C1-6 alkyl optionally substituted by 1 to 5 substituent(s) selected from the above group B,
                
                
                (n) —(CH2)t—NRa29SO2—Ra25 
                
                    wherein Ra29 is as defined above, and Ra25 is hydrogen atom, optionally substituted C1-6 alkyl (as defined above), C6-14 aryl optionally substituted by 1 to 5 substituent(s) selected from the above group B or heterocyclic group optionally substituted by 1 to 5 substituent(s) selected from the above group B,
                
                
                (o) —(CH2)t—S(O)q—Ra25 
                
                    wherein Ra25 is as defined above, and q is 0, 1 or 2,
                
                
                (p) —(CH2)t—SO2—NHRa26 
                
                    wherein Ra26 is hydrogen atom, optionally substituted C1-6 alkyl (as defined above), C6-14 aryl optionally substituted by 1 to 5 substituent(s) selected from the above group B or heterocyclic group optionally substituted by 1 to 5 substituent(s) selected from the above group B,
                
                
                and
                (q) heterocyclic group having 1 to 4 heteroatom(s) selected from an oxygen atom, a nitrogen atom and a sulfur atom, and
            
            
        
        
        w is an integer of 1 to 3, and
        Y is
        
            (1′) a single bond,
            (2′) C1-6 alkylene,
            (3′) C2-6 alkenylene,
            (4′) —(CH2)m—O—(CH2)n—,
            
                (hereinafter m and n are each independently 0 or an integer of 1 to 6),
            
            
            (5′) —CO—,
            (6′) —CO2—(CH2)n—,
            (7′) —CONH—(CH2)n—NH—,
            (8′) —NHCO2—,
            (9′) —NHCONH—,
            (10′) —O—(CH2)n—CO—,
            (11′) —O—(CH2)n—O—,
            (12′) —SO2—,
            (13′) —(CH2)m—NRa12—(CH2)n—
            
                wherein Ra12 is
                (1′′) hydrogen atom,
                (2′′) optionally substituted C1-6 alkyl (as defined above),
                (3′′) C6-14 aryl C1-6 alkyl optionally substituted by 1 to 5 substituent(s) selected from the above group B,
                (4′′) C6-14 aryl optionally substituted by 1 to 5 substituent(s) selected from the above group B,
                (5′′) —CORb5 
                
                    wherein Rb5 is hydrogen atom, optionally substituted C1-6 alkyl (as defined above), C6-14 aryl optionally substituted by 1 to 5 substituent(s) selected from the above group B or C6-14 aryl C1-6 alkyl optionally substituted by 1 to 5 substituent(s) selected from the above group B,
                
                
                (6′′) —COORb5 (Rb5 is as defined above) or
                (7′′) —SO2Rb5 (Rb5 is as defined above),
            
            
            (14′) —NRa12CO—(Ra12 is as defined above),
            (15′) —CONRa13—(CH2)n—
            
                wherein Ra13 is hydrogen atom, optionally substituted C1-6 alkyl (as defined above) or C6-14 aryl C1-6 alkyl optionally substituted by 1 to 5 substituent(s) selected from the above group B,
            
            
            (16′) —CONH—CHRa14—
            
                wherein Ra14 is C6-14 aryl optionally substituted by 1 to 5 substituent(s) selected from the above group B,
            
            
            (17′) —O—(CH2)m—CRa15Ra16—(CH2)n—
            
                wherein Ra15 and Ra16 are each independently
                (1′′) hydrogen atom,
                (2′′) carboxyl,
                (3′′) C1-6 alkyl,
                (4′′) —ORb6 
                wherein Rb7 is C1-6 alkyl or C6-14 aryl C1-6 alkyl,

or

                (5′′) —NHRb7 
                wherein Rb7 is hydrogen atom, C1-6 alkyl, C1-6 alkanoyl or C6-14 aryl C1-6 alkyloxycarbonyl, or Ra15 is optionally
                (6′′)





 

  wherein n′, ring B′, Z′ and w′ are the same as the above-mentioned n, ring B, Z and w, respectively, and may be the same as or different from the respective counterparts,

            
            
            (18′) —(CH2)n—NRa12—CHRa15—(Ra12 and Ra15 are each as defined above),
            (19′) —NRa17SO2—
            
                wherein Ra17 is hydrogen atom or C1-6 alkyl,
            
            
            (20′) —S(O)e—(CH2)m—CRa15Ra16—(CH2)n— (e is 0, 1 or 2, Ra15 and Ra16 are each as defined above),
            
                or
            
            
            (21′) —(CH2)m—CRa15Ra16—(CH2)n—(Ra15 and Ra16 are each as defined above).
        
        
    
    


(2) The therapeutic agent of (1) above, wherein 1 to 4 of the G1, G2, G3, G4, G5, G6, G7, G8 and G9 is (are) a nitrogen atom.
(3) The therapeutic agent of (2) above, wherein G2 is C(—R2) and G6 is a carbon atom.
(4) The therapeutic agent of (2) or (3) above, wherein G5 is a nitrogen atom.
(5) The therapeutic agent of (1) above, wherein, in formula [I], the moiety





 

is a fused ring selected from








 

(6) The therapeutic agent of (5) above, wherein, in formula [I], the moiety





 

is a fused ring selected from





 

(7) The therapeutic agent of (6) above, which comprises a fused ring compound of the following formula [I-1]





 

wherein each symbol is as defined in (1), or a pharmaceutically acceptable salt thereof as an active ingredient.

(8) The therapeutic agent of (6) above, which comprises a fused ring compound of the following formula [I-2]





 

wherein each symbol is as defined in (1), or a pharmaceutically acceptable salt thereof as an active ingredient.

(9) The therapeutic agent of (6) above, which comprises a fused ring compound of the following formula [I-3]





 

wherein each symbol is as defined in (1),

or a pharmaceutically acceptable salt thereof as an active ingredient.

(10) The therapeutic agent of (6) above, which comprises a fused ring compound of the following formula [I-4]





 

wherein each symbol is as defined in (1),

or a pharmaceutically acceptable salt thereof as an active ingredient.

(11) The therapeutic agent of any of (1) to (10) above, wherein at least one of R1, R2, R3 and R4 is carboxyl, —COORa1, CONRa2Ra3, —SO2Ra7 (wherein Ra1, Ra2, Ra3 and Ra7 are as defined in (1)),





 

(12) The therapeutic agent of (11) above, wherein at least one of R1, R2, R3 and R4 is carboxyl, —COORa1, —CONRa2Ra3 or —SO2Ra7 wherein Ra1, Ra2, Ra3 and Ra7 are as defined in (1).
(13) The therapeutic agent of any of (1) to (10) above, wherein at least one of R1, R2, R3 and R4 is —COORa1 wherein Ra1 is glucuronic acid residue.
(14) The therapeutic agent of any of (1) to (10) above, wherein at least one of R1, R2, R3 and R4 is heterocyclic group having 1 to 4 heteroatom(s) selected from an oxygen atom, a nitrogen atom and a sulfur atom.
(15) The therapeutic agent of any of (1) to (14) above, wherein the ring Cy is cyclopentyl, cyclohexyl, cycloheptyl, tetrahydrothiopyranyl or piperidino.
(16) The therapeutic agent of any of (1) to (14) above, wherein the ring Cy is





 

wherein each symbol is as defined in (1).

(17) The therapeutic agent of any of (1) to (16) above, wherein the ring A is C6-14 aryl.
(18) The therapeutic agent of any of (1) to (17) above, wherein at least one substituent optionally substituted by group A is a substituent substituted by C1-6 alkoxy C1-6 alkoxy.
(19) The therapeutic agent of any of (1) to (18) above, wherein the Y is —(CH2)m—CRa15Ra16—(CH2)n— wherein each symbol is as defined in (1).
(20) The therapeutic agent of any of (1) to (19) above, wherein at least one group represented by Z is heterocycle C1-6 alkyl optionally substituted by 1 to 5 substituent(s) selected from the group D.
(21) The therapeutic agent of any of (1) to (19) above, wherein at least one group represented by Z is a heterocyclic group optionally substituted by 1 to 5 substituent(s) selected from the group D, wherein said heterocyclic group is selected from the following groups:





 

wherein E1 is an oxygen atom, a sulfur atom or N(—Ra35), E2 is an oxygen atom, CH2 or N(—Ra35) , E3 is an oxygen atom or a sulfur atom, wherein each Ra35 is independently hydrogen atom or C1-6 alkyl, f is an integer of 1 to 3, and h and h′ are the same or different and each is an integer of 1 to 3.

(22) The therapeutic agent of (21) above, wherein at least one group represented by Z is heterocyclic group optionally substituted by 1 to 5 substituent(s) selected from the group D wherein said heterocyclic group is selected from the following groups:





 

wherein each symbol is as defined in (21).

(23) The therapeutic agent of any of (1) to (19) above, wherein at least one group represented by group D is —(CH2)t—CONRa27Ra28 wherein each symbol is as defined in (1), and at least one of Ra27 and Ra28 is C1-6 alkoxy.
(24) The therapeutic agent of any of (1) to (19) above, wherein at least one group represented by group D is —(CH2)t—C(═NRa33)NH2 wherein each symbol is as defined in (1), and Ra33 is hydroxyl group or C1-6 alkoxy.
(25) The therapeutic agent of any of (1) to (19) above, wherein at least one group represented by group D is —(CH2)t—O—(CH2)p—CORa21, wherein each symbol is as defined in (1), and Ra21 is amino.
(26) The therapeutic agent of any of (1) to (19) above, wherein at least one group represented by group D is —(CH2)t—NRa29CO—Ra24 wherein each symbol is as defined in (1), and Ra24 is amino or C1-6 alkylamino.
(27) The therapeutic agent of any of (1) to (19) above, wherein at least one group represented by group D is —(CH2)t—NRa22Ra23 wherein each symbol is as defined in (1), and at lease one of Ra22 and Ra23 is heterocyclic group optionally substituted by 1 to 5 substituent(s) selected from the group B.
(28) The therapeutic agent of any of (1) to (19) above, wherein at least one group represented by group D is heterocyclic group having 1 to 4 heteroatom(s) selected from an oxygen atom, a nitrogen atom and a sulfur atom.
(29) A fused ring compound of the following formula [II]





 

wherein

the moiety





 

is a fused ring selected from





 

wherein R1, R2, R3 and R4 are each independently,

    
    
        (1) hydrogen atom,
        (2) C1-6 alkanoyl,
        (3) carboxyl,
        (4) cyano,
        (5) nitro,
        (6) C1-6 alkyl optionally substituted by 1 to 3 substituent(s) selected from the following group A, group A; halogen atom, hydroxyl group, carboxyl, amino, C1-6 alkoxy, C1-6 alkoxy C1-6 alkoxy, C1-6 alkoxycarbonyl and C1-6 alkylamino,
        (7) —COORa1 
        
            wherein Ra1 is optionally substituted C1-6 alkyl (as defined above), C6-14 aryl C1-6 alkyl optionally substituted by 1 to 5 substituent(s) selected from the following group B or glucuronic acid residue, group B; halogen atom, cyano, nitro, C1-6 alkyl, halogenated C1-6 alkyl, C1-6 alkanoyl, —(CH2)r—COORb1, —(CH2)r—CONRb1Rb2, —(CH2)r—NRb1Rb2, —(CH2)r—NRb1—CORb2, —(CH2)r—NHSO2Rb1, —(CH2)r—ORb1, —(CH2)r—SRb1, —(CH2)r—SO2Rb1 and —(CH2)r—SO2NRb1Rb2 wherein Rb1 and Rb2 are each independently hydrogen atom or C1-6 alkyl and r is 0 or an integer of 1 to 6,
        
        
        (8) —CONRa2Ra3 
        
            wherein Ra2 and Ra3 are each independently hydrogen atom, C1-6 alkoxy or optionally substituted C1-6 alkyl (as defined above),
        
        
        (9) —C(═NRa4)NH2 
        
            wherein Ra4 is hydrogen atom or hydroxyl group,
        
        
        (10) —NHRa5 
        
            wherein Ra5 is hydrogen atom, C1-6 alkanoyl or C1-6 alkylsulfonyl,
        
        
        (11) —ORa6 
        
            wherein Ra6 is hydrogen atom or optionally substituted C1-6 alkyl (as defined above),
        
        
        (12) —SO2Ra7 
        
            wherein Ra7 is hydroxyl group, amino, C1-6 alkyl or C1-6 alkylamino,
        
        
        (13) —P(═O)(ORa31)2 
        
            wherein Ra31 is hydrogen atom, optionally substituted C1-6 alkyl (as defined above) or C6-14 aryl C1-6 alkyl optionally substituted by 1 to 5 substituent(s) selected from the above group B,
        
        
        or
        (14) heterocyclic group having 1 to 4 heteroatom(s) selected from an oxygen atom, a nitrogen atom and a sulfur atom, and
        R7 is hydrogen atom or optionally substitute C1-6 alkyl (as defined above),
    
    
    ring Cy′ is
    
        (1) C3-8 cycloalkyl optionally substituted by 1 to 5 substituent(s) selected from the following group C, group C; hydroxyl group, halogen atom, C1-6 alkyl and C1-6 alkoxy, or
        (2)





 

 wherein u and v are each independently an integer of 1 to 3,

    
    


ring A′0 is a group selected from a group consisting of phenyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, cyclohexyl, cyclohexenyl, furyl and thienyl,

    R5 and R6′ are each independently
    
        (1) hydrogen atom,
        (2) halogen atom,
        (3) optionally substituted C1-6 alkyl (as defined above) or
        (4) hydroxyl group
    
    
    ring B is
    
        (1) C6-14 aryl,
        (2) C3-8 cycloalkyl or
        (3) heterocyclic group having 1 to 4 heteroatom(s) selected from an oxygen atom, a nitrogen atom and a sulfur atom,
    
    
    each Z is independently
    
        (1) a group selected from the following group D,
        (2) C6-14 aryl optionally substituted by 1 to 5 substituent(s) selected from the following group D,
        (3) C3-8 cycloalkyl optionally substituted by 1 to 5 substituent(s) selected from the following group D,
        (4) C6-14 aryl C1-6 alkyl optionally substituted by 1 to 5 substituent(s) selected from the following group D,
        (5) heterocyclic group optionally substituted by 1 to 5 substituent(s) selected from the following group D wherein the heterocyclic group has 1 to 4 heteroatom(s) selected from an oxygen atom, a nitrogen atom and a sulfur atom, or
        (6) heterocycle C1-6 alkyl optionally substituted by 1 to 5 substituent(s) selected from the following group D wherein the heterocycle C1-6 alkyl is C1-6 alkyl substituted by heterocyclic group optionally substituted by 1 to 5 substituent(s) selected from the group D, as defined above, group D:
        
            (a) hydrogen atom,
            (b) halogen atom,
            (c) cyano,
            (d) nitro,
            (e) optionally substituted C1-6 alkyl (as defined above),
            (f) —(CH2)t—CORa10, (hereinafter each t means independently 0 or an integer of 1 to 6),
            
                wherein Ra18 is
                (1′) optionally substituted C1-6 alkyl (as defined above),
                (2′) C6-14 aryl optionally substituted by 1 to 5 substituent(s) selected from the above group B or
                (3′) heterocyclic group optionally substituted by 1 to 5 substituent(s) selected from the above group B wherein the heterocyclic group has 1 to 4 heteroatom(s) selected from an oxygen atom, a nitrogen atom and a sulfur atom,
            
            
            (g) —(CH2)t—COORa19 
            
                wherein Ra19 is hydrogen atom, optionally substituted C1-6 alkyl (as defined above) or C6-14 aryl C1-6 alkyl optionally substituted by 1 to 5 substituent(s) selected from the above group B,
            
            
            (h) —(CH2)t—CONRa27Ra28 
            
                wherein Ra27 and Ra28 are each independently,
                (1′) hydrogen atom,
                (2′) optionally substituted C1-6 alkyl (as defined above),
                (3′) C6-14 aryl optionally substituted by 1 to 5 substituent(s) selected from the above group B,
                (4′) C6-14 aryl C1-6 alkyl optionally substituted by 1 to 5 substituent(s) selected from the above group B,
                (5′) heterocyclic group optionally substituted by 1 to 5 substituent(s) selected from the above group B,
                (6′) heterocycle C1-6 alkyl optionally substituted by 1 to 5 substituent(s) selected from the above group B,
                wherein the heterocycle C1-6 alkyl is C1-6 alkyl substituted by heterocyclic group optionally substituted by 1 to 5 substituent(s) selected from the above group B, as defined above,
                (7′) C3-8 cycloalkyl optionally substituted by 1 to 5 substituent(s) selected from the above group B,
                (8′) C3-8 cycloalkyl C1-6 alkyl optionally substituted by 1 to 5 substituent(s) selected from the above group B,
                (9′) hydroxyl group or
                (10′) C1-6 alkoxy,
            
            
            (i) —(CH2)L—C(═NRa33)NH2 
            
                wherein Ra33 is hydrogen atom, C1-6 alkyl, hydroxyl group or C1-6 alkoxy,
            
            
            (j) —(CH2)t—ORa20 
            
                wherein Ra20 is
                (1′) hydrogen atom,
                (2′) optionally substituted C1-6 alkyl (as defined above),
                (3′) optionally substituted C2-6 alkenyl (as defined above),
                (4′) C2-6 alkynyl optionally substituted by 1 to 3 substituent(s) selected from the above group A,
                (5′) C6-14 aryl optionally substituted by 1 to 5 substituent(s) selected from the above group B,
                (6′) C6-14 aryl C1-6 alkyl optionally substituted by 1 to 5 substituent(s) selected from the above group B,
                (7′) heterocyclic group optionally substituted by 1 to 5 substituent(s) selected from the above group B,
                (8′) heterocycle C1-6 alkyl optionally substituted by 1 to 5 substituent(s) selected from the above group B,
                (9′) C3-8 cycloalkyl optionally substituted by 1 to 5 substituent(s) selected from the above group B, or
                (10′) C3-8 cycloalkyl C1-6 alkyl optionally substituted by 1 to 5 substituent(s) selected from the above group B,
            
            
            (k) —(CH2)t—O—(CH2)P—CORa21 
            
                wherein Ra21 is amino, C1-6 alkylamino or heterocyclic group optionally substituted by 1 to 5 substituent(s) selected from the above group B,
                and p is 0 or an integer of 1 to 6,
            
            
            (l) —(CH2)t—NRa22Ra23 
            
                wherein Ra22 and Ra23 are each independently
                (1′) hydrogen atom,
                (2′) optionally substituted C1-6 alkyl (as defined above),
                (3′) C6-14 aryl optionally substituted by 1 to 5 substituent(s) selected from the above group B,
                (4′) C6-14 aryl C1-6 alkyl optionally substituted by 1 to 5 substituent(s) selected from the above group B,
                (5′) heterocycle C1-6 alkyl optionally substituted by 1 to 5 substituent(s) selected from the above group B or
                (6′) heterocyclic group optionally substituted by 1 to 5 substituent(s) selected from the above group B,
            
            
            (m) —(CH2)t—NRa29CO—Ra24 
            
                wherein Ra29 is hydrogen atom, C1-6 alkyl or C1-6 alkanoyl, and
                Ra24 is
                (1′) amino,
                (2′) C1-6 alkylamino,
                (3′) optionally substituted C1-6 alkyl (as defined above),
                (4′) C6-14 aryl optionally substituted by 1 to 5 substituent(s) selected from the above group B,
                (5′) heterocyclic group optionally substituted by 1 to 5 substituent(s) selected from the above group B, or
                (6′) heterocycle C1-6 alkyl optionally substituted by 1 to 5 substituent(s) selected from the above group B,
            
            
            (n) —(CH2)5—NRa29SO2—Ra25 
            
                wherein Ra29 is as defined above, and Ra25 is hydrogen atom, optionally substituted C1-6 alkyl (as defined above), C6-14 aryl optionally substituted by 1 to 5 substituent(s) selected from the above group B or heterocyclic group optionally substituted by 1 to 5 substituent(s) selected from the above group B,
            
            
            (o) —(CH2)t—S(O)q—Ra25 
            
                wherein Ra25 is as defined above, and q is 0, 1 or 2,
            
            
            (p) —(CH2)t—SO2—NHRa26 
            
                wherein Ra26 is hydrogen atom, optionally substituted C1-6 alkyl (as defined above), C6-14 aryl optionally substituted by 1 to 5 substituent(s) selected from the above group B or heterocyclic group optionally substituted by 1 to 5 substituent(s) selected from the above group B,
            
            
            and
            (q) heterocyclic group having 1 to 4 heteroatom(s) selected from an oxygen atom, a nitrogen atom and a sulfur atom,
            is an integer of 1 to 3, and
            y is
            (1) a single bond,
            (2) C1-6 alkylene,
            (3) C2-6 alkenylene,
            (4) —(CH2)m—O—(CH2)n—, (hereinafter m and n are each independently 0 or an integer of 1 to 6),
            (5) —CO—,
            (6) —CO2—(CH2)n—,
            (7) —CONH—(CH2)n—NH—,
            (8) —NHCO2—,
            (9) —NHCONH—,
            (10) —O—(CH2)n—CO—,
            (11) —O—(CH2)n—O—,
            (12) —SO2—,
            (13) —(CH2)m—NRa12—(CH2)n—
            
                wherein Ra12 is
                (1′) hydrogen atom,
                (2′) optionally substituted C1-6 alkyl (as defined above),
                (3′) C6-14 aryl C1-6 alkyl optionally substituted by 1 to 5 substituent(s) selected from the above group B,
                (4′) C6-14 aryl optionally substituted by 1 to 5 substituent(s) selected from the above group B,
                (5′) —CORb5 
                
                    wherein Rb5 is hydrogen atom, optionally substituted C1-6 alkyl (as defined above), C6-14 aryl optionally substituted by 1 to 5 substituent(s) selected from the above group B or C6-14 aryl C1-6 alkyl optionally substituted by 1 to 5 substituent(s) selected from the above group B,
                
                
                (6′) —COORb5 (Rb5 is as defined above) or
                (7′) —SO2Rb5 (Rb5 is as defined above),
            
            
            (14) —NRa12CO— (Ra12 is as defined above),
            (15) —CONRa13—(CH2)n—
            
                wherein Ra13 is hydrogen atom, optionally substituted C1-6 alkyl (as defined above) or C6-14 aryl C1-6 alkyl optionally substituted by 1 to 5 substituent(s) selected from the above group B,
            
            
            (16) —CONH—CHRa14—
            
                wherein Ra14 is C6-14 aryl optionally substituted by 1 to 5 substituent(s) selected from the above group B,
            
            
            (17) —O—(CH2)m—CRa15Ra16—(CH2)n—
            
                wherein Ra15 and Ra16 are each independently
                (1′) hydrogen atom,
                (2′) carboxyl,
                (3′) C1-6 alkyl,
                (4′) —ORb6 
                wherein Rb6 is C1-6 alkyl or C6-14 aryl C1-6 alkyl, or
                (5′) —NHRb7 
                wherein Rb7 is hydrogen atom, C1-6 alkyl, C1-6 alkanoyl or C6-14 aryl C1-6 alkyloxycarbonyl, or Ra15 is optionally
                (6′)





 

  wherein n′, ring B′, Z′ and w′ are the same as the above-mentioned n, ring B, Z and w, respectively, and may be the same as or different from the respective counterparts,

            
            
            (18) —(CH2)n—NRa12—CHRa15— (Ra12 and Ra15 are each as defined above),
            (19) —NRa17SO2—
            
                wherein Ra17 is hydrogen atom or C1-6 alkyl,
            
            
            (20) —S(O)e—(CH2)m—CRa15Ra16—(CH2)n— (e is 0, 1 or 2, Ra15 and Ra16 are each as defined above),
            or
            (21) —(CH2)m—CRa15Ra16—(CH2)n— (Ra15 and Ra16 are each as defined above),

or a pharmaceutically acceptable salt thereof.

        
        
    
    


(30) The fused ring compound of (29) above, which is represented by the following formula [II-1]





 

wherein each symbol is as defined in (29),

or a pharmaceutically acceptable salt thereof.

(31) The fused ring compound of (29) above, which is represented by the following formula [II-2]





 

wherein each symbol is as defined in (29),

or a pharmaceutically acceptable salt thereof.

(32) The fused ring compound of (29) above, which is represented by the following formula [II-3]





 

wherein each symbol is as defined in (29),

or a pharmaceutically acceptable salt thereof.

(33) The fused ring compound of (29) above, which is represented by the following formula [II-4]





 

wherein each symbol is as defined in (29),

or a pharmaceutically acceptable salt thereof.

(34) The fused ring compound of any of (29) to (33) above, wherein at least one of R1, R2, R3 and R4 is carboxyl, —COORa1, —CONRa2Ra3, —SO2Ra7 (wherein Ra1, Ra2, Ra3 and Ra7 are as defined in (29)),





 

or a pharmaceutically acceptable salt thereof.

(35) The fused ring compound of (34) above, wherein at least one of R1, R2, R3 and R4 is carboxyl, —COORa1 or —SO2Ra7 wherein Ra1 and Ra7 are as defined in (29), or a pharmaceutically acceptable salt thereof.
(36) The fused ring compound of (35) above, wherein at least one of R1, R2, R3 and R4 is carboxyl or —COORa1 wherein Ra1 is as defined in (29), or a pharmaceutically acceptable salt thereof.
(37) The fused ring compound of (36) above, wherein R2 is carboxyl and R1, R3 and R4 are hydrogen atoms, or a pharmaceutically acceptable salt thereof.
(38) The fused ring compound of any of (29) to (33) above, wherein at least one of R1, R2, R3 and R4 is —COORa1 wherein Ra1 is glucuronic acid residue, or a pharmaceutically acceptable salt thereof.
(39) The fused ring compound of any of (29) to (33) above, wherein at least one of R1, R2, R3 and R4 is heterocyclic group having 1 to 4 heteroatom(s) selected from an oxygen atom, a nitrogen atom and a sulfur atom, or a pharmaceutically acceptable salt thereof.
(40) The fused ring compound of any of (29) to (33) above, wherein the ring Cy′ is cyclopentyl, cyclohexyl, cycloheptyl or tetrahydrothiopyranyl, or a pharmaceutically acceptable salt thereof.
(41) The fused ring compound of (40) above, wherein the ring Cy′ is cyclopentyl, cyclohexyl or cycloheptyl, or a pharmaceutically acceptable salt thereof.
(42) The fused ring compound of any of (29) to (39) above, wherein the ring Cy′ is





 

wherein each symbol is as defined in (29), or a pharmaceutically acceptable salt thereof.

(43) The fused ring compound of any of (29) to (42) above, wherein the ring A′ is phenyl, pyridyl, pyrazinyl, pyrimidinyl or pyridazinyl, or a pharmaceutically acceptable salt thereof.
(44) The fused ring compound of (43) above, wherein the ring A′ is phenyl or pyridyl, or a pharmaceutically acceptable salt thereof.
(45) The fused ring compound of (44) above, wherein the ring A′ is phenyl, or a pharmaceutically acceptable salt thereof.
(46) The fused ring compound of any of (29) to (45) above, wherein at least one substituent optionaly substituted by group A is a substituent substituted by C1-6 alkoxy C1-6 alkoxy, or a pharmaceutically acceptable salt thereof.
(47) The fused ring compound of any of (29) to (46) above, wherein the Y is —(CH2)m—O—(CH2)n—, —NHCO2—, —CONH—CHRa14—, —(CH2)m—NRa12—(CH2)n, —CONRa13—(CH2)n—, —O—(CH2)m—CRa15R126—(CH2)n— or —(CH2)n—NRa12—CHRa15— (wherein each symbol is as defined in (29)), or a pharmaceutically acceptable salt thereof.
(48) The fused ring compound of (47) above, wherein the Y is —(CH2)m—O—(CH2)n— or —O—(CH2)m—CRa15Ra16—(CH2)n— (wherein each symbol is as defined in (29)), or a pharmaceutically acceptable salt thereof.
(49) The fused ring compound of (48) above, wherein the Y is —(CH2)m—O—(CH2)n— wherein each symbol is as defined in (29), or a pharmaceutically acceptable salt thereof.
(50) The fused ring compound of any of (29) to (46) above, wherein the Y is —(CH2)mCRa15Ra16—(CH2)n— (wherein each symbol is as defined in (29)), or a pharmaceutically acceptable salt thereof.
(51) The fused ring compound of any of (29) to (50) above, wherein the R2 is carboxyl, R1, R3 and R4 are hydrogen atoms, the ring Cy′ is cyclopentyl, cyclohexyl or cycloheptyl, and the ring A′ is phenyl, or a pharmaceutically acceptable salt thereof.
(52) The fused ring compound of any of (29) to (51) above, wherein at least one group represented by Z is heterocycle C1-6 alkyl optionally substituted by 1 to 5 substituent(s) selected from the group D, or a pharmaceutically acceptable salt thereof.
(53) The fused ring compound of any of (29) to (51) above, wherein at least one group represented by Z is heterocyclic group optionally substituted by 1 to 5 substituent(s) selected from the group D, wherein said heterocyclic group is selected from the following groups:





 

wherein E1 is an oxygen atom, a sulfur atom or N(—Ra35), E2 is an oxygen atom, CH2 or N(—Ra35), E3 is an oxygen atom or a sulfur atom, wherein each Ra35 is independently hydrogen atom or C1-6 alkyl, f is an integer of 1 to 3, and h and h′ are the same or different and each is an integer of 1 to 3, or a pharmaceutically acceptable salt thereof.

(54) The fused ring compound of (53) above, wherein at least one group represented by Z is heterocyclic group optionally substituted by 1 to 5 substituent(s) selected from the group D, wherein said heterocyclic group is selected from the following groups:





 

wherein each symbol is as defined in (53), or a pharmaceutically acceptable salt thereof.

(55) The fused ring compound of any of (29) to (51) above, wherein at least one group represented by group D is —(CH2)t—CONRa27Ra28 wherein each symbol is as defined in (29), and at least one of Ra27 and Ra28 is C1-6 alkoxy, or a pharmaceutically acceptable salt thereof.
(56) The fused ring compound of any of (29) to (51) above, wherein at least one group represented by group D is —(CH2)t—C(═NRa33)NH2 wherein each symbol is as defined in (29), and Ra33 is hydroxyl group or C1-6 alkoxy, or a pharmaceutically acceptable salt thereof.
The fused ring compound of any of (29) to (51) above, wherein at least one group represented by group D is —(CH2)t—O—(CH2)p—CORa21 wherein each symbol is as defined in (29), and Ra21 is amino, or a pharmaceutically acceptable salt thereof.
The fused ring compound of any of (29) to (51) above, wherein at least one group represented by group D is —(CH2)t—NRa29CO—Ra24 wherein each symbol is as defined in (29), and Ra24 is amino or C1-6 alkylamino, or a pharmaceutically acceptable salt thereof.
The fused ring compound of any of (29) to (51) above, wherein at least one group represented by group D is —(CH2)t—NRa22Ra23 wherein each symbol is as defined in (29), and at least one of Ra22 and Ra23 is heterocyclic group optionally substituted by 1 to 5 substituent(s) selected from the group B, or a pharmaceutically acceptable salt thereof.
The fused ring compound of any of (29) to (51) above, wherein at least one group represented by group D is heterocyclic group having 1 to 4 heteroatom(s) selected from an oxygen atom, a nitrogen atom and a sulfur atom, or a pharmaceutically acceptable salt thereof.
The fused ring compound of the formula [I] or a pharmaceutically acceptable salt thereof, which is selected from the group consisting of

    ethyl 2-[4-(3-bromophenoxy)phenyl]-1-cyclohexylbenzimidazole-5-carboxylate (Example 1),
    2-[4-(3-bromophenoxy)phenyl]-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 2),
    ethyl 1-cyclohexyl-2-(4-hydroxyphenyl)benzimidazole-5-carboxylate (Example 3),
    ethyl 2-[4-(2-bromo-5-chlorobenzyloxy)phenyl]-1-cyclohexylbenzimidazole-5-carboxylate (Example 4),
    ethyl 2-{4-[2-(4-chlorophenyl)-5-chlorobenzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylate (Example 5),
    2-{4-[2-(4-chlorophenyl)-5-chlorobenzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 6),
    ethyl 2-[4-(2-bromo-5-methoxybenzyloxy)phenyl]-1-cyclohexylbenzimidazole-5-carboxylate (Example 7),
    ethyl 2-{4-[2-(4-chlorophenyl)-5-methoxybenzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylate (Example 8),
    2-{4-[2-(4-chlorophenyl)-5-methoxybenzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 9),
    ethyl 1-cyclohexyl-2-{4-[(E)-2-phenylvinyl]phenyl}benzimidazole-5-carboxylate (Example 10),
    1-cyclohexyl-2-{4-[(E)-2-phenylvinyl]phenyl}benzimidazole-5-carboxylic acid (Example 11),
    2-(4-benzyloxyphenyl)-1-cyclopentylbenzimidazole-5-carboxylic acid (Example 12),
    2-(4-benzyloxyphenyl)-1-cyclopentylbenzimidazole-5-carboxamide (Example 13),
    2-(4-benzyloxyphenyl)-5-cyano-1-cyclopentylbenzimidazole (Example 14),
    2-(4-benzyloxyphenyl)-1-cyclopentylbenzimidazole-5-carboxamide oxime (Example 15),
    ethyl 1-cyclohexyl-2-{4-[{4-(4-fluorophenyl)-2-methyl-5-thiazolyl}methoxy]phenyl}benzimidazole-5-carboxylate (Example 16),
    1-cyclohexyl-2-{4-[{4-(4-fluorophenyl)-2-methyl-5-thiazolyl}-methoxy]phenyl}benzimidazole-5-carboxylic acid (Example 17),
    ethyl 1-cyclohexyl-2-(2-fluoro-4-hydroxyphenyl)benzimidazole-5-carboxylate (Example 18),
    ethyl 2-{4-[bis(3-fluorophenyl)methoxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylate (Example 19),
    2-{4-[bis(3-fluorophenyl)methoxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 20),
    ethyl 1-cyclopentyl-2-(4-nitrophenyl)benzimidazole-5-carboxylate (Example 21),
    ethyl 2-(4-aminophenyl)-1-cyclopentylbenzimidazole-5-carboxylate (Example 22),
    ethyl 2-(4-benzoylaminophenyl)-1-cyclopentylbenzimidazole-5-carboxylate (Example 23),
    2-(4-benzoylaminophenyl)-1-cyclopentylbenzimidazole-5-carboxylic acid (Example 24),
    ethyl 2-{4-[3-(3-chlorophenyl)phenoxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylate (Example 25),
    2-{4-[3-(3-chlorophenyl)phenoxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 26),
    ethyl 2-[4-(3-acetoxyphenyloxy)phenyl]-1-cyclohexylbenzimidazole-5-carboxylate (Example 27),
    ethyl 1-cyclohexyl-2-[4-(3-hydroxyphenyloxy)phenyl]-benzimidazole-5-carboxylate (Example 28),
    ethyl 1-cyclohexyl-2-{4-[3-(4-pyridylmethoxy)phenyloxy]phenyl}-benzimidazole-5-carboxylate (Example 29),
    1-cyclohexyl-2-{4-[3-(4-pyridylmethoxy)phenyloxy]phenyl}-benzimidazole-5-carboxylic acid (Example 30),
    2-(4-benzyloxyphenyl)-1-cyclopentylbenzimidazole (Example 31),
    ethyl 2-(4-benzyloxyphenyl)-1-cyclopentylbenzimidazole-5-carboxylate (Example 32),
    2-(4-benzyloxyphenyl)-1-cyclopentyl-N,N-dimethylbenzimidazole-5-carboxamide (Example 33),
    2-(4-benzyloxyphenyl)-1-cyclopentyl-N-methoxy-N-methylbenzimidazole-5-carboxamide (Example 34),
    2-(4-benzyloxyphenyl)-1-cyclopentyl-5-(1-hydroxy-1-methylethyl)benzimidazole (Example 35),
    5-acetyl-2-(4-benzyloxyphenyl)-1-cyclopentylbenzimidazole (Example 36),
    2-(4-benzyloxyphenyl)-1-cyclopentyl-N-(2-dimethylaminoethyl)-benzimidazole-5-carboxamide dihydrochloride (Example 37),
    2-(4-benzyloxyphenyl)-1-cyclopentyl-5-nitrobenzimidazole (Example 38),
    5-amino-2-(4-benzyloxyphenyl)-1-cyclopentylbenzimidazole hydrochloride (Example 39),
    5-acetylamino-2-(4-benzyloxyphenyl)-1-cyclopentylbenzimidazole (Example 40),
    2-(4-benzyloxyphenyl)-1-cyclopentyl-5-methanesulfonyl-aminobenzimidazole (Example 41),
    5-sulfamoyl-2-(4-benzyloxyphenyl)-1-cyclopentylbenzimidazole (Example 42),
    2-[4-(4-tert-butylbenzyloxy)phenyl]-1-cyclopentylbenzimidazole-5-carboxylic acid (Example 43),
    2-[4-(4-carboxybenzyloxy)phenyl]-1-cyclopentylbenzimidazole-5-carboxylic acid (Example 44),
    2-[4-(4-chlorobenzyloxy)phenyl]-1-cyclopentylbenzimidazole-5-carboxylic acid (Example 45),
    2-{4-[(2-chloro-5-thienyl)methoxy]phenyl}-1-cyclopentylbenzimidazole-5-carboxylic acid (Example 46),
    1-cyclopentyl-2-[4-(4-trifluoromethylbenzyloxy)phenyl]-benzimidazole-5-carboxylic acid (Example 47),
    1-cyclopentyl-2-[4-(4-methoxybenzyloxy)phenyl]benzimidazole-5-carboxylic acid (Example 48),
    1-cyclopentyl-2-[4-(4-pyridylmethoxy)phenyl]benzimidazole-5-carboxylic acid hydrochloride (Example 49),
    1-cyclopentyl-2-[4-(4-methylbenzyloxy)phenyl]benzimidazole-5-carboxylic acid (Example 50),
    1-cyclopentyl-2-{4-[(3,5-dimethyl-4-isoxazolyl)methoxy]phenyl}-benzimidazole-5-carboxylic acid (Example 51),
    1-cyclopentyl-2-(4-hydroxyphenyl)benzimidazole-5-carboxylic acid (Example 52),
    [2-(4-benzyloxyphenyl)-1-cyclopentylbenzimidazol-5-yl]-carbonylaminoacetic acid (Example 53),
    2-[4-(2-chlorobenzyloxy)phenyl]-1-cyclopentylbenzimidazole-5-carboxylic acid (Example 54),
    2-[4-(3-chlorobenzyloxy)phenyl]-1-cyclopentylbenzimidazole-5-carboxylic acid (Example 55),
    2-(4-benzyloxyphenyl)-3-cyclopentylbenzimidazole-5-carboxylic acid (Example 56),
    2-[4-(benzenesulfonylamino)phenyl]-1-cyclopentylbenzimidazole-5-carboxylic acid (Example 57),
    1-cyclopentyl-2-[4-(3,5-dichlorophenylcarbonylamino)phenyl]-benzimidazole-5-carboxylic acid (Example 58),
    2-{4-[(4-chlorophenyl)carbonylamino]phenyl}-1-cyclopentylbenzimidazole-5-carboxylic acid (Example 59),
    2-{4-[(4-tert-butylphenyl)carbonylamino]phenyl}-1-cyclopentylbenzimidazole-5-carboxylic acid (Example 60),
    2-{4-[(4-benzyloxyphenyl)carbonylamino]phenyl}-1-cyclopentylbenzimidazole-5-carboxylic acid (Example 61),
    trans-4-[2-(4-benzyloxyphenyl)-5-carboxybenzimidazol-1-yl]cyclohexan-1-ol (Example 62),
    trans-1-[2-(4-benzyloxyphenyl)-5-carboxybenzimidazol-1-yl]-4-methoxycyclohexane (Example 63),
    2-(4-benzyloxyphenyl)-5-carboxymethyl-1-cyclopentylbenzimidazole (Example 64),
    2-[1-benzyloxycarbonyl-4-piperidyl]-1-cyclopentylbenzimidazole-5-carboxylic acid (Example 65),
    2-[(4-cyclohexylphenyl)carbonylamino]-1-cyclopentylbenzimidazole-5-carboxylic acid (Example 66),
    1-cyclopentyl-2-[4-(3,5-dichlorobenzyloxy)phenyl]benzimidazole-5-carboxylic acid (Example 67),
    1-cyclopentyl-2-[4-(3,4-dichlorobenzyloxy)phenyl]benzimidazole-5-carboxylic acid (Example 68),
    1-cyclopentyl-2-[4-(phenylcarbamoylamino)phenyl]benzimidazole-5-carboxylic acid (Example 69),
    1-cyclopentyl-2-[4-(diphenylmethoxy)phenyl]benzimidazole-5-carboxylic acid (Example 70),
    1-cyclopentyl-2-(4-phenethyloxyphenyl)benzimidazole-5-carboxylic acid (Example 71),
    trans-1-[2-(4-benzyloxyphenyl)-5-carboxybenzimidazol-1-yl]-4-tert-butylcyclohexane (Example 72),
    2-(4-benzyloxyphenyl)-5-carboxymethoxy-1-cyclopentylbenzimidazole (Example 73),
    2-(4-benzylaminophenyl)-1-cyclopentylbenzimidazole-5-carboxylic acid (Example 74),
    2-[4-(N-benzenesulfonyl-N-methylamino)phenyl]-1-cyclopentylbenzimidazole-5-carboxylic acid (Example 75),
    2-[4-(N-benzyl-N-methylamino)phenyl]-1-cyclopentylbenzimidazole-5-carboxylic acid (Example 76),
    1-cyclohexyl-2-(4-phenethylphenyl)benzimidazole-5-carboxylic acid (Example 77),
    2-(1-benzyl-4-piperidyl)-1-cyclopentylbenzimidazole-5-carboxylic acid (Example 78),
    2-(1-benzoyl-4-piperidyl)-1-cyclopentylbenzimidazole-5-carboxylic acid (Example 79),
    1-cyclopentyl-2-[1-(p-toluenesulfonyl)-4-piperidyl]-benzimidazole-5-carboxylic acid (Example 80),
    1-cyclohexyl-2-[4-(3,5-dichlorobenzyloxy)phenyl]benzimidazole-5-carboxylic acid (Example 81),
    1-cyclohexyl-2-[4-(diphenylmethoxy)phenyl]benzimidazole-5-carboxylic acid (Example 82),
    1-cyclohexyl-2-[4-(3,5-di-tert-butylbenzyloxy)phenyl]-benzimidazole-5-carboxylic acid (Example 83),
    2-(4-benzyloxyphenyl)-1-(4-methylcyclohexyl)benzimidazole-5-carboxylic acid (Example 84),
    1-cyclohexyl-2-{4-[2-(2-naphthyl)ethoxy]phenyl}benzimidazole-5-carboxylic acid (Example 85),
    1-cyclohexyl-2-[4-(1-naphthyl)methoxyphenyl]benzimidazole-5-carboxylic acid (Example 86),
    1-cyclohexyl-2-[4-(dibenzylamino)phenyl]benzimidazole-5-carboxylic acid (Example 87),
    2-[4-(2-biphenylylmethoxy)phenyl]-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 88),
    2-(4-benzyloxyphenyl)-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 89),
    1-cyclohexyl-2-[4-(dibenzylmethoxy)phenyl]benzimidazole-5-carboxylic acid (Example 90),
    2-(4-benzoylmethoxyphenyl)-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 91),
    2-(4-benzyl-1-piperazinyl)-1-cyclohexylbenzimidazole-5-carboxylic acid dihydrochloride (Example 92),
    1-cyclohexyl-2-[4-(3,3-diphenylpropyloxy)phenyl]benzimidazole-5-carboxylic acid (Example 93),
    2-[4-(3-chloro-6-phenylbenzyloxy)phenyl]-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 94),
    2-(4-benzyloxypiperidino)-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 95),
    1-cyclohexyl-2-{4- [2-(phenoxy)ethoxy]phenyl}benzimidazole-5-carboxylic acid (Example 96),
    1-cyclohexyl-2-[4-(3-phenylpropyloxy)phenyl]benzimidazole-5-carboxylic acid (Example 97),
    1-cyclohexyl-2-[4-(5-phenylpentyloxy)phenyl]benzimidazole-5-carboxylic acid (Example 98),
    2-(3-benzyloxy-5-isoxazolyl)-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 99),
    2-(2-benzyloxy-5-pyridyl)-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 100),
    1-cyclohexyl-2-{4-[2-(3,4,5-trimethoxyphenyl)ethoxy]phenyl}-benzimidazole-5-carboxylic acid (Example 101),
    2-(4-benzyloxyphenyl)-1-(4,4-dimethylcyclohexyl)benzimidazole-5-carboxylic acid (Example 102),
    1-cyclohexyl-2-{4-[2-(1-naphthyl)ethoxy]phenyl}benzimidazole-5-carboxylic acid (Example 103),
    2-[4-(2-benzyloxyphenoxy)phenyl]-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 104),
    2-[4-(3-benzyloxyphenoxy)phenyl]-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 105),
    1-cyclohexyl-2-[4-(2-hydroxyphenoxy)phenyl]benzimidazole-5-carboxylic acid (Example 106),
    1-cyclohexyl-2-[4-(3-hydroxyphenoxy)phenyl]benzimidazole-5-carboxylic acid (Example 107),
    1-cyclohexyl-2-[4-(2-methoxyphenoxy)phenyl]benzimidazole-5-carboxylic acid (Example 108),
    1-cyclohexyl-2-[4-(3-methoxyphenoxy)phenyl]benzimidazole-5-carboxylic acid (Example 109),
    1-cyclohexyl-2-[4-(2-propoxyphenoxy)phenyl]benzimidazole-5-carboxylic acid (Example 110),
    1-cyclohexyl-2-[4-(3-propoxyphenoxy)phenyl]benzimidazole-5-carboxylic acid (Example 111),
    1-cyclohexyl-2-{4-[2-(3-methyl-2-butenyloxy)phenoxy]phenyl}-benzimidazole-5-carboxylic acid (Example 112),
    1-cyclohexyl-2-{4-[3-(3-methyl-2-butenyloxy)phenoxy]phenyl}-benzimidazole-5-carboxylic acid (Example 113),
    1-cyclohexyl-2-[4-(2-isopentyloxyphenoxy)phenyl]benzimidazole-5-carboxylic acid (Example 114),
    1-cyclohexyl-2-[4-(3-isopentyloxyphenoxy)phenyl]benzimidazole-5-carboxylic acid (Example 115),
    1-cyclohexyl-2-{4-[2-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)ethoxy]phenyl}benzimidazole-5-carboxylic acid (Example 116),
    1-cyclohexyl-2-{4-[2-(4-trifluoromethylphenyl)benzyloxy]-phenyl}benzimidazole-5-carboxylic acid (Example 117),
    2-{4-[bis(4-chlorophenyl)methoxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 118),
    1-cyclohexyl-2-{4-[2-(4-methoxyphenyl)ethoxy]phenyl}-benzimidazole-5-carboxylic acid (Example 119),
    1-cyclohexyl-2-{4-[2-(2-methoxyphenyl)ethoxy]phenyl}-benzimidazole-5-carboxylic acid (Example 120),
    1-cyclohexyl-2-{4-[2-(3-methoxyphenyl)ethoxy]phenyl}-benzimidazole-5-carboxylic acid (Example 121),
    2-(4-benzyloxyphenyl)-1-cycloheptylbenzimidazole-5-carboxylic acid (Example 122),
    1-cyclohexyl-2-[4-(2-phenethyloxyphenoxy)phenyl]benzimidazole-5-carboxylic acid (Example 123),
    1-cyclohexyl-2-[4-(3-phenethyloxyphenoxy)phenyl]benzimidazole-5-carboxylic acid (Example 124),
    1-cyclohexyl-2-[4-(2,2-diphenylethoxy)phenyl]benzimidazole-5-carboxylic acid (Example 125),
    2-(4-benzyloxyphenyl)-1-(3-cyclohexenyl)benzimidazole-5-carboxylic acid (Example 126),
    cis-1-[2-(4-benzyloxyphenyl)-5-carboxybenzimidazol-1-yl]-4-fluorocyclohexane (Example 127),
    1-cyclohexyl-2-[4-(2-phenoxyphenoxy)phenyl]benzimidazole-5-carboxylic acid (Example 128),
    1-cyclohexyl-2-[4-(3-phenoxyphenoxy)phenyl]benzimidazole-5-carboxylic acid (Example 129),
    2-{4-[(2R)-2-benzyloxycarbonylamino-2-phenylethoxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 130),
    1-cyclohexyl-2-{2-fluoro-4-[2-(4-trifluoromethylphenyl)-benzyloxy]phenyl}benzimidazole-5-carboxylic acid (Example 131),
    2-[4-(4-benzyloxyphenoxy)phenyl]-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 132),
    2-{4-[bis(4-methylphenyl)methoxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 133),
    2-{4-[bis(4-fluorophenyl)methoxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 134),
    1-cyclohexyl-6-methoxy-2-[4-(3-phenylpropoxy)phenyl]-benzimidazole-5-carboxylic acid (Example 135),
    1-cyclohexyl-6-hydroxy-2-[4-(3-phenylpropoxy)phenyl]-benzimidazole-5-carboxylic acid (Example 136),
    1-cyclohexyl-6-methyl-2-[4-(3-phenylpropoxy)phenyl]-benzimidazole-5-carboxylic acid (Example 137),
    2-{4-[2-(2-benzyloxyphenyl)ethoxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 138),
    2-{4-[2-(3-benzyloxyphenyl)ethoxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 139),
    2-[4-(2-carboxymethyloxyphenoxy)phenyl]-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 140),
    2-[4-(3-carboxymethyloxyphenoxy)phenyl]-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 141),
    2-{4-[3-chloro-6-(4-methylphenyl)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 142),
    2-{4-[3-chloro-6-(4-methoxyphenyl)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 143),
    1-cyclohexyl-2-{2-methyl-4-[2-(4-trifluoromethylphenyl)-benzyloxy]phenyl}benzimidazole-5-carboxylic acid (Example 144),
    2-{4-[2-(4-tert-butylphenyl)-5-chlorobenzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 145),
    2-{4-(3-chloro-6-phenylbenzyloxy)-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 146),
    2-{4-[3-chloro-6-(3,5-dichlorophenyl)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 147),
    2-{4-[bis(4-fluorophenyl)methoxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 148),
    2-{4-(4-benzyloxyphenoxy)-2-chlorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 149),
    2-{4-(4-benzyloxyphenoxy)-2-trifluoromethylphenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 150),
    2-{4-[3-chloro-6-(2-trifluoromethylphenyl)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 151),
    2-{4-[(2R)-2-amino-2-phenylethoxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 152),
    2-[4-(2-biphenylyloxy)phenyl]-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 153),
    2-[4-(3-biphenylyloxy)phenyl]-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 154),
    2-{4-[2-{(1-tert-butoxycarbonyl-4-piperidyl)methoxy}phenoxy]-phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 155),
    2-{4-[3-{(1-tert-butoxycarbonyl-4-piperidyl)methoxy}phenoxy]-phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 156),
    2-{4-[3-chloro-6-(3,4,5-trimethoxyphenyl)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 157),
    2-{4-[2-(2-biphenylyl)ethoxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 158),
    2-[4-(2-biphenylylmethoxy)phenyl]-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 159),
    1-cyclohexyl-2-{4-[2-(4-piperidylmethoxy)phenoxy]phenyl}-benzimidazole-5-carboxylic acid hydrochloride (Example 160),
    1-cyclohexyl-2-{4-[3-(4-piperidylmethoxy)phenoxy]phenyl}-benzimidazole-5-carboxylic acid hydrochloride (Example 161),
    2-{4-[(2R)-2-acetylamino-2-phenylethoxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 162),
    1-cyclohexyl-2-{4-[3-(4-methyl-3-pentenyloxy)phenoxy]phenyl}-benzimidazole-5-carboxylic acid (Example 163),
    1-cyclohexyl-2-{4-[3-(3-methyl-3-butenyloxy)phenoxy]phenyl}-benzimidazole-5-carboxylic acid (Example 164),
    2-{4-[{(2S)-1-benzyl-2-pyrrolidinyl}methoxy]phenyl}-1-cyclohexyl-benzimidazole-5-carboxylic acid hydrochloride (Example 165),
    2-{4-[3-chloro-6-(4-methylthiophenyl)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 166),
    2-{4-[3-chloro-6-(4-methanesulfonylphenyl)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 167),
    2-{4-[3-chloro-6-(2-thienyl)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 168),
    2-{4-[3-chloro-6-(3-chlorophenyl)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 169),
    2-{4-[3-chloro-6-(3-pyridyl)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 170),
    2-{4-[3-chloro-6-(4-fluorophenyl)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 171),
    2-[4-(4-benzyloxyphenoxy)-3-fluorophenyl]-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 172),
    2-[4-(2-bromo-5-chlorobenzyloxy)phenyl]-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 173),
    2-{4-[3-chloro-6-(4-chlorophenyl)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 174),
    2-{4-[2-{(1-acetyl-4-piperidyl)methoxy}phenoxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 175),
    2-{4-[3-{(1-acetyl-4-piperidyl)methoxy}phenoxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 176),
    1-cyclohexyl-2-{4-[3-(2-propynyloxy)phenoxy]phenyl}benzimidazole-5-carboxylic acid (Example 177),
    1-cyclohexyl-2-{4-[3-(3-pyridylmethoxy)phenoxy]phenyl}-benzimidazole-5-carboxylic acid (Example 178),
    2-(4-benzyloxy-2-methoxyphenyl)-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 179),
    2-[4-(2-bromo-5-methoxybenzyloxy)phenyl]-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 180),
    2-[4-(carboxydiphenylmethoxy)phenyl]-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 181),
    2-{4-[2-(4-chlorophenyl)-5-nitrobenzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 182),
    2-{4-[3-acetylamino-6-(4-chlorophenyl)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 183),
    2-{4-[2-(4-carboxyphenyl)-5-chlorobenzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 184),
    2-{4-[{(2S)-1-benzyloxycarbonyl-2-pyrrolidinyl}methoxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 185),
    2-{2-chloro-4-[2-(4-trifluoromethylphenyl)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 186),
    1-cyclohexyl-2-{4-[3-(2-pyridylmethoxy)phenoxy]phenyl}-benzimidazole-5-carboxylic acid (Example 187),
    2-{4-[2-(4-chlorophenyl)-5-fluorobenzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 188),
    2-{4-[3-carboxy-6-(4-chlorophenyl)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 189),
    2-{4-[3-carbamoyl-6-(4-chlorophenyl)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 190),
    1-cyclohexyl-2-{4-[2-(dimethylcarbamoylmethoxy)phenoxy]-phenyl}benzimidazole-5-carboxylic acid (Example 191),
    1-cyclohexyl-2-{4-[2-(piperidinocarbonylmethoxy)phenoxy]-phenyl}benzimidazole-5-carboxylic acid (Example 192),
    2-{4-[{(2S)-1-benzenesulfonyl-2-pyrrolidinyl}methoxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 193),
    2-{4-[{(2S)-1-benzoyl-2-pyrrolidinyl}methoxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 194),
    2-{4-[2-(4-carbamoylphenyl)-5-chlorobenzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 195),
    1-cyclohexyl-2-{4-[3-(dimethylcarbamoylmethoxy)phenoxy]-phenyl}benzimidazole-5-carboxylic acid (Example 196),
    1-cyclohexyl-2-{4-[3-(piperidinocarbonylmethoxy)phenoxy]-phenyl}benzimidazole-5-carboxylic acid (Example 197),
    1-cyclohexyl-2-{4-[3-{(1-methanesulfonyl-4-piperidyl)methoxy}-phenoxy]phenyl}benzimidazole-5-carboxylic acid (Example 198),
    1-cyclohexyl-2-{4-[{2-methyl-5-(4-chlorophenyl)-4-oxazolyl}-methoxy]phenyl}benzimidazole-5-carboxylic acid (Example 199),
    2-{4-[3-(3-chlorobenzyloxy)phenoxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 200),
    2-{4-[3-(4-chlorobenzyloxy)phenoxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 201),
    1-cyclohexyl-2-{4-[3-(4-fluorobenzyloxy)phenoxy]phenyl}-benzimidazole-5-carboxylic acid (Example 202),
    1-cyclohexyl-2-{4-[{(2S)-1-(4-nitrophenyl)-2-pyrrolidinyl}-methoxy]phenyl}benzimidazole-5-carboxylic acid (Example 203),
    1-cyclohexyl-2-{4-[{(2S)-1-phenyl-2-pyrrolidinyl}methoxy]-phenyl}benzimidazole-5-carboxylic acid hydrochloride (Example 204),
    2-{4-[{(2S)-1-(4-acetylaminophenyl)-2-pyrrolidinyl}methoxy]-phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 205),
    2-{4-[{5-(4-chlorophenyl)-2-methyl-4-thiazolyl}methoxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 206),
    2-{4-[bis(3-fluorophenyl)methoxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 207),
    1-cyclohexyl-2-{4-[2-(4-chlorophenyl)-3-nitrobenzyloxy]phenyl}-benzimidazole-5-carboxylic acid (Example 208),
    1-cyclohexyl-2-{4-[3-(4-tetrahydropyranyloxy)phenoxy]phenyl}-benzimidazole-5-carboxylic acid (Example 209),
    1-cyclohexyl-2-{4-[3-(4-trifluoromethylbenzyloxy)phenoxy]phenyl}-benzimidazole-5-carboxylic acid (Example 210),
    1-cyclohexyl-2-{4-[3-{(1-methyl-4-piperidyl)methoxy}phenoxy]-phenyl}benzimidazole-5-carboxylic acid (Example 211),
    2-{4-[3-(4-tert-butylbenzyloxy)phenoxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 212),
    2-{4-[3-(2-chlorobenzyloxy)phenoxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 213),
    1-cyclohexyl-2-{4-[3-(3-pyridyl)phenoxy]phenyl}benzimidazole-5-carboxylic acid (Example 214),
    2-{4-[3-(4-chlorophenyl)phenoxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 215),
    1-cyclohexyl-2-{4-[3-(4-methoxyphenyl)phenoxy]phenyl}-benzimidazole-5-carboxylic acid (Example 216),
    1-cyclohexyl-2-{4-[{4-(4-methanesulfonylphenyl)-2-methyl-5-thiazolyl}methoxy]phenyl}benzimidazole-5-carboxylic acid (Example 217),
    2-{4-[{4-(4-chlorophenyl)-2-methyl-5-thiazolyl}methoxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 218),
    2-{4-[1-(4-chlorobenzyl)-3-piperidyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 219),
    1-cyclohexyl-2-{4-[3-{(2-methyl-4-thiazolyl)methoxy}phenoxy]-phenyl}benzimidazole-5-carboxylic acid (Example 220),
    1-cyclohexyl-2-{4-[3-{(2,4-dimethyl-5-thiazolyl)methoxy}phenoxy]-phenyl}benzimidazole-5-carboxylic acid (Example 221),
    1-cyclohexyl-2-{4-[3-(3,5-dichlorophenyl)phenoxy]phenyl}-benzimidazole-5-carboxylic acid (Example 222),
    2-{4-[1-(4-chlorobenzyl)-4-piperidyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 223),
    2-{4-[3-(4-chlorobenzyloxy)piperidino]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 224),
    2-{4-[4-carbamoyl-2-(4-chlorophenyl)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 225),
    2-{4-[4-(4-chlorobenzyloxy)piperidino]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 226),
    2-{4-[3-{(2-chloro-4-pyridyl)methoxy}phenoxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 227),
    2-{4-[{(2S)-1-(4-dimethylcarbamoylphenyl)-2-pyrrolidinyl}-methoxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 228),
    2-{4-[2-(4-chlorophenyl)-5-ethoxycarbonylbenzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 229),
    1-cyclohexyl-2-[4-(3-trifluoromethylphenoxy)phenyl]-benzimidazole-5-carboxylic acid (Example 230),
    1-cyclohexyl-2-{4-[{4-(4-dimethylcarbamoylphenyl)-2-methyl-5-thiazolyl}methoxy]phenyl}benzimidazole-5-carboxylic acid (Example 231),
    2-{4-[2-(4-chlorophenyl)-5-dimethylcarbamoylbenzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 232),
    2-{4-[{4-(4-chlorophenyl)-2-methyl-5-pyrimidinyl}methoxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 233),
    2-{4-[{2-(4-chlorophenyl)-3-pyridyl}methoxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid dihydrochloride (Example 234),
    2-{4-[{3-(4-chlorophenyl)-2-pyridyl}methoxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 235),
    2-{4-[2-(3-chlorophenyl)-4-methylamino-1,3,5-triazin-6-yloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid trifluoroacetate (Example 236),
    2-{4-[2-(4-chlorophenyl)-4-(5-tetrazolyl)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 237),
    2-[4-(4-benzyloxy-6-pyrimidinyloxy)phenyl]-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 238),
    1-cyclohexyl-2-{4-[4-(4-pyridylmethoxy)-6-pyrimidinyloxy]phenyl}-benzimidazole-5-carboxylic acid (Example 239),
    2-{4-[4-(3-chlorophenyl)-6-pyrimidinyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 240),
    methyl 2-{4-[2-(4-chlorophenyl)-5-methoxybenzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylate (Example 241),
    2-{4-[2-(4-chlorophenyl)-5-methoxybenzyloxy]phenyl}-1-cyclohexyl-benzimidazole-5-carboxylic acid hydrochloride (Example 242),
    ethyl 2-{4-[3-(4-chlorophenyl)pyridin-2-ylmethoxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylate (Example 243),
    methyl 2-[4-(2-bromo-5-tert-butoxycarbonylbenzyloxy)phenyl]-1-cyclohexylbenzimidazole-5-carboxylate (Example 244),
    methyl 2-{4-[5-tert-butoxycarbonyl-2-(4-chlorophenyl)benzyloxy]-phenyl}-1-cyclohexylbenzimidazole-5-carboxylate (Example 245),
    methyl 2-{4-[5-carboxy-2-(4-chlorophenyl)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylate hydrochloride (Example 246),
    methyl 2-{4-[2-(4-chlorophenyl)-5-methylcarbamoylbenzyloxy]-phenyl}-1-cyclohexylbenzimidazole-5-carboxylate (Example 247),
    2-{4-[2-(4-chlorophenyl)-5-methylcarbamoylbenzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 248),
    2-{4-[3-(tert-butylsulfamoyl)-6-(4-chlorophenyl)benzyloxy]-phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 249),
    2-{4-[2-(4-chlorophenyl)-5-sulfamoylbenzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid trifluoroacetate (Example 250),
    2-(4-benzyloxycyclohexyl)-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 251),
    2-[2-(2-biphenylyloxymethyl)-5-thienyl]-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 252),
    2-[2-(2-biphenylyloxymethyl)-5-furyl]-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 253),
    1-cyclohexyl-2-{4-[{4-(4-fluorophenyl)-2-hydroxymethyl-5-thiazolyl}methoxy]phenyl}benzimidazole-5-carboxylic acid (Example 254),
    1-cyclohexyl-2-{4-[{4-(4-carboxyphenyl)-2-methyl-5-thiazolyl}-methoxy]phenyl}benzimidazole-5-carboxylic acid hydrochloride (Example 255),
    1-cyclohexyl-2-{2-fluoro-4-[4-fluoro-2-(3-fluorobenzoyl)-benzyloxy]phenyl}benzimidazole-5-carboxylic acid (Example 256),
    2-{4-[2-(4-chlorophenyl)-5-methoxybenzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-sulfonic acid (Example 257),
    2-{4-[2-(4-chlorophenyl)-5-methoxybenzyloxy]phenyl}-3-cyclohexylbenzimidazole-4-carboxylic acid (Example 258),
    1-cyclohexyl-2-{4-[3-dimethylcarbamoyl-5-(4-pyridylmethoxy)-phenoxy]phenyl}benzimidazole-5-carboxylic acid dihydrochloride (Example 259),
    1-cyclohexyl-2-{4-[3-carboxy-5-(4-pyridylmethoxy)phenoxy]-phenyl}benzimidazole-5-carboxylic acid dihydrochloride (Example 260),
    2-{4-[2-(4-chlorophenyl)-5-methoxybenzyloxy]phenyl}-1-cyclohexylbenzimidazole-4-carboxylic acid (Example 261),
    2-{4-[3-carbamoyl-6-(4-chlorophenyl)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 262),
    2-{4-[{2-(4-carboxyphenyl)-3-pyridyl}methoxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 263),
    2-{4-[2-(4-chlorophenyl)-5-methoxybenzyloxy]phenyl}-1-(4-tetrahydrothiopyranyl)benzimidazole-5-carboxylic acid (Example 264),
    2-{4-[2-(4-chlorophenyl)-5-dimethylcarbamoylbenzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 265),
    1-cyclohexyl-2-{4-[3-dimethylcarbamoyl-6-(4-trifluoromethylphenyl)benzyloxy]phenyl}benzimidazole-5-carboxylic acid hydrochloride (Example 266),
    1-cyclohexyl-2-{4-[3-dimethylcarbamoyl-6-(4-methylthiophenyl)-benzyloxy]phenyl}benzimidazole-5-carboxylic acid hydrochloride (Example 267),
    2-{4-[2-(4-chlorophenyl)-5-methylcarbamoylbenzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 268),
    2-{4-[2-(4-chlorophenyl)-5-dimethylcarbamoylbenzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 269),
    2-{4-[3-carbamoyl-6-(4-chlorophenyl)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 270),
    2-{4-[3-dimethylcarbamoyl-6-(4-methanesulfonylphenyl)benzyloxy]-phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 271),
    2-{4-[3-dimethylcarbamoyl-6-(3-pyridyl)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid dihydrochloride (Example 272),
    2-{4-[3-dimethylcarbamoyl-6-(4-dimethylcarbamoylphenyl)-benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 273),
    2-{4-[2-(4-chlorophenyl)-5-methoxybenzyloxy]phenyl}-1-(1-oxo-4-tetrahydrothiopyranyl)benzimidazole-5-carboxylic acid (Example 274),
    2-{4-[2-(4-chlorophenyl)-5-methoxybenzyloxy]phenyl}-1-(1,1-dioxo-4-tetrahydrothiopyranyl)benzimidazole-5-carboxylic acid (Example 275),
    2-{4-[2-(4-chlorophenyl)-5-methoxybenzyloxy]-2-fluorophenyl}-1-(4-tetrahydrothiopyranyl)benzimidazole-5-carboxylic acid (Example 276),
    2-{4-[2-(4-chlorophenyl)-5-methoxybenzyloxy]-2-fluorophenyl}-1-(1-oxo-4-tetrahydrothiopyranyl)benzimidazole-5-carboxylic acid (Example 277),
    2-{4-[2-(4-chlorophenyl)-5-methoxybenzyloxy]-2-fluorophenyl}-1-(1,1-dioxo-4-tetrahydrothiopyranyl)benzimidazole-5-carboxylic acid (Example 278),
    2-{4-[2-(4-chlorophenyl)-5-dimethylsulfamoylbenzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 279),
    2-{4-[2-(4-chlorophenyl)-5-methanesulfonylbenzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 280),
    methyl 2-{4-[5-carboxy-2-(4-chlorophenyl)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylate hydrochloride (Example 281),
    2-{4-[2-(4-chlorophenyl)-5-dimethylaminobenzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid dihydrochloride (Example 282),
    2-{4-[2-(4-chlorophenyl)-5-methanesulfonylaminobenzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 283),
    2-{4-[2-(4-chlorophenyl)-5-diethylcarbamoylbenzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 284),
    2-{4-[2-(4-chlorophenyl)-5-isopropylcarbamoylbenzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 285),
    2-{4-[2-(4-chlorophenyl)-5-piperidinocarbonylbenzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 286),
    2-{4-[2-(4-chlorophenyl)-5-(1-pyrrolidinyl)carbonylbenzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 287),
    2-{4-[2-(4-chlorophenyl)-5-(2-hydroxyethyl)carbamoylbenzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 288),
    2-{4-[2-(4-chlorophenyl)-5-(4-hydroxypiperidino)-carbonylbenzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 289),
    2-{4-[2-(4-chlorophenyl)-5-morpholinocarbonylbenzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 290),
    2-{4-[2-(4-chlorophenyl)-5-thiomorpholinocarbonylbenzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 291),
    2-{4-[3-(carboxymethylcarbamoyl)-6-(4-chlorophenyl)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 292),
    2-{4-[2-{4-(2-carboxyethyl)phenyl}-5-chlorobenzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 293),
    2-{4-[3-chloro-6-(4-hydroxymethylphenyl)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 294),
    2-{4-[3-chloro-6-(4-methoxymethylphenyl)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 295),
    2-{4-[2-(3-carboxyphenyl)-5-chlorobenzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 296),
    2-{4-[2-(4-chlorophenyl)-5-methylthiobenzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 297),
    2-{4-[2-(4-chlorophenyl)-5-methylsulfinylbenzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 298),
    2-{4-[2-(4-chlorophenyl)-5-cyanobenzyloxy]phenyl}-1-cyclohexyl-benzimidazole-5-carboxylic acid hydrochloride (Example 299),
    2-{4-[bis(3-pyridyl)methoxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 300),
    2-{4-[bis(4-dimethylcarbamoylphenyl)methoxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 301),
    sodium 2-{4-[2-thienyl-3-thienylmethoxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylate (Example 302),
    methyl 2-{4-[2-(4-chlorophenyl)-5-(dimethylcarbamoyl)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylate (Example 303),
    sodium 2-{4-[2-(4-chlorophenyl)-5-(dimethylcarbamoyl)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylate (Example 304),
    2-{4-[5-carboxy-2-(4-chlorophenyl)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 305),
    2-{4-[2-(4-carboxyphenyl)-5-methoxybenzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 306),
    2-{4-[2-(4-carbamoylphenyl)-5-(dimethylcarbamoyl)benzyloxy]-phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 307),
    2-{4-[5-amino-2-(4-chlorophenyl)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 308),
    2-{4-[5-(4-chlorophenyl)-2-methoxybenzylsulfinyl]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 309),
    2-{4-[5-(4-chlorophenyl)-2-methoxybenzylsulfonyl]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 310),
    2-{4-[2-(4-chlorophenyl)-5-methoxybenzylthio]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 311),
    2-{4-[bis(4-carboxyphenyl)methoxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 312),
    2-[4-(phenyl-3-pyridylmethoxy)-2-fluorophenyl]-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 313),
    methyl 2-{4-[2-(4-chlorophenyl)-5-(methylcarbamoyl)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylate (Example 314),
    2-{4-[5-chloro-2-(4-pyridyl)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 315),
    2-{4-[2-(4-chlorophenyl)-5-(benzylcarbamoyl)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 316),
    2-{4-[2-(4-chlorophenyl)-5-(cyclohexylmethylcarbamoyl)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 317),
    2-{4-[2-(4-chlorophenyl)-5-(4-pyridylmethylcarbamoyl)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid dihydrochloride (Example 318),
    2-{4-[2-(4-chlorophenyl)-5-(N-benzyl-N-methylcarbamoyl)-benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 319),
    2-{4-[5-dimethylaminocarbonyl-2-(4-pyridyl)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid dihydrochloride (Example 320),
    2-{4-[2-(4-chlorophenyl)-5-(4-methylpiperazin-1-ylcarbonyl)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid dihydrochloride (Example 321),
    2-{4-[2-(4-chlorophenyl)-5-{N-(3-pyridylmethyl)carbamoyl}-benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid dihydrochloride (Example 322),
    2-{4-[2-(4-chlorophenyl)-5-{N-(2-pyridylmethyl)carbamoyl}-benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid dihydrochloride (Example 323),
    2-{4-[2-(4-chlorophenyl)-5-(cyclohexylcarbamoyl)benzyloxy]-phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 324),
    2-{4-[2-(4-chlorophenyl)-5-(2-pyridin-4-ylethylcarbamoyl)-benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid dihydrochloride (Example 325),
    2-{4-[(4-fluorophenyl){4-(dimethylaminocarbonyl)phenyl}methoxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 326),
    2-{4-[(4-fluorophenyl)(4-carboxyphenyl)methoxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 327),
    2-{4-[2-(4-chlorophenyl)-5-(4-oxopiperidinocarbonyl)-benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 328),
    2-{4-[2-(4-chlorophenyl)-5-hydroxybenzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 329),
    2-{4-[2-(4-chlorophenyl)-5-(isopropylcarbamoyl)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 330),
    2-{4-[2-(4-chlorophenyl)-5-(N-isopropyl-N-methylcarbamoyl)-benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 331),
    2-{4-[2-(4-chlorophenyl)-5-(phenylcarbamoyl)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 332),
    2-{4-[2-(4-chlorophenyl)-5-(4-methoxypiperidinocarbonyl)-benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 333),
    2-{4-[2-(4-chlorophenyl)-5-(3-hydroxypropyloxy)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 334),
    2-{4-[2-(4-chlorophenyl)-5-(2-hydroxyethoxy)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 335),
    methyl 2-[4-(2-bromo-5-nitrobenzyloxy)-2-fluorophenyl]-1-cyclohexylbenzimidazole-5-carboxylate (Example 336),
    methyl 2-[4-{2-(4-chlorophenyl)-5-nitrobenzyloxy}-2-fluorophenyl]-1-cyclohexylbenzimidazole-5-carboxylate (Example 337),
    methyl 2-[4-{5-amino-2-(4-chlorophenyl)benzyloxy}-2-fluorophenyl]-1-cyclohexylbenzimidazole-5-carboxylate (Example 338),
    methyl 2-[4-{2-(4-chlorophenyl)-5-(2-oxopyrrolidin-1-yl)benzyloxy}-2-fluorophenyl]-1-cyclohexylbenzimidazole-5-carboxylate (Example 339),
    2-[4-{2-(4-chlorophenyl)-5-(2-oxopyrrolidin-1-yl)benzyloxy}-2-fluorophenyl]-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 340),
    2-{4-[2-(4-chlorophenyl)-5-(4-methylpiperidin-1-ylcarbonyl)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 341),
    2-{4-[5-acetyl-2-(4-chlorophenyl)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 342),
    2-{4-[2-(4-chlorophenyl)-5-{(4-hydroxypiperidin-1-ylcarbonyl)-methoxy}benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 343),
    2-{4-[2-(4-chlorophenyl)-5-(2-methoxyethoxy)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 344),
    2-{4-[2-(4-chlorophenyl)-5-{2-(2-methoxyethoxy)ethoxy}-benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 345),
    2-{4-[2-(4-chlorophenyl)-5-(isobutylcarbonyl)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 346),
    2-{4-[2-(4-chlorophenyl)-5-(2-methylthiazol-4-yl)benzyloxy]-phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 347),
    2-{4-[2-(4-chlorophenyl)-5-(3,4-dihydroxypiperidin-1-ylcarbonyl)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 348),
    2-{4-[2-(4-chlorophenyl)-5-(3-methyl-1,2,4-oxadiazol-5-yl)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 349),
    2-{4-[2-(4-chlorophenyl)-4-(isopropylcarbamoyl)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 350),
    2-{4-[2-(4-chlorophenyl)-4-(piperidinocarbonyl)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 351),
    2-{4-[2-(4-chlorophenyl)-5-{(1-hydroxy-2-methylpropan-2-yl)carbamoylbenzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 352),
    2-{4-[2-(4-chlorophenyl)-5-(4,4-dimethyl-2-oxazolin-2-yl)}benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid dihydrochloride (Example 353),
    2-{4-[2-(4-chlorophenyl)-4-(4-hydroxypiperidin-1-ylcarbonyl)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 354),
    2-{4-[2-(4-chlorophenyl)-4-{(2-hydroxyethyl)carbamoyl}-benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 355),
    2-{4-[2-(4-chlorophenyl)-4-{(4-pyridylmethyl)carbamoyl}-benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 356),
    2-{4-[2-(4-chlorophenyl)-4-(dimethylcarbamoyl)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 357),
    2-{4-[5-(2-aminothiazol-4-yl)-2-(4-chlorophenyl)benzyloxy]-phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid dihydrochloride (Example 358),
    2-{4-[2-(4-chlorophenyl)-5-(4-hydroxypiperidin-1-ylsulfonyl)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 359),
    2-{4-[5-(dimethylcarbamoyl)-2-(4-fluorophenyl)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 360),
    2-{4-[5-(dimethylcarbamoyl)-2-(3-fluorophenyl)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 361),
    2-{4-[2-(5-chlorothiophen-2-yl)-5-(dimethylcarbamoyl)benzyloxy]-phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 362),
    2-{4-[2-bromo-5-(5-methyloxazol-2-yl)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 363),
    2-{4-[2-bromo-5-(5-methylthiazol-2-yl)benzyloxylphenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 364),
    2-{4-[2-(4-chlorophenyl)-5-(5-methyloxazol-2-yl)benzyloxy]-phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 365),
    2-{4-[2-(4-chlorophenyl)-5-(5-methylthiazol-2-yl)benzyloxy]-phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 366),
    2-{4-[2-(4-chlorophenyl)-5-tetrazol-5-ylbenzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 367),
    2-{4-[5-chloro-2-(4-cyanophenyl)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 368),
    2-{4-[5-chloro-2-(4-tetrazol-5-ylphenyl)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 369),
    2-{4-[2-(4-chlorophenyl)-5-{2-(4-hydroxypiperidin-1-yl)ethoxy}benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 370),
    2-{4-[2-(4-chlorophenyl)-5-(2-oxopiperidin-1-yl)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 371),
    2-{4-[3-(4-chlorophenyl)-5-(dimethylcarbamoyl)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 372),
    2-{4-[2-(4-chlorophenyl)-5-(N-hydroxyamidino)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid dihydrochloride (Example 373),
    2-{4-[2-(4-chlorophenyl)-5-(2,5-dihydro-5-oxo-4H-1,2,4-oxadiazol-3-yl)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 374),
    2-{4-[2-(4-chlorophenyl)-5-(2-oxo-3H-1,2,3,5-oxathiadiazol-4-yl)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 375),
    2-{4-[2-(4-chlorophenyl)-5-(2,5-dihydro-5-oxo-4H-1,2,4-thiadiazol-3-yl)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 376),
    2-{4-[2-(4-chlorophenyl)-5-(cyclopropylcarbamoyl)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 377),
    2-{4-[2-(4-chlorophenyl)-5-(cyclobutylcarbamoyl)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 378),
    2-{4-[2-(4-chlorophenyl)-5-(tert-butylcarbamoyl)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 379),
    2-{4-[2-(4-chlorophenyl)-5-(isobutylcarbamoyl)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 380),
    2-{4-[2-(4-chlorophenyl)-5-{(1-hydroxypropan-2-yl)carbamoyl}-benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 381),
    2-{4-[2-(4-chlorophenyl)-5-(methoxycarbamoyl)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 382),
    2-{4-[2-(4-chlorophenyl)-5-{(2,3-dihydroxypropyl)carbamoyl}-benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 383),
    2-{4-[2-(4-chlorophenyl)-5-(N-ethyl-N-methylcarbamoyl)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 384),
    2-{4-[2-(4-chlorophenyl)-5-(N-methyl-N-propylcarbamoyl)-benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 385),
    2-{4-[2-(4-chlorophenyl)-5-(N-isopropyl-N-methylcarbamoyl)-benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 386),
    2-{4-[2-(4-chlorophenyl)-5-(2,6-dimethylpiperidin-1-ylcarbonyl)-benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 387),
    2-{4-[5-(butylcarbamoyl)-2-(4-chlorophenyl)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 388),
    2-{4-[2-(4-chlorophenyl)-5-(propylcarbamoyl)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 389),
    2-{4-[2-(4-chlorophenyl)-5-(ethylcarbamoyl)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 390),
    2-{4-[2-(4-chlorophenyl)-5-{(dimethylcarbamoyl)amino}benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 391),
    2-{4-[2-(4-chlorophenyl)-5-{(morpholinocarbonyl)amino}benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 392),
    2-{4-[2-(4-chlorophenyl)-5-ureidobenzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 393),
    2-{4-[2-(4-chlorophenyl)-5-{(ethylcarbamoyl)amino}benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 394),
    2-{4-[2-(4-chlorophenyl)-5-{(isopropylcarbamoyl)amino}benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 395),
    2-{4-[2-(3,4-difluorophenyl)-5-(isopropylcarbamoyl)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 396),
    2-{4-[2-(2,4-difluorophenyl)-5-(isopropylcarbamoyl)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 397),
    2-{4-[2-(3,5-dichlorophenyl)-5-(isopropylcarbamoyl)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 398),
    2-{4-[2-(3-chloro-4-fluorophenyl)-5-(isopropylcarbamoyl)-benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 399),
    2-{4-[2-(3,4-dichlorophenyl)-5-(isopropylcarbamoyl)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 400),
    2-{4-[2-(4-chloro-2-fluorophenyl)-5-(isopropylcarbamoyl)-benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 401),
    2-{4-[2-(4-chloro-2-fluorophenyl)-5-(pyrrolidin-1-ylcarbonyl)-benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 402),
    2-{4-[2-(4-chloro-3-fluorophenyl)-5-(pyrrolidin-1-ylcarbonyl)-benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 403),
    2-{4-[2-(4-chloro-3-fluorophenyl)-5-(isopropylcarbamoyl)-benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 404),
    2-{4-[2-{4-(methylthio)phenyl}-5-(2-oxopyrrolidin-1-yl)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 405),
    2-{4-[2-{4-(methylthio)phenyl}-5-(isopropylcarbamoyl)benzyloxy]-2-fluorophenyl}-1- cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 406),
    2-{4-[4-chloro-2-(4-chlorophenyl)-5-(1,1-dioxoisothiazolidin-2-yl)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 407),
    2-{4-[4-chloro-2-(4-chlorophenyl)-5-(2-oxopyrrolidin-1-yl)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 408),
    2-{4-[2-(4-chlorophenyl)-5-(isopropylaminosulfonyl)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 409),
    2-{4-[2-(4-chlorophenyl)-5-(dimethylcarbamoyl)benzyloxy]-2-fluorophenyl}-1-cyclopentylbenzimidazole-5-carboxylic acid hydrochloride (Example 410),
    2-{4-[2-(4-chlorophenyl)-5-(4-hydroxypiperidin-1-ylcarbonyl)-benzyloxy]-2-fluorophenyl}-1-cyclopentylbenzimidazole-5-carboxylic acid hydrochloride (Example 411),
    2-{4-[2-(4-chlorophenyl)-5-(isopropylcarbamoyl)benzyloxy]-2-fluorophenyl}-1-cyclopentylbenzimidazole-5-carboxylic acid hydrochloride (Example 412),
    2-{4-[2-(4-chlorophenyl)-5-(isopropylcarbamoyl)benzyloxy]phenyl}-1-cyclopentylbenzimidazole-5-carboxylic acid hydrochloride (Example 413),
    2-{4-[2-(4-chlorophenyl)-5-(dimethylcarbamoyl)benzyloxy]phenyl}-1-cyclopentylbenzimidazole-5-carboxylic acid hydrochloride (Example 414),
    2-{4-[2-(4-chlorophenyl)-5-(4-hydroxypiperidin-1-ylcarbonyl)benzyloxy]phenyl}-1-cyclopentylbenzimidazole-5-carboxylic acid hydrochloride (Example 415),
    2-{4-[2-(4-chlorophenyl)-5-(isopropylcarbamoyl)benzyloxy]phenyl}-1-(tetrahydrothiopyran-4-yl)benzimidazole-5-carboxylic acid hydrochloride (Example 416),
    2-{4-[2-(4-chlorophenyl)-5-(pyrrolidin-1-ylcarbonyl)benzyloxy]-phenyl}-1-(tetrahydrothiopyran-4-yl)benzimidazole-5-carboxylic acid hydrochloride (Example 417),
    2-{4-[2-(4-chlorophenyl)-5-(isopropylcarbamoyl)benzyloxy]-2-fluorophenyl}-1-(tetrahydrothiopyran-4-yl)benzimidazole-5-carboxylic acid hydrochloride (Example 418),
    2-{4-[2-(4-chlorophenyl)-5-(2-oxopyrrolidin-1-yl)benzyloxy]-2-fluorophenyl}-1-(tetrahydrothiopyran-4-yl)benzimidazole-5-carboxylic acid hydrochloride (Example 419),
    2-{4-[2-(4-chlorophenyl)-5-(isopropylcarbamoyl)benzyloxy]-2-fluorophenyl}-1-piperidinobenzimidazole-5-carboxylic acid hydrochloride (Example 420),
    2-{4-[2-(4-chlorophenyl)-5-(pyrrolidin-1-ylcarbonyl)benzyloxy]-2-fluorophenyl}-1-piperidinobenzimidazole-5-carboxylic acid (Example 421),
    2-{4-[2-(4-chlorophenyl)-5-(2-imidazolin-2-yl)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid dihydrochloride (Example 422),
    2-{4-[2-(4-chlorophenyl)-5-(2-oxooxazolidin-3-yl)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 423),
    2-{4-[2-(4-chlorophenyl)-5-(2-oxoimidazolidin-1-yl)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 424),
    2-{4-[2-(4-chlorophenyl)-5-(2-oxazolin-2-ylamino)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid dihydrochloride (Example 425),
    2-{4-[{2-[{(dimethylcarbamoyl)methoxy}methyl]-4-(4-fluorophenyl)thiazol-5-yl}methoxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 426),
    2-{4-[{4-(4-fluorophenyl)-2-(4-hydroxypiperidin-1-ylmethyl)thiazol-5-yl}methoxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid dihydrochloride (Example 427),
    2-{4-[{4-(4-fluorophenyl)-2-[(carbamoylmethoxy)methyl]thiazol-5-yl}methoxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 428),
    2-{4-[{4-(4-fluorophenyl)-2-(methylcarbamoyl)thiazol-5-yl}methoxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 429),
    2-{4-[{4-(4-fluorophenyl)-2-{(2-hydroxyethyl)carbamoyl}thiazol-5-yl}methoxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 430),
    2-{4-[{2-(4-fluorophenyl)-5-(dimethylcarbamoyl)thiophen-3-yl}methoxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 431),
    2-{4-[{2-(4-fluorophenyl)-5-(isopropylcarbamoyl)thiophen-3-yl}methoxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 432),
    2-{4-[{2-(4-fluorophenyl)-5-(4-hydroxypiperidin-1-ylcarbonyl)thiophen-3-yl}methoxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 433),
    2-{4-[2-(4-chlorophenyl)-5-(dimethylcarbamoyl)benzyloxy]-2-fluorophenyl}-1-cyclohexyl-5-tetrazol-5-ylbenzimidazole (Example 434),
    2-{4-[2-(4-carboxyphenyl)-5-chlorobenzyloxy]-2-fluorophenyl}-1-cyclohexyl-5-tetrazol-5-ylbenzimidazole hydrochloride (Example 435),
    2-{4-[2-(4-chlorophenyl)-5-(isopropylcarbamoyl)benzyloxy]-2-fluorophenyl}-1-cyclohexyl-5-(2,5-dihydro-5-oxo-4H-1,2,4-oxadiazol-3-yl)benzimidazole hydrochloride (Example 436),
    2-{4-[5-carboxy-2-(4-chlorophenyl)benzyloxy]-2-fluorophenyl}-5-cyano-1-cyclohexylbenzimidazole (Example 437),
    2-{4-[2-(4-chlorophenyl)-5-(dimethylcarbamoyl)benzyloxy]-2-fluorophenyl}-5-cyano-1-cyclohexylbenzimidazole (Example 438),
    2-{4-[{N-(4-dimethylcarbamoyl)-N-(4-fluorophenyl)amino}-methyl]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 439),
    2-{5-[bis(3-fluorophenyl)methyl]-2-fluoro-4-hydroxyphenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 440),
    2-{3-[bis(3-fluorophenyl)methyl]-2-fluoro-4-hydroxyphenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 441),
    2-{4-[(3-dimethylcarbamoylphenyl)(4-fluorophenyl)methoxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 442),
    2-{4-[{3-(4-hydroxypiperidyl-1-ylcarbonyl)phenyl}(4-fluorophenyl)methoxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 443),
    1-{[2-{4-([4-(4-fluorophenyl)-2-methylthiazol-5-yl]methoxy)phenyl}-1-cyclohexylbenzimidazol-5-yl]carbonyl}-β-D-glucuronic acid (Example 444),
    {[2-{4-[bis(3-fluorophenyl)methoxy]-2-fluorophenyl}-1-cyclohexylbenzimidazol-5-yl]carbonyl}-β-D-glucuronic acid (Example 445),
    2-{4-[2-(4-chlorophenyl)-5-(1,1-dioxoisothiazolidin-2-yl)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 446),
    3-([4-(5-aminosulfonyl-1-cyclohexylbenzimidazol-2-yl)-3-fluorophenoxy]methyl)-4-(4-chlorophenyl)-N-isopropylbenzamide (Example 447),
    2-[4-{2-(4-chlorophenyl)-6-(isopropylaminocarbonyl)benzyloxy}-2-fluorophenyl]-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 448),
    2-[4-(2-(4-chlorophenyl)-4-fluoro-5-(1,1-dioxoisothiazolidin-2-yl)benzyloxy}-2-fluorophenyl]-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 449),
    2-[4-{2-(4-chlorophenyl)-5-(isopropylaminocarbonyl)benzyloxy}-2-fluorophenyl]-1-cyclohexyl-4-methoxybenzimidazole-5-carboxylic acid hydrochloride (Example 450),
    2-[4-{2-(4-chlorophenyl)-5-(N-isopropylcarbonyl-N-methylamino)benzyloxy}-2-fluorophenyl]-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 451),
    2-[4-{2-(4-chlorophenyl)-5-(isopropylcarbonylamino)benzyloxy}-2-fluorophenyl]-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 452),
    2-[3-{[4-(4-fluorophenyl)-2-methylthiazol-5-yl]methyl}-4-hydroxyphenyl]-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 453),
    2-[4-{2-(4-chlorophenyl)-4-fluoro-5-(2-oxopyrrolidin-1-yl)benzyloxy}-2-fluorophenyl]-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 454),
    2-[4-{2-(4-chlorophenyl)-5-(methylsulfonylamino)benzyloxy}-2-fluorophenyl]-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 455),
    2-[4-{2-(4-chlorophenyl)-5-[N-methyl-N-(methylsulfonyl)amino]benzyloxy}-2-fluorophenyl]-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 456),
    2-[4-{[3-(4-chlorophenyl)-6-(2-oxopyrrolidin-1-yl)pyridin-2-yl]methyloxy}-2-fluorophenyl]-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 457),
    2-[4-{2-(4-chlorophenyl)-5-(acetylamino)benzyloxy}-2-fluorophenyl]-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 458),
    2-[4-{2-(4-chlorophenyl)-5-(N-acetyl-N-ethylamino)benzyloxy}-2-fluorophenyl]-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 459),
    2-[4-{2-(4-chlorophenyl)-5-(N-acetyl-N-propylainiro)benzyloxy}-2-fluorophenyl]-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 460),
    2-[4-{2-(4-chlorophenyl)-5-[N-ethyl-N-(methylsulfonyl)amino]-benzyloxy}-2-fluorophenyl]-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 461),
    2-[4-{2-(4-chlorophenyl)-5-[N-(methylsulfonyl)-N-propylamino]benzyloxy}-2-fluorophenyl]-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 462),
    2-[4-{2-(4-chlorophenyl)-5-(N-acetyl-N-methylamino)benzyloxy}-2-fluorophenyl]-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 463),
    2-[4-{2-(4-chlorophenyl)-5-[N-(ethylsulfonyl)-N-methylamino]-benzyloxy}-2-fluorophenyl]-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 464),
    2-[4-{2-(4-chlorophenyl)-5-[N-ethyl-N-(ethylsulfonyl)amino]-benzyloxy}-2-fluorophenyl]-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 465),
    2-[4-{2-(4-chlorophenyl)-5-[N-(ethylcarbonyl)-N-methylamino]-benzyloxy}-2-fluorophenyl]-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 466),
    2-[4-{2-(4-chlorophenyl)-5-[N-ethyl-N-(ethylcarborlyl)amino]-benzyloxy}-2-fluorophenyl]-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 467),
    2-[4-{2-(4-chlorophenyl)-5-methoxybenzyloxy}-2-fluorophenyl]-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 468),
    2-[4-{2-(4-chlorophenyl)-5-(N-acetyl-N-isopropylamino)-benzyloxy}-2-fluorophenyl]-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 469),
    {[2-{4-[2-(4-chlorophenyl)-5-(2-oxopyrrolidin-1-yl)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzoimidazol-5-yl]carbonyl-β-D-glucuronic acid (Example 470),
    methyl 2-{4-[2-(4-chlorophenyl)-5-methoxybenzyloxy]phenyl}-1-cyclohexyl-1H-indole-5-carboxylate (Example 501),
    2-{4-[2-(4-chlorophenyl)-5-methoxybenzyloxy]phenyl}-1-cyclohexyl-1H-indole-5-carboxylic acid (Example 502),
    2-(4-benzyloxyphenyl)-1-cyclopentyl-1H-indole-5-carboxylic acid (Example 503),
    ethyl 2-(4-benzyloxyphenyl)-3-cyclohexylimidazo[1,2-a]pyridine-7-carboxylate (Example 601),
    2-(4-benzyloxyphenyl)-3-cyclohexylimidazo[1,2-a]pyridine-7-carboxylic acid (Example 602),
    2-{4-[2-(4-chlorophenyl)-5-methoxybenzyloxy]phenyl}-3-cyclohexyl-3H-imidazo[4,5-b]pyridine-6-carboxylic acid (Example 701),
    2-{4-[2-(4-chlorophenyl)-5-(isopropylcarbamoyl)benzyloxy]phenyl}-3-cyclohexyl-3H-dimidazo[4,5-b]pyridine-6-carboxylic acid hydrochloride (Example 702), and
    2-{4-[2-(4-chlorophenyl)-5-(pyrrolidin-1-ylcarbonyl)benzyloxy]-phenyl}-3-cyclohexyl-3H-imidazo[4,5-b]pyridine-6-carboxylic acid hydrochloride (Example 703).


The fused ring compound of the formula [I] or a pharmaceutically acceptable salt thereof, which is selected from the group consisting of

    2-{4-[2-(4-chlorophenyl)-5-(4-oxopiperidinocarbonyl)-benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 328),
    2-{4-[2-(4-chlorophenyl)-5-hydroxybenzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 329),
    2-{4-[2-(4-chlorophenyl)-5-(isopropylcarbamoyl)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 330),
    2-{4-[2-(4-chlorophenyl)-5-(N-isopropyl-N-methylcarbamoyl)-benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 331),
    2-{4-[2-(4-chlorophenyl)-5-(phenylcarbamoyl)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 332),
    2-{4-[2-(4-chlorophenyl)-5-(4-methoxypiperidinocarbonyl)-benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 333),
    2-{4-[2-(4-chlorophenyl)-5-(3-hydroxypropyloxy)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 334),
    2-{4-[2-(4-chlorophenyl)-5-(2-hydroxyethoxy)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 335),
    methyl 2-[4-(2-bromo-5-nitrobenzyloxy)-2-fluorophenyl]-1-cyclohexylbenzimidazole-5-carboxylate (Example 336),
    methyl 2-[4-{2-(4-chlorophenyl)-5-nitrobenzyloxy}-2-fluorophenyl]-1-cyclohexylbenzimidazole-5-carboxylate (Example 337),
    methyl 2-[4-{5-amino-2-(4-chlorophenyl)benzyloxy}-2-fluorophenyl]-1-cyclohexylbenzimidazole-5-carboxylate (Example 338),
    methyl 2-[4-{2-(4-chlorophenyl)-5-(2-oxopyrrolidin-1-yl)benzyloxy}-2-fluorophenyl]-1-cyclohexylbenzimidazole-5-carboxylate (Example 339),
    2-[4-{2-(4-chlorophenyl)-5-(2-oxopyrrolidin-1-yl)benzyloxy}-2-fluorophenyl]-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 340),
    2-{4-[2-(4-chlorophenyl)-5-(4-methylpiperidin-1-ylcarbonyl)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 341),
    2-{4-[5-acetyl-2-(4-chlorophenyl)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 342),
    2-{4-[2-(4-chlorophenyl)-5-{(4-hydroxypiperidin-1-ylcarbonyl)-methoxy}benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 343),
    2-{4-[2-(4-chlorophenyl)-5-(2-methoxyethoxy)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 344),
    2-{4-[2-(4-chlorophenyl)-5-{2-(2-methoxyethoxy)ethoxy}-benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 345),
    2-{4-[2-(4-chlorophenyl)-5-(isobutylcarbonyl)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 346),
    2-{4-[2-(4-chlorophenyl)-5-(2-methylthiazol-4-yl)benzyloxy]-phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 347),
    2-{4-[2-(4-chlorophenyl)-5-(3,4-dihydroxypiperidin-1-ylcarbonyl)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 348),
    2-{4-[2-(4-chlorophenyl)-5-(3-methyl-1,2,4-oxadiazol-5-yl)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 349),
    2-{4-[2-(4-chlorophenyl)-4-(isopropylcarbamoyl)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 350),
    2-{4-[2-(4-chlorophenyl)-4-(piperidinocarbonyl)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 351),
    2-{4-[2-(4-chlorophenyl)-5-{(1-hydroxy-2-methylpropan-2-yl)carbamoyl}benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 352),
    2-{4-[2-(4-chlorophenyl)-5-(4,4-dimethyl-2-oxazolin-2-yl)}benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid dihydrochloride (Example 353),
    2-{4-[2-(4-chlorophenyl)-4-(4-hydroxypiperidin-1-ylcarbonyl)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 354),
    2-{4-[2-(4-chlorophenyl)-4-{(2-hydroxyethyl)carbamoyl}-benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 355),
    2-{4-[2-(4-chlorophenyl)-4-{(4-pyridylmethyl)carbamoyl}-benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 356),
    2-{4-[2-(4-chlorophenyl)-4-(dimethylcarbamoyl)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 357),
    2-{4-[5-(2-aminothiazol-4-yl)-2-(4-chlorophenyl)benzyloxy]-phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid dihydrochloride (Example 358),
    2-{4-[2-(4-chlorophenyl)-5-(4-hydroxypiperidin-1-ylsulfonyl)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 359),
    2-{4-[5-(dimethylcarbamoyl)-2-(4-fluorophenyl)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 360),
    2-{4-[5-(dimethylcarbamoyl)-2-(3-fluorophenyl)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 361),
    2-{4-[2-(5-chlorothiophen-2-yl)-5-(dimethylcarbamoyl)benzyloxy]-phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 362),
    2-{4-[2-bromo-5-(5-methyloxazol-2-yl)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 363),
    2-{4-[2-bromo-5-(5-methylthiazol-2-yl)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 364),
    2-{4-[2-(4-chlorophenyl)-5-(5-methyloxazol-2-yl)benzyloxy]-phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 365),
    2-{4-[2-(4-chlorophenyl)-5-(5-methylthiazol-2-yl)benzyloxy]-phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 366),
    2-{4-[2-(4-chlorophenyl)-5-tetrazol-5-ylbenzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 367),
    2-{4-[5-chloro-2-(4-cyanophenyl)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 368),
    2-{4-[5-chloro-2-(4-tetrazol-5-ylphenyl)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 369),
    2-{4-[2-(4-chlorophenyl)-5-{2-(4-hydroxypiperidin-1-yl)ethoxy}benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 370),
    2-{4-[2-(4-chlorophenyl)-5-(2-oxopiperidin-1-yl)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 371),
    2-{4-[3-(4-chlorophenyl)-5-(dimethylcarbamoyl)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 372),
    2-{4-[2-(4-chlorophenyl)-5-(N-hydroxyamidino)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid dihydrochloride (Example 373),
    2-{4-[2-(4-chlorophenyl)-5-(2,5-dihydro-5-oxo-4H-1,2,4-oxadiazol-3-yl)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 374),
    2-{4-[2-(4-chlorophenyl)-5-(2-oxo-3H-1,2,3,5-oxathiadiazol-4-yl) benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 375),
    2-{4-[2-(4-chlorophenyl)-5-(2,5-dihydro-5-oxo-4H-1,2,4-thiadiazol-3-yl)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 376),
    2-{4-[2-(4-chlorophenyl)-5-(cyclopropylcarbamoyl)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 377),
    2-{4-[2-(4-chlorophenyl)-5-(cyclobutylcarbamoyl)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 378),
    2-{4-[2-(4-chlorophenyl)-5-(tert-butylcarbamoyl)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 379),
    2-{4-[2-(4-chlorophenyl)-5-(isobutylcarbamoyl)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 380),
    2-{4-[2-(4-chlorophenyl)-5-{(1-hydroxypropan-2-yl)carbamoyl}-benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 381),
    2-{4-[2-(4-chlorophenyl)-5-(methoxycarbamoyl)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 382),
    2-{4-[2-(4-chlorophenyl)-5-{(2,3-dihydroxypropyl)carbamoyl}-benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 383),
    2-{4-[2-(4-chlorophenyl)-5-(N-ethyl-N-methylcarbamoyl)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 384),
    2-{4-[2-(4-chlorophenyl)-5-(N-methyl-N-propylcarbamoyl)-benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 385),
    2-{4-[2-(4-chlorophenyl)-5-(N-isopropyl-N-methylcarbamoyl)-benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 386),
    2-{4-[2-(4-chlorophenyl)-5-(2,6-dimethylpiperidin-1-ylcarbonyl)-benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 387),
    2-{4-(5-(butylcarbamoyl)-2-(4-chlorophenyl)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 388),
    2-{4-[2-(4-chlorophenyl)-5-(propylcarbamoyl)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 389),
    2-{4-[2-(4-chlorophenyl)-5-(ethylcarbamoyl)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 390),
    2-{4-[2-(4-chlorophenyl)-5-{(dimethylcarbamoyl)amino}benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 391),
    2-{4-[2-(4-chlorophenyl)-5-{(morpholinocarbonyl)amino}benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 392),
    2-{4-[2-(4-chlorophenyl)-5-ureidobenzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 393),
    2-{4-[2-(4-chlorophenyl)-5-{(ethylcarbamoyl)amino}benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 394),
    2-{4-[2-(4-chlorophenyl)-5-{(isopropylcarbamoyl)amino}benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 395),
    2-{4-[2-(3,4-difluorophenyl)-5-(isopropylcarbamoyl)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 396),
    2-{4-[2-(2,4-difluorophenyl)-5-(isopropylcarbamoyl)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 397),
    2-{4-[2-(3,5-dichlorophenyl)-5-(isopropylcarbamoyl)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 398),
    2-{4-[2-(3-chloro-4-fluorophenyl)-5-(isopropylcarbamoyl)-benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 399),
    2-{4-[2-(3,4-dichlorophenyl)-5-(isopropylcarbamoyl)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 400),
    2-{4-[2-(4-chloro-2-fluorophenyl)-5-(isopropylcarbamoyl)-benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 401),
    2-{4-[2-(4-chloro-2-fluorophenyl)-5-(pyrrolidin-1-ylcarbonyl)-benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 402),
    2-{4-[2-(4-chloro-3-fluorophenyl)-5-(pyrrolldin-1-ylcarbonyl)-benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 403),
    2-{4-[2-(4-chloro-3-fluorophenyl)-5-(isopropylcarbamoyl)-benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 404),
    2-{4-[2-{4-(methylthio)phenyl}-5-(2-oxopyrrolidin-1-yl)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 405),
    2-{4-[2-{4-(methylthio)phenyl}-5-(isopropylcarbamoyl)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 406),
    2-{4-[4-chloro-2-(4-chlorophenyl)-5-(1,1-dioxoisothiazolidin-2-yl)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 407),
    2-{4-[4-chloro-2-(4-chlorophenyl)-5-(2-oxopyrrolidin-1-yl)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 408),
    2-{4-[2-(4-chlorophenyl)-5-(isopropylaminosulfonyl)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 409),
    2-{4-[2-(4-chlorophenyl)-5-(dimethylcarbamoyl)benzyloxy]-2-fluorophenyl}-1-cyclopentylbenzimidazole-5-carboxylic acid hydrochloride (Example 410),
    2-{4-[2-(4-chlorophenyl)-5-(4-hydroxypiperidin-1-ylcarbonyl)-benzyloxy]-2-fluorophenyl}-1-cyclopentylbenzimidazole-5-carboxylic acid hydrochloride (Example 411),
    2-{4-[2-(4-chlorophenyl)-5-(isopropylcarbamoyl)benzyloxy]-2-fluorophenyl}-1-cyclopentylbenzimidazole-5-carboxylic acid hydrochloride (Example 412),
    2-{4-[2-(4-chlorophenyl)-5-(isopropylcarbamoyl)benzyloxy]phenyl}-1-cyclopentylbenzimidazole-5-carboxylic acid hydrochloride (Example 413),
    2-{4-[2-(4-chlorophenyl)-5-(dimethylcarbamoyl)benzyloxy]phenyl}-1-cyclopentylbenzimidazole-5-carboxylic acid hydrochloride (Example 414),
    2-{4-[2-(4-chlorophenyl)-5-(4-hydroxypiperidin-1-ylcarbonyl)benzyloxy]phenyl}-1-cyclopentylbenzimidazole-5-carboxylic acid hydrochloride (Example 415),
    2-{4-[2-(4-chlorophenyl)-5-(isopropylcarbamoyl)benzyloxy]phenyl}-1-(tetrahydrothiopyran-4-yl)benzimidazole-5-carboxylic acid hydrochloride (Example 416),
    2-{4-[2-(4-chlorophenyl)-5-(pyrrolidin-1-ylcarbonyl)benzyloxy]-phenyl}-1-(tetrahydrothiopyran-4-yl)benzimidazole-5-carboxylic acid hydrochloride (Example 417),
    2-{4-[2-(4-chlorophenyl)-5-(isopropylcarbamoyl)benzyloxy]-2-fluorophenyl}-1-(tetrahydrothiopyran-4-yl)benzimidazole-5-carboxylic acid hydrochloride (Example 418),
    2-{4-[2-(4-chlorophenyl)-5-(2-oxopyrrolidin-1-yl)benzyloxy]-2-fluorophenyl}-1-(tetrahydrothiopyran-4-yl)benzimidazole-5-carboxylic acid hydrochloride (Example 419),
    2-{4-[2-(4-chlorophenyl)-5-(isopropylcarbamoyl)benzyloxy]-2-fluorophenyl}-1-piperidinobenzimidazole-5-carboxylic acid hydrochloride (Example 420),
    2-{4-[2-(4-chlorophenyl)-5-(pyrrolidin-1-ylcarbonyl)benzyloxy]-2-fluorophenyl}-1-piperidinobenzimidazole-5-carboxylic acid (Example 421),
    2-{4-[2-(4-chlorophenyl)-5-(2-imidazolin-2-yl)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid dihydrochloride (Example 422),
    2-{4-[2-(4-chlorophenyl)-5-(2-oxooxazolidin-3-yl)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 423),
    2-{4-[2-(4-chlorophenyl)-5-(2-oxoimidazolidin-1-yl)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 424),
    2-{4-[2-(4-chlorophenyl)-5-(2-oxazolin-2-ylamino)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid dihydrochloride (Example 425),
    2-{4-[{2-[{(dimethylcarbamoyl)methoxy}methyl]-4-(4-fluorophenyl)thiazol-5-yl}methoxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 426),
    2-{4-[{4-(4-fluorophenyl)-2-(4-hydroxypiperidin-1-ylmethyl)thiazol-5-yl}methoxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid dihydrochloride (Example 427),
    2-{4-[{4-(4-fluorophenyl)-2-[(carbamoylmethoxy)methyl]thiazol-5-yl}methoxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 428),
    2-{4-[{4-(4-fluorophenyl)-2-(methylcarbamoyl)thiazol-5-yl}methoxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 429),
    2-{4-[{4-(4-fluorophenyl)-2-{(2-hydroxyethyl)carbamoyl}thiazol-5-yl}methoxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 430),
    2-{4-[{2-(4-fluorophenyl)-5-(dimethylcarbamoyl)thiophen-3-yl}methoxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 431),
    2-{4-[{2-(4-fluorophenyl)-5-(isopropylcarbamoyl)thiophen-3-yl}methoxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 432),
    2-{4-[{2-(4-fluorophenyl)-5-(4-hydroxypiperidin-1-ylcarbonyl)thiophen-3-yl}methoxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 433),
    2-{4-[2-(4-chlorophenyl)-5-(dimethylcarbamoyl)benzyloxy]-2-fluorophenyl}-1-cyclohexyl-5-tetrazol-5-ylbenzimidazole (Example 434),
    2-{4-[2-(4-carboxyphenyl)-5-chlorobenzyloxy]-2-fluorophenyl}-1-cyclohexyl-5-tetrazol-5-ylbenzimidazole hydrochloride (Example 435),
    2-{4-[2-(4-chlorophenyl)-5-(isopropylcarbamoyl)benzyloxy]-2-fluorophenyl}-1-cyclohexyl-5-(2,5-dihydro-5-oxo-4H-1,2,4-oxadiazol-3-yl)benzimidazole hydrochloride (Example 436),
    2-{4-[5-carboxy-2-(4-chlorophenyl)benzyloxy]-2-fluorophenyl}-5-cyano-1-cyclohexylbenzimidazole (Example 437),
    2-{4-[2-(4-chlorophenyl)-5-(dimethylcarbamoyl)benzyloxy]-2-fluorophenyl}-5-cyano-1-cyclohexylbenzimidazole (Example 438),
    2-{4-[{N-(4-dimethylcarbamoyl)-N-(4-fluorophenyl)amino}-methyl]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 439),
    2-{5-[bis(3-fluorophenyl)methyl]-2-fluoro-4-hydroxyphenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 440),
    2-{3-[bis(3-fluorophenyl)methyl]-2-fluoro-4-hydroxyphenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 441),
    2-{4-[(3-dimethylcarbamoylphenyl) (4-fluorophenyl)methoxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 442),
    2-{4-[{3-(4-hydroxypiperidyl-1-ylcarbonyl)phenyl}(4-fluorophenyl)methoxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 443),
    1-{[2-{4-([4-(4-fluorophenyl)-2-methylthiazol-5-yl]methoxy)phenyl}-1-cyclohexylbenzimidazol-5-yl]carbonyl}-β-D-glucuronic acid (Example 444),
    {[2-{4-[bis(3-fluorophenyl)methoxy]-2-fluorophenyl}-1-cyclohexylbenzimidazol-5-yl]carbonyl}-β-D-glucuronic acid (Example 445),
    2-{4-[2-(4-chlorophenyl)-5-(1,1-dioxoisothiazolidin-2-yl)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 446),
    3-{[4-(5-aminosulfonyl-1-cyclohexylbenzimidazol-2-yl)-3-fluorophenoxy]methyl}-4-(4-chlorophenyl)-N-isopropylbenzamide (Example 447),
    2-[4-{2-(4-chlorophenyl)-6-(isopropylaminocarbonyl)benzyloxy}-2-fluorophenyl]-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 448),
    2-[4-{2-(4-chlorophenyl)-4-fluoro-5-(1,1-dioxoisothiazolidin-2-yl)benzyloxy}-2-fluorophenyl]-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 449),
    2-[4-{2-(4-chlorophenyl)-5-(isopropylaminocarbonyl)benzyloxy}-2-fluorophenyl]-1-cyclohexyl-4-methoxybenzimidazole-5-carboxylic acid hydrochloride (Example 450),
    2-[4-{2-(4-chlorophenyl)-5-(N-isopropylcarbonyl-N-methylamino)benzyloxy}-2-fluorophenyl]-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 451),
    2-[4-{2-(4-chlorophenyl)-5-(isopropylcarbonylamino)benzyloxy}-2-fluorophenyl]-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 452),
    2-[3-{[4-(4-fluorophenyl)-2-methylthiazol-5-yl]methyl}-4-hydroxyphenyl]-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 453),
    2-[4-{2-(4-chlorophenyl)-4-fluoro-5-(2-oxopyrrolidin-1-yl)benzyloxy}-2-fluorophenyl]-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 454),
    2-[4-{2-(4-chlorophenyl)-5-(methylsulfonylamino)benzyloxy}-2-fluorophenyl]-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 455),
    2-[4-(2-{4-chlorophenyl)-5-[N-methyl-N-(methylsulfonyl)amino]benzyloxy}-2-fluorophenyl]-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 456),
    2-[4-{[3-(4-chlorophenyl)-6-(2-oxopyrrolidin-1-yl)pyridin-2-yl]methyloxy}-2-fluorophenyl]-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 457),
    2-[4-{2-(4-chlorophenyl)-5-(acetylamino)benzyloxy}-2-fluorophenyl]-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 458),
    2-[4-{2-(4-chlorophenyl)-5-(N-acetyl-N-ethylamino)benzyloxy}-2-fluorophenyl]-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 459),
    2-[4-{2-(4-chlorophenyl)-5-(N-acetyl-N-propylamino)benzyloxy}-2-fluorophenyl]-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 460),
    2-[4-{2-(4-chlorophenyl)-5-[N-ethyl-N-(methylsulfonyl)amino]-benzyloxy}-2-fluorophenyl]-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 461),
    2-[4-{2-(4-chlorophenyl)-5-[N-(methylsulfonyl)-N-propylamino]benzyloxy}-2-fluorophenyl]-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 462),
    2-[4-{2-(4-chlorophenyl)-5-(N-acetyl-N-methylamino)benzyloxy}-2-fluorophenyl]-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 463),
    2-[4-{2-(4-chlorophenyl)-5-[N-(ethylsulfonyl)-N-methylamino]-benzyloxy}-2-fluorophenyl]-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 464),
    2-[4-{2-(4-chlorophenyl)-5-[N-ethyl-N-(ethylsulfonyl)amino]-benzyloxy}-2-fluorophenyl]-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 465),
    2-[4-{2-(4-chlorophenyl)-5-[N-(ethylcarbonyl)-N-methylamino]-benzyloxy}-2-fluorophenyl]-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 466),
    2-[4-{2-(4-chlorophenyl)-5-[N-ethyl-N-(ethylcarbonyl)amino]-benzyloxy}-2-fluorophenyl]-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 467),
    2-[4-{2-(4-chlorophenyl)-5-methoxybenzyloxy}-2-fluorophenyl]-1-cyclohexylbenzimidazole-5-carboxylic acid (Example 468),
    2-[4-{2-(4-chlorophenyl)-5-(N-acetyl-N-isopropylamino)-benzyloxy}-2-fluorophenyl]-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride (Example 469),
    {[2-{4-[2-(4-chlorophenyl)-5-(2-oxopyrrolidin-1-yl)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzoimidazol-5-yl]carbonyl-β-D-glucuronic acid (Example 470),
    2-{4-[2-(4-chlorophenyl)-5-(isopropylcarbamoyl)benzyloxy]phenyl}-3-cyclohexyl-3H-dimidazo[4,5-b]pyridine-6-carboxylic acid hydrochloride (Example 702), and
    2-{4-[2-(4-chlorophenyl)-5-(pyrrolidin-1-ylcarbonyl)benzyloxy]-phenyl}-3-cyclohexyl-3H-imidazo[4,5-b]pyridine-6-carboxylic acid hydrochloride (Example 703).


A pharmaceutical composition comprising a fused ring compound of any of (29) to (62) above, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
A hepatitis C virus polymerase inhibitor comprising a fused ring compound of any of (1) to (28) and (29) to (62) above, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
An anti-hepatitis C virus agent comprising a fused ring compound of any of (1) to (28) and (29) to (62) above, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
A therapeutic agent for hepatitis C comprising a fused ring compound of any of (29) to (62) above, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
An anti-hepatitis C virus agent comprising (a) the anti-hepatitis C virus agent of (65) above and (b) at least one agent selected from the group consisting of a different antiviral agent, an antiinflammatory agent and an immunostimulant.
An anti-hepatitis C virus agent comprising (a) the anti-hepatitis C virus agent of (65) above and (b) interferon.
A therapeutic agent for hepatitis C comprising (a) the hepatitis C virus polymerase inhibitor of (64) above and (b) at least one agent selected from the group consisting of a different antiviral agent, an antiinflammatory agent and an immunostimulant.
A therapeutic agent for hepatitis C comprising (a) the hepatitis C virus polymerase inhibitor of (64) above and (b) interferon.
A benzimidazole compound of the folllowing formula [III]





 

wherein Ra36 is hydrogen atom or carboxyl-protecting group, Ra37 is cyclopentyl or cyclohexyl, and Ra38 is hydrogen atom or fluorine atom, or a salt thereof.

A thiazole compound selected from the group consisting of 4-(4-fluorophenyl)-5-hydroxymethyl-2-methylthiazole and 4-(4-fluorophenyl)-5-chloromethyl-2-methylthiazole, or a pharmaceutically acceptable salt thereof.
A biphenyl compound selected from the group consisting of 1-(4′-chloro-2-hydroxymethyl-biphenyl-4-yl)-2-pyrrolidinone and 1-(4′-chloro-2-chloromethyl-biphenyl-4-yl)-2-pyrrolidinone, or a pharmaceutically acceptable salt thereof.
A pharmaceutical composition comprising (a) a fused ring compound of the formula [I] of (1) above or a pharmaceutically acceptable salt thereof and (b) at least one agent selected from the group consisting of an antiviral agent other than the compound of (1) above, an antiinflammatory agent and an immunostimulant.
A pharmaceutical composition comprising (a) a fused ring compound of the formula [I] of (1) above or a pharmaceutically acceptable salt thereof and (b) interferon.
A method for treating hepatitis C, which comprises administering an effective amount of a fused ring compound of the formula [I] of (1) above or a pharmaceutically acceptable salt thereof.
The method of (76) above, further comprising administering an effective amount of at least one agent selected from the group consisting of an antiviral agent other than the compound of claim 1, an antiinflammatory agent and an immunostimulant.
The method of (76) above, further comprising administering an effective amount of interferon.
A method for inhibiting hepatitis C virus polymerase, which comprises administering an effective amount of a fused ring compound of the formula [I] of (1) above or a pharmaceutically acceptable salt thereof.
The method of (79) above, further comprising administering an effective amount of at least one agent selected from the group consisting of an antiviral agent other than the compound of (1) above, an antiinflammatory agent and an immunostimulant.
The method of (79) above, further comprising administering an effective amount of interferon.
Use of a fused ring compound of the formula [I] of (1) above or a pharmaceutically acceptable salt thereof for the production of a pharmaceutical agent for treating hepatitis C.
Use of a fused ring compound of the formula [I] of (1) above or a pharmaceutically acceptable salt thereof for the production of a hepatitis C virus polymerase inhibitor.
A pharmaceutical composition for the treatment of hepatitis C, which comprises a fused ring compound of the formula [I] of (1) above or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
A pharmaceutical composition for inhibiting hepatitis C virus polymerase, which comprises a fused ring compound of the formula [I] of (1) above or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
A commercial package comprising a pharmaceutical composition of (84) above and a written matter associated therewith, the written matter stating that the pharmaceutical composition can or should be used for treating hepatitis C.
A commercial package comprising a pharmaceutical composition of (85) above and a written matter associated therewith, the written matter stating that the pharmaceutical composition can or should be used for inhibiting hepatitis C virus polymerase.
1-Cyclohexyl-2-(3-furanyl)-1H-benzimidazole-5-carboxylic acid (Example 471).


DETAILED DESCRIPTION OF THE INVENTION
The definitions of respective substituents and moieties used in the present specification are as follows.
The halogen atom is a fluorine atom, chlorine atom, is bromine atom or iodine atom, preferably fluorine atom, chlorine atom or bromine atom.
Particularly preferably, the halogen atom is fluorine atom at R5, R5′, R6, R6′, group A and group C, and fluorine atom or chlorine atom at X, Z, Z′, group B and group D.
The C1-6 alkyl is straight chain or branched chain alkyl having 1 to 6 carbon atoms, and is exemplified by methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, tert-pentyl, hexyl and the like.
Preferably, it is straight chain or branched chain alkyl having 1 to 4 carbon atoms, and is particularly preferably methyl at Ra7, Ra8, Ra9, Ra15, Ra16, Ra17, Ra33, Ra35, Rb6 and Rb7 and methyl or tert-butyl at Rb1, Rb2, group B and group C, and methyl, ethyl, propyl or isopropyl at Ra29.
The halogenated C1-6 alkyl is the above-defined C1-6 alkyl except that it is substituted by the above-defined halogen atom. Preferably, it is halogenated alkyl wherein the alkyl moiety thereof is straight chain or branched chain alkyl having 1 to 4 carbon atoms. Examples thereof include fluoromethyl, difluoromethyl, trifluoromethyl, bromomethyl, chloromethyl, 1,2-dichloromethyl, 2,2-dichloromethyl, 2,2,2-trifluoroethyl and the like.
The halogenated C1-6 alkyl is particularly preferably trifluoromethyl at group B.
The C1- 6 alkylene is straight chain alkylene having 1 to 6 carbon atoms, and is exemplified by methylene, ethylene, trimethylene, tetramethylene, pentamethylene or hexamethylene.
The C1-6 alkylene is preferably methylene or ethylene at Y.
The C2-6 alkenylene is straight chain alkenylene having 2 to 6 carbon atoms, and is exemplified by vinylene, propenylene, 1-butenylene, 1,3-butadienylene and the like.
The C2-6 alkenylene is preferably vinylene at Y.
The C1-6 alkoxy is alkyloxy wherein the alkyl moiety thereof is the above-defined C1-6 alkyl. Preferably, it is alkoxy wherein the alkyl moiety thereof is straight chain or branched chain alkyl having 1 to 4 carbon atoms. Examples thereof include methoxy, ethoxy, propoxy, isopropyloxy, butoxy, isobutyloxy, tert-butyloxy, pentyloxy, hexyloxy and the like.
The C1-6 alkoxy is particularly preferably methoxy at Ra2, Ra3, Ra27, Ra28, Ra33, group A and group C.
The C1-6 alkoxy C1-6 alkoxy is that wherein C1-6 alkoxy in the above definition is substituted by C1-6 alkoxy defined above and is preferably that wherein the alkyl moiety thereof is straight chain or branched chain alkyl having 1 to 4 carbon atoms. Specific examples include methoxymethyl, ethoxymethyl, methoxyethoxy, methoxypropoxy, isopropyloxyethoxy and the like.
The group A is particularly preferably methoxyethoxy.
The C1-6 alkanoyl is alkylcarbonyl wherein the alkyl moiety thereof is the above-defined C1-6 alkyl. Preferably, it is alkanoyl wherein the alkyl moiety thereof is straight chain or branched chain alkyl having 1 to 4 carbon atoms. Examples thereof include acetyl, propionyl, butyryl, isobutyryl, pivaloyl and the like.
The C1-6 alkanoyl is particularly preferably acetyl at R1, R2, R3, R4, Ra5, Ra29, Rb7 and group B.
The C1-6 alkoxycarbonyl is alkyloxycarbonyl wherein the alkoxy moiety thereof is the above-defined C1-6 alkoxy. Preferably, it is alkoxycarbonyl wherein the alkyl moiety thereof is straight chain or branched chain alkyl having 1 to 4 carbon atoms. Examples thereof include methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropyloxycarbonyl, butoxycarbonyl, isobutyloxycarbonyl, tert-butyloxycarbonyl, pentyloxycarbonyl, hexyloxycarbonyl and the like.
The C1-6 alkoxycarbonyl is particularly preferably methoxycarbonyl or ethoxycarbonyl at Ra10 and group A.
The C1-6 alkylamino is alkylamino or dialkylamino wherein the alkyl moiety thereof is the above-defined C1-6 alkyl. Preferably, it is alkylamino or dialkylamino wherein the alkyl moiety thereof is straight chain or branched chain alkyl having 1 to 4 carbon atoms. Examples thereof include methylamino, ethylamino, propylamino, isopropylamino, butylamino, isobutylamino, tert-butylamino, pentylamino, hexylamino, dimethylamino, diethylamino, methylethylamino, N-isopropyl-N-isobutylamino and the like.
The C1-6 alkylamino is particularly preferably methylamino at Ra7, and particularly preferably dimethylamino at Ra21 and group A, and particularly preferably dimethylamino, ethylamino or isopropylamino at Ra24.
The C1-6 alkanoylamino is alkylcarbonylamino wherein the alkanoyl moiety thereof is the above-defined C1-6 alkanoyl. Preferably, it is alkylcarbonylamino wherein the alkyl moiety thereof is straight chain or branched chain alkyl having 1 to 4 carbon atoms. Examples thereof include acetylamino, propionylamino, butyrylamino, isobutyrylamino, pivaloylamino and the like.
The C1-6 alkanoylamino is particularly preferably acetylamino at X and Ra10.
The C1-6 alkylsulfonyl is alkylsulfonyl wherein the alkyl moiety thereof is the above-defined C1-6 alkyl. Preferably, it is alkylsulfonyl wherein the alkyl moiety thereof is straight chain or branched chain alkyl having 1 to 4 carbon atoms. Examples thereof include methylsulfonyl, ethylsulfonyl, propylsulfonyl, isopropylsulfonyl, butylsulfonyl, isobutylsulfonyl, tert-butylsulfonyl, pentylsulfonyl, hexylsulfonyl and the like.
The C1-6 alkylsulfonyl is particularly preferably methylsulfonyl at X and Ra5.
The C6-14 aryl is aromatic hydrocarbon having 6 to 14 carbon atoms. Examples thereof include phenyl, naphthyl, anthryl, indenyl, azulenyl, fluorenyl, phenanthryl and the like.
The C6-14 aryl is preferably phenyl or naphthyl, particularly preferably phenyl at the ring A, ring A′, ring B and ring B′.
The C3-8 cycloalkyl is saturated cycloalkyl having 3 to 8, preferably 5 to 7, carbon atoms. Examples thereof include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl.
The C3-8 cycloalkyl is particularly preferably cyclohexyl at the ring A, ring A′, ring B and ring B′.
The C3-8 cycloalkenyl is cycloalkenyl having 3 to 8, preferably 5 to 7, carbon atoms and has at least 1, preferably 1 or 2, double bond(s). Examples thereof include cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclopentadienyl, cyclohexenyl, 2,4-cyclohexadien-1-yl, 2,5-cyclohexadien-1-yl, cycloheptenyl and cyclooctenyl and the like, but do not include aryl (e.g., phenyl) or completely saturated cycloalkyl.
The C3-8 cycloalkenyl is preferably cyclohexenyl at the ring A and ring A′.
The heterocyclic group has, as an atom constituting the ring, 1 to 4 heteroatom(s) selected from an oxygen atom, a nitrogen atom and a sulfur atom, besides a carbon atom, and includes saturated ring and unsaturated ring, monocyclic ring and fused ring having the number of ring atom constituting the ring of 3 to 14.
The heterocyclic group as a moriocyclic ring includes, for example, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, 1,3,5-triazinyl, pyrrolyl, pyrazolyl, imidazolyl, 1,2,4-triazolyl, tetrazolyl, thienyl, furyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrrolinyl, pyrrolidinyl, imidazolidinyl, piperidyl, piperazinyl, morpholinyl, thiomorpholinyl, tetrahydropyranyl and the like.
The heterocyclic group includes the groups of the following formulas.





 

wherein E1 is an oxygen atom, a sulfur atom or N(—Ra35), E2 is an oxygen atom, CH2 or N(—Ra35), E3 is an oxygen atom or a sulfur atom, wherein Ra35 is independently hydrogen atom or C1-6 alkyl, f is an integer of 1 to 3, and h and h′ are the same or different and each is an integer of 1 to 3.

Specific examples of the heterocyclic group include








 

and the like.

Examples of the heterocyclic group as a fused ring include quinolyl, isoquinolyl, quinazolinyl, quinoxalyl, phthalazinyl, cinnolinyl, naphthyridinyl, 5,6,7,8-tetrahydroquinolyl, indolyl, benzimidazolyl, 2,3-dihydrobenzimidazolyl, 2,3-dihydro-2-oxobenzimidazolyl, indolinyl, benzofuranyl, benzothienyl, benzoxazolyl, benzothiazolyl and the like.
Preferably, it is a heterocyclic group which is a 5-membered or a 6-membered monocyclic group. Examples thereof include pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, 1,3,5-triazinyl, pyrrolyl, pyrazolyl, imidazolyl, 1,2,4-triazolyl, tetrazolyl, thienyl, furyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrrolidinyl, piperidyl, piperazinyl








 

and the like.

At R1, R2, R3, R4, Z and group D, tetrazolyl and 5-oxo-Δ2-1,2,4-oxadiazolin-3-yl are particularly preferable.
The heterocyclic group is preferably pyridyl, pyrazinyl, pyrimidinyl or pyridazinyl which is an aromatic group, and particularly preferably pyridyl at the ring A and ring A′.
The heterocyclic group is particularly preferably pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, 1,3,5-triazinyl, pyrrolyl, pyrazolyl, imidazolyl, 1,2,4-triazolyl, tetrazolyl, thienyl, furyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl or thiadiazolyl, which is an aromatic group, at the ring B and ring B′. More preferably it is pyridyl or thiazolyl, most preferably thiazolyl.
The C6-14 aryl C1-6 alkyl is arylalkyl wherein the alkyl moiety thereof is the above-defined C1-6 alkyl and the aryl moiety is the above-defined C6-14 aryl. Preferably, it is arylalkyl wherein the alkyl moiety thereof is straight chain alkyl having 1 to 4 carbon atoms and the aryl moiety is phenyl. Examples thereof include benzyl, phenethyl, 3-phenylpropyl, 2-phenylpropyl, 4-phenylbutyl and the like.
The C6-14 aryl C1-6 alkyl is particularly preferably benzyl at Ra8 and Rb6.
The glucuronic acid residue is glucuronic acid less any hydroxyl group, preferably β-D-glucuronic acid substituted at 1-position.
The C6-14 aryl C1-6 alkyloxycarbonyl is arylalkyloxycarbonyl wherein the C6-14 aryl C1-6 alkyl moiety thereof is the above-defined C6-14 aryl C1-6 alkyl. Preferably, it is arylalkyloxycarbonyl wherein the alkyl moiety thereof is straight chain alkyl having 1 to 4 carbon atoms and the aryl moiety is phenyl. Examples thereof include benzyloxycarbonyl, phenethyloxycarbonyl, 3-phenylpropyloxycarbonyl, 2-phenylpropyloxycarbonyl, 4-phenylbutyloxycarbonyl and the like.
The C6-14 aryl C1-6 alkyloxycarbonyl is particularly preferably benzyloxycarbonyl at Rb7.
The optionally substituted C1-6 alkyl is the above-defined C1-6 alkyl, preferably that wherein straight chain or branched chain alkyl having 1 to 4 carbon atoms is optionally substituted with 1 to 3 substituent(s), and includes unsubstituted alkyl. The substituent(s) is(are) selected from the above-defined halogen atom, hydroxyl group, carboxyl, amino, the above-defined C1-6 alkoxy, the above-defined C1-6 alkoxy C1-6 alkoxy, the above-defined C1-6 alkoxycarbonyl and the above-defined C1-6 alkylamino. Examples of optionally substituted C1-6 alkyl include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, tert-pentyl, neopentyl, 1-ethylpropyl, hexyl, trifluoromethyl, hydroxymethyl, 2-hydroxyethyl, 3-hydroxypropyl, 4-hydroxybutyl, 1-hydroxy-1-methylethyl, 1-hydroxypropan-2-yl, 1,3-dihydroxypropan-2-yl, 1-hydroxy-2-methylpropan-2-yl, carboxylmethyl, 2-carboxylethyl, methoxymethyl, methoxyethyl, methoxyethoxyethyl, ethoxycarbonylmethyl, 2-ethoxycarbonylethyl, 2-dimethylaminoethyl and the like.
Preferably, the optionally substituted C1-6 alkyl is methyl, 1-hydroxy-1-methylethyl, carboxylmethyl or 2-dimethylaminoethyl at R1, R2, R3 and R4, methyl or trifluoromethyl at R5, R5′, R6 and R6′, methyl at R7, R8, Ra31 and Rb5, methyl, ethyl or isopropyl at Ra24, methyl or isopropyl at Ra18, methyl or ethyl at Ra1, Ra19 and Ra25, methyl, carboxylmethyl or 2-dimethylaminoethyl at Ra2 and Ra3, methyl or carboxylmethyl at Ra6, methyl, ethyl, isopropyl, butyl or trifluoromethyl at X, methyl, ethyl, isopropyl, butyl, isobutyl, tert-butyl, isopentyl, neopentyl, 1-ethylpropyl or carboxylmethyl at Ra10, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, trifluoromethyl, 2-hydroxyethyl or carboxylmethyl at Ra11, methyl or 4-hydroxybutyl at Ra12, methyl, ethyl, isopropyl, butyl, 2-hydroxyethyl, 4-hydroxybutyl, ethoxycarbonylmethyl, 2-(ethoxycarbonyl)ethyl or 2-dimethylaminoethyl at Ra13, methyl, propyl, butyl, isopentyl, trifluoromethyl, hydroxymethyl, 2-hydroxyethyl, 3-hydroxypropyl, methoxyethyl, methoxyethoxyethyl or carboxymethyl at Ra20, methyl or ethyl at Ra22 and Ra23, methyl isopropyl or tert-butyl at Ra26, methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, isobutyl, 2-hydroxyethyl, 1-hydroxypropan-2-yl, 1-hydroxy-2-methylpropan-2-yl or carboxylmethyl at Ra27 and Ra28, and methyl, ethyl, propyl, isopropyl, tert-butyl, trifluoromethyl, hydroxymethyl, 2-hydroxyethyl, 2-carboxylethyl, methoxymethyl or ethoxycarbonylmethyl at Z, Z′ and group D.
It is particularly preferably, trifluoromethyl at R5, R5′, R6 and R6′, methyl or tert-butyl at Ra26, methyl, tert-butyl, trifluoromethyl or hydroxymethyl at Z, Z′ and group D, and methyl at other substituents.
The optionally substituted C2-6 alkenyl is that wherein straight chain or branched chain alkenyl having 2 to 6 carbon atoms is optionally substituted by 1 to 3 substituent(s), and includes unsubstituted alkenyl. The substituent(s) is(are) selected from the above-defined halogen atom, hydroxyl group, carboxyl, amino, the above-defined C1-6 alkoxy, the above-defined C1-6 alkoxy C1-6 alkoxy, the above-defined C1-6 alkoxycarbonyl and the above-defined C1-6 alkylamino. Examples of optionally substituted C2-6 alkenyl include vinyl, allyl, 1-propenyl, isopropenyl, 1-butenyl, 2-butenyl, 1,3-butadienyl, 2-isopentenyl, 3-isohexenyl, 4-methyl-3-pentenyl, 2-carboxylethenyl and the like.
The optionally substituted C2-6 alkenyl is preferably 2-carboxylethenyl at X, and preferably 2-isopentenyl, 3-isohexenyl or 4-methyl-3-pentenyl at Ra20.
The optionally substituted C2-6 alkynyl is that wherein straight chain or branched chain alkynyl having 2 to 6 carbon atoms is optionally substituted by 1 to 3 substituent(s), and includes unsubstituted alkynyl. The substituent(s) is(are) selected from the above-defined halogen atom, hydroxyl group, carboxyl, amino, the above-defined C1-6 alkoxy, the above-defined C1-6 alkoxycarbonyl and the above-defined C1-6 alkylamino. Examples thereof include ethynyl, 1-propynyl, 2-propynyl, 3-butynyl and the like.
The optionally substituted C2-6 alkynyl is preferably 2-propynyl at Ra20.
The C6-14 aryl optionally substituted by 1 to 5 substituent(s) selected from group B is that wherein the above-defined C6-14 aryl is optionally substituted by 1 to 5 substituent(s), and includes unsubstituted aryl. The substituent(s) is(are) selected from the above-defined halogen atom, cyano, nitro, the above-defined C1-6 alkyl, the above-defined halogenated C1-6 alkyl, the above-defined C1-6 alkanoyl, —(CH2)r—COORb1, —(CH2)r—CONRb1Rb2, —(CH2)r—NRb1Rb2, —(CH2)r—NRb1—CORb2, —(CH2)r—NHSO2Rb1, —(CH2)r—ORb1, —(CH2)r—SRb1, —(CH2)r—SO2Rb1 and —(CH2)r—SO2NRb1Rb2 (wherein Rb1 and Rb2 are each independently hydrogen atom or the above-defined C1-6 alkyl and r is 0 or an integer of 1 to 6).
Examples thereof include phenyl, naphthyl, anthryl, indenyl, azulenyl, fluorenyl, phenanthryl, 3-fluorophenyl, 4-fluorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2,4-dichlorophenyl, 3,5-dichlorophenyl, pentafluorophenyl, 4-methylphenyl, 4-tert-butylphenyl, 2-trifluoromethyiphenyl, 4-trifluoromethylphenyl, 4-nitrophenyl, 4-cyanophenyl, 4-acetylphenyl, 4-carboxylphenyl, 4-carbamoylphenyl, 4-aminophenyl, 4-dimethylaminophenyl, 4-acetylaminophenyl, 4-(methylsulfonylamino)phenyl, 4-methoxyphenyl, 3,4,5-trimethoxyphenyl, 4-methylthiophenyl, 4-methylsulfonylphenyl, 4-aminosulfonylphenyl, 3-nitro-4-methoxyphenyl and 4-nitro-3-methoxyphenyl.
The aryl moiety is preferably phenyl, the group B here is preferably the above-defined halogen atom, nitro, the above-defined C1-6 alkyl, the above-defined halogenated C1-6 alkyl or —(CH2)r—ORb1. Examples of group B include fluorine atom, chlorine atom, nitro, methyl, tert-butyl, trifluoromethyl and methoxy. Particularly preferably, it is fluorine atom or chlorine atom.
With regard to “C6-14 aryl optionally substituted by 1 to 5 substituent(s) selected from group B”, it is preferably phenyl, 4-tert-butylphenyl, 4-fluorophenyl, 3-chlorophenyl, 4-chlorophenyl, 4-methoxyphenyl or 4-trifluoromethylphenyl at Ra12, Ra27 and Ra28, phenyl at Ra14,Ra22, Ra23, Ra26 and Rb5,phenyl or 3-fluorophenyl at Ra18, phenyl or 2,4-dichlorophenyl at Ra20, phenyl, 4-chlorophenyl, 4-trifluoromethylphenyl, 3,5-dichlorophenyl, 3-nitro-4-methoxyphenyl or 4-nitro-3-methoxyphenyl at Ra24, and phenyl or 4-methylphenyl at Ra25.
It is particularly preferably phenyl at other substituents.
The C6-14 aryl optionally substituted by 1 to 5 substituent(s) selected from group D is that wherein the above-defined C6-14 aryl is optionally substituted by 1 to 5 substituent(s), and includes unsubstituted aryl. The substituent(s) is(are) selected from the above-mentioned group D (substituents shown under (a) to (q)).
Examples of group D here include fluorine atom, chlorine atom, bromine atom, nitro, cyano, methyl, ethyl, propyl, isopropyl, tert-butyl, trifluoromethyl, hydroxymethyl, 2-hydroxyethyl, methoxymethyl, 2-carboxylethyl, methoxycarbonylmethyl, ethoxycarbonylmethyl, acetyl, carboxyl, methoxycarbonyl, ethoxycarbonyl, carbamoyl, methylaminocarbonyl, isopropylaminocarbonyl, dimethylaminocarbonyl, diethylaminocarbonyl, (2-hydroxyethyl)aminocarbonyl, (carboxylmethyl)aminocarbonyl, hydroxyl group, methoxy, ethoxy, propyloxy, isopropyloxy, isopentyloxy, 2-isopentenyloxy, 3-isohexenyloxy, 4-methyl-3-pentenyloxy, 2-propynyloxy, hydroxymethyloxy, carboxylmethyloxy, (dimethylaminocarbonyl)methyloxy, amino, methylamino, dimethylamino, diethylamino, acetylamino, methylsulfonylamino, methylthio, methylsulfonyl, methylsulfinyl, aminosulfonyl, methylaminosulfonyl, dimethylaminosulfonyl and tetrazolyl.
Examples of C6-14 aryl optionally substituted by 1 to 5 substituent(s) selected from group D include phenyl, naphthyl, anthryl, indenyl, azulenyl, fluorenyl, phenanthryl, 3-fluorophenyl, 4-fluorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2,4-dichlorophenyl, 3,5-dichlorophenyl, 4-bromophenyl, 4-nitrophenyl, pentafluorophenyl, 4-methylphenyl, 4-tert-butylphenyl, 2-trifluoromethylphenyl, 4-trifluoromethylphenyl, 4-(hydroxymethyl)phenyl, 4-(methoxymethyl)phenyl, 4-(2-carboxylethyl)phenyl, 3-carboxylphenyl, 4-carboxylphenyl, 4-methoxyphenyl, 3,4,5-trimethoxyphenyl, 4-carbamoylphenyl, 4-methylthiophenyl, 4-(dimethylaminocarbonyl)phenyl, 4-methylsulfonylphenyl, 4-acetylaminophenyl, 4-cyanophenyl, 4-acetylphenyl, 4-aminophenyl, 4-dimethylaminophenyl, 4-(methylsulfonylamino)phenyl, 4-methylsulfinylphenyl, 4-aminosulfonylphenyl and 3-nitro-4-methoxyphenyl, 4-nitro-3-methoxyphenyl and 4-tetrazol-5-ylphenyl.
At Z and Z′, the aryl moiety is preferably phenyl.
The group D here is preferably the above-defined halogen atom, nitro, the above-defined optionally substituted C1-6 alkyl, —(CH2)t—COORa19, —(CH2)t—CONRa27Ra28, —(CH2)t—ORa20, —(CH2)t—NRa29CO—Ra24, —(CH2)t—S(O)q—Ra25 or —(CH2)t—SO2—NHRa26.
Particularly preferably, it is the above-defined halogen atom, the above-defined optionally substituted C1-6 alkyl, —(CH2)t—COORa19, —(CH2)t—CONRa27Ra28, —(CH2)t—ORa20 or —(CH2)t—S(O)q—Ra25, which is specifically fluorine atom, chlorine atom, bromine atom, nitro, methyl, tert-butyl, carboxyl, trifluoromethyl, hydroxymethyl, methoxymethyl, 2-carboxylethyl, methoxy, carbamoyl, methylthio, dimethylaminocarbonyl, methylsulfonyl or acetylamino. More preferably, it is fluorine atom, chlorine atom, methyl, tert-butyl, carboxyl, methoxy, carbamoyl, methylthio, dimethylaminocarbonyl, methylsulfonyl or acetylamino, most preferably fluorine atom or chlorine atom.
Examples of C6-14 aryl optionally substituted by 1 to 5 substituent(s) selected from group D preferably include phenyl, 3-fluorophenyl, 4-fluorophenyl, 3-chlorophenyl, 4-chlorophenyl, 3,5-dichlorophenyl, 4-bromophenyl, 4-nitrophenyl, 4-methylphenyl, 4-tert-butylphenyl, 2-trifluoromethylphenyl, 4-trifluoromethylphenyl, 4-(hydroxymethyl)phenyl, 4-(methoxymethyl)phenyl, 4-(2-carboxylethyl)phenyl, 3-carboxylphenyl, 4-carboxylphenyl, 4-methoxyphenyl, 3,4,5-trimethoxyphenyl, 4-carbamoylphenyl, 4-methylthiophenyl, 4-(dimethylaminocarbonyl)phenyl, 4-methylsulfonylphenyl, 4-acetylaminophenyl, 4-methylsulfinylphenyl, 4-aminosulfonylphenyl, 4-cyanophenyl and 4-tetrazolylphenyl, particularly preferably 4-chlorophenyl.
The heterocyclic group optionally substituted by 1 to 5 substituent(s) selected from group B is that wherein the above-defined heterocyclic group is optionally substituted by 1 to 5 slbstituent(s), and includes unsubstituted heterocyclic group. The substituent(s) is(are) selected from the above-defined halogen atom, cyano, nitro, the above-defined C1-6 alkyl, the above-defined halogenated C1-6 alkyl, the above-defined C1-6 alkanoyl, —(CH2)r—COORb1, —(CH2)r—CONRb1Rb2, —(CH2)r—NRb1Rb2, —(CH2)r—NRb1—CORb2, —(CH2)r—NHSO2Rb1, —(CH2)r—ORb1, —(CH2)r—SRb1, —(CH2)r—SO2Rb1 and —(CH2)r—SO2NRb1Rb2 wherein Rb1 and Rb2 are each independently hydrogen atom or the above-defined C1-6 alkyl and r is 0 or an integer of 1 to 6.
Examples thereof include 2-pyridyl, 3-pyridyl, 4-pyridyl, 3-fluoropyridin-4-yl, 3-chloropyridin-4-yl, 4-chloropyridin-3-yl, pyrazinyl, pyrimidinyl, pyridazinyl, 1,3,5-triazinyl, pyrrolyl, pyrazolyl, imidazolyl, 1,2,4-triazolyl, tetrazolyl, 2-thienyl, 3-thienyl, furyl, oxazolyl, 2-methyloxazol-4-yl, isoxazolyl, thiazolyl, 2-methylthiazol-4-yl, 2,5-dimethylthiazol-4-yl, 2,4-dimethylthiazol-5-yl, isothiazolyl, thiadiazolyl, pyrrolinyl, pyrrolidinyl, 3-hydroxypyrrolidinyl, imidazolidinyl, azetidinyl, piperidyl, 3-hydroxypiperidino, 4-hydroxypiperidino, 3,4-dihydroxypiperidino, 4-methoxypiperidino, 4-carboxypiperidino, 4-(hydroxymethyl)piperidino, 2-oxopiperidino, 4-oxopiperidino, 2,2,6,6-tetramethylpiperidino, 2,2,6,6-tetramethyl-4-hydroxypiperidino, N-methylpiperidin-4-yl, N-(tert-butoxycarbonyl)piperidin-4-yl, N-acetylpiperidin-4-yl, N-methylsulfonylpiperidin-4-yl, piperazinyl, 4-methylpiperazinyl, 4-methylsulfonylpiperazinyl, morpholinyl, thiomorpholinyl, 1-oxothiomorpholin-4-yl, 1,1-dioxothiomorpholin-4-yl, tetrahydropyranyl, quinolyl, isoquinolyl, quinazolinyl, quinoxalyl, phthalazinyl, cinnolinyl, naphthyridinyl, 5,6,7,8-tetrahydroquinolyl, indolyl, benzimidazolyl, indolinyl, benzofuranyl, benzothienyl, benzoxazolyl, benzothiazolyl,








 

and the like.

The heterocyclic moiety is preferably a heterocyclic group which is a 5-membered or a 6-membered monocyclic group. Examples thereof include pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, 1,3,5-triazinyl, pyrrolyl, pyrazolyl, imidazolyl, 1,2,4-triazolyl, tetrazolyl, thienyl, furyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrrolidinyl, piperidyl, piperazinyl, morpholinyl, thiomorpholinyl and tetrahydropyranyl, and the group B here is preferably the above-defined halogen atom, the above-defined C1-6 alkyl, the above-defined halogenated C1-6 alkyl, the above-defined C1-6 alkanoyl, —(CH2)r—COORb1, —(CH2)r—CONRb1Rb2 or —(CH2)r—ORb1.
Examples of heterocyclic group optionally substituted by 1 to 5 substituent(s) selected from group B preferably include piperidino, 4-methylpiperidino, 2,6-dimethylpiperidino, 4-hydroxypiperidino, 1-piperazinyl, 1-(methylsulfonyl)piperidin-4-yl, 1-pyrrolidinyl, morpholino, 4-thiomorpholinyl, tetrahydropyranyl, pyridyl, thiazolyl,





 

Particularly preferably, it is piperidino, 4-methylpiperidino, 2,6-dimethylpiperidino, 4-hydroxypiperidino, 1-piperazinyl, 1-pyrrolidinyl, morpholino or 4-thioiorpholinyl at Ra18, tetrahydropyranyl or 4-hydroxypiperidino at Ra20, piperidino, 4-hydroxypiperidino or 3,4-dihydroxypiperidino at Ra21, pyridyl or morpholino at Ra24, pyridyl or 4-hydroxypiperidino at Ra25, pyridyl or thiazolyl at Ra26 and at Ra27 and Ra28, it is 1-(methylsulfonyl)piperidin-4-yl, 3-hydroxypyrrolidinyl, 3-hydroxypiperidino, 4-hydroxypiperidino, 3,4-dihydroxypiperidino, 4-methoxypiperidino, 4-carboxypiperidino, 4-(hydroxymethyl)piperidino, 2-oxopiperidino, 4-oxopiperidino, 2,2,6,6-tetramethylpiperidino, 2,2,6,6-tetramethyl-4-hydroxypiperidino, 4-methylsulfonylpiperazinyl, 1-oxothiomorpholin-4-yl or 1,1-dioxothiomorpholin-4-yl, and 2-oxazolin-2-yl at Ra22 and Ra23.
The heterocyclic group optionally substituted by 1 to 5 substituent(s) selected from group D is that wherein the above-defined heterocyclic group is optionally substituted by 1 to 5 substituent(s), and includes unsubstituted heterocyclic group. The substituent(s) is(are) selected from the substituent(s) of the above-mentioned group D (substituents shown under (a) to (q)).
Examples of the group D here include the substituent(s) exemplified for C6-14 aryl optionally substituted by 1 to 5 substituent(s) selected from group D.
Examples of heterocyclic group optionally substituted by 1 to 5 substituent(s) selected from group D include 2-pyridyl, 3-pyridyl, 4-pyridyl, 3-fluoropyridin-4-yl, 3-chloropyridin-4-yl, 4-chloropyridin-3-yl, pyrazinyl, pyrimidinyl, pyridazinyl, 1,3,5-triazinyl, pyrrolyl, pyrazolyl, imidazolyl, 1,2,4-triazolyl, tetrazolyl, 2-thienyl, 3-thienyl, furyl, oxazolyl, 2-methyloxazol-4-yl, isoxazolyl, thiazolyl, 2-methylthiazol-4-yl, 2,5-dimethylthiazol-4-yl, 2,4-dimethylthiazol-5-yl, isothiazolyl, thiadiazolyl, pyrrolinyl, pyrrolidinyl, imidazolidinyl, piperidyl, N-methylpiperidin-4-yl, N-(tert-butoxycarbonyl)piperidin-4-yl, N-acetylpiperidin-4-yl, N-methylsulfonylpiperidin-4-yl, piperazinyl, morpholinyl, thiomorpholinyl, tetrahydropyranyl, quinolyl, isoquinolyl, quinazolinyl, quinoxalyl, phthalazinyl, cinnolinyl, naphthyridinyl, 5,6,7,8-tetrahydroquinolyl, indolinyl, benzimidazolyl, indolinyl, benzofuranyl, benzothienyl, benzoxazolyl, benzothiazolyl





 

and the like.

In addition, the heterocyclic group may be substituted at the 3-, 4-, 5- or 6-position of 2-pyridyl, at the 2-, 4-, 5- or 6-position of 3-pyridyl, at the 2-, 3-, 5- or 6-position of 4-pyridinyl, at the 3-, 4- or 5-position of 2-thienyl, or at the 2-, 4- or 5-position of 3-thienyl, by fluorine atom, chlorine atom, bromine atom, nitro, methyl, tert-butyl, carboxyl, trifluoromethyl, hydroxymethyl, methoxymethyl, 2-carboxylethyl, methoxy, carbamoyl, methylthio, dimethylaminocarbonyl, methylsulfonyl, amino or acetylamino.
At Z and Z′, the heterocyclic moiety is preferably a heterocyclic group which is a 5-membered or 6-membered monocyclic group. Examples thereof include pyridyl, pyrazinyl, pyrimidinyl, is pyridazinyl, 1,3,5-triazinyl, pyrrolyl, 2-oxopyrrolidinyl, 2-oxopiperidyl, pyrazolyl, imidazolyl, 2-imidazolinyl, 2-oxoimidazolidinyl, 1,2,4-triazolyl, tetrazolyl, thienyl, furyl, oxazolyl, isoxazolyl, 2-oxazolinyl, thiazolyl, isothiazolyl, 1,1-dioxoisothiazolidinyl, thiadiazolyl, pyrrolidinyl, piperidyl, piperazinyl, morpholinyl, thiomorpholinyl, tetrahydropyranyl, Δ2-1,2,4-oxadiazolyl, 5-oxo-Δ2-1,2,4-oxadiazolyl, 5-oxo-Δ2-1,2,4-thiadiazolinyl and 2-oxo-3H-1,2,3,5-oxathiadiazolinyl. The group D here is preferably the above-defined halogen atom, nitro, the above-defined optionally substituted C1-6 alkyl, —(CH2)t—COORa19, —(CH2)t—CONRa27Ra28, —(CH2)t—ORa20, —(CH2)t—NRa29CO—Ra24, —(CH2)t—S(O)q—Ra25 or —(CH2)t—SO2—NHRa26.
Examples of heterocyclic group optionally substituted by 1 to 5 substituent(s) selected from group D preferably include piperidino, 4-hydroxypiperidino, 2-oxopiperidin-1-yl, 1-piperazinyl, 1-pyrrolidinyl, 2-oxopyrrolidin-1-yl, morpholino, 4-thiomorpholinyl, 4-tetrahydropyranyl, 3-pyridyl, 2-pyrimidinyl, 2-imidazolin-2-yl, 2-oxoimidazolidin-1-yl, 2-oxooxazolidin-1-yl, 5-tetrazolyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 2-methylthiazol-4-yl, 5-methylthiazol-2-yl, 2-aminothiazol-4-yl, 3-methyl-1,2,4-oxadiazol-5-yl, 1,1-dioxoisothiazolidin-2-yl, 4,4-dimethyl-Δ2-oxazolin-2-yl, 2-thienyl, 5-chlorothiophen-2-yl, 5-methyloxazol-2-yl, 5-oxo-Δ2-1,2,4-oxadiazolin-3-yl, 5-oxo-Δ2-1,2,4-thiadiazolin-3-yl and 2-oxo-3H-1,2,3,5-oxathiazolin-4-yl.
Particularly preferably, it is pyridyl, pyrimidinyl, tetrazolyl, thienyl, piperidyl, 2-oxopiperidin-1-yl, 2-oxopyrrolidin-1-yl, 2-imidazolin-2-yl, 2-oxoimidazolidin-1-yl, 2-oxooxazolidin-1-yl, 2-methylthiazol-4-yl, 5-methylthiazol-2-yl, 2-aminothiazol-4-yl, 3-methyl-1,2,4-oxadiazol-5-yl, 1,1-dioxoisothiazolidin-2-yl, 4,4-dimethyl-Δ2-oxazolin-2-yl, 5-chlorothiophen-2-yl, 5-methyloxazol-2-yl, 5-oxo-Δ2-1,2,4-oxadiazolin-3-yl, 5-oxo-Δ2-1,2,4-thiadiazolin-3-yl or 2-oxo-3H-1,2,3,5-oxathiadiazolin-4-yl, more preferably 2-oxopiperidin-1-yl, 2-oxopyrrolidin-1-yl, 2-oxoimidazolidin-1-yl, 2-oxooxazolidin-1-yl or 1,1-dioxoisothiazolidin-2-yl, most preferably 2-oxopyrrolidin-1-yl.
The C3-8 cycloalkyl optionally substituted by 1 to 5 substituent(s) selected from group C is that wherein the above-defined C3-8 cycloalkyl is optionally substituted by the 1 to 5 substituent(s) selected from hydroxyl group, the above-defined halogen atom, the above-defined C1-6 alkyl and the above-defined C1-6 alkoxy, which may be unsubstituted. Examples thereof include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, 4-fluorocyclohexyl, 2-methylcyclopentyl, 3-methylcyclohexyl, 4-methylcyclohexyl, 4,4-dimethylcyclohexyl, 3,5-dimethylcyciohexyl, 4-tert-butylcyclohexyl, 4-hydroxycyclohexyl, 4-methoxycyclohexyl and 2,3,4,5,6-pentafluorocyclohexyl.
The cycloalkyl moiety is preferably cyclopentyl or cyclohexyl, particularly preferably cyclohexyl.
At the ring Cy and ring Cy′, the C3-8 cycloalkyl optionally substituted by 1 to 5 substituent(s) selected from group C is preferably cyclopentyl, cyclohexyl, 4-fluorocyclohexyl, 4-methylcyclohexyl, 4,4-dimethylcyclohexyl, 4-tert-butylcyclohexyl, 4-hydroxycyclohexyl or 4-methoxycyclohexyl, more preferably cyclopentyl or cyclohexyl, particularly preferably cyclohexyl.
The C3-8 cycloalkyl optionally substituted by 1 to 5 substituent(s) selected from the above group B is that wherein the above-defined C3-8 cycloalkyl is optionally substituted by 1 to 5 substituent(s), and includes unsubstituted cycloalkyl. The substituents are selected from the above group B.
Specific examples thereof include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, 4-fluorocyclohexyl, 2-methylcyclopentyl, 3-methylcyclohexyl, 4-methylcyclohexyl, 4,4-dimethylcyclohexyl, 3,5-dimethylcyclohexyl, 4-tert-butylcyclohexyl, 4-hydroxycyclohexyl, 4-methoxycyclohexyl and 2,3,4,5,6-pentafluorocyclohexyl.
Also exemplified are those wherein cyclopentyl or cyclohexyl is substituted by fluorine atom, chlorine atom, bromine atom, nitro, methyl, tert-butyl, carboxyl, trifluoromethyl, hydroxymethyl, methoxymethyl, 2-carboxylethyl, methoxy, carbamoyl, methylthio, dimethylaminocarbonyl, methylsulfonyl or acetylamino.
At cycloalkyl moiety, it is preferably cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl. As the C3-8 cycloalkyl optionally substituted by 1 to 5 substituent(s) selected from the above group B, it is particularly preferably cyclopropyl, cyclobutyl, cyclohexyl or 4-hydroxycyclohexyl at Ra27 and Ra28.
The C3-8 cycloalkyl optionally substituted by 1 to 5 substituent(s) selected from group D is that wherein the above-defined C3-8 cycloalkyl is optionally substituted by 1 to 5 substituent(s), and includes unsubstituted cycloalkyl. The substituent(s) is(are) selected from the substituent(s) of the above-mentioned group D (substituents shown under (a) to (q)).
The group D here includes the substituents recited with regard to C6-14 aryl optionally substituted by 1 to 5 substituent(s) selected from group D.
Examples thereof include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, 4-fluorocyclohexyl, 2-methylcyclopentyl, 3-methylcyclohexyl, 4-methylcyclohexyl, 4,4-dimethylcyclohexyl, 3,5-dimethylcyclohexyl, 4-tert-butylcyclohexyl, 4-hydroxycyclohexyl, 4-methoxycyclohexyl and 2,3,4,5,6-pentafluorocyclohexyl.
The group D may be, for example, cyclopentyl or cyclohexyl substituted by fluorine atom, chlorine atom, bromine atom, nitro, methyl, tert-butyl, carboxyl, trifluoromethyl, hydroxymethyl, methoxymethyl, 2-carboxylethyl, methoxy, carbamoyl, methylthio, dimethylaminocarbonyl, methylsulfonyl or acetylamino.
The cycloalkyl moiety is preferably cyclopentyl or cyclohexyl, and at Z and Z′, it is particularly preferably cyclohexyl.
The optionally substituted C3-8 cycloalkenyl is that wherein the above-defined C3-8 cycloalkenyl is optionally substituted by substituent(s) selected from hydroxyl group, the above-defined halogen atom, the above-defined C1-6 alkyl and the above-defined C1-6 alkoxy, which may be unsubstituted. Examples thereof include cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclopentadienyl, cyclohexenyl, 4-fluoro-2-cyclohexenyl, 4-methyl-2-cyclohexenyl, 4-methyl-3-cyclohexenyl, 2,4-cyclohexadien-1-yl, 2,5-cyclohexadien-1-yl, cycloheptenyl and cyclooctenyl and the like, but do not include aryl (e.g., phenyl) or completely saturated cycloalkyl.
The optionally substituted C3-8 cycloalkenyl is particularly preferably cyclohexenyl at the ring Cy.
The C6-14 aryl C1-6 alkyl optionally substituted by 1 to 5 substituent(s) selected from group B is that wherein the above-defined C6-14 aryl C1-6 alkyl is optionally substituted by 1 to 5 substituent(s), and includes unsubstituted arylalkyl. The substituent(s) is(are) selected from the above-mentioned group B.
Examples thereof include benzyl, 1-naphthylmethyl, 2-naphthylmethyl, phenethyl, 3-phenylpropyl, 2-phenylpropyl, 3-fluorobenzyl, 4-fluorobenzyl, 3-chlorobenzyl, 4-chlorobenzyl, 2,4-dichlorobenzyl, 3,5-dichlorobenzyl, pentafluorobenzyl, 4-methylbenzyl, 4-tert-butylbenzyl, 2-trifluoromethylbenzyl, 4-trifluoromethylbenzyl, 4-nitrobenzyl, 4-cyanobenzyl, 4-acetylbenzyl, 4-carboxylbenzyl, 4-carbamoylbenzyl, 4-aminobenzyl, 4-dimethylaminobenzyl, 4-acetylaminobenzyl, 4-(methylsulfonylamino)benzyl, 4-methoxybenzyl, 3,4,5-trimethoxybenzyl, 4-methylthiobenzyl, 4-methylsulfonylbenzyl, 4-aminosulfonylbenzyl, 3-nitro-4-methoxybenzyl and 4-nitro-3-methoxybenzyl.
The C6-14 aryl C1-6 alkyl moiety is preferably benzyl or phenethyl, particularly preferably benzyl. The group B is preferably the above-defined halogen atom, nitro, the above-defined C1-6 alkyl, the above-defined halogenated C1-6 alkyl or —(CH2)r—ORb1. Examples thereof include fluorine atom, chlorine atom, nitro, methyl, tert-butyl, trifluoromethyl, methoxy or trifluoromethyloxy, particularly preferably fluorine atom or chlorine atom.
The specific C6-14 aryl C1-6 alkyl optionally substituted by 1 to 5 substituent(s) selected from group B at Ra12 and Ra13 is preferably benzyl, phenethyl, 3-chlorobenzyl, 4-chlorobenzyl, 4-tert-butylbenzyl or 3-trifluoromethylbenzyl, it is preferably benzyl at Ra1, Ra19, Ra27, Ra28, Ra3l and Rb5, it is preferably benzyl, phenethyl, 4-fluorobenzyl, 2-chlorobenzyl, 3-chlorobenzyl, 4-chlorobenzyl, 4-tert-butylbenzyl or 4-trifluoromethylbenzyl at Ra20, and 4-chlorobenzyl, 3,5-dichlorobenzyl or 4-trifluoromethylbenzyl at Ra22 and Ra23.
It is particularly preferably benzyl at other substituents.
The C6-14 aryl C1-6 alkyl optionally substituted by 1 to 5 substituent(s) selected from group D is that wherein the above-defined C6-14 aryl C1-6 alkyl is optionally substituted by 1 to 5 substituent(s), and includes unsubstituted aryl. The substituent(s) is(are) selected from the substituent(s) of the above-mentioned group D (substituents shown under (a) to (q)).
Examples of group D include fluorine atom, chlorine atom, bromine atom, nitro, cyano, methyl, ethyl, propyl, isopropyl, tert-butyl, trifluoromethyl, hydroxymethyl, 2-hydroxyethyl, methoxymethyl, 2-carboxylethyl, methoxycarbonylmethyl, ethoxycarbonylmethyl, acetyl, carboxyl, methoxycarbonyl, ethoxycarbonyl, carbamoyl, methylaminocarbonyl, isopropylaminocarbonyl, dimethylaminocarbonyl, diethylaminocarbonyl, (2-hydroxyethyl)aminocarbonyl, (carboxylmethyl)aminocarbonyl, hydroxyl group, methoxy, ethoxy, isopropyloxy, hydroxymethyloxy, carboxylmethyloxy, (dimethylaminocarbonyl)methyloxy, amino, methylamino, dimethylamino, diethylamino, acetylamino, methylsulfonylamino, methylthio, methylsulfonyl, methylsulfinyl, aminosulfonyl, methylaminosulfonyl and dimethylaminosulfonyl.
Examples of C6-14 aryl C1-6 alkyl optionally substituted by 1 to 5 substituent(s) selected from group D include benzyl, 1-naphthylmethyl, 2-naphthylmethyl, phenethyl, 3-phenylpropyl, 2-phenylpropyl, 3-fluorobenzyl, 4-fluorobenzyl, 3-chlorobenzyl, 4-chlorobenzyl, 2,4-dichlorobenzyl, 3,5-dichlorobenzyl, 4-bromobenzyl, 4-nitrobenzyl, pentafluorobenzyl, 4-methylbenzyl, 4-tert-butylbenzyl, 2-trifluoromethylbenzyl, 4-trifluoromethylbenzyl, 4-(hydroxymethyl)benzyl, 4-(methoxymethyl)benzyl, 4-(2-carboxylethyl)benzyl, 3-carboxylbenzyl, 4-carboxylbenzyl, 4-methoxybenzyl, 3,4,5-trimethoxybenzyl, 4-carbamoylbenzyl, 4-methylthiobenzyl, 4-(dimethylaminocarbonyl)benzyl, 4-methylsulfonylbenzyl, 4-(acetylamino)benzyl, 4-cyanobenzyl, 4-acetylbenzyl, 4-aminobenzyl, 4-dimethylaminobenzyl, 4-(methylsulfonylamino)benzyl, 4-methylsulfinylbenzyl, 4-aminosulfonylbenzyl, (3-nitro-4-methoxyphenyl)methyl and (4-nitro-3-methoxyphenyl)methyl.
At Z and Z′, the C6-14 aryl C1-6 alkyl moiety is preferably benzyl or phenethyl, and the group D here is preferably the above-defined halogen atom, nitro, the above-defined optionally substituted C1-6 alkyl, —(CH2)t—COORa19, —(CH2)t—CONRa27Ra28, —(CH2)t—ORa20, —(CH2)t—NRa29CO—Ra24, —(CH2)t—S(O)q—Ra25 or —(CH2)t—SO2—NHRa26 .
The C6-14 aryl C1-6 alkyl optionally substituted by 1 to 5 substituent(s) selected from group D is preferably benzyl, 3-fluorobenzyl, 4-fluorobenzyl, 3-chlorobenzyl, 4-chlorobenzyl, 3,5-dichlorobenzyl, 4-bromobenzyl, 4-nitrobenzyl, 4-methylbenzyl, 4-tert-butylbenzyl, 2-trifluoromethylbenzyl, 4-trifluoromethylbenzyl, 4-(hydroxymethyl)benzyl, 4-(methoxymethyl)benzyl, 4-(2-carboxylethyl)benzyl, 3-carboxylbenzyl, 4-carboxylbenzyl, 4-methoxybenzyl, 3,4,5-trimethoxybenzyl, 4-carbamoylbenzyl, 4-methylthiobenzyl, 4-(dimethylaminocarbonyl)benzyl, 4-methylsulfonylbenzyl, 4-acetylaminobenzyl, 4-methylsulfinylbenzyl or 4-aminosulfonylbenzyl.
It is particularly preferably the above-defined halogen atom, the above-defined optionally substituted C1-6 alkyl, —(CH2)t—COORa19, —(CH2)t—CONRa27Ra28, —(CH2)5—ORa20 or —(CH2)t—S(O)q—Ra25. Examples thereof include fluorine atom, chlorine atom, bromine atom, nitro, methyl, tert-butyl, carboxyl, trifluoromethyl, hydroxymethyl, methoxymethyl, 2-carboxylethyl, methoxy, carbamoyl, methylthio, dimethylaminocarbonyl, methylsulfonyl and acetylamino. It is more preferably fluorine atom, chlorine atom, methyl, tert-butyl, carboxyl, methoxy, carbamoyl, methylthio, dimethylaminocarbonyl or methylsulfonyl, most preferably fluorine atom or chlorine atom.
The heterocycle C1-6 alkyl optionally substituted by 1 to 5 substituent(s) selected from group B is that wherein the above-defined heterocycle C1-6 alkyl is optionally substituted by 1 to 5 substituent(s), and includes unsubstituted heterocycle C1-6 alkyl. The substituent(s) is(are) selected from the above-mentioned group B.
Examples thereof include 2-pyridylmethyl, 3-pyridylmethyl, 2-chloropyridin-4-ylmethyl, 4-pyridylmethyl, pyrrolylmethyl, imidazolylmethyl, 2-thienylmethyl, 3-thienylmethyl, 2-furylmethyl, 2-oxazolylmethyl, 5-isothiazolylmethyl, 2-methyloxazol-4-ylmethyl, 2-thiazolylmethyl, 4-thiazolylmethyl, 5-thiazolylmethyl, 2-methylthiazol-4-ylmethyl, 2-methlylthiazol-5-ylmethyl, 2,5-dimethylthiazol-4-ylmethyl, 4-methylthiazol-2-ylmethyl, 2,4-dimethylthiazol-5-ylmethyl, 2-isothiazolylmethyl, 2-pyrrolinylmethyl, pyrrolidinylmethyl, piperidylmethyl, 4-piperidylmethyl, 1-methylpiperidin-4-ylmethyl, 4-hydroxypiperidinomethyl, 3-hydroxypyrrolidinylmethyl, 2-(4-hydroxypiperidino)ethyl, 1-(tert-butoxycarbonyl)piperidin-4-ylmethyl, 1-acetylpiperidin-4-ylmethyl, 1-methylsulfonylpiperidin-4-ylmethyl, piperazinylmethyl, morpholinomethyl, thiomorpholinylmethyl, 1-tetrahydropyranylmethyl, 2-quinolylmethyl, 1-isoquinolylmethyl and the like.
The heterocyclic moiety is preferably a heterocyclic group which is a 5-membered or 6-membered monocyclic group. Examples thereof include pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, 1,3,5-triazinyl, pyrrolyl, pyrazolyl, imidazolyl, 1,2,4-triazolyl, tetrazolyl, thienyl, furyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrrolidinyl, piperidyl, piperazinyl, morpholinyl, thiomorpholinyl and tetrahydropyranyl, and the alkyl moiety thereof is preferably straight chain alkyl having 1 to 4 carbon atoms. The group B here is preferably the above-defined halogen atom, the above-defined C1-6 alkyl, the above-defined halogenated C1-6 alkyl, the above-defined C1-6 alkanoyl, —(CH2)r—COORb1, —(CH2)r—CONRb1Rb2 or —(CH2)r—ORb1.
Examples of heterocycle C1-6 alkyl optionally substituted by 1 to 5 substituent(s) selected from group B preferably include 2-pyridylmethyl, 3-pyridylmethyl, 2-chloropyridin-4-ylmethyl, 4-pyridylmethyl, piperidin-4-ylmethyl, 1-methylpiperidin-4-ylmethyl, 2-(4-hydroxypiperidino)ethyl, 1-acetylpiperidin-4-ylmethyl, 1-(tert-butoxycarbonyl)piperidin-4-ylmethyl, 1-(methylsulfonyl)-piperidin-4-ylmethyl, 2-thiazolylmethyl, 4-thiazolylmethyl, 2-methylthiazolin-4-ylmethyl, 2,4-dimethylthiazolin-5-ylmethyl and 4-methylthiazol-2-ylmethyl. Particularly preferably, it is 2-pyridylmethyl, 3-pyridylmethyl, 2-chloropyridin-4-ylmethyl, 4-pyridylmethyl, piperidin-4-ylmethyl, 1-methylpiperidin-4-ylmethyl, 2-(4-hydroxypiperidino)ethyl, 1-acetylpiperidin-4-ylmethyl, 1-(tert-butoxycarbonyl)piperidin-4-ylmethyl, 1-(methylsulfonyl)piperidin-4-ylmethyl, 2-methylthiazolin-4-ylmethyl, 2,4-dimethylthiazolin-5-ylmethyl or 4-methylthiazol-2-ylmethyl at Ra20, 2-pyridylmethyl at Ra22 and Ra23, and 4-pyridylmethyl or 4-methylthiazol-2-ylmethyl at Ra27 and Ra28.
The heterocycle C1-6 alkyl optionally substituted by 1 to 5 substituent(s) selected from group D is that wherein the above-defined heterocycle C1-6 alkyl is optionally substituted by 1 to 5 substituent(s), and includes unsubstituted heterocycle C1-6 alkyl. The substituent(s) is(are) selected from the above-mentioned group D (substituents shown under (a) to (q)).
Examples of group D here include fluorine atom, chlorine atom, bromine atom, nitro, cyano, methyl, ethyl, propyl, isopropyl, tert-butyl, trifluoromethyl, hydroxymethyl, 2-hydroxyethyl, methoxymethyl, 2-carboxylethyl, methoxycarbonylmethyl, ethoxycarbonylmethyl, acetyl, carboxyl, methoxycarbonyl, ethoxycarbonyl, carbamoyl, methylaminocarbonyl, isopropylaminocarbonyl, dimethylaminocarbonyl, diethylaminocarbonyl, (2-hydroxyethyl)aminocarbonyl, (carboxylmethyl)aminocarbonyl, hydroxyl group, methoxy, ethoxy, isopropyloxy, hydroxymethyloxy, carboxylmethyloxy, (dimethylaminocarbonyl)methyloxy, amino, methylamino, dimethylamino, diethylamino, acetylamino, methylsulfonylamino, methyltiio, methylsulfonyl, methylsulfinyl, aminosulfonyl, methylaminosulfonyl and dimethylaminosulfonyl.
Examples of heterocycle C1-6 alkyl optionally substituted by 1 to 5 substituent(s) selected from group D include 2-pyridylmethyl, 3-pyridylmethyl, 2-chloropyridin-4-ylmethyl, 4-pyridylmethyl, pyrrolylmethyl, imidazolylmethyl, 2-thienylmethyl, 3-thienylmethyl, 2-furylmethyl, 2-oxazolylmethyl, 5-isothiazolylmethyl, 2-methyloxazol-4-ylmethyl, 2-thiazolylmethyl, 4-thiazolylmethyl, 5-thiazolylmethyl, 2-methylthiazol-4-ylmethyl, 2-methylthiazol-5-ylmethyl, 2,5-dimethylthiazol-4-ylmethyl, 4-methylthiazol-2-ylmethyl, 2,4-dimethylthiazol-5-ylmethyl, 2-isothiazolylmethyl, 2-pyrrolinylmethyl, pyrrolidinylmethyl, piperidylmethyl, 4-piperidylmethyl, 1-methylpiperidin-4-ylmethyl, 4-hydroxypiperidinomethyl, 2-(4-hydroxypiperidino)ethyl, 1-(tert-butoxycarbonyl)piperidin-4-ylmethyl, 1-acetylpiperidin-4-ylmethyl, 1-methylsulfonylpiperidin-4-ylmethyl, piperazinylmethyl, morpholinomethyl, thiomorpholinylmethyl, 1-tetrahydropyranylmethyl, 2-quinolylmethyl, 1-isoquinolylmethyl, and the like.
Preferable heterocyclic moiety at Z and Z′ is heterocylic group which is 5-membered or 6-membered monocyclic group. Examples of the heterocyclic moiety include pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, 1,3,5-triazinyl, pyrrolyl, pyrazolyl, imidazolyl, 1,2,4-triazolyl, tetrazolyl, thienyl, furyl, oxazolyl, isooxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrrolidinyl, piperidyl, piperazinyl, morpholinyl, thiomorpholinyl and tetrahydropyranyl, and the alkyl moiety is preferably straight chain alkyl having 1 to 4 carbon atoms, particularly methyl (i.e., methylene).
Preferable group D is the above-defined halogen atom, nitro, the above-defined optionally substituted C1-6 alkyl, (CH2)t—COORa19, —(CH2)t—CONRa27Ra28, —(CH2)t—(CH2)tORa20, —(CH2)t—NRa29CO—Ra24, —(CH2)t—S(O)a—Ra25 or —(CH2)t—SO2—NHRa26.
Preferable examples of heterocycle C1-6 alkyl optionally substituted by 1 to 5 substituent(s) selected from group D include 2-pyridylmethyl, 3-pyridylmethyl, 2-chloropyridin-4-ylmethyl, 4-pyridylmethyl, piperidin-4-ylmethyl, 1-methylpiperidin-4-ylmethyl, 4-hydroxypiperidinomethyl, 2-(4-hydroxypiperidino)ethyl, 1-acetylpiperidin-4-ylmethyl, 1-(tert-butoxycarbonyl)piperidin-4-ylmethyl, 1-(methylsulfonyl)piperidin-4-ylmethyl, 2-thiazolylmethyl, 4-thiazolylmethyl, 2-methylthiazolin-4-ylmethyl, 2,4-dimethylthiazolin-5-ylmethyl and 4-methylthiazol-2-ylmethyl.
Particularly preferred is 4-hydroxypiperidinomethyl.
The C3-8 cycloalkyl C1-6 alkyl optionally substituted by 1 to 5 substituent(s) selected from the above group B is that wherein the above-defined C3-8 cycloalkyl C1-6 alkyl is optionally substituted by 1 to 5 substituent(s), and includes unsubstituted cycloalkylalkyl. The substituents are selected from the above group B.
Specific examples thereof include cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, 2-(cyclopentyl)ethyl, 2-(cyclohexyl)ethyl, cycloheptylmethyl, 4-fluorocyclohexylmethyl, 2-methylcyclopentylmethyl, 3-methylcyclohexylmethyl, 4-methylcyclohexylmethyl, 4,4-dimethylcyclohexylmethyl, 3,5-dimethylcyclohexylmethyl, 4-tert-butylcyclohexylmethyl, 4-hydroxycyclohexylmethyl, 4-methoxycyclohexylmethyl and 2,3,4,5,6-pentafluorocyclohexylmethyl.
Also exemplified are those wherein cyclopentylmethyl or cyclohexylmethyl is substituted by fluorine atom, chlorine atom, bromine atom, nito, methyl, tert-butyl, carboxyl, trifluoromethyl, hydroxymethyl, methoxymethyl, 2-carboxylethyl, methoxy, carbamoyl, methylthio, dimethylaminocarbonyl, methylsulfonyl or acetylamino.
At cycloalkyl moiety, it is preferably cyclopentylmethyl or cyclohexylmethyl, and at Ra20, Ra27 and Ra28, it is particularly preferably cyclohexylmethyl.
The carboxyl-protecting group only needs to be suitable for reaction conditions, and is capable of protecting and deprotecting and may be, for example, methyl; substituted methyl group such as methoxymethyl, methylthiomethyl, 2-tetrahydropyranyl, methoxyethoxymethyl, benzyloxymethyl, phenacyl, diacylmethyl, phthalimidomethyl etc.; ethyl; substituted ethyl group such as 2,2,2-trichloroethyl, 2-chloroethyl, 2-(trimethylsilyl)ethyl, 2-methylthioethyl, 2-(p-toluenesulfonyl)ethyl, t-butyl etc.; benzyl; substituted benzyl group such as diphenylmethyl, triphenylmethyl, p-nitrobenzyl, 4-picolyl, p-methoxybenzyl, 2-(9,10-dioxo)anthrylmethyl etc.; silyl group such as trimethylsilyl, t-butyldimethylsilyl, phenyldimethylsilyl etc.; and the like.
Preferred are industrially effective protecting groups and specifically preferred as Ra36 are methyl and ethyl.
In formula [I], X is preferably





 

wherein each symbol is as defined above.

G1, G2, G3 and G4 are each preferably (C—R1), (C—R2), (C—R3) and (C—R4), G5 is preferably a nitrogen atom, and G6, G8 and G9 are preferably a carbon atom. G7 is preferably C(—R7) or unsubstituted nitrogen atom, wherein R7 is preferably hydrogen atom.
A preferable combination is G2 of (C—R2) and G6 of a carbon atom, particularly preferably G2 of (C—R2), G6 of a carbon atom and G5 of a nitrogen atom, most preferably G2 of (C—R2), G6 of a carbon atom, G5 of a nitrogen atom and G7 of unsubstituted nitrogen atom.
In formulas [I] and [II], 1 to 4 of G1 to G9 in the moiety





 

is(are) preferably a nitrogen atom, specifically preferably








 

It is also a preferable embodiment wherein the moiety is aromatic ring.





 

R1 and R3 are preferably hydrogen atom or —ORa6 (Ra6 is as defined above), particularly preferably hydrogen atom. R2 is preferably carboxyl, —COORa1, —CONRa2Ra3, —SO2Ra7 (each symbol is as defined above) or heterocyclic group having 1 to 4 heteroatom(s) selected from an oxygen atom, a nitrogen atom and a sulfur atom, particularly preferably carboxyl, —COORa1 or —SO2Ra7, more preferably carboxyl or —COORa1, most preferably carboxyl. R4 is preferably hydrogen atom.
Ra1 is preferably optionally substituted C1-6 alkyl.
When R2 is carboxyl or —COORa1, at least one of R1, R3 and R4 is preferably hydroxyl group, halogen atom (particularly fluorine atom, chlorine atom) or —ORa6 (wherein Ra6 is preferably hydrogen atom or methyl).
The ring Cy and ring Cy′ are preferably cyclopentyl, cyclohexyl, cycloheptyl, tetrahydrothiopyranyl or piperidino, particularly preferably cyclopentyl, cyclohexyl or cycloheptyl, more preferably cyclohexyl.
The ring A and ring A′ are preferably phenyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, cyclohexyl, cyclohexenyl, furyl or thienyl, particularly preferably phenyl, pyridyl, pyrazinyl, pyrimidinyl or pyridazinyl, more preferably phenyl or pyridyl, and most preferably phenyl.
The ring B and ring B′ are preferably C1-6 aryl or heterocyclic group, specifically preferably, phenyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, 1,3,5-triazinyl, pyrrolyl, pyrazolyl, imidazolyl, 1,2,4-triazolyl, tetrazolyl, thienyl, furyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl or thiadiazolyl, particularly preferably phenyl, pyridyl, pyrimidinyl, 1,3,5-triazinyl or thiazolyl, more preferably, phenyl, pyridyl or thiazolyl, and most preferably phenyl or thiazolyl.
With regard to R5 and R6, one of them is preferably hydrogen atom and the other is halogen atom, particularly fluorine atom. Alternatively, the both are preferably hydrogen atoms. When ring A is phenyl, R5 and R6 preferably are present at an ortho position from G6. The same applies to R5, and R6′.
Y is preferably —(CH2)m—O—(CH2)n—, —NHCO2—, —CONH—CHRa14—, —(CH2)m—NRa12—(CH2)n—, —CONRa13—(CH2)n—, —O—(CH2)m—CRa15Ra16—(CH2)n— or —(CH2)n—NRa12—CHRa15— (each symbol is as defined above), more preferably, —(CH2)m—O—(CH2)n— or —O—(CH2)m—CRa15Ra16—(CH2)n—, most preferably —(CH2)m—O—(CH2)n—.
The l, m and n are preferably 0 or an integer of 1 to 4, particularly preferably 0, 1 or 2, at Y. In —(CH2)m—O—(CH2)n—, m=n=0 or m=0 and n=1 is more preferable, most preferably m=0 and n=1. In —O—(CH2)m—CRa15Ra16—(CH2)n—, m=n=0, m=0 and n=1, m=1 and n=0 or m=1 and n=1 is more preferable, most preferably m=0 and n=1.
When Y is —O—(CH2)m—CRa15Ra16—(CH2)n—, Ra16 is preferably hydrogen atom, Ra15 is preferably





 

moiety is preferably symmetric. The preferable mode of n, ring B, Z and w and the preferable mode of n′, ring B′, Z′ and w′ are the same.

When ring A is phenyl, X or Y is preferably present at the para-position relative to G6. When ring B and ring B′ are phenyl, Z is preferably present at the ortho or meta-position relative to Y. It is preferable that the 3-position on phenyl have one substituent or the 2-position and the 5-position on phenyl each have one substituent.
When ring B is bonded to Y as pyridin-2-yl, Z is preferably substituted at the 3-position and 6-position of pyridyl; when it is bonded to Y as pyridin-3-yl, Z is preferably substituted at the 2-position and 5-position of pyridyl; and when it is bonded to Y as pyridin-4-yl, Z is preferably substituted at the 2-position and 5-position of pyridyl.
When ring B is thiazolyl, Y is preferably substituted at the 5-position, and Z is preferably substituted at the 2-position, the 4-position or the 2-position and the 4-position. Similarly, when ring B′ is thiazolyl, (CH2)n is also preferably substituted at the 5-position, and Z′ is preferably substituted at the 2-position, the 4-position or the 2-position and the 4-position.
Z and Z′ are preferably group D, “C6-14 aryl optionally substituted by 1 to 5 substituent(s) selected from group D” or “heterocyclic group optionally substituted by 1 to 5 substituent(s) selected from group D”, particularly preferably group D or “C6-14 aryl optionally substituted by 1 to 5 substituent(s) selected from group D”.
More preferably, they are the above-defined halogen atom, nitro, the above-defined optionally substituted C1-6 alkyl, —(CH2)t—COORa19, —(CH2)t—CONRa27Ra28, —(CH2)t—ORa20, —(CH2)t—NRa29CO—Ra24, —(CH2)t—S(O)q—Ra25 or —(CH2)t—SO2—NHRa26, or C6-14 aryl or heterocyclic group optionally substituted by these.
With regard to Z and Z′, the preferable mode of group D that directly substitutes each ring B and ring B′ and the preferable mode of group D that substitutes C6-14 aryl, C3-8 cycloalkyl, C6-14 aryl C1-6 alkyl or heterocyclic group are the same, wherein they may be the same with or different from each other.
Specific examples of the substituent preferably include fluorine atom, chlorine atom, bromine atom, nitro, cyano, methyl, ethyl, propyl, isopropyl, tert-butyl, trifluoromethyl, hydroxymethyl, 2-hydroxyethyl, methoxymethyl, 2-carboxylethyl, methoxycarbonylmethyl, ethoxycarbonylmethyl, carbamoylmethoxymethyl, (dimethylaminocarbonyl)methoxymethyl, acetyl, isovaleryl, carboxyl, methoxycarbonyl, ethoxycarbonyl, carbamoyl, methylaminocarbonyl, hydroxyaminocarbonyl, ethylaminocarbonyl, propylaminocarbonyl, isopropylaminocarbonyl, butylaminocarbonyl, isobutylaminocarbonyl, tert-butylaminocarbonyl, (4-hydroxybutyl)aminocarbonyl, (1-hydroxypropan-2-yl)aminocarbonyl, (2,3-dihydroxypropyl)aminocarbonyl, (1,3-dihydroxypropan-2-yl)aminocarbonyl, methoxyaminocarbonyl, {2-[2-(methoxy)ethoxy]ethyl}aminocarbonyl, N-ethyl-N-methylaminocarbonyl, N-methyl-N-propylaminocarbonyl, N-isopropyl-N-methylaminocarbonyl, dimethylaminocarbonyl, diethylaminocarbonyl, (2-hydroxyethyl)aminocarbonyl, (2-hydroxy-2-methylpropan-2-yl)aminocarbonyl, (carboxylmethyl)aminocarbonyl, hydroxyl group, methoxy, ethoxy, propyloxy, isopropyloxy, butyloxy, isopentyloxy, 2-isopentenyloxy, 3-isohexenyloxy, 4-methyl-3-pentenyloxy, 2-propynyloxy, trifluoromethyloxy, hydroxymethyloxy, carboxylmethyloxy, (dimethylaminocarbonyl)methyloxy, amino, methylamino, dimethylamino, diethylamino, acetylamino, N-acetyl-N-methylamino, N-acetyl-N-ethylamino, N-acetyl-N-propylamino, N-acetyl-N-isopropylamino, N-ethylcarbonyl-N-methylamino, N-ethyl-N-(ethylcarbonyl)amino, ureido, isopropylcarbonylamino, isobutylcarbonylamino, tert-butylcarbonylamino, (ethylamino)carbonylamino, (isopropylamino)carbonylamino, (dimethylamino)carbonylamino, (4-hydroxypiperidino)carbonylamino, [(4-hydroxypiperidino)methyl]carbonylamino, [(3-hydroxypyrrolidinyl)methyl]carbonylamino, methylsulfonylamino, isopropylsulfonylamino, N-(methylsulfonyl)-N-methylamino, N-(ethylsulfonyl)-N-methylamino, N-(isopropylsulfonyl)-N-methylamino, N-(methylsulfonyl)-N-ethylamino, N-(methylsulfonyl)-N-propylamino, N-(ethylsulfonyl)-N-ethylamino, methylthio, methylsulfonyl, isopropylsulfonyl, isobutylsulfonyl, methylsulfinyl, isopropylsulfinyl, aminosulfonyl, methylaminosulfonyl, dimethylaminosulfonyl, isopropylaminosulfonyl, tert-butylaminosulfonyl, hydroxyamidino, phenyl, 3-fluorophenyl, 4-fluorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2,4-difluorophenyl, 3,4-difluorophenyl, 3,4-dichlorophenyl, 3,5-dichlorophenyl, 4-chloro-3-fluorophenyl, 4-chloro-2-fluorophenyl, 4-bromophenyl, 4-nitrophenyl, 4-cyanophenyl, 4-methylphenyl, 4-ethylphenyl, 4-propylphenyl, 4-isopropylphenyl, 4-tert-butylphenyl, 2-trifluoromethylphenyl, 4-trifluoromethylphenyl, 4-(hydroxymethyl)phenyl, 4-(2-hydroxyethyl)phenyl, 4-(methoxymethyl)phenyl, 4-(2-carboxylethyl)phenyl, 4-(methoxycarbonylmethyl)phenyl, 4-(ethoxycarbonylmethyl)phenyl, 4-acetylphenyl, 3-carboxylphenyl, 4-carboxylphenyl, 4-(methoxycarbonyl)phenyl, 4-(ethoxycarbonyl)phenyl, 4-carbamoylphenyl, 4-(methylaminocarbonyl)phenyl, 4-(isopropylaminocarbonyl)phenyl, 4-(dimethylaminocarbonyl)phenyl, 4-(diethylaminocarbonyl)phenyl, 4-[(2-hydroxyethyl)aminocarbonyl]phenyl, 4-[(carboxylmethyl)aminocarbonyl]phenyl, 4-hydroxyphenyl, 4-methoxyphenyl, 3,4,5-trimethoxyphenyl, 4-ethoxyphenyl, 4-propyloxyphenyl, 4-isopropyloxyphenyl, 4-butyloxyphenyl, 4-isopentyloxyphenyl, 4-(2-isopentenyloxy)phenyl, 4-(3-isohexenyloxy)phenyl, 4-(4-methyl-3-pentenyloxy)phenyl, 4-(2-propynyloxy)phenyl, 4-(trifluoromethyloxy)phenyl, 4-(hydroxymethyloxy)phenyl, 4-(carboxylmethyloxy)phenyl, 4-[(dimethylaminocarbonyl)methyloxy]phenyl, 4-aminophenyl, 4-(methylamino)phenyl, 4-(dimethylaminophenyl), 4-(diethylamino)phenyl, 4-(acetylamino)phenyl, N-acetyl-N-methylamino, 4-(N-acetyl-N-methylamino)phenyl, 4-(N-acetyl-N-ethylamino)phenyl, 4-(N-acetyl-N-propylamino)phenyl, 4-(N-acetyl-N-isopropylamino)phenyl, 4-(N-ethylcarbonyl-N-methylamino)phenyl, 4-[N-ethyl-N-(ethylcarbonyl)amino]phenyl, 4-(methylsulfonylamino)phenyl, 4-(methylthio)phenyl, 4-(methylsulfonyl)phenyl, 4-(methylsulfinyl)phenyl, 4-(aminosulfonyl)phenyl, 4-(methylaminosulfonyl)phenyl, 4-(dimethylaminosulfonyl)phenyl, 4-(tert-butylaminosulfonyl)phenyl, tetrazol-5-ylphenyl, cyclohexyl, benzyl, 4-chlorobenzyl, phenethyl, benzyloxy, 4-fluorobenzyloxy, 2-chlorobenzyloxy, 3-chlorobenzyloxy, 4-chlorobenzyloxy, 4-tert-butylbenzyloxy, 4-trifluoromethylbenzyloxy, phenethyloxy, 2-thienyl, 2-thiazolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 6-fluoropyridin-3-yl, 5-fluoropyridin-2-yl, 6-chloropyridin-3-yl, 6-methylpyridin-3-yl, 2-pyrimidinyl, 5-tetrazolyl, piperidino, 2-oxopiperidin-1-yl, 2-oxopyrrolidin-1-yl, 2-imidazolin-2-yl, 2-oxoimidazolidin-1-yl, 2-oxooxazolidin-1-yl, 2-methylthiazol-4-yl, 5-methylthiazol-2-yl, 2-aminothiazol-4-yl, 3-methyl-1,2,4-oxadiazol-5-yl, 1,1-dioxoisothiazolidin-2-yl, 4,4-dimethyl-Δ2-oxazolin-2-yl, 5-chlorothiophen-2-yl, 5-methyloxazol-2-yl, 5-oxo-Δ2-1,2,4-oxadiazolin-3-yl, 5-oxo-Δ2-1,2,4-thiadiazolin-3-yl, 2-oxo-3H-1,2,3,5-oxathiadiazolin-4-yl, 4-hydroxypiperidinomethyl, piperidinocarbonyl, 4-hydroxypiperidinocarbonyl, 3,4-dihydroxypiperidinocarbonyl, 1-piperazinylcarbonyl, 1-pyrrolidinylcarbonyl, morpholinocarbonyl, 4-thiomorpholinylcarbonyl, phenoxy, 2,4-dichlorophenoxy, tetrahydropyranyloxy, 2-pyridylmethyloxy, 3-pyridylmethyloxy, 2-chloropyridin-4-ylmethyloxy, 4-pyridylmethyloxy, 2-piperidylmethyloxy, 3-piperidylmethyloxy, 4-piperidylmethyloxy, 1-methylpiperidin-4-ylmethyloxy, 1-acetylpiperidin-4-ylmethyloxy, 1-(tert-butoxycarbonyl)piperidin-4-ylmethyloxy, 1-(methylsulfonyl)piperidin-4-ylmethyloxy, 2-methylthiazolin-4-yloxy, 2,4-dimethylthiazolin-5-yloxy, dimethylaminocarbonylmethyloxy, piperidinocarbonylmethyloxy, 4-hydroxypiperidinocarbonylmethyloxy, 2-methylthiazol-4-yl, (2-methylthiazol-4-yl)methyloxy, (2,4-dimethylthiazol-5-yl)methyloxy, benzoyl, 3-fluorobenzoyl, 4-chlorobenzylamino, 3,5-dichlorobenzylamino, 4-trifluoromethylbenzylamino, 2-pyridylmethylamino, benzoylamino, 4-chlorobenzoylamino, 4-trifluoromethylbenzoylamino, 3,5-dichlorobenzoylamino, 3-nitro-4-methoxybenzoylamino, 4-nitro-3-methoxybenzoylamino, 3-pyridylcarbonylamino, 4-morpholinocarbonylamino, 2-oxazolinylamino, 4-hydroxypiperidinosulfonyl, methylphenylsulfonylamino, 2-thiazolylaminosulfonyl, 2-pyridylaminosulfonyl, benzylaminocarbonyl, N-benzyl-N-methylaminocarbonyl, (4-pyridylmethyl)aminocarbonyl or (cyclohexylmethyl)aminocarbonyl, 2-hydroxyethyloxy, 3-hydroxypropyloxy, 2-methoxyethoxy, 2-(2-methoxyethoxy)ethoxy, azetidinylcarbonyl, 3-hydroxypyrrolidinylcarbonyl, 3-hydroxypiperidinocarbonyl, 4-hydroxypiperidinocarbonyl, 3,4-dihydroxypiperidinocarbonyl, 4-methoxypiperidinocarbonyl, 4-carboxypiperidinocarbonyl, 4-(hydroxymethyl)piperidinocarbonyl, 2-oxopiperidinocarbonyl, 4-oxopiperidinocarbonyl, 2,6-dimethylpiperidinocarbonyl, 2,2,6,6-tetramethylpiperidinocarbonyl, 2,2,6,6-tetramethyl-4-hydroxypiperidinocarbonyl, 1-oxothiomorpholin-4-ylcarbonyl, 1,1-dioxothiomorpholin-4-ylcarbonyl, 1-(methylsulfonyl)piperidin-4-ylaminocarbonyl, 4-methylsulfonylpiperazinylcarbonyl, 4-methylpiperazinylcarbonyl, N,N-bis(2-hydroxyethyl)aminocarbonyl, phenylaminocarbonyl, cyclopropylaminocarbonyl, cyclobutylaminocarbonyl, cyclohexylaminocarbonyl, 4-hydroxycyclohexylaminocarbonyl, 4-methylthiazol-2-ylmethylaminocarbonyl, 2-(4-hydroxypiperidino)ethyloxy, 2-pyridylmethylaminocarbonyl, 3-pyridylmethylaminocarbonyl, N-methyl-N-(4-pyridylmethyl)aminocarbonyl, cyclohexylmethyloxy, 4-hydroxypiperidinocarbonylmethyloxy and 4-methylthiazol-2-ylmethyloxy.
Particularly preferable examples of the substituent include fluorine atom, chlorine atom, bromine atom, nitro, cyano, methyl, hydroxymethyl, carboxyl, carbamoyl, methylaminocarbonyl, isopropylaminocarbonyl, dimethylaminocarbonyl, diethylaminocarbonyl, (2-hydroxylethyl)aminocarbonyl, (carboxymethyl)aminocarbonyl, methoxy, 2-isopentenyloxy, 2-propynyloxy, methylthio, methylamino, dimethylamino, acetylamino, N-acetyl-N-methylamino, N-acetyl-N-ethylamino, N-acetyl-N-propylamino, N-acetyl-N-isopropylamino, N-ethylcarbonyl-N-methylamino, N-ethyl-N-(ethylcarbonyl)amino, methylsulfonylamino, methylsulfonyl, aminosulfonyl, dimethylaminosulfonyl, tert-butylaminosulfonyl, phenyl, 3-fluorophenyl, 4-fluorophenyl, 3-chlorophenyl, 4-chlorophenyl, 3,5-dichlorophenyl, 4-nitrophenyl, 4-methylphenyl, 4-tert-butylphenyl, 4-trifluoromethylphenyl, 4-(methoxymethyl)phenyl, 4-(2-hydroxylethyl)phenyl, 3-carboxylphenyl, 4-carboxylphenyl, 4-methoxyphenyl, 4-carbamoylphenyl, 4-methylthiophenyl, 4-(dimethylaminocarbonyl)phenyl, 4-methylsulfonylphenyl, benzyl, phenethyl, benzyloxy, 4-fluorobenzyloxy, 4-chlorobenzyloxy, 2-thiazolyl, 3-pyridyl, 4-pyridyl, 4-pyridylmethyloxy, 2-piperidylmethyloxy, 3-piperidylmethyloxy, 4-piperidylmethyloxy, 1-methylpiperidin-4-ylmethyloxy, 1-acetylpiperidin-4-ylmethyloxy, 2-chloropiperidin-4-ylmethyloxy, 1-(methylsulfonyl)piperidin-4-ylmethyloxy, 2-methylthiazol-4-yl, (2-methylthiazol-4-yl)methyloxy, (2,4-dimethylthiazol-5-yl)methyloxy, 5-tetrazolyl, 3-fluorobenzoyl, piperidinocarbonyl, 4-hydroxylpiperidinocarbonyl, 1-pyrrolidinylcarbonyl, morpholinocarbonyl, 4-thiomorpholinylcarbonyl, benzylaminocarbonyl, N-benzyl-N-methylaminocarbonyl, (4-pyridylmethyl)aminocarbonyl and (cyclohexylmethyl)aminocarbonyl.
Most preferable substituents are fluorine atom, chlorine atom, methyl, hydroxymethyl, carboxyl, carbamoyl, methylaminocarbonyl, dimethylaminocarbonyl, methoxy, methylamino, acetylamino, aminosulfonyl, dimethylaminosulfonyl, tert-butylaminosulfonyl, phenyl, 3-fluorophenyl, 4-fluorophenyl, 3-chlorophenyl, 4-chlorophenyl, 3,5-dichlorophenyl, 4-methylphenyl, 4-tert-butylphenyl, 4-trifluoromethylphenyl, 4-carboxylphenyl, 4-methoxyphenyl, 4-carbamoylphenyl, 4-methylthiophenyl, 4-(dimethylaminocarbonyl)phenyl, 4-methylsulfonylphenyl and 2-oxopyrrolidin-1-yl.
The w is preferably 1 or 2, r and t are preferably 0, 1 or 2, particularly preferably 0 or 1, more preferably 0, p is preferably 1, and q is preferably 0 or 2.
In formula [I], when X is





 

wherein each symbol is as defined above and w is 2 or above, one of Z is preferably C6-14 aryl optionally substituted by 1 to 5 substituent(s) selected from group D or heterocyclic group optionally substituted by 1 to 5 substituent(s) selected from group D, particularly preferably C6-14 aryl optionally substituted by 1 to 5 substituent(s) selected from group D.

When ring B is phenyl, w is 2 and phenyl is bonded to Y at the 1-position, one of the most preferable embodiments is that wherein Z is bonded to the 2-position and 5-position of phenyl, Z at the 2-position is “C6-14 aryl optionally substituted by 1 to 5 substituent(s) selected from group D” and Z at the 5-position is “heterocyclic group optionally substituted by 1 to 5 substituent(s) selected from group D”.
The pharmaceutically acceptable salt may be any as long as it forms a non-toxic salt with a compound of the above-mentioned formula [I] or [II]. Such salt can be obtained by reacting the compound with an inorganic acid, such as hydrochloric acid, sulfuric acid, phosphoric acid, hydrobromic acid and the like, or an organic acid, such as oxalic acid, malonic acid, citric acid, fumaric acid, lactic acid, malic acid, succinic acid, tartaric acid, acetic acid, trifluoroacetic acid, gluconic acid, ascorbic acid, methylsulfonic acid, benzylsulfonic acid, meglumine acid and the like, or an inorganic base, such as sodium hydroxide, potassium hydroxide, calcium hydroxide, magnesium hydroxide, ammonium hydroxide and the like, or an organic base, such as methylamine, diethylamine, triethylamine, triethanolamine, ethylenediamine, tris(hydroxymethyl)methylamine, guanidine, choline, cinchonine and the like, with an amino acid, such as lysine, arginine, alanine and the like. The present invention encompasses water-retaining product, hydrate and solvate of each compound.
The compounds of the above-mentioned formula [I] or [II] have various isomers. For example, E compound and Z compound are present as geometric isomers, and when the compound has an asymmetric carbon, an enantiomer and a diastereomer are present due to the asymmetric carbon. A tautomer may be also present. The present invention encompasses all of these isomers and mixtures thereof.
The present invention also encompasses prodrug and metabolite of each compound.
A prodrug means a derivative of the compound of the present invention, which is capable of chemical or metabolic decomposition, which shows inherent efficacy by reverting to the original compound after administration to a body, and which includes salts and complexes without a covalent bond.
When the inventive compound is used as a pharmaceutical preparation, the inventive compound is generally admixed with pharmaceutically acceptable carriers, excipients, diluents, binders, disintegrators, stabilizers, preservatives, buffers, emulsifiers, aromatics, coloring agents, sweeteners, thickeners, correctives, solubilizers, and other additives such as water, vegetable oil, alcohol such as ethanol, benzyl alcohol and the like, polyethylene glycol, glycerol triacetate, gelatin, lactose, carbohydrate such as starch and the like, magnesium stearate, talc, lanolin, petrolatum and the like, and prepared into a dosage form of tablets, pills, powders, granules, suppositories, injections, eye drops, liquids, capsules, troches, aerosols, elixirs, suspensions, emulsions, syrups and the like, which can be administered systemically or topically and orally or parenterally.
While the dose varies depending on the age, body weight, general condition, treatment effect, administration route and the like, it is from 0.1 mg to 1 g for an adult per dose, which is given one to several times a day.
The prophylaxis of hepatitis C means, for example, administration of a pharmaceutical agent to an individual found to carry an HCV by a test and the like but without a symptom of hepatitis C, or to an individual who shows an improved disease state of hepatitis after a treatment of hepatitis C, but who still carries an HCV and is associated with a risk of recurrence of hepatitis.
The therapeutic agent for hepatitis C of the present invention is expected to provide a synergestic effect when concurrently used with other antiviral agents, antiinflammatory agents or immunostimulants.
The medicaments with the prospect of synergestic effect include, for example, interferon-α, interferon-β, interferon-γ, interleukin-2, interleukin-8, interleukin-10, interleukin-12, TNFα, recombinant or modified products thereof, agonists, antibodies, vaccines, ribozymes, antisense nucleotides and the like.
As evidenced in the combination therapy of anti-HIV agents, which is also called a cocktail therapy, the combined use of various anti-virus agents againt viruses showing frequent genetic mutations is expected to show effect for suppressing emergence and increase of drug tolerant viruses. For example, 2 or 3 agents from HCV-IRES inhibitors, HCV-NS3 protease inhibitors, HCV-NS2NS3 protease inhibitors, HCV-NS5A inhibitors and HCV polymerase inhibitor may be used in combination. Specifically, the combined use with Ribavirin(R), interferon-α (IFN-α, Roferon(R), Intron A(R), Sumiferon(R), MultiFeron(R), Infergen(R), Omniferon(R), Pegasys(R), PEG-Intron A(R)), interferon-β (Frone(R), Rebif(R), AvoneX(R), IFNβMOCHIDA(R)), interferon-ω, 1-β-L-ribofuranosyl-1H-1,2,4-triazole-3-carboxamide, 16α-bromo-3β-hydroxy-5α-androstan-17-one, 1H-imidazole-4-ethanamide dihydrochloride, HCV ribozyme Heptazyme(R), polyclonal antibody Civacir(R), lactoferrin GPX-400, (1S,2R,8R,8aR)-1,2,8-trihydroxyoctahydroindolizidinium chloride, HCV vaccine (MTH-68/B, Innivax C(R), Engerix B(R)), antisense oligonucleotide ISIS-14803, HCV-RNA transcriptase inhibitor VP-50406, tetrachlorodecaoxide (high concentration Oxoferin(R)), tetrahydrofuran-3-yl (S)-N-3-[3-(3-methoxy-4-oxazol-5-ylphenyl)ureido]benzylcarbamate, 4-amino-2-ethoxymethyl-α,α-dimethyl-1H-imidazo[4,5-c]quinoline-1-ethanol, interleukin-2 (Proleukin(R)), thymosin α1 and the like is exemplified, wherein (R) shows product names.
Furthermore, the combined use with the compounds disclosed in JP-A-08-268890, JP-A-10-101591, JP-A-07-069899, WO99/61613 and the like as HCV IRES inhibitors; the compounds disclosed in WO98/22496, WO99/07733, WO99/07734, WO00/09543, WO00/09558, WO01/59929, WO98/17679, EP932617, WO99/50230, WO00/74768, WO97/43310, U.S. Pat. No. 5,990,276, WO01/58929, WO01/77113, WO02/8198, WO02/8187, WO02/8244, WO02/8256, WO01/07407, WO01/40262, WO01/64678, WO98/46630, JP-A-11-292840, JP-A-10-298151, JP-A-11-127861, JP-A-2001-103993, WO98/46597, WO99/64442, WO00/31129, WO01/32961, WO93/15730, U.S. Pat. No. 7,832,236, WO00/200400, WO02/8251, WO01/16379, WO02/7761 and the like as HCV protease inhibitors; the compounds disclosed in WO97/36554, U.S. Pat. No. 5,830,905, ,WO97/36866, U.S. Pat. No. 5,633,388, WO01/07027, WO00/24725 and the like as HCV helicase inhibitors; the compounds disclosed in WO00/10573, WO00/13708, WO00/18231, WO00/06529, WO02/06246, WO01/32153, WO01/60315, WO01/77091, WO02/04425, WO02/20497, WO00/04141 and the like as HCV polymerase inhibitors; the compounds disclosed in WO01/58877, JP-A-11-180981, WO01/12214 and the like as interferon agonists or enhancers; and the like is also exemplified.
Inasmuch as HCV is known to be a virus associated with many genetic mutations, a compound effective for many genotypes is one of the preferable modes. If a compound ensures high blood concentration when administered as a pharmaceutical agent to an animal infected with HCV, it is also one of the preferable modes. From these aspects, a compound having high inhibitory activity on both HCV type 1a and type 1b and high blood concentration, such as 2-{4-[2-(4-chlorophenyl)-5-(2-oxopyrrolidin-1-yl)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride, is particularly preferable.
The fused ring compound of the formula [I] or [II] of the present invention can be administered to mammals inclusive of human for the purpose of prevention or treatment of hepatitis C or inhibition of hepatitis C virus polymerase. The fused ring compound of the present invention can be also administered to mammals inclusive of human along with at least one pharmaceutical agent (hereinafter combination drug) selected from an antiviral agent other than the compound of the formula [I], an antiinflammatory agent and an immunostimulant for the purpose of prevention or treatment of hepatitis C or inhibition of hepatitis C virus polymerase. In the case of combined administration, the compound of the present invention can be administered simultaneously with the combination drug or administered at certain time intervals. In the case of combined administration, a pharmaceutical composition containing the compound of the present invention and a combination drug can be administered. Alternatively, a pharmaceutical composition containing the compound of the present invention and a pharmaceutical composition containing a combination drug may be administered separately. The administration route may be the same or different.
In the case of a combined administration, the compound of the present invention can be administered once a day or several times a day in a single dose of 0.1 mg to 1 g, or may be administered in a smaller dose. The combination drug can be administered in a dose generally used for the prevention or treatment of hepatitis C or in a smaller dose.
Examples of other antiviral agent include interferons (interferon α, interferon β, interferon γ etc.), Ribavirin (1-β-D-ribofuranosyl-1H-1,2,4-triazole-3-carboxamide) and the like.
Examples of the production method of the compound to be used for the practice of the present invention are given in the following. However, the production method of the compound of the present invention is not limited to these examples.
Even if no directly corresponding disclosure is found in the following Production Methods, the steps may be modified for efficient production of the compound, such as introduction of a protecting group into a functional group with deprotection in a subsequent step, and changing the order of Production Methods and steps.
The treatment after reaction in each step may be conventional ones, for which typical methods, such as isolation and purification, crystallization, recrystallization, silica gel chromatography, preparative HPLC and the like, can be appropriately selected and combined.
Production Method 1
In this Production Method, a benzimidazole compound is formed from a nitrobenzene compound.
Production Method 1-1





 
wherein Hal is halogen atom, such as chlorine atom, bromine atom and the like, Rcl is halogen atom, such as chlorine atom, bromine atom and the like, or hydroxyl group, and other symbols are as defined above.
Step 1
A compound [1] obtained by a conventional method or a commercially available compound [1] is reacted with amine compound [2] in a solvent such as N,N-dimethylformamide (DMF), acetonitrile, tetrahydrofuran (THF), toluene and the like in the presence or absence of a base such as potassium carbonate, triethylamine, potassium t-butoxide and the like at room temperature or with heating to give compound [3].
Step 2
The compound [3] is hydrogenated in a solvent such as methanol, ethanol, THF, ethyl acetate, acetic acid, water and the like in the presence of a catalyst such as palladium carbon, palladium hydroxide, platinum oxide, Raney nickel and the like at room temperature or with heating to give compound [4]. In addition, compound [3] is reduced with a reducing agent such as zinc, iron, tin(II) chloride, sodium sulfite and the like, or reacted with hydrazine in the presence of iron(III) chloride to give compound [4]. The compound [4] can be also obtained by reacting compound [3] with sodium hydrosulfite under alkaline conditions.
Step 3
The compound [4] is condensed with carboxylic acid compound [5] in a solvent such as DMF, acetonitrile, THF, chloroform, ethyl acetate, methylene chloride, toluene and the like using a condensing agent such as dicyclohexylcarbodiimide, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride, diphenylphosphoryl azide and the like and, where necessary, adding N-hydroxysuccinimide, 1-hydroxybenzotriazole and the like to give amide compound [6]. Alternatively, amide compound [6] can be obtained from compound [5] as follows. The carboxylic acid compound [5] is converted to an acid halide derived with thionyl chloride, oxalyl chloride and the like, or an active ester (e.g., mixed acid anhydride derived with ethyl chlorocarbonate and the like), which is then reacted in the presence of a base, such as triethylamine, potassium carbonate, pyridine and the like, or in an amine solvent, such as pyridine and the like, to give amide compound [6].
Step 4
The compound [6] is heated in a solvent such as ethanol, methanol, toluene, DMF, chloroform and the like or without a solvent in the presence of an acid such as acetic acid, formic acid, hydrochloric acid, dilute sulfuric acid, phosphoric acid, polyphosphoric acid, p-toluenesulfonic acid and the like, a halogenating agent such as zinc chloride, phosphorus oxychloride, thionyl chloride and the like or acid anhydride such as acetic anhydride and the like, to allow cyclization to give compound [I-2].
Production Method 1-2
This Production Method is an alternative method for producing compound [I-2].





 

wherein each symbol is as defined above.

Step 1

The compound [3] obtained in the same manner as in Step 1 of Production Method 1-1 is subjected to amide condensation with compound [5] in the same manner as in Step 3 of Production Method 1-1 to give compound [7].
Step 2
The compound [7] is reduced in the same manner as in Step 2 of Production Method 1-1 to give compound [8].
Step 3
The compound [8] is subjected to cyclization in the same manner as in Step 4 of Production Method 1-1 to give compound [I-2].
Production Method 1-3





 
wherein Rc2 is alkyl such as methyl, ethyl and the like, and other symbols are as defined above.
The compound [4] is reacted with imidate compound [9] in a solvent such as methanol, ethanol, acetic acid, DMF, THF, chloroform and the like at room temperature or with heating to give compound [I-2].
In addition, compound [4] may be reacted with aldehyde compound [10] in a solvent such as acetic acid, formic acid, acetonitrile, DMF, nitrobenzene, toluene and the like in the presence or absence of an oxidizing agent such as benzofuroxan, manganese dioxide, 2,3-dichloro-5,6-dicyano-p-benzoquinone, iodine, potassium ferricyanide and the like with heating to give compound [I-2].
Alternatively, compound [4] and carboxylic acid compound [11] may be heated to allow reaction in the presence of polyphosphoric acid, phosphoric acid, phosphorus oxychloride, hydrochloric acid and the like to give compound [I-2].
Production Method 2
In this Production Method, conversion of the substituents (R1, R2, R3, R4) on the benzene ring of benzimidazole is shown. While a method of converting R2 when R1, R3 and R4 are hydrogen atoms is shown, this Production Method is applicable irrespective of the position of substitution.
Production Method 2-1
Conversion of carboxylic acid ester moiety to amide





 
wherein E is a single bond, —(CH2)s—, —O—(CH2)s— or —NH—(CH2)s— (wherein s is an integer of 1 to 6), Rc3, Rc4 and Rc5 are C1-6 alkyl, and other symbols are as defined above.
Step 1
The compound [I-2-1] obtained in the same manner as in the above-mentioned Production Method is subjected to hydrolysis in a solvent such as methanol, ethanol, THF, dioxane and the like, or in a mixed solvent of these solvents and water under basic conditions with sodium hydroxide, potassium hydroxide, potassium carbonate, lithium hydroxide and the like or under acidic conditions with hydrochloric acid, sulfuric acid and the like to give compound [I-2-2].
Step 2
The compound [I-2-2] is reacted with compound [12] in the same manner as in Step 3 of Production Method 1-1 to give compound [I-2-3].
Production Method 2-2
Conversion of cyano group to substituted amidino group





 
wherein each symbol is as defined above.
The compound [I-2-4] obtained in the same manner as in the above-mentioned Production Method is reacted with hydroxylamine in a solvent such as water, methanol, ethanol, THF, DMF and the like to give compound [I-2-5]. When a salt of hydroxylamine such as hydrochloride and the like is used, the reaction is carried out in the presence of a base such as sodium hydrogencarbonate, sodium hydroxide, triethylamine and the like.
Production Method 2-3
Conversion of sulfonic acid ester moiety to sulfonic acid





 
wherein Rc6 is C1-6 alkyl, and other symbols are as defined above.
The compound [I-2-6] obtained in the same manner as in the above-mentioned Production Method is reacted with iodide salt such as sodium iodide, lithium iodide and the like, bromide salt such as sodium bromide, trimethylammonium bromide and the like, amine such as pyridine, trimethylamine, triazole and the like, phosphine such as triphenylphosphine and the like in a solvent such as DMF, dimethyl sulfoxide (DMSO), acetonitrile, methanol, ethanol, water and the like with heating to give compound [I-2-7].
Production Method 3
This Production Method relates to convertion of the substituent(s) on phenyl group at the 2-position of benzimidazole. This Production Method can be used even when phenyl is a different ring.
Production Method 3-1
Conversion of hydroxyl group to ether





 
wherein Rc7 is optionally substituted alkyl corresponding to Ra11, G1 is a single bond, *—(CH2)n—, *—(CH2)n—O—, *—(CH2)n—CO— or *—(CH2)m—CRa15Ra16 )—(CH2)n—, wherein * show the side to be bonded to Rc1, and other symbols are as defined above.
When Rc1 of compound [13] is halogen atom, compound [I-2-8] obtained in the same manner as in the above-mentioned Production Method is reacted with compound [13] in a solvent such as DMF, DMSO, acetonitrile, ethanol, THF and the like in the presence of a base such as sodium hydride, sodium hydroxide, potassium hydroxide, potassium carbonate, sodium ethoxide, potassium t-butoxide and the like at room temperature or with heating to give compound [II-2-1].
When Rc1 of compound [13] is hydroxyl group, the hydroxyl group of compound [13] is converted to halogen atom with thionyl chloride, phosphorus tribromide, carbon tetrabromide-triphenylphosphine and the like and reacted with compound [I-2-8] by the aforementioned method to give compound [II-2-1]. In this case, compound [I-2-8] may be subjected to Mitsunobu reaction with compound [13] in a solvent such as DMF, acetonitrile, THF and the like using triphenylphosphine-diethyl azodicarboxylate and the like to give compound [II-2-1].
The compound [I-2-9] can be obtained in the same manner from compound [I-2-8] and compound [14].
Production Method 3-2
Conversion of nitro to substituted amino group





 
wherein Rc8 is C1-6 alkyl, G2 is *—(CH2)n— or *—CHRa15, G3 is —CO—, *—CO2—, *—CONH— or —SO2—, and other symbols are as defined above.
Step 1
The nitro compound [I-2-10] obtained in the same manner as in the above-mentioned Production Method is reacted in the same manner as in Step 2 of Production Method 1-1 to give compound [I-2-11].
Step 2
The compound [I-2-11] is alkylated with compound [15] in the same manner as in Production Method 3-1 to give compound [II-2-2].
Step 3
When G3 of compound [16] is —CO—, —CO2— or —CONH—, compound [I-2-11] is acylated with compound [16] in the same manner as in Step 3 of Production Method 1-1 to give compound [II-2-3].
When G3 of compound [16] is —SO2—, sulfonylation is conducted using sulfonyl halide instead of acid halide used in Step 3 of Production Method 1-1 to give compound [II-2-3].
The compound [I-2-11] is acylated with compound [17] in the same manner as above to give compound [I-2-12].
This Production Method is applied in the same manner as above to give disubstituted compounds (tertiary amine) of compound [II-2-2], compound [II-2-3] and compound [I-2-12].
Production Method 3-3
Conversion of carboxylic acid ester moiety to amide





 
wherein Rc9 is C1-6 alkyl, G4 is #—(CH2)n—, #—(CH2)n—NH— or #—CHRa14— wherein # shows the side that is bounded to amine and other symbols are as defined above.
Step 1
The compound [I-2-13] obtained in the same manner as in the above-mentioned Production Method is reacted in the same manner as in Step 1 of Production Method 2-1 to give compound [I-2-14].
Step 2
The compound [I-2-14] is reacted with compound [18] in the same manner as in Step 2 of Production Method 2-1 to give compound [II-2-4].
The compound [I-2-15] is obtained from compound [I-2-14] and compound [19] in the same manner as above.
Production Method 4
In this Production Method, additional substituent(s) is(are) introduced into ring B on phenyl group that substitutes the 2-position of benzimidazole. This Production Method is applicable even when phenyl is a different ring.
Production Method 4-1
Direct bonding of ring Z′′ to ring B





 
wherein ring Z′′-M is aryl metal compound, ring Z′′ moiety is optionally substituted C6-14 aryl or optionally substituted heterocyclic group corresponding to substituent Z, and the metal moiety contains boron, zinc, tin, magnesium and the like, such as phenylboronic acid, w′′ is 0, 1 or 2, and other symbols are as defined above.
The compound [II-2-5] obtained in the same manner as in the above-mentioned Production Method is reacted with aryl metal compound [20] in a solvent such as DMF, acetonitrile, 1,2-dimethoxyethane, THF, toluene, water and the like in the presence of a palladium catalyst such as tetrakis(triphenylphosphine)palladium, bis(triphenylphosphine)palladium(II) dichloride, palladium acetate-triphenylphosphine and the like, a nickel catalyst such as nickel chloride, [1,3-bis(diphenylphosphino)propane]nickel(II) chloride and the like, and a base such as potassium carbonate, potassium hydrogencarbonate, sodium hydrogencarbonate, potassium phosphate, triethylamine and the like at room temperature or with heating, to give compound [II-2-6].
Production Method 4-2
Conversion of hydroxyl group to ether





 
wherein Rc10 is —Ra20 or —(CH2)p—CORa21 corresponding to substituent Z, and other symbols are as defined above.
The compound [II-2-7] obtained in the same manner as in the above-mentioned Production Method is reacted with compound [21] in the same manner as in Production Method 3-1 to give compound [II-2-8].
Production Method 4-3
Synthesis in advance of ring B part such as compound [13] in Production Method 3-1





 
wherein Rc11 is leaving group such as chlorine atom, bromine atom, iodine atom, trifluoromethanesulfonyloxy and the like, Rc12 is formyl, carboxyl or carboxylic acid ester such as methoxycarbonyl, ethoxycarbonyl, tert-butoxycarbonyl and the like, and other symbols are as defined above.

Step 1

Commercially available compound [22] or compound [22] obtained by a conventional method is reacted with aryl metal compound [20] in the same manner as in Production Method 4-1 to give compound [23].
Step 2
The compound [23] obtained in the same manner as in the above-mentioned Production Method is reduced according to a conventional method to give compound [24].
For example, compound [23] is reacted with in a solvent such as methanol, ethanol, THF and the like in the presence of a reducing agent such as lithium aluminum hydride, sodium borohydride and the like under cooling to heating to give compound [24].
Step 3
The compound [24] obtained in the same manner as in the above-mentioned Production Method is reacted in a solvent such as 1,4-dioxane, diethyl ether, THF, dichloromethane, chloroform, toluene and the like with a halogenating agent, such as phosphorus pentachloride, phosphorus tribromide, thionyl chloride and the like, to give compound [25]. For an accerelated reaction, the reaction may be carried out in the presence of a tertiary amine such as DMF, pyridine and the like, or under heating.
Step 4
The compound [24] or [25] obtained in the same manner as in the above-mentioned Production Method is reacted with compound [I-2-8] in the same manner as in Production Method 3-1 to give compound [II-2-9].
Production Method 4-4





 
wherein M′ is a metal such as magnesium, lithium, zinc and the like, and other symbols are as defined above.
Step 1
Commercially available compound [41] or compound [41] obtained by a conventional method is converted to aryl metal reagent by a conventional method to give compound [42].
For example, when M′ is magnesium, magnesium is reacted with compound [41] in a solvent such as THF, diethyl ether, benzene, toluene and the like, preferably THF, from cooling to heating preferably at −100° C. to 100° C. to give compound [42].
Step 2
The compound [42] obtained in the same manner as in the above-mentioned Production Method is reacted with compound [43] to give compound [44].
The compound [42] is reacted in a solvent such as diethyl ether, benzene, toluene, THF and the like, preferably THF, from cooling to room temperature, preferably at −100° C. to 30° C. to give compound [44].
Step 3
The compound [44] obtained in the same manner as in the above-mentioned Production Method is halogenated in the same manner as in Step 3 of Production Method 4-3 to give compound [45].
The compound [44] is reacted with thionyl chloride and pyridine preferably in toluene solvent to give compound [45].
When compound [45] is symmetric, namely, when the ring B-(Z)w moiety and the ring B′-(Z′)w′ moiety are the same, compound [42] is reacted with formate such as methyl formate, ethyl formate and the like, preferably ethyl formate, in a solvent such as diethyl ether, benzene, toluene, THF and the like, preferably THF, from cooling to room temperature, preferably at −100° C. to 30° C., to give compound [45].
Production Method 4-5
Method including steps to introduce a protecting group into a functional group








 
wherein Rc13 is carboxylic acid protecting group such as tert-butyl and the like, Rc14 is carboxylic acid protecting group such as methyl and the like and other symbols are as defined above.
Step 1
Commercially available compound [26] or compound [26] obtained by a conventional method is protected by a conventional method to give compound [27].
For example, when Rc13 is tert-butyl, compound [26] is converted to acid halide with thionyl chloride, oxalyl chloride and the like in a solvent such as THF, chloroform, dichloromethane, toluene and the like, and reacted with potassium tert-butoxide to give compound [27].
As used herein, Rc13 may be a different protecting group as long as it is not removed during the Step 2 or Step 3 but removed in Step 4 without affecting —CO2Rc14.
Step 2
The methyl group of compound [27] obtained in the same manner as in the above-mentioned Production Method is converted to bromomethyl with N-bromosuccinimide and N,N′-azobisisobutyronitrile and reacted with compound [I-2-16] in the same manner as in Production Method 3-1 to give compound [II-2-10].
Step 3
The compound [II-2-10] obtained in the same manner as in the above-mentioned Production Method is reacted with aryl metal compound [20] in the same manner as in Production Method 4-1 to give compound [II-2-11].
Step 4
The Rc13 of the compound [II-2-11] obtained in the same manner as in the above-mentioned Production Method is removed by a conventional method to give compound [II-2-12].
The protecting group of carboxylic acid can be removed by a conventional deprotection method according to the protecting group. In this Step, the conditions free from reaction of Rc14 are preferable. For example, when Rc13 is tert-butyl, compound [II-2-11] is treated with trifluoroacetic acid in a solvent such as dichloromethane, chloroform and the like to give compound [II-2-12].
Step 5
The compound [II-2-12] obtained in the same manner as in the above-mentioned Production Method is subjected to amide condensation with compound [28] in the same manner as in Step 3 of Production-Method 1-1 to give compound [II-2-13].
Step 6
The compound [II-2-13] obtained in the same manner as in the above-mentioned Production Method is deprotected in the same manner as in Step 1 of Production Method 2-1 to give compound [II-2-14].
As used herein, Rc14 is preferably a protecting group that does not react during the Step 1 through Step 5 but removed in this Step.
For example, when Rc14 is methyl, compound [II-2-13] is reacted in an alcohol solvent such as methanol, ethanol, n-propanol, isopropanol and the like or a mixed solvent of alcohol solvent and water in the presence of a base such as potassium carbonate, sodium carbonate, lithium hydroxide, sodium hydroxide, potassium hydroxide and the like from cooling to heating for deprotection, followed by acidifying the reaction solution to give compound [II-2-14].
Production Method 4-6





 
wherein g is an integer of 1 to 5, and other sumbols are as defined above.
Step 1
The compound [I-2-16] obtained by the above-mentioned Production Method is reacted with toluene derivative [41] in the same manner as in Step 2 of Production Method 4-5 to give compound [II-2-17].
Step 2
The compound [II-2-17] obtained by the above-mentioned Production Method is reacted with aryl metal compound [20] in the same manner as in Production Method 4-1 to give compound [II-2-18].
Step 3
The compound [II-2-18] obtained by the above-mentioned Production Method is reduced in the same manner as in Step 2 of Production Method 1-1 to give compound [II-2-19].
Step 4
The compound [II-2-19] obtained by the above-mentioned Production Method is amide condensed with compound [42] in the same manner as in Step 3 of Production Method 1-1 and subjected to cyclization in the same manner as in Step 1 of Production Method 1-1 to give compound [II-2-20].
Step 5
The compound [II-2-20] obtained by the above-mentioned Production Method is hydrolyzed in the same manner as in Step 1 of Production Method 2-1 to give compound [II-2-21].
Production Method 4-7








 
wherein each symbol is as defined above.
Step 1
Commercially available product or compound [46] obtained by a conventional method is reacted with compound [20] in the same manner as in Production Method 4-1 to give compound [47].
Step 2
The compound [47] obtained in the same manner as in the above-mentioned Production Method is reduced in the same manner as in the above-mentioned Production Method 4-3 Step 2 to give compound [48].
Step 3
The compound [48] obtained in the same manner as in the above-mentioned Production Method is reduced in the same manner as in the above-mentioned Production Method 1-1 Step 2 to give compound [49].
Step 4
The compound [49] obtained in the same manner as in the above-mentioned Production Method is reacted with compound [42] in a solvent such as DMF, acetonitrile, THF, chloroform, ethyl acetate, methylene chloride and toluene to give compound [50]. To enhance the reaction selectivity for amino group, acetic acid and sodium acetate may be added in an equivalent amount ratio.
Step 5
The compound [50] obtained in the same manner as in the above-mentioned Production Method is subjected to cyclization reaction in the same manner as in the above-mentioned Production Method 1-1 Step 1 to give compound [51].
Step 6
The compound [51] obtained in the same manner as in the above-mentioned Production Method is halogenated in the same manner as in the above-mentioned Production Method 4-3 Step 3 to give compound [52].
Step 7
The compound [52] obtained in the same manner as in the above-mentioned Production Method is reacted in the same manner as in the above-mentioned Production Method 3-1 with compound [I-2-16] obtained in the same manner as in the above-mentioned Production Method to give compound [II-2-20].
Step 8
The compound [II-2-20] obtained in the same manner as in the above-mentioned Production Method is hydrolyzed in the same manner as in the above-mentioned Production Method 2-1 Step 1 to give compound [II-2-21].
Production Method 5
Formation of indole ring





 
wherein Rc15 is protecting group such as trimethylsilyl, tert-butyldimethylsilyl, tert-butyldiphenylsilyl and the like, and other symbols are as defined above.
Step 1
The compound [29] obtained in the same manner as in the above-mentioned Production Method or conventional method is reacted with compound [30] in a solvent such as DMF, acetonitrile, 1,2-dimethoxyethane, THF, toluene, water and the like using a palladium catalyst such as tetrakis(triphenylphosphine)palladium, bis(triphenylphosphine)palladium(II) dichloride, palladium acetate-triphenylphosphine and the like, a copper catalyst such as copper(I) iodide and the like or a mixture thereof, and in the presence of a base such as potassium carbonate, potassium hydrogencarbonate, sodium hydrogencarbonate, potassium phosphate, triethylamine and the like to give compound [31].
Step 2
The compound [31] obtained in the same manner as in the above-mentioned Production Method is reacted in an alcohol solvent such as methanol, ethanol and the like or a mixed solvent of an alcohol solvent and a solvent such as DMF, acetonitrile, THF, chloroform, dichloromethane, ethyl acetate, methylene chloride, toluene and the like in the presence of a base such as potassium carbonate, sodium carbonate, lithium hydroxide, sodium hydroxide, potassium hydroxide, lithium hydride, sodium hydride, potassium hydride and the like at room temperature or with heating for deprotection, and reacted with compound [32] obtained in the same manner as in Step 1 of Production Method 1-1 in the same manner as in Step 1 of Production Method 5 to give compound [33].
Step 3
The compound [33] obtained in the same manner as in the above-mentioned Production Method was subjected to cyclization in a solvent such as DMF, acetonitrile, THF, chloroform, dichloromethane, ethyl acetate, methylene chloride, toluene and the like in the presence of a copper catalyst such as copper(I) iodide and the like or a palladium catalyst such as palladium(II) chloride and the like at room temperature or with heating to give compound [II-2-15].
Production Method 6
Formation of imidazo[1,2-a]pyridine ring





 
wherein Rc16 and Rc17 are each independently alkyl, such as methyl, ethyl and the like, and other symbols are as defined above.
Step 1
The compound [34] obtained by the above-mentioned Production Method or a conventional method is subjected to amide condensation with compound [35] in the same manner as in Step 3 of Production Method 1-1 to give compound [36].
Step 2
The compound [36] obtained by the above-mentioned Production Method is reacted with Grignard reagent [37] obtained by a conventional method to give compound [38].
Alternatively, an acid halide of compound [34] may be used instead of compound [36].
Step 3
The compound [38] obtained by the above-mentioned Production Method is subjected to halogenation by a conventional method to give compound [39].
For example, when Hal is a bromine atom, compound [38] is reacted with bromine under cooling or at room temperature in a solvent such as DMF, acetonitrile, THF, chloroform, dichloromethane, ethyl acetate, toluene and the like to give compound [39].
Alternatively, a halogenating agent such as hypohalite (e.g., hypochlorite and the like), N-bromosuccinimide and the like may be used instead of bromine for halogenation.
Step 4
The compound [39] obtained by the above-mentioned Production Method is subjected to cyclization with compound [40] obtained by a conventional or known method (JP-A-8-48651) in the presence of a base such as potassium carbonate, sodium carbonate, lithium hydroxide, sodium hydroxide, potassium hydroxide, lithium hydride, sodium hydride, potassium hydride and the like in a solvent or without a solvent at room temperature or with heating to give compound [II-2-16].
In the compounds of the formulas [I] and [II], a desired heterocyclic group can be formed according to a method similar to the methods disclosed in known publications. Examples of such heterocyclic group and reference publications are recited in the following.

    5-oxo-Δ2-1,2,4-oxadiazolin-3-yl (or 2,5-dihydro-5-oxo-4H-1,2,4-oxadiazol-3-yl), 5-oxo-Δ2-1,2,4-thiadiazolin-3-yl (or 2,5-dihydro-5-oxo-4H-1,2,4-thiadiazol-3-yl), 2-oxo-Δ3-1,2,3,5-oxathiadiazolin-4-yl (or 2-oxo-Δ3-1,2,4-oxathiadiazol-4-yl): Journal of Medicinal Chemistry, 39(26), 5228-35, 1996,
    5-oxo-Δ2-1,2,4-triazolin-3-yl: J Org Chem, 61(24), 8397-8401, 1996,
    1-oxo-Δ3-1,2,3,5-thiatriazolin-4-yl: Liebigs Ann Chem, 1376, 1980,
    3-oxo-Δ4-1,2,4-oxadiazolin-5-yl: EP145095,
    5-oxo-Δ2-1,3,4-oxadiazolin-2-yl: J Org Chem, 20, 412, 1955,
    5-oxo-Δ3-1,2,4-dioxazolin-3-yl: J Prakt Chem, 314, 145, 1972,
    3-oxo-Δ4-1,2,4-thiadiazolin-5-yl: JP-A-61-275271,
    5-oxo-Δ3-1,2,4-dithiazolin-3-yl: J Org Chem, 61(19), 6639-6645, 1996,
    2-oxo-Δ4-1,3,4-dioxazolin-5-yl: J Org Chem, 39, 2472, 1974,
    2-oxo-Δ4-1,3,4-oxathiazolin-5-yl: J Med Chem, 35(20), 3691-98, 1992,
    5-oxo-Δ2-1,3,4-thiadiazolin-2-yl: J Prakt Chem, 332(1), 55, 1990,
    5-oxo-Δ2-1,4,2-oxathiazolin-3-yl: J Org Chem, 31, 2417, 1966,
    2-oxo-Δ4-1,3,4-dithiazolin-5-yl: Tetrahedron Lett, 23, 5453, 1982,
    2-oxo-Δ4-1,3,2,4-dioxathiazolin-5-yl: Tetrahedron Lett, 319, 1968,
    3,5-dioxoisooxazolidin-4-yl: Helv Chim Acta, 1973, 48, 1965,
    2,5-dioxoimidazolidin-4-yl: Heterocycles, 43(1), 49-52, 1996,
    5-oxo-2-thioxoimidazolidin-4-yl: Heterocycles, 5, 391, 1983,
    2,4-dioxooxazolidin-5-yl: J Am Chem Soc, 73, 4752, 1951,
    4-oxo-2-thioxooxazolidin-5-yl: Chem Ber, 91, 300, 1958,
    2,4-dioxothiazolidin-5-yl: JP-A-57-123175,
    4-oxo-2-thioxothiazolidin-5-yl: Chem Pharm Bull, 30, 3563, 1982,


The Production Methods shown in the above-mentioned Production Methods 2 to 4 can be used for the synthesis of compounds other than benzimidazole of the formulas [I] and [II], such as compounds [II-2-15] and [II-2-16].
The compounds of the formulas [I], [II] and [III], 4-(4-fluorophenyl)-5-hydroxymethyl-2-methylthiazole and 4-(4-fluorophenyl)-5-chloromethyl-2-methylthiazole and production methods thereof of the present invention are explained in detail in the following by way of Examples. It is needless to say that the present invention is not limited by these Examples.
Example 1
Production of ethyl 2-[4-(3-bromophenoxy)phenyl]-1-cyclohexylbenzimidazole-5-carboxylate
Step 1: Production of ethyl 4-chloro-3-nitrobenzoate
4-Chloro-3-nitrobenzoic acid (300 g) was dissolved in ethyl alcohol (1500 ml) and concentrated sulfuric acid (100 ml) was added with ice-cooling. The mixture was refluxed under heating for 7 hr. The reaction mixture was poured into ice-cold water and the precipitated crystals were collected by filtration to give the title compound (332 g, yield 97%).
1H-NMR (300 MHz, CDCl3): 8.50 (1H, d, J=2.1 Hz), 8.16(1H, dd, J=8.4, 2.1 Hz), 7.63(1H, d, J=8.4 Hz), 4.43(2H, q, J=7.5 Hz), 1.42(3H, t, J=7.5 Hz)
Step 2: Production of ethyl 4-cyclohexylamino-3-nitrobenzoate
Ethyl 4-chloro-3-nitrobenzoate (330 g) obtained in the previous step was dissolved in acetonitrile (1500 ml), and cyclohexylamine (220 g) and triethylamine (195 g) were added. The mixture was refluxed under heating overnight. The reaction mixture was poured into ice-cold water and the precipitated crystals were collected by filtration to give the title compound (400 g, yield 94%).
1H-NMR (300 MHz, CDCl3): 8.87(1H, d, J=2.1 Hz), 8.35-8.46(1H, m), 8.02(1H, dd, J=9.1, 2.1 Hz), 6.87(1H, d, J=9.1 Hz), 4.35(2H, q, J=7.1 Hz), 3.65-3.50(1H, m), 2.14-1.29(10H, m), 1.38(3H, t, J=7.1 Hz)
Step 3: Production of ethyl 3-amino-4-cyclohexylaminobenzoate
Ethyl 4-cyclohexylamino-3-nitrobenzoate (400 g) obtained in the previous step was dissolved in ethyl acetate (1500 ml) and ethyl alcohol (500 ml), and 7.5% palladium carbon (50% wet, 40 g) was added. The mixture was hydrogenated for 7 hr at atmospheric pressure. The catalyst was filtered off and the filtrate was concentrated under reduced pressure. Diisopropyl ether was added to the residue and the precipitated crystals were collected by filtration to give the title compound (289 g, yield 80%).
1H-NMR (300 MHz, CDCl3): 7.57(1H, dd, J=8.4, 1.9 Hz), 7.41(1H, d, J=1.9 Hz), 6.59(1H, d, J=8.4 Hz), 4.30(2H, q, J=7.1 Hz), 3.40-3.30(1H, m), 2.18-2.02(2H, m), 1.88-1.15(8H, m), 1.35(3H, t, J=7.1 Hz)
Step 4: Production of ethyl 3-[4-(3-bromophenoxy)benzoyl]amino-4-cyclohexylaminobenzoate
4-(3-Bromophenoxy)benzoic acid (74 g) was dissolved in chloroform (500 ml), and oxalyl chloride (33 ml) and dimethylformamide (catalytic amount) were added. The mixture was stirred for 4 hr at room temperature. The reaction mixture was concentrated under reduced pressure and dissolved in dichloromethane (150 ml). The resulting solution was added dropwise to a solution of ethyl 3-amino-4-cyclohexylaminobenzoate (66 g) obtained in the previous step in dichloromethane (500 ml) and triethylamine (71 ml), and the mixture was stirred for 1 hr at room temperature. The reaction mixture was poured into water and extracted with dichloromethane. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. Diethyl ether was added to the residue for crystallization and the crystals were collected by filtration to give the title compound (129 g, yield 95%).
1H-NMR (300 MHz, CDCl3): 8.00-7.78(4H, m), 7.66(1H, brs), 7.37-7.18(3H, m), 7.13-6.59(3H, m), 6.72(1H, d, J=8.7 Hz), 4.50(1H, brs), 4.29(2H, q, J=7.2 Hz), 3.36(1H, m), 2.12-1.96(2H, m), 1, 83-1.56(3H, m), 1.47-1.12(5H, m), 1.37(3H, t, J=7.2 Hz)
Step 5: Production of ethyl 2-[4-(3-bromophenoxy)phenyl]-1-cyclohexylbenzimidazole-5-carboxylate
Ethyl 3-[4-(3-bromophenoxy)benzoyl]amino-4-cyclohexylaminobenzoate (129 g) obtained in the previous step was suspended in acetic acid (600 ml) and the resulting suspension was refluxed under heating for 3 hr. The reaction mixture was concentrated under reduced pressure. Water was added to the residue and the precipitated crystals were collected by filtration to give the title compound (124 g, yield 99%).
1H-NMR (300 MHz, CDCl3): 8.51(1H, d, J=1.5 Hz), 8.00(1H, dd, J=8.4, 1.5 Hz), 7.67(1H, d, J=8.4 Hz), 7.63(2H, d, J=8.7 Hz), 7.35-7.21(3H, m), 7.17(2H, d, J=8.7 Hz), 7.14(1H, m), 4.42(2H, q, J=7.2 Hz), 4.38(1H, m), 2.43-2.22(2H, m), 2.07-1.87(4H, m), 1.80(1H, m), 1.42(3H, t, J=7.2 Hz), 1.40-1.27(3H, m)
Example 2
Production of 2-[4-(3-bromophenoxy)phenyl]-1-cyclohexylbenzimidazole-5-carboxylic acid
Ethyl 2-[4-(3-bromophenoxy)phenyl]-1-cyclohexylbenzimidazole-5-carboxylate (1.0 g) obtained in Example 1 was dissolved in tetrahydrofuran (10 ml) and ethyl alcohol (10 ml), and 4N sodium hydroxide (10 ml) was added. The mixture was refluxed under heating for 1 hr. The reaction mixture was concentrated under reduced pressure and water was added to the residue. The mixture was acidified with 6N hydrochloric acid and the precipitated crystals were collected by filtration to give the title compound (0.9 g, yield 96%).
melting point: 255-256° C.
FAB-Ms: 491(MH+)
1H-NMR (300 MHz, DMSO-d6): (12.75(1H, brs), 8.24(1H, s), 7.96(1H, d, J=8.7 Hz), 7.86(1H, d, J=8.7 Hz), 7.71(2H, d, J=8.6 Hz), 7.47-7.34(3H, m), 7.24(2H, d, J=8.6 Hz), 7.20(1H, m), 4.31(1H, m), 2.38-2.18(2H, m), 2.02-1.79(4H, m), 1.65(1H, m), 1.44-1.20(3H, m)
Example 3
Production of ethyl 1-cyclohexyl-2-(4-hydroxyphenyl)benzimidazole-5-carboxylate
Ethyl 3-amino-4-cyclohexylaminobenzoate (130 g) obtained in Example 1, Step 3, and methyl 4-hydroxybenzimidate hydrochloride (139 g) were added to methyl alcohol (1500 ml), and the mixture was refluxed under heating for 4 hr. The reaction mixture was allowed to cool and the precipitated crystals were collected by filtration to give the title compound (131 g, yield 72%).
1H-NMR (300 MHz, CDCl3): 10.02(1H, brs), 8.21(1H, d, J=1.4 Hz), 7.93(1H, d, J=8.6 Hz), 7.83(1H, dd, J=8.6, 1.4 Hz), 7.48(2H, d, J=8.6 Hz), 6.95(2H, d, J=8.6 Hz), 4.39-4.25(1H, m), 4.33(1H, q, J=7.0 Hz), 2.35-2.18(2H, m), 1.98-1.79(4H, m), 1.70-1.60(1H, m), 1.46-1.19(3H, m), 1.35(3H, t, J=7.0 Hz)
Example 4
Production of ethyl 2-[4-(2-bromo-5-chlorobenzyloxy)phenyl]-1-cyclohexylbenzimidazole-5-carboxylate
2-Bromo-5-chlorobenzyl bromide prepared from 2-bromo-5-chlorotoluene (50 g), N-bromosuccinimide and N,N′-azobisisobutyronitrile, and ethyl 1-cyclohexyl-2-(4-hydroxyphenyl)benzimidazole-5-carboxylate (50 g) obtained in Example 3 were suspended in dimethylformamide (300 ml). Potassium carbonate (38 g) was added and the mixture was stirred for 1 hr at 80° C. with heating. The reaction mixture was allowed to cool and then added to a mixed solvent of water-ethyl acetate. The precipitated crystals were collected by filtration to give the title compound (50 g, yield 64%).
1H-NMR (300 MHz, CDCl3): 8.50(1H, d, J=1.4 Hz), 7.97(1H, dd, J=8.6, 1.4 Hz), 7.70-7.57(5H, m), 7.20(1H, dd, J=8.4, 2.5 Hz), 7.14(2H, d, J=8.7 Hz), 5.17(2H, s), 4.46-4.30(1H, m), 4.41(2H, q, J=7.1 Hz), 2.40-2.20(2H, m), 2.02-1.21(8H, m), 1.42(3H, t, J=7.1 Hz)
Example 5
Production of ethyl 2-{4-[2-(4-chlorophenyl)-5-chlorobenzyloxy]-phenyl}-1-cyclohexylbenzimidazole-5-carboxylate
Ethyl 2-[4-(2-bromo-5-chlorobenzyloxy)phenyl]-1-cyclohexylbenzimidazole-5-carboxylate (49 g) obtained in Example 4, 4-chlorophenylboronic acid (18 g) and tetrakis(triphenylphosphine)palladium (10 g) were suspended in 1,2-dimethoxyethane (600 ml). Saturated aqueous sodium hydrogencarbonate solution (300 ml) was added and the mixture was refluxed under heating for 2 hr. Chloroform was added to the reaction mixture. The organic layer was washed successively with saturated aqueous sodium hydrogencarbonate solution, water and saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel flash chromatography (developing solvent, chloroform:ethyl acetate=97:3). Ethyl acetate and diisopropyl ether were added to the resulting oil for crystallization and the resulting crystals were collected by filtration to give the title compound (44 g, yield 85%).
1H-NMR (300 MHz, CDCl3): 8.49(1H, d, J=1.4 Hz), 7.97(1H, dd, J=8.6, 1.6 Hz), 7.70-7.60(2H, m), 7.55(2H, d, J=8.7 Hz), 4.95(2H, s), 4.48-4.28(1H, m), 4.40(2H, m), 2.02-1.20(8H, m), 1.41(3H, t, J=7.1 Hz)
Example 6
Production of 2-{4-[2-(4-chlorophenyl)-5-chlorobenzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid
Ethyl 2-{4-[2-(4-chlorophenyl)-5-chlorobenzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylate (43 g) obtained in Example 5 was treated in the same manner as in Example 2 to give the title compound (33 g, yield 76%).
melting point: 243-244° C.
FAB-Ms: 571(MH+)
1H-NMR (300MHz, DMSO-d6): 8.32(1H, s), 8.28 (1H, d, J=8.9Hz), 8.05(1H, d, J=8.8Hz), 7.76-7.72(3H, m), 7.58-7.46(5H, m), 7.40(1H, d, J=8.3Hz), 7.24(2H, d, J=8.9Hz), 5.11(2H, s), 4.36(1H, m), 2.40-2.15(2H, m), 2.15-1.95(2H, m), 1.95-1.75(2H, m), 1.75-1.55(1H, m), 1.55-1.15(3H, m)
Example 7
Production of ethyl 2-[4-(2-bromo-5-methoxybenzyloxy)phenyl]-1-cyclohexylbenzimidazole-5-carboxylate
Ethyl 1-cyclohexyl-2-(4-hydroxyphenyl)benzimidazole-5-carboxylate obtained in Example 3 and 2-bromo-5-methoxybenzyl bromide were treated in the same manner as in Example 4 to give the title compound (59 g).
Example 8
Production of ethyl 2-{4-[2-(4-chlorophenyl)-5-methoxybenzyloxy]-phenyl}-1-cyclohexylbenzimidazole-5-carboxylate
Ethyl 2-[4-(2-bromo-5-methoxybenzyloxy)phenyl]-1-cyclohexylbenzimidazole-5-carboxylate obtained in Example 7 was treated in the same manner as in Example 5 to give the title compound (48 g, yield 77%).
1H-NMR (300MHz, CDCl3): 8.49(1H, d, J=1.4Hz), 7.97(1H, dd, J=8.6, 1.4Hz), 7.64(1H, d, J=8.6Hz), 7.54(2H, d, J=8.7Hz), 7.37(2H, d, J=8.6Hz), 7.31(2H, d, J=8.6Hz), 7.25(1H, d, J=8.4Hz), 7.19(1H, d, J=2.7Hz), 7.00(2H, d, J=8.7Hz), 6.97(1H, dd, J=8.4, 2.7Hz), 4.98(2H, s), 4.41(2H, q, J=7.1Hz), 4.42-4.29(1H, m), 3.88(3H, s), 2.40-2.20(2H, m), 2.01-1.88(4H, m), 1.83-1.73(1H, m), 1.42(3H, t, J=7.1Hz), 1.41-1.25(3H, m)
Example 9
Production of 2-{4-[2-(4-chlorophenyl)-5-methoxybenzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid
Ethyl 2-{4-[2-(4-chlorophenyl)-5-methoxybenzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylate (52 g) obtained in Example 8 was treated in the same manner as in Example 2 to give the title compound (44 g, yield 89%).
melting point: 248-249° C.
FAB-Ms: 568(MH+)
1H-NMR (300MHz, DMSO-d6): 8.20(1H, s), 7.88(1H, d, J=8.7Hz), 7.85(1H, d, J=8.7Hz), 7.57(d, 2H, J=8.6Hz), 7.46(2H, d, J=8.6Hz), 7.44(2H, d, J=8.6Hz), 7.29(1H, d, J=8.5Hz), 7.24(1H, d, J=2.6Hz), 7.11(2H, d, J=8.6Hz), 7.06(1H, dd, J=8.5, 2.6Hz), 5.04(2H, s), 4.26(1H, m), 3.83(3H, s), 2.38-2.29(2H, m)
Example 10
Production of ethyl 1-cyclohexyl-2-{4-[(E)-2-phenylvinyl]phenyl}-benzimidazole-5-carboxylate
Ethyl 3-amino-4-cyclohexylaminobenzoate (500 mg) obtained in Example 1, Step 3, was dissolved in methyl alcohol (6 ml) and trans-4-stilbenecarbaldehyde (397 mg) was added under ice-cooling. The mixture was stirred overnight at room temperature. The reaction mixture was ice-cooled and benzofuroxan (259 mg) dissolved in acetonitrile (2 ml) was added. The mixture was stirred for 7 hr at 50° C. The reaction mixture was ice-cooled. After 1N sodium hydroxide was added, ethyl acetate was added and the mixture was extracted. The organic layer was washed with water and saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel flash chromatography (developing solvent, n-hexane:ethyl acetate=4:1) to give the title compound (540 mg, yield 63%).
1H-NMR (300MHz, DMSO-d6): 8.28(1H, d, J=1.4Hz), 8.01(1H, d, J=8.7Hz), 7.90-7.80(3H, m), 7.75-7.65(4H, m), 7.50-7.25(5H, m), 4.35(2H, q, J=7.0Hz), 4.31(1H, m), 2.40-2.20(2H, m), 2.00-1.80(4H, m), 1.63(1H, m), 1.40-1.20(3H, m), 1.36(3H, t, J=7.0Hz)
Example 11
Production of 1-cyclohexyl-2-{4-[(E)-2-phenylvinyl]phenyl}-benzimidazole-5-carboxylic acid
Ethyl 1-cyclohexyl-2-{4-[(E)-2-phenylvinyl]phenyl}-benzimidazole-5-carboxylate (127 mg) obtained in Example 10 was treated in the same manner as in Example 2 to give the title compound (116 mg, yield 97%).
melting point: not lower than 300° C.
FAB-Ms: 423(MH+) 1H-NMR (300MHz, DMSO-d6): 8.25(1H, s), 7.96-7.29(13H, m), 4.33(1H, brt), 2.41-2.23(2H, m), 2.03-1.78(4H, m), 1.71-1.59(1H, m), 1.49-1.20(3H, m)
Example 12
Production of 2-(4-benzyloxyphenyl)-1-cyclopentylbenzimidazole-5-carboxylic acid
In the same manner as in Examples 1 and 2, the title compound (700 mg) was obtained.
FAB-Ms: 413(MH+)
1H-NMR (300MHz, CDCl3): 8.60(1H, s), 8.04(1H, d, J=9.0Hz), 7.63(2H, d, J=8.4Hz), 7.51-7.32(6H, m), 7.14(2H, d, J=9.0Hz), 5.16(2H, s), 5.03-4.89(1H, m), 2.41-1.63(8H, m)
Example 13
Production of 2-(4-benzyloxyphenyl)-1-cyclopentylbenzimidazole-5-carboxamide
2-(4-Benzyloxyphenyl)-1-cyclopentylbenzimidazole-5-carboxylic acid (700 mg) obtained in Example 12 was dissolved in dimethylformamide (10 ml), and ammonium chloride (108 mg), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (390 mg), 1-hydroxybenzotriazole (275 mg) and triethylamine (0.3 ml) were added. The mixture was stirred overnight at room temperature. Water was added to the reaction mixture and the mixture was extracted with ethyl acetate. The organic layer was washed successively with saturated aqueous sodium hydrogencarbonate, water and saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. Ethyl acetate and diisopropyl ether were added to the residue for crystallization and the crystals were collected by filtration to give the title compound (571 mg, yield 81%).
melting point: 232-233° C.
FAB-Ms: 412(MH+)
1H-NMR (300MHz, CDCl3): 8.23(1H, d, =1.5Hz), 7.86(1H, dd, J=8.5, 1.5Hz), 7.65-7.30(8H, m), 7.13(2H, d, J=8.8Hz), 5.16(2H, s), 4.93(1H, quint, J=8.8Hz), 2.40-1.60(8H, m)
Example 14
Production of 2-(4-benzyloxyphenyl)-5-cyano-1-cyclopentylbenzimidazole
In the same manner as in Example 1, the title compound (400 mg) was obtained.
FAB-Ms: 394(MH+)
1H-NMR (300MHz, CDCl3): 8.11(1H, s), 7.68-7.30(9H, m), 7.13(2H, s), 5.16(2H, s), 4.94(1H, quint, J=8.9Hz), 2.35-1.60(8H, m)
Example 15
Production of 2-(4-benzyloxyphenyl)-1-cyclopentylbenzimidazole-5-carboxamide oxime
2-(4-Benzyloxyphenyl)-5-cyano-1-cyclopentylbenzimidazole (400 mg) obtained in Example 14 was suspended in ethyl alcohol (3 ml) and water (1.5 ml), and hydroxylamine hydrochloride (141 mg) and sodium hydrogencarbonate (170 mg) were added. The mixture was refluxed under heating overnight. The reaction mixture was allowed to cool and the precipitated crystals were collected by filtration to give the title compound (312 mg, yield 71%).
melting point: 225-226° C.
FAB-Ms: 456(MH+)
1H-NMR (300MHz, DMSO-d6): 8.20(1H, s), 7.50-7.31(9H, m), 7.12(2H, d, J=8.7Hz), 5.15(2H, s), 4.94(1H, quint, J=8.7Hz), 3.61(3H, s), 3.40(3H, s), 2.41-1.42(8H, m)
Example 16
Production of ethyl 1-cyclohexyl-2-{4-[{4-(4-fluorophenyl)-2-methyl-5-thiazolyl}methoxy]phenyl}benzimidazole-5-carboxylate
Step 1: Production of 4-(4-fluorophenyl)-5-hydroxymethyl-2-methylthiazole
Ethyl 4-(4-fluorophenyl)-2-methyl-5-thiazolecarboxylate (59 g) prepared by a known method (Chem. Pharm. Bull., 43(6), 947, 1995) was dissolved in tetrahydrofuran (700 ml). Lithium aluminum hydride (13 g) was added under ice-cooling and the mixture was stirred for 30 min. Water (13 ml), 15% sodium hydroxide (13 ml) and water (39 ml) were added successively to the reaction mixture, and the precipitated insoluble materials were filtered off. The filtrate was concentrated under reduced pressure to give the title compound (37 g, yield 71%).
1H-NMR (300MHz, CDCl3): 7.60(2H, dd, J=8.7, 6.6Hz), 7.11(2H, t, J=8.7Hz), 4.80(2H, s), 2.70(3H, s)
Step 2: Production of 5-chloromethyl-4-(4-fluorophenyl)-2-methylthiazole
4-(4-Fluorophenyl)-5-hydroxymethyl-2-methylthiazole (37 g) obtained in the previous step was dissolved in chloroform (500 ml), and thionyl chloride (24 ml) and pyridine (2 ml) were added. The mixture was stirred for 3 hr at room temperature. The reaction mixture was poured into ice-cold water. The mixture was extracted with chloroform, and washed with water and saturated brine. The organic layer was dried over sodium sulfate, and concentrated under reduced pressure to give the title compound (29 g, yield 76%).
1H-NMR (300MHz, CDCl3): 7.67(2H, dd, J=8.8, 5.4Hz), 7.16(2H, t, J=8.7Hz), 4.79(2H, s), 2.73(3H, s)
Step 3: Production of ethyl 1-cyclohexyl-2-{4-[{4-(4-fluorophenyl)-2-methyl-5-thiazolyl}methoxy]phenyl}benzimidazole-5-carboxylate
5-Chloromethyl-4-(4-fluorophenyl)-2-methylthiazole (28 g) obtained in the previous step and ethyl 1-cyclohexyl-2-(4-hydroxyphenyl)benzimidazole-5-carboxylate (36 g) obtained in Example 3 were treated in the same manner as in Example 4 to give the title compound (61 g, yield 100%).
APCI-Ms: 570(MH+)
1H-NMR (300MHz, DMSO-d6): 8.25(1H, d, J=1.5Hz), 7.97(1H, d, J=8.7Hz), 7.86(1H, dd, J=8.6, 1.6Hz), 7.74(2H, dd, J=8.8, 5.5Hz), 7.62(2H, d, J=8.7Hz), 7.33(2H, t, J=8.9Hz), 7.22(2H, t, J=8.9Hz), 5.41(2H, s), 4.34(2H, q, J=7.1Hz), 4.31(1H, m), 2.71(3H, s), 2.40-2.15(2H, m), 2.05-1.75(4H, m), 1.55-1.15(3H, m), 1.36(3H, t, J=7.1Hz)
Example 17
Production of 1-cyclohexyl-2-{4-[{4-(4-fluorophenyl)-2-methyl-5-thiazolyl}methoxy]phenyl}benzimidazole-5-carboxylic acid
Ethyl 1-cyclohexyl-2-{4-[{4-(4-fluorophenyl)-2-methyl-5-thiazolyl}methoxy]phenyl}benzimidazole-5-carboxylate (60 g) obtained in Example 16 was treated in the same manner as in Example 2 to give the title compound (39 g, yield 69%).
melting point: 196-198° C.
FAB-Ms: 542(MH+)
1H-NMR (300MHz, DMSO-d6): 13.1(1H, brs), 8.34(1H, s), 8.29(1H, d, J=8.8Hz), 8.06(1H, d, J=8.7Hz), 7.80-7.72(4H, m), 7.36-7.31(4H, m), 5.46(2H, s), 4.38(1H, m), 2.72(3H, s), 2.45-2.15(2H, m), 2.15-1.95(2H, m), 1.95-1.75(2H, m), 1.75-1.55(1H, m), 1.55-1.20(3H, m)
Example 18
Production of ethyl 1-cyclohexyl-2-(2-fluoro-4-hydroxyphenyl)-benzimidazole-5-carboxylate
In the same manner as in Example 3, the title compound (50 g) was obtained.
Example 19
Production of ethyl 2-{4-[bis(3-fluorophenyl)methoxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylate
Step 1: Production of 3,3′-difluorobenzhydrol
To a stirred solution of magnesium strip (35.4 g) in THF (200 ml), iodine strip was added and the mixture was heated with stirring under nitrogen stream until most of color of iodine was disappeared. A solution of 3-fluoro-bromobenzene (250.0 g) in THF (1000 ml) was added dropwise over 2.5 hr while the temperature of the solution was maintained at 60° C. After the completion of the addition of the solution, the resulting mixture was refluxed for 1 hr with heating. The resulting Grignard solution was ice-cooled and a solution of ethyl formate (63.2 g) in THF (200 ml) was added dropwise over 1 hr. After a stirring of the reaction solution for an additional 30 min, saturated aqueous ammonium chloride solution (700 ml) was added dropwise with ice-cooling and water (300 ml) was added. The mixture was stirred for 10 min. The organic layer and water layer were separated. Water layer was extracted with ethyl acetate, and the combined organic layer was washed with 2N hydrochloric acid, saturated aqueous sodium hydrogencarbonate and saturated brine. The organic layer was dried over anhydrous magnesium sulfate, filtered, and the solvent was evaporated off under reduced pressure to give the title compound (156.2 g, yield 99%).
1H-NMR (300MHz, CDCl3): 7.31(2H, td, J=7.9, 5.8Hz), 7.15-7.80(4H, m), 6.97-6.94(2H, m), 5.82(1H, d, J=3.3Hz), 2.30(1H, d, J=3.3Hz)
Step 2: Production of 3,3′-difluorobenzhydryl chloride
To a solution of 3,3′-difluorobenzhydrol (150.0 g) obtained in the previous step in toluene (400 ml), pyridine (539 mg) was added at room temperature. To the solution, thionyl chloride (89.1 g) was added dropwise over 1 hr at room temperature and the resulting solution was stirred for an additional 2 hr. The solution was heated so that the temperature of the solution was at 40° C., and then stirred for an additional 1.5 hr. Thionyl chloride (8.1 g) was added again and the mixture was stirred for 30 min. To the reaction mixture, water was added. The organic layer was separated, and washed with water, saturated aqueous sodium hydrogencarbonate and saturated brine. The organic layer was dried over anhydrous magnesium sulfate, filtered, the solvent was evaporated off under reduced pressure to give the title compound (158.2 g, yield 97%).
1H-NMR (300MHz, CDCl3): 7.32(2H, td, J=8.0, 5.9Hz), 7.18-7.10(4H, m), 7.01(2H, tdd, J=8.2, 2.5, 1.2Hz), 6.05(1H, s)
Step 3: Production of ethyl 2-{4-[bis(3-fluorophenyl)methoxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylate
Ethyl 1-cyclohexyl-2-(2-fluoro-4-hydroxyphenyl)-benzimidazole-5-carboxylate (50 g) obtained in Example 18 and 3,3′-difluorobenzhydryl chloride (34 g) obtained in the previous step were treated in the same manner as in Example 4 to give the title compound (76 g, yield 99%).
FAB-Ms: 585(MH+)
1H-NMR (300MHz, DMSO-d6): 8.24(1H, d, J=1.4Hz), 7.98(1H, d, J=8.7Hz), 7.88(1H, d, J=8.7Hz), 7.56(1H, t, J=8.6Hz), 7.50-1.40(6H, m), 6.82(1H, s), 4.34(2H, q, J=7.1Hz), 3.95(1H, m), 2.20-2.10(2H, m), 1.90-1.80(4H, m), 1.6(1H, m), 1.35(3H, t, J=7.2Hz), 1.30-1.20(3H, mz)
Example 20
Production of 2-{4-(bis[3-fluorophenyl]methoxy)-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid
Ethyl 2-{4-[bis(3-fluorophenyl)methoxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylate (75 g) obtained in Example 19 was treated in the same manner as in Example 2 to give the title compound (48 g, yield 62%).
melting point: 242-243° C.
FAB-Ms: 557(MH+)
1H-NMR (300MHz, DMSO-d6): 8.29(1H, s), 8.16(1H, d, J=8.8Hz), 7.99(1H, d, J=8.7Hz), 7.66(1H, t, J=8.7Hz), 7.51-7.40(6H, m), 7.30(1H, d, J=12.1Hz), 7.20-7.14(3H, m), 6.88(1H, s), 4.07(1H, m), 2.40-2.10(2H, m), 2.00-1.75(4H, m), 1.70-1.55(1H, m), 1.50-1.15(3H, m)
Example 21
Production of ethyl 1-cyclopentyl-2-(4-nitrophenyl)benzimidazole-5-carboxylate
In the same manner as in Example 1, the title compound (12 g) was obtained.
Example 22
Production of ethyl 2-(4-aminophenyl)-1-cyclopentylbenzimidazole-5-carboxylate
Ethyl 1-cyclopentyl-2-(4-nitrophenyl)benzimidazole-5-carboxylate (12 g) obtained in Example 21 was dissolved in tetrahydrofuran (200 ml) and ethyl alcohol (50 ml), 7.5% palladium carbon (50% wet, 1 g) was added. The mixture was hydrogenated for 1 hr at atmospheric pressure. The catalyst was filtered off and the filtrate was concentrated under reduced pressure. Tetrahydrofuran was added to the residue to allow crystallization and the crystals were collected by filtration to give the title compound (11 g, yield 98%).
1H-NMR (300MHz, CDCl3): 8.49(1H, d, J=1.3Hz), 7.95(1H, dd, J=8.5, 1.3Hz), 7.50-7.40(3H, m), 6.79(2H, d, J=4.6Hz), 4.97(1H, quint, J=8.9Hz), 4.40(2H, q, J=7.1Hz), 3.74(2H, brs), 2.40-1.60(8H, m), 1.41(3H, t, J=7.1Hz)
Example 23
Production of ethyl 2-(4-benzoylaminophenyl)-1-cyclopentylbenzimidazole-5-carboxylate
Ethyl 1-cyclopentyl-2-(4-aminophenyl)benzimidazole-5-carboxylate (300 mg) obtained in Example 22 was dissolved in pyridine (3 ml) and chloroform (3 ml), and benzoyl chloride (127 mg) was added. The mixture was stirred for 30 min at room temperature. The reaction mixture was concentrated under reduced pressure and water was added to the residue to allow crystallization. The crystals were collected by filtration to give the title compound (403 mg, yield 100%).
1H-NMR (300MHz, CDCl3): 8.58(1H, s), 8.00(1H, d, J=9.0Hz), 7.84(2H, d, J=7.5Hz), 7.60-7.40(6H, m), 7.14(2H, d, J=7.5Hz), 4.84(1H, quint, J=8.7Hz), 4.41(2H, q, J=7.5Hz), 2.20-1.30(8H, m), 1.41(3H, t, J=7.5Hz)
Example 24
Production of 2-(4-benzoylaminophenyl)-1-cyclopentylbenzimidazole-5-carboxylic acid
Ethyl 2-(4-benzoylaminophenyl)-1-cyclopentylbenzimidazole-5-carboxylate (200 mg) obtained in Example 23 was treated in the same manner as in Example 2 to give the title compound (131 mg, yield 70%).
melting point: not lower than 300° C.
FAB-Ms: 426(MH+)
1H-NMR (300MHz, DMSO-d6): 10.75(1H, s), 8.35(1H, s), 8.15 and 7.85(4H, ABq, J=8.9Hz), 8.10-7.98(4H, m), 7.70-7.55(3H, m), 5.02(1H, quint, J=8.7Hz), 2.36-2.15(4H, m), 2.14-1.95(2H, m), 1.80-1.62(2H, m)
Example 25
Production of ethyl 2-{4-[3-(3-chlorophenyl)phenoxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylate
Ethyl 2-(4-[3-bromophenoxy)phenyl]-1-cyclohexylbenzimidazole-5-carboxylate (65 g) obtained in Example 1 and 3-chlorophenylboronic acid (23 g) were treated in the same manner as in Example 5 to give the title compound (59 g, yield 85%).
1H-NMR (300MHz, CDCl3): 8.51(1H, d, J=1.8Hz), 7.99(1H, dd, J=8.7, 1.8Hz), 7.71-7.55(4H, m), 7.51-7.43(2H, m), 7.43-7.27(4H, m), 7.19(1H, d, J=8.4Hz), 7.12(1H, m), 4.41(2H, q, J=7.2Hz), 4.39(1H, m), 2.42-2.22(2H, m), 2.03-1.87(4H, m), 1.79(1H, m), 1.42(3H, t, J=7.2Hz), 1.39-1.29(3H, m)
Example 26
Production of 2-{4-[3-(3-chlorophenyl)phenoxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid
Ethyl 2-{4-[3-(3-chlorophenyl)phenoxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylate (59 g) obtained in Example 25 was treated in the same manner as in Example 2 to give the title compound (43 g, yield 76%).
melting point: 253-254° C.
FAB-Ms: 523(MH+)
1H-NMR (300MHz, DMSO-d6): 12.82(1H, brs), 8.24(1H, d, J=1.3Hz), 7.98(1H, d, J=8.7Hz), 7.89(1H, dd, J=8.7, 1.3Hz), 7.78(1H, s), 7.72(2H, d, J=9.7Hz), 7.70(1H, m), 7.64-7.42(5H, m), 7.25(2H, d, J=8.7Hz), 7.20(1H, m), 4.33(1H, m), 2.39-2.17(2H, m), 2.00-1.76(4H, m), 1.65(1H, m), 1.50-1.22(3H, m)
Example 27
Production of ethyl 2-[4-(3-acetoxyphenyloxy)phenyl]-1-cyclohexylbenzimidazole-5-carboxylate
In the same manner as in Example 1, the title compound (87 g) was obtained.
Example 28
Production of ethyl 1-cyclohexyl-2-[4-(3-hydroxyphenyloxy)-phenyl]benzimidazole-5-carboxylate
Ethyl 2-[4-(3-acetoxyphenyloxy)phenyl]-1-cyclohexylbenzimidazole-5-carboxylate (87 g) obtained in Example 27 was dissolved in methyl alcohol (250 ml) and tetrahydrofuran (250 ml), and potassium carbonate (31 g) was added. The mixture was stirred for 30 min at room temperature. The insoluble materials were filtered off and the filtrate was concentrated under reduced pressure. Water was added to the residue and the mixture was neutralized with 2N hydrochloric acid. The precipitated crystals were collected by filtration to give the title compound (78 g, yield 97%).
1H-NMR (300MHz, DMSO-d6): 9.71(1H, s), 7.98(1H, d, J=8.7Hz), 7.87(1H, d, J=8.7Hz), 7.68(2H, d, J=8.6Hz), 7.24(1H, t, J=8.1Hz), 7.18(2H, d, J=8.6Hz), 6.63(1H, d, J=8.1Hz), 6.57(1H, d, J=8.1Hz), 6.51(1H, s), 4.38-4.23(1H, m), 4.35(2H, q, J=6.9Hz), 2.36-2.18(2H, m), 1.99-1.78(4H, m), 1.71-1.59(1H, m), 1.45-1.20(3H, m), 1.36(3H, t, J=6.9Hz)
Example 29
Production of ethyl 1-cyclohexyl-2-{4-[3-(4-pyridylmethoxy)-phenyloxy]phenyl}benzimidazole-5-carboxylate
Ethyl 1-cyclohexyl-2-[4-(3-hydroxyphenyloxy)phenyl]-benzimidazole-5-carboxylate (78 g) obtained in Example 28 was suspended in dimethylformamide (800 ml), and sodium hydride (60% oil, 14 g) was added under ice-cooling. The mixture was stirred for 1 hr at room temperature. After the reaction mixture was ice-cooled, 4-chloromethylpyridine hydrochloride (29 g) was added and the mixture was stirred for 30 min. The mixture was then stirred overnight at room temperature. Water was added to the reaction mixture and the precipitated crystals were collected by filtration. The resulting crystals were recrystallized from ethyl alcohol to give the title compound (77 g, yield 82%).
1H-NMR (300MHz, CDCl3): 8.63(2H, d, J=6.0Hz), 8.51(1H, s), 7.99(1H, d, J=8.7Hz), 7.66(2H, d, J=8.7Hz), 7.62(2H, d, J=8.7Hz), 7.36(2H, d, J=8.7Hz), 7.31(1H, t, J=8.2Hz), 7.26(1H, s), 7.16(2H, d, J=8.7Hz), 6.79-6.70(3H, m), 5.09(2H, s), 4.47-4.31(1H, m), 4.42(2H, q, J=7.0Hz), 2.42-2.22(2H, m), 2.04-1.71(5H, m), 1.45-1.25(3H, m), 1.42(3H, t, J=7.0Hz)
Example 30
Production of 1-cyclohexyl-2-{4-[3-(4-pyridylmethoxy)phenyloxy]-phenyl}benzimidazole-5-carboxylic acid
Ethyl 1-cyclohexyl-2-{4-[3-(4-pyridylmethoxy)phenyloxy]-phenyl}benzimidazole-5-carboxylate (60 g) obtained in Example 29 was treated in the same manner as in Example 2 to give the title compound (54 g, yield 75%).
melting point: 235-237° C.
FAB-Ms: 520(MH+)
1H-NMR (300MHz, DMSO-d6): 8.58(2H, d, J=6.0Hz), 8.23(1H, s), 7.96 and 7.86(2H, ABq, J=8.7Hz), 7.68 and 7.17(4H, A′B′q, J=8.7Hz), 7.44(2H, d, J=8.7Hz), 7.39(1H, t, J=8.3Hz), 6.90(1H, d, J=8.1Hz), 6.84(1H, s), 6.75(1H, d, J=8.1Hz), 5.22(2H, s), 4.40-4.22(1H, m), 2.40-2.19(2H, m), 2.00-1.80(4H, m)
Example 241
Production of methyl 2-{4-[2-(4-chlorophenyl)-5-methoxybenzyloxylphenyl}-1-cyclohexylbenzimidazole-5-carboxylate
Step 1: Production of 2-bromo-5-methoxybenzaldehyde
3-Methoxybenzaldehyde (15 g) was dissolved in acetic acid (75 ml), and a solution of bromine (5.7 ml) dissolved in acetic acid (15 ml) was added dropwise. The mixture was stirred overnight at room temperature and water (150 ml) was added to the reaction mixture. The precipitated crystals were collected by filtration, washed with water and dried under reduced pressure to give the title compound (21 g, yield 88%).
1H-NMR (300MHz, CDCl3): 10.31(1H, s), 7.52(1H, d, J=8.8Hz), 7.41(1H, d, J=3.3Hz), 7.03(1H, dd, J=8.8, 3.3Hz), 3.48(3H, s)
Step 2: Production of 2-(4-chlorophenyl)-5-methoxybenzaldehyde
2-Bromo-5-methoxybenzaldehyde (10 g) obtained in the previous step was treated in the same method as in Example 5 to give the title compound (11 g, yield 96%).
1H-NMR (300MHz, CDCl3): 9.92(1H, s), 7.50(1H, d, J=2.6Hz), 7.48-7.14(6H, m), 3.90(3H, s)
Step 3: Production of 2-(4-chlorophenyl)-5-methoxybenzyl alcohol
2-(4-Chlorophenyl)-5-methoxybenzaldehyde (10 g) obtained in the previous step was dissolved in tetrahydrofuran (30 ml). The solution was added dropwise to a suspension of sodium borohydride (620 mg) in isopropyl alcohol (50 ml) and the mixture was stirred for 1 hr. The solvent was evaporated under reduced pressure and water was added to the residue. The precipitated crystals were collected by filtration and dried under reduced pressure. The resulting crystals were recrystallized from a mixture of methanol and water to give the title compound (9.2 g, yield 91%).
1H-NMR (300MHz, CDCl3): 7.37(2H, d, J=8.6Hz), 7.27(2H, d, J=8.6Hz), 7.17(1H, d, J=8.6Hz), 7.11(1H, d, J=2.6Hz), 6.89(1H, dd, J=8.6, 2.6Hz), 4.57(2H, s), 3.86(3H, s)
Step 4: Production of 2-(4-chlorophenyl)-5-methoxybenzyl chloride
2-(4-Chlorophenyl)-5-methoxybenzyl alcohol (20 g) obtained in the previous step was dissolved in ethyl acetate (100 ml) and pyridine (0.5 ml), and thionyl chloride (11 ml) was added dropwise. The mixture was stirred for 1 hr. Water was added to the reaction mixture and the mixture was extracted with ethyl acetate. The organic layer was washed with water, saturated aqueous sodium hydrogencarbonate, water and saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. Isopropyl alcohol was added to the residue to allow crystallization. The resulting crystals were collected by filtration and dried under reduced pressure to give the title compound (16 g, yield 74%).
1H-NMR (300MHz, CDCl3): 7.43-7.29(4H, m), 7.17(1H, d, J=8.6Hz), 7.05(1H, d, J=2.6Hz), 6.96-6.89(1H, m), 4.46(2H, s), 3.86(3H, s)
Step 5: Production of methyl 2-{4-[2-(4-chlorophenyl)-5-methoxybenzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylate
2-(4-Chlorophenyl)-5-methoxybenzyl chloride (4.0 g) obtained in the previous step and methyl 1-cyclohexyl-2-(4-hydroxyphenyl)-benzimidazole-5-carboxylate (5.0 g) obtained in the same manner as in Example 3 were treated in the same manner as in Example 4 to give the title compound (6.0 g, yield 72%).
1H-NMR (300MHz, CDCl3): 8.48(1H, s), 8.00-7.93(1H, m), 7.68-7.62(1H, m), 7.54(2H, d, J=9.0Hz), 7.41-7.16(6H, m), 7.04-6.93(3H, m), 4.97(2H, s), 4.36(1H, m), 3.94(3H, s), 3.87(3H, s), 2.39-2.21(2H, m), 2.02-1.88(4H, m), 1.85-1.45(4H, m)
Example 242
Production of 2-{4-[2-(4-chlorophenyl)-5-methoxybenzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride
Methyl 2-{4-[2-(4-chlorophenyl)-5-methoxybenzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylate (5.0 g) obtained in Example 241 was treated in the same manner as in Example 2 to give the title compound (5.1 g, yield 98%).
APCI-Ms: 568(MH+)
1H-NMR (300MHz, DMSO-d6): 8.30(1H, d, J=1.4Hz), 8.24(1H, d, J=8.7Hz), 8.03(1H, d, J=8.7Hz), 7.72(2H, d, J=8.7Hz), 7.51-7.39(4H, m), 7.34-7.18(4H, m), 7.11-7.03(1H, m), 5.08(2H, s), 4.35(1H, m), 3.83(3H, m), 2.40-2.18(2H, m), 2.10-1.96(2H, m), 1.93-1.78(2Hm), 1.72-1.18(4H, m)
Example 243
Production of ethyl 2-{4-[3-(4-chlorophenyl)pyridin-2-ylmethoxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylate
Step 1: Production of methyl 3-hydroxypicolinate
3-Hydroxypicolinic acid (1.0 g) was suspended in methanol (10 ml) and concentrated sulfuric acid (1.0 ml) was added. The mixture was refluxed under heating for 5 hr. The reaction mixture was ice-cooled, neutralized with saturated aqueous sodium hydrogencarbonate, and extracted with chloroform. The organic layer was washed with water and saturated brine, and dried over anhydrous magnesium sulfate. The solvent was evaporated under reduced pressure to give the title compound (711 mg, yield 64%). 1H-NMR (300MHz, CDCl3): 10.63(1H, s), 8.28(1H, dd, J=3.7, 1.8Hz), 7.47-7.35(2H, m), 4.06(3H, s)
Step 2: Production of methyl 3-(trifluoromethylsulfonyloxy)-pyridine-2-carboxylate
Methyl 3-hydroxypicolinate (710 mg) obtained in the previous step and triethylamine (0.77 ml) were dissolved in dichloromethane (7 ml), and trifluoromethanesulfonic anhydride (0.86 ml) was added under ice-cooling. The reaction mixture was allowed to warm to room temperature and the mixture was stirred for 2 hr. Water was added to the reaction mixture and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine and dried over anhydrous magnesium sulfate. The solvent was evaporated under reduced pressure to give the title compound (1.2 g, yield 90%).
1H-NMR (300MHz, CDCl3): 8.80-8.73(1H, m), 7.75-7.70(1H, m), 7.63(1H, dd, J=8.2, 4.5Hz), 4.05(3H, s)
Step 3: Production of methyl 3-(4-chlorophenyl)pyridine-2-carboxylate
Methyl 3-(trifluoromethylsulfonyloxy)pyridine-2-carboxylate (1.2 g) obtained in the previous step was treated in the same manner as in Example 5 to give the title compound (728 mg, yield 69%).
1H-NMR (300MHz, CDCl3): 8.73-8.66(1H, m), 7.77-7.68(1H, m), 7.49(1H, dd, J=7.8, 4.5Hz), 7.46-7.37(2H, m), 7.32-7.23(2H, m), 3.80(3H, s)
Step 4: Production of (3-(4-chlorophenyl)pyridin-2-yl]methanol
Methyl 3-(4-chlorophenyl)pyridine-2-carboxylate (720 mg) obtained in the previous step was dissolved in tetrahydrofuran (10 ml) and the solution was ice-cooled. Lithium aluminum hydride (160 mg) was added to the solution and the mixture was stirred for 1 hr. To the reaction mixture were added successively water (1.6 ml), 15% sodium hydroxide (1.6 ml) and water (4.8 ml). The insoluble materials were filtered off and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel flash chromatography (developing solvent, n-hexane:ethyl acetate=1:1) to give the title compound (208 mg, yield 32%).
1H-NMR (300MHz, CDCl3): 8.60(1H, dd, J=4.8, 1.5Hz), 7.60-7.55(1H, m), 7.40-7.48(2H, m), 7.29-7.36(1H, m), 7.27-7.20(3H, m), 4.63(2H, s)
Step 5: Production of ethyl 2-{4-[3-(4-chlorophenyl)pyridin-2-ylmethoxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylate
[3-(4-Chlorophenyl)pyridin-2-yl]methanol (200 mg) obtained in the previous step was dissolved in chloroform (3 ml), and thionyl chloride (0.13 ml) and pyridine (catalytic amount) were added. The mixture was stirred for 1 hr at room temperature and concentrated under reduced pressure. The residue was dissolved in dimethylformamide (3 ml), and ethyl 1-cyclohexyl-2-(4-hydroxyphenyl)benzimidazole-5-carboxylate (232 mg) obtained in the same manner as in Example 3 and potassium carbonate (250 mg) were added. The mixture was stirred for 3 hr with heating at 80° C. The reaction mixture was then allowed to cool. Water was added and the mixture was extracted with ethyl acetate. The organic layer was washed with water and saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was purified by silica gel flash chromatography (developing solvent, n-hexane:ethyl acetate=1:2) to give the title compound (246 mg, yield 68%).
1H-NMR (300MHz, CDCl3): 8.71(1H, dd, J=4.7, 1.4Hz), 8.49(1H, d, J=2.1Hz), 7.96(1H, d, J=10.2Hz), 7.71-7.62(2H, m), 7.53(2H, d, J=8.7Hz), 7.45-7.34(5H, m), 7.04(2H, d, J=8.7Hz), 5.14(2H, s), 4.48-4.29(3H, m), 2.38-2.19(2H, m), 2.02-1.22(11H, m)
Example 244
Production of methyl 2-[4-(2-bromo-5-tert-butoxycarbonyl-benzyloxy)phenyl]-1-cyclohexylbenzimidazole-5-carboxylate
Step 1: Production of tert-butyl 4-bromo-3-methylbenzoate
4-Bromo-3-methylbenzoic acid (25 g) was suspended in dichloromethane (200 ml), and oxalyl chloride (12 ml) and dimethylformamide (catalytic amount) were added. The mixture was stirred for 2 hr at room temperature and the solvent was evaporated under reduced pressure. The residue was dissolved in tetrahydrofuran (200 ml) and the solution was ice-cooled. To the solution was added dropwise a solution of potassium tert-butoxide dissolved in tetrahydrofuran (150 ml) and the mixture was stirred for 30 min. Water was added to the reaction mixture and the mixture was extracted with ethyl acetate. The organic layer was washed with water and saturated brine, and dried over anhydrous magnesium sulfate. The solvent was evaporated under reduced pressure to give the title compound (27 g, yield 85%).
1H-NMR (300MHz, CDCl3): 7.83(1H, d, J=2.2Hz), 7.67-7.53(2H, m), 2.43(3H, s), 1.58(9H, s)
Step 2: Production of methyl 2-[4-(2-bromo-5-tert-butoxycarbonylbenzyloxy)phenyl]-1-cyclohexylbenzimidazole-5-carboxylate
tert-Butyl 4-bromo-3-methylbenzoate (7.0 q) obtained in the previous step and methyl 1-cyclohexyl-2-(4-hydroxyphenyl)-benzimidazole-5-carboxylate (6.3 g) obtained in the same manner as in Example 3 were treated in the same manner as in Example 4 to give the title compound (8.8 g, yield 77%).
1H-NMR (300MHz, CDCl3): 8.49(1H, d, J=1.5Hz), 8.21(1H, d, J=2.1Hz), 7.97(1H, d, J=10.2Hz), 7.82(1H, d, J=10.2Hz), 7.71-7.58(4H, m), 7.16(2H, d, J=8.7Hz), 5.23(2H, s), 4.38(1H, m), 3.95(3H, s), 2.40-2.23(2H, m), 2.04-1.90(4H, m), 1.84-1.73(1H, m), 1.59(9H, s), 1.44-1.27(3H, m)
Example 245
Production of methyl 2-4-[5-tert-butoxycarbonyl-2-(4-chlorophenyl)benzyloxy)phenyl]-1-cyclohexylbenzimidazole-5-carboxylate
Methyl 2-[4-(2-bromo-5-tert-butoxycarbonylbenzyloxy)phenyl]-1-cyclohexylbenzimidazole-5-carboxylate (4.5 g) obtained in Example 244 was treated in the same manner as in Example 5 to give the title compound (3.6 g, yield 76%).
1H-NMR (300MHz, CDCl3): 8.48(1H, s), 8.27(1H, d, J=1.8Hz), 8.04(1H, dd, J=7.9, 1.5Hz), 7.96(1H, dd, J=7.0, 1.5Hz), 7.65(1H, d, J=8.6Hz), 7.55(2H, d, J=8.6Hz), 7.43-7.32(5H, m), 7.01(2H, d, J=8.6Hz), 4.99(2H, s), 4.43-4.29(1H, m), 3.95(3H, s), 2.41-2.21(2H, m), 2.02-1.89(4H, m), 1.82-1.73(1H, m), 1.62(9H, s), 1.46-1.28(3H, m)
Example 246
Production of methyl 2-{4-[5-carboxy-2-(4-chlorophenyl)-benzyloxylphenyl}-1-cyclohexylbenzimidazole-5-carboxylate hydrochloride
Methyl 2-{4-(5-tert-butoxycarbonyl-2-(4-chlorophenyl)-benzyloxylphenyl}-1-cyclohexylbenzimidazole-5-carboxylate (3.5 g) obtained in Example 245 was dissolved in dichloromethane (35 ml), and trifluoroacetic acid (35 ml) was added. The mixture was stirred for 1 hr at room temperature and the reaction mixture was concentrated under reduced pressure. The residue was dissolved in ethyl acetate, and 4N hydrochloric acid-ethyl acetate was added. The precipitated crystals were collected by filtration and dried under reduced pressure to give the title compound (3.3 g, yield 97%).
1H-NMR (300MHz, DMSO-d6): 8.33(1H, d, J=1.5Hz), 8.29(1H, s), 8.24(1H, d, J=1.8Hz), 8.09-8.00(2H, m), 7.74(2H, d, J=8.6Hz), 7.61-7.44(5H, m), 7.24(2H, d, J=8.6Hz), 5.19(2H, s), 4.36(1H, m), 3.93(3H, s), 2.37-1.21(10H, m)
Example 247
Production of methyl 2-{4-[2-(4-chlorophenyl)-5-methylcarbamoyl-benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylate
Methyl 2-{4-[5-carboxy-2-(4-chlorophenyl)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylate hydrochloride (400 mg) obtained in Example 246 was suspended in dichloromethane (5 ml), and oxalyl chloride (0.08 ml) and dimethylformamide (catalytic amount) were added. The mixture was stirred for 2 hr at room temperature. The reaction mixture was concentrated under reduced pressure and the residue was dissolved in dichloromethane (5 ml). The resulting solution was added dropwise to a mixed solution of 40% aqueous methylamine solution (5 ml) and tetrahydrofuran (5 ml) under ice-cooling. The reaction mixture was stirred for 1 hr and concentrated under reduced pressure. Water was added to the residue and the mixture was extracted with ethyl acetate. The organic layer was washed with water, saturated aqueous sodium hydrogencarbonate and saturated brine, and dried over anhydrous magnesium sulfate. The solvent was evaporated under reduced pressure and the residue was crystallized from ethyl acetate and diisopropyl ether. The crystals were collected by filtration and dried under reduced pressure to give the title compound (335 mg, yield 86%).
1H-NMR (300MHz, CDCl3): 8.47(1H, s), 8.06(1H, d, J=1.8Hz), 7.96(1H, dd, J=8.6, 1.5Hz), 7.82(1H, dd, J=8.2, 2.2Hz), 7.64(1H, d, J=8.6Hz), 7.54(2H, d, J=9.0Hz), 7.44-7.31(5H, m), 6.99(2H, d, J=9.0Hz), 6.35-6.26(1H, m), 5.00(2H, s), 4.35(1H, m), 3.95(3H, s), 3.05(3H, d, J=4.8Hz), 2.40-1.24(10H, m)
Example 248
Production of 2-{4-(2-(4-chlorophenyl)-5-methylcarbamoylbenzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylate hydrochloride
Methyl 2-{4-[2-(4-chlorophenyl)-5-methylcarbamoylbenzyloxy]-phenyl}-1-cyclohexylbenzimidazole-5-carboxylate (150 mg) obtained in Example 247 and tetrahydrofuran (2 ml) were treated in the same manner as in Example 2 to give the title compound (141 mg, yield 90%).
APCI-Ms: 594(MH+)
1H-NMR (300MHz, DMSO-d6): 8.65-8.58(1H, m), 8.27(1H, d, J=1.5Hz), 8.21(1H, d, J=8.2Hz), 8.15(1H, d, J=1.5Hz), 8.05-7.90(2H, m), 7.70(2H, d, J=8.6Hz), 7.56-7.43(5H, m), 7.21(2H, d, J=8.6Hz), 5.14(2H, s), 4.34(1H, m), 2.81(3H, d, J=4.5Hz), 2.39-1.19(10H, m)
Example 336
Production of methyl 2-[4-(2-bromo-5-nitrobenzyloxy)-2-fluorophenyl]-1-cyclohexylbenzimidazole-5-carboxylate
Commercially available 2-bromo-5-nitrotoluene was dissolved in carbon tetrachloride (30 ml), and N-bromosuccinimide (2.9 g) and N,N′-azobisisobutyronitrile (228 mg) were added, which was followed by refluxing under heating overnight. The reaction mixture was allowed to cool, water was added and the mixture was extracted with chloroform. The organic layer was dried over magnesium sulfate and concentrated under reduced pressure. The residue was dissolved in dimethylformamide (30 ml) and methyl 2-(2-fluoro-4-hydroxyphenyl)-1-cyclohexylbenzimidazole-5-carboxylate (3.8 g) obtained in the same manner as in Example 3 and potassium carbonate (3.8 g) were added, which was followed by stirring at 80° C. for 1 hr. The reaction mixture was allowed to cool, water was added and the mixture was extracted with ethyl acetate. The organic layer was washed with water and saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was purified by silica gel flash chromatography (n-hexane:ethyl acetate=1:1) to give the title compound (3.7 g, yield 61%).
1H-NMR (300MHz, CDCl3): 8.55-8.45(2H, m), 8.15-8.05(1H, m), 7.99(1H, dd, J=8.6Hz, 1.5Hz), 7.70-7.55(2H, m), 7.05-6.85(2H, m), 5.24(2H, s), 4.06(1H, m), 3.95(3H, s), 2.35-2.15(2H, m), 2.05-1.85(4H, m), 1.80-1.70(1H, m), 1.45-1.20(3H, m)
Example 337
Production of methyl 2-[4-{2-(4-chlorophenyl)-5-nitrobenzyloxy}-2-fluorophenyl]-1-cyclohexylbenzimidazole-5-carboxylate
Methyl 2-[4-(2-bromo-5-nitrobenzyloxy)-2-fluorophenyl]-1-cyclohexylbenzimidazole-5-carboxylate (2.0 g) obtained in Example 336, 4-chlorophenylboronic acid (590 mg) and tetrakis(triphenylphosphine)palladium (396 mg) were suspended in dimethoxyethane (40 ml), and saturated aqueous sodium hydrogencarbonate solution (20 ml) was added, which was followed by refluxing under heating for 1 hr. The reaction mixture was allowed to cool, water was added and the mixture was extracted with chloroform. The organic layer was dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was purified by silica gel flash chromatography (n-hexane:ethyl acatate=2:1) to give the title compound (1.9 g, yield 90%).
1H-NMR (300MHz, CDCl3): 8.55(1H, d, J=2.3Hz), 8.49(1H, d, J=1.4Hz), 8.29(1H, dd, J=8.4Hz, 2.3Hz), 7.98(1H, dd, J=8.6Hz, 1.5Hz), 7.60-7.30(6H, m), 6.85-6.70(2H, m), 5.03(2H, s), 4.02(1H, m), 3.95(3H, s), 2.35-2.10(2H, m), 2.05-1.70(5H, m), 1.40-1.20(3H, m)
Example 338
Production of methyl 2-[4-{5-amino-2-(4-chlorophenyl)benzyloxy}-2-fluorophenyl]-1-cyclohexylbenzimidazole-5-carboxylate
Methyl 2-[4-{2-(4-chlorophenyl)-5-nitrobenzyloxy}-2-fluorophenyl]-1-cyclohexylbenzimidazole-5-carboxylate (1.9 g) obtained in Example 337 was suspended in ethanol (40 ml), and tin(II) chloride dihydrate (3.5 g) was added, which was followed by refluxing under heating for 30 min. The reaction mixture was concentrated under reduced pressure, 4N sodium hydroxide was added and the mixture was extracted with chloroform. The organic layer was washed with 2N sodium hydroxide and water, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. Diisopropyl ether was added to the residue, and the precipitated crystals were collected by filtration to give the title compound (1.5 g, yield 82%).
1H-NMR (300MHz, CDCl3): 8.49(1H, d, J=12Hz), 7.98(1H, dd, J=9.0, 1.5Hz), 7.66(1H, d, J=8.7Hz), 7.49(1H, t, J=8.4Hz), 7.40-7.20(3H, m),7.13(1H, d, J=8.1Hz), 6.92(1H, d, J=2.7Hz), 6.85-6.65(4H, m), 4.92(2H, s), 4.03(1H, m), 3.95(3H, s), 3.82(2H, brs), 2.30-2.10(2H, m), 2.05-1.80(4H, m), 1.80-1.70(1H, m), 1.40-1.10(3H, m)
Example 339
Production of methyl 2-[4-{2-(4-chlorophenyl)-5-(2-oxopyrrolidin-1-yl)benzyloxy}-2-fluorophenyl]-1-cyclohexylbenzimidazole-5-carboxylate
Methyl 2-[4-{5-amino-2-(4-chlorophenyl)benzyloxy}-2-fluorophenyl]-1-cyclohexylbenzimidazole-5-carboxylate (500 mg) obtained in Example 338 and triethylamine (0.14 ml) were dissolved in chloroform (5 ml), and commercially available chlorobutyryl chloride (0.1 ml) was added under ice-cooling, which was followed by stirring at room temperature for 3 hr. Water was added to the reaction mixture and the mixture was extracted with ethyl acetate. The organic layer was washed with water and saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was dissolved in dimethylformamide (6 ml) and potassium carbonate (244 mg) was added, which was followed by stirring at 80° C. for 1 hr. The reaction mixture was allowed to cool, water was added and the precipitated crystals were collected by filtration to give the title compound (502 mg, yield 89%).
1H-NMR (300MHz, CDCl3): 4.89(1H, d, J=1.5Hz), 7.98(1H, dd, J=8.6Hz, 1.6Hz), 7.72(1H, d, J=2.2Hz), 7.75-7.65(2H, m), 7.49(1H, t, J=8.3Hz), 7.45-7.20(5H, m), 6.85-7.65(2H, m), 4.99(2H, s), 4.10-3.85(6H, m), 2.66(2H, t, J=7.8Hz), 2.30-2.15(4H, m), 2.00-1.85(4H, m), 1.80-1.70(1H, m), 1.45-1.20(3H, m)
Example 340
Production of 2-[4-{2-(4-chlorophenyl)-5-(2-oxopyrrolidin-1-yl)benzyloxy}-2-fluorophenyl]-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride
Methyl 2-[4-{2-(4-chlorophenyl)-5-(2-oxopyrrolidin-1-yl)benzyloxy}-2-fluorophenyl]-1-cyclohexylbenzimidazole-5-carboxylate (200 mg) obtained in Example 339 was treated in the same manner as in Example 2 to give the title compound (182 mg, yield 87%).
Ms: 638(M+1)
1H-NMR (300MHz, CDCl3): 8.28(1H, d, J=1.3Hz), 8.10(1H, d, J=8.7Hz), 8.05-7.90(2H, m), 7.77(1H, dd, J=8.4Hz, 2.2Hz), 7.61(1H, t, J=8.5Hz), 7.55-7.35(5H, m), 7.00-7.20(2H, m), 5.09(2H, s), 4.06(1H, in), 3.90(2H, t, J=6.9Hz), 2.60-2.45(2H, m), 2.30-2.00(4H, m), 1.95-1.75(4H, m), 1.70-1.55(1H, m), 1.45-1.15(3H, m)
Example 340-2
Step 1: Production of 4′-chloro-4-nitro-biphenyl-2-carbaldehyde
To a solution of 2-chloro-5-nitrobenzaldehyde (100 g) in 1,2-dimethoxyethane (1000 ml) were added 4-chlorophenylboronic acid (93 g), bistriphenylphosphine palladium(II) dichloride (380 mg), sodium hydrogencarbonate (68 g) and water (500 ml), and the mixture was refluxed for 1 hr. The reaction mixture was cooled to 50° C., ethyl acetate (1000 ml) was added thereto and the mixture was stirred. The aqueous layer was separated and the organic layer was washed with water (500 ml), 1N aqueous sodium hydroxide solution (500 ml), water (500 ml), 28% aqueous ammonia (500 ml), water (500 ml), 2N hydrochloric acid (500 ml) and saturated brine (500 ml), dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was suspended in diisopropyl ether (500 ml), filtrated and vacuum dried to give the title compound (120 g, yield 85%).
1H-NMR (300MHz, DMSO-d6): 9.92(1H, s), 8.61 (1H, d, J=2.5Hz), 8.53(1H, dd, J=2.6Hz, 8.5Hz), 7.82(1H, d, J=8.5Hz), 7.64(2H, d, J=8.7Hz), 7.59(2H, d, J=8.7Hz)
Step 2: Production of (4′-chloro-4-nitro-biphenyl-2-yl)methanol
A solution of 4′-chloro-4-nitro-biphenyl-2-carbaldehyde (120 g) obtained in the previous step in tetrahydrofuran (900 ml) was added dropwise to a suspension of sodium borohydride (47 g) in 2-propanol (600 ml), over 70 min under water-cooling. The reaction mixture was stirred at room temperature for 1 hr, and 2N hydrochloric acid (185 ml) was dropwise added thereto over 40 min under water-cooling. The mixture was stirred at room temperature for 30 min and concentrated under reduced pressure. The residue was suspended in 2-propanol (300 ml), and water (1000 ml) was added with stirring. After stirring the mixture for 30 min, the crystals were collected by filtration and vacuum dried to give the title compound (116 g, yield 96%).
1H-NMR (300MHz, DMSO-d6): 8.43(1H, d, J=2.5Hz), 8.19(1H, dd, J=2.6Hz, 8.4Hz), 7.57(2H, d, J=8.5Hz), 7.52(1H, d, J=8.4Hz), 7.47(2H, d, J=8.6Hz), 5.59(1H, brs), 4.48(2H, s)
Step 3: Production of (4-amino-4′-chloro-biphenyl-2-yl)methanol
To a suspension of (4′-chloro-4-nitro-biphenyl-2-yl)methanol (1.0 g) obtained in the previous step and sodium hydrosulfite (2.0 g) in N,N-dimethylformamide (4 ml) and methanol (1 ml) was added water (0.3 ml, 50 μl each time in 6 portions) every 20 min at 100° C. Water (5 ml) was added threto at room temperature. Conc. hydrochloric acid (2.5 ml) was added threto at room temperature. The mixture was stirred at 55° C. for 2.5 hr, and a solution of sodium hydroxide (1.2 g) in water (3 ml) was added under ice-cooling. Water (5 ml) was added and the mixture was stirred at room temperature for 1 hr. The precipitate was filtrated and washed with water (3 ml). The crystals were vacuum dried to give the title compound (700 mg, yield 79%).
1H-NMR (400MHz, DMSO-d6): 7.39(2H, d, J=8.5Hz), 7.35(2H, d, J=8.5Hz), 6.90(1H, d, J=8.4Hz), 6.82(1H, s), 6.56(1H, d, J=8.4Hz), 5.20(2H, brs), 5.04(1H, t, J=5.4Hz), 4.29(2H, d, J=5.4Hz)
Step 4: Production of 4-chloro-N-(4′-chloro-2-hydroxymethyl-biphenyl-4-yl)butyramide
To a solution of (4-amino-4′-chloro-biphenyl-2-yl)-methanol (1.0 g) obtained in the previous step in tetrahydrofuran (10 ml) were added sodium acetate (390 mg) and acetic acid (0.27 ml) at room temperature.
4-Chlorobutyryl chloride (0.48 ml) was gradually added dropwise under ice-cooling. After stirring the mixture at room temperature for 30 min, water (20 ml) and ethyl acetate (20 ml) were added to the reaction mixture and the organic layer was separated. The organic layer was washed with saturated aqueous sodium hydrogencarbonate (20 ml) and saturated brine (20 ml). The organic layer was dried over sodium sulfate, filtrated and the solvent was evaporated to give the title compound (1.44 g, yield 99%).
1H-NMR (300MHz, CDCl3): 7.68(1H, s), 7.55(1H, d, J=8.4Hz), 7.39(2H, d, J=8.5Hz), 7.28(2H, d, J=8.5Hz), 7.22(1H, d, J=8.3Hz), 4.58(2H, s), 3.69(2H, t, J=6.1Hz), 2.60(2H, t, J=7.0Hz), 2.22(2H, m)
Step 5: Production of 1-(4′-chloro-2-hydroxymethyl-biphenyl-4-yl)-2-pyrrolidinone
To a solution of 4-chloro-N-(4′-chloro-2-hydroxymethyl-biphenyl-4-yl)butyramide (1.44 g) obtained in the previous step in N,N-dimethylformamide (15 ml) was added potassium carbonate (710 mg) at room temperature. After stirring the mixture at 100° C. for 90 min, 1N hydrochloric acid, (5 ml) and water (20 ml) were added at room temperature and the precipitated crystals were collected by filtration and washed with water (5 ml). The crystals were vacuum dried to give the title compound (970 mg, yield 76%).
1H-NMR (300MHz, CDCl3): 7.76(1H, d, J=2.3Hz), 7.62(1H, dd, J=2.4Hz, 8.3Hz), 7.38(2H, d, J=8.5Hz), 7.29(2H, d, J=8.5Hz), 7.25(1H, d, J=8.3Hz), 4.61(2H, s), 3.91(2H, t, J=7.0Hz), 2.62(2H, t, J=7.8Hz), 2.18(2H, m)
Step 6: Production of 1-(4′-chloro-2-chloromethyl-biphenyl-4-yl)-2-pyrrolidinone
To a mixed solution of 1-(4′-chloro-2-hydroxymethyl-biphenyl-4-yl)-2-pyrrolidinone (900 mg) obtained in the previous step in N,N-dimethylformamide (2 ml) and toluene (7 ml) was dropwise added thionyl chloride (0.26 ml) under ice-cooling. After stirring the mixture at room temperature for 3 hr, the reaction mixture was diluted with ethyl acetate (20 ml) and washed with water (20 ml), saturated aqueous sodium hydrogencarbonate (20 ml) and saturated brine (20 ml). The organic layer was dried over sodium sulfate, filtrated and the solvent was evaporated under reduced pressure to give the title compound (954 mg, yield 99%).
1H-NMR (300MHz, CDCl3): 7.77(1H, d, J=2.3Hz), 7.69(1H, dd, J=2.4Hz, 8.5Hz),7.42(2H, d, J=8.6Hz), 7.34(2H, d, J=8.6Hz), 7.26(1H, d, J=8.4Hz), 4.50(2H, s), 3.92(2H, t, J=7.0Hz), 2.65(2H, t, J=7.8Hz), 2.20(2H, m)
Step 7: Production of methyl 2-[4-{2-(4-chlorophenyl)-5-(2-oxopyrrolidin-1-yl)benzyloxy}-2-fluorophenyl]-1-cyclohexylbenzimidazole-5-carboxylate
To a suspension of methyl 1-cyclohexyl-2-(2-fluoro-4-hydroxyphenyl)benzimidazole-5-carboxylate (915 mg) obtained in Example 18 in N,N-dimethylformamide (6 ml) was added 1-(4′-chloro-2-chloromethyl-biphenyl-4-yl)-2-pyrrolidinone (954 mg) obtained in the previous step and potassium carbonate (415 mg) at room temperature. After stirring the mixture at 100° C. for 1 hr, 1N hydrochloric acid (3 ml) and water (8 ml) were added at room temperature and the precipitated crystals were collected by filtration and washed with water (5 ml). The crystals were vacuum dried to give the title compound (1.6 g, yield 100%).
1H-NMR (300MHz, CDCl3): 8.49(1H, d, J=1.5Hz), 7.98(1H, dd, J=1.6Hz, 8.6Hz), 7.90(1H, d, J=2.2Hz), 7.72-7.65(2H, m), 7.49(1H, t, J=8.3Hz), 7.40(2H, d, J=8.5Hz), 7.34(1H, d, J=8.7Hz), 7.31(2H, d, J=8.6Hz), 6.80 (1H, d, J=8.6Hz), 6.71(1H, d, J=11.6Hz), 4.99(2H, s), 4.04(1H, m), 3.95(3H, s), 3.93(2H, t, J=7.1Hz), 2.66(2H, t, J=7.8Hz), 2.30-2.15(4H, m), 2.00-1.85(4H, m), 1.80-1.70(1H, m), 1.45-1.20(3H, m)
Step 8: Production of 2-[4-{2-(4-chlorophenyl)-5-(2-oxopyrrolidin-1-yl)benzyloxy}-2-fluorophenyl]-1-cyclohexylbenzimidazole-5-carboxylic acid
Methyl 2-[4-{2-(4-chlorophenyl)-5-(2-oxopyrrolidin-1-yl)benzyloxy}-2-fluorophenyl]-1-cyclohexylbenzimidazole-5-carboxylate (2.0 g) obtained in the previous step was suspended in methanol (4.0 ml) and tetrahydrofuran (8.0 ml), and 2N aqueous sodium hydroxide solution (2.3 ml) was added. The mixture was heated under reflux for 3 hr. The reaction mixture was allowed to cool and tetrahydrofuran (1.0 ml) and water (5.0 ml) were added. 2N Hydrochloric acid (2.3 ml) was gradually added at room temperature. After stirring the mixture at room temperature for 2 hr, the precipitated crystals were collected by filtration and washed successively with methanol-water (1:1) mixed solution (6.0 ml), water (6.0 ml) and methanol-water (1:1) mixed solution (6.0 ml), and vacuum dried to give the title compound (1.84 g, yield 94%).
1H-NMR (300MHz, DMSO-d6): 12.75(1H, brs), 8.26(1H, s), 7.99(1H, s), 7.96(1H, d, J=9.0Hz), 7.89(1H, d, J=9.0Hz), 7.78(1H, dd, J=2.1Hz, 8.4Hz), 7.54(1H, t, J=9.0Hz), 7.49(2H, d, J=8.7Hz), 7.45(2H, d, J=8.4Hz), 7.38(1H, d, J=8.4Hz), 7.08(1H, dd, J=2.1Hz, 12.0Hz), 6.96(1H, dd, J=2.1Hz, 8.7Hz), 5.09(2H, s), 3.99(1H, m), 3.91(2H, t, J=6.6Hz), 2.54(2H, t, J=7.8Hz), 2.30-2.00(4H, m), 1.95-1.50(5H, m), 1.45-1.20(3H, m)
Step 9: Production of 2-[4-{2-(4-chlorophenyl)-5-(2-oxopyrrolidine-1-yl)benzyloxy}-2-fluorophenyl]-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride
To 4N hydrochloric acid (50 ml) were successively added 2-[4-{2-(4-chlorophenyl)-5-(2-oxopyrrolidin-1-yl)benzyloxy}-2-fluorophenyl]-1-cyclohexylbenzimidazole-5-carboxylic acid (10.0 g) obtained in the previous step and acetone-methyl ethyl ketone (3:2) mixed solution (20 ml). The mixture was stirfed at 60° C. for 3 hr and at room temperature for 1 hr. The crystals were collected by filtration, washed twice with acetone (10 ml) and vacuum dried to give the title compound (9.62 g, yield 91%).
melting point: 243-246° C.
Ms: 638(M+1)
1H-NMR (300MHz, DMSO-d6): 8.33(1H, d, J=1.1Hz), 8.21 (1H, d, J=8.8Hz), 8.02(1H, d, J=8.8Hz), 8.00(1H, d, J-2.2Hz), 7.77(1H, dd, J=2.2Hz, 8.4Hz), 7.68(1H, t, J=8.4Hz), 7.50(2H, d, J=8.4Hz), 7.45(2H, d, J=8.4Hz), 7.39(1H, d, J=8.4Hz), 7.20(1H, dd, J=2.2Hz, 12.1Hz), 7.06(1H, dd, J=2.2Hz, 8.8Hz), 5.11(2H, s), 4.13(1H, m), 3.91(2H, t, J=7.0Hz), 2.54(2H, t, J=8.1Hz), 2.40-2.05(4H, m), 2.00-1.75(4H, m), 1.70-1.55(1H, m), 1.50-1.20(3H, m)
In the same manner as in Examples 1-30, 241-248 and 336-340 and optionally using other conventional methods, where necessary, the compounds of Examples 31-240, 249-335, 341-471, 701-703 and 1001-1559 were obtained. The chemical structures and properties are shown in Table 1 to 177, 185 to 212, 219 to 221 and 225 to 269.
Example 501
Production of methyl 2-{4-(2-(4-chlorophenyl)-5-methoxybenzyloxylphenyl}-1-cyclohexyl-1H-indole-5-carboxylate
Step 1: Production of methyl 3-bromo-4-cyclohexylaminobenzoate 3-Bromo-4-fluorobenzoic acid (2.0 g) was dissolved in methanol (20 ml) and concentrated sulfuric acid (2 ml) was added. The mixture was refluxed for 3 hr. The reaction mixture was poured into ice-cold water and extracted with ethyl acetate (50 ml). The organic layer was washed with water (30 ml) and saturated brine (30 ml), and dried over sodium sulfate. After filtration, the solvent was evaporated under reduced pressure. The residue was dissolved in dimethyl sulfoxide (20 ml) and cyclohexylamine (10.3 ml) was added. The mixture was stirred overnight at 120° C. The reaction mixture was poured into 10% aqueous citric acid solution (100 ml) and extracted with ethyl acetate (100 ml). The organic layer was washed with water (50 ml) and saturated brine (50 ml), and dried over sodium sulfate. After filtration, the solvent was evaporated under reduced pressure and the residue was purified by silica gel flash chromatography (developing solvent, n-hexane:ethyl acetate=10:1) to give the title compound (2.6 g, yield 92%).
1H-NMR (300MHz, CDCl3): 8.10(1H, d, J=1.9Hz), 7.83(1H, dd, J=1.9Hz, 8.6Hz), 6.59(1H, d, J=8.7Hz), 4.73(1H, brd, J=7.3Hz), 3.85(3H, s), 3.38(1H, m), 2.10-2.00(2H, m), 1.90-1.20(8H, m)
Step 2: Production of 4′-chloro-2-(4-iodophenoxymethyl)-4-methoxybiphenyl
4-Iodophenol (5.0 g) was dissolved in acetone (50 ml), and potassium carbonate (4.7 g) and 4′-chloro-2-chloromethyl-4-methoxybiphenyl (6.0 g) obtained in Example 241, Step 4 were added. The mixture was refluxed for 10 hr. The reaction mixture was concentrated and 4N aqueous sodium hydroxide solution (50 ml) was added. The precipitated crystals were collected by filtration, washed with water, and dried under reduced pressure to give the title compound (10.0 g, yield 98%).
1H-NMR (300MHz, CDCl3): 7.52(2H, d, J=8.9Hz), 7.35(2H, d, J=8.5Hz), 7.27-7.20(3H, m), 7.12(1H, s), 6.95(1H, d, J=8.5Hz), 6.62(2H, d, J=8.9Hz), 4.84(2H, s), 3.85(3H, s)
Step 3: Production of [4-(4′-chloro-4-methoxybiphenyl-2-ylmethoxy)phenylethynyl]trimethylsilane
4′-Chloro-2-(4-iodophenoxymethyl)-4-methoxybiphenyl (7.0 g) obtained in the previous step was dissolved in acetonitrile (50 ml), and trimethylsilylacetylene (2.3 g), tetrakis-(triphenylphosphine)palladium complex (1.8 g), copper(I) iodide (0.6 g) and triethylamine (50 ml) were added. The mixture was stirred overnight at room temperature and concentrated. Water (30 ml) was added and the mixture was extracted with ethyl acetate (50 ml). The organic layer was washed with water (30 ml) and saturated brine (30 ml) and dried over sodium sulfate. After filtration, the solvent was evaporated under reduced pressure and the residue was purified by silica gel flash chromatography (developing solvent, n-hexane:ethyl acetate=10:1) to give the title compound (5.1 g, yield 79%).
1H-NMR (300MHz, CDCl3): 7.37(2H, d, J=8.9Hz), 7.34(2H, d, J=8.2Hz), 7.28-7.21(3H, m), 7.13(1H, s), 6.94(1H, d, J=8.2Hz), 6.75(2H, d, J=8.9Hz), 4.87(2H, s), 3.85(3H, s), 0.23(9H, s)
Step 4: Production of methyl 3-[4-(4′-chloro-4-methoxybiphenyl-2-ylmethoxy)phenylethynyl]-4-cyclohexylaminobenzoate
[4-(4′-Chloro-4-methoxybiphenyl-2-ylmethoxy)phenylethynyl]-trimethylsilane (5.1 g) obtained in the previous step was dissolved in methanol (50 ml) and chloroform (50 ml), and potassium carbonate (2.5 g) was added. The mixture was stirred for 3 hr at room temperature and concentrated. Water (30 ml) was added and the mixture was extracted with ethyl acetate (50 ml). The organic layer was washed with water (30 ml) and saturated brine (30 ml) and dried over sodium sulfate. After filtration, the solvent was evaporated under reduced pressure to give white crystals (3.8 g). The white crystals (2.3 g) were dissolved in acetonitrile (10 ml), and methyl 3-bromo-4-cyclohexylamino-benzoate (1.0 g) obtained in Step 1, tetrakis(triphenyl-phosphine)palladium complex (0.4 g), copper(I) iodide (0.1 g) and triethylamine (10 ml) were added. The mixture was stirred overnight at 100° C. and concentrated under reduced pressure. Water (30 ml) was added and the mixture was extracted with ethyl acetate (50 ml). The organic layer was washed with water (30 ml) and saturated brine (30 ml), and dried over sodium sulfate. After filtration, the solvent was evaporated under reduced pressure and the residue was purified by silica gel flash chromatography (developing solvent, n-hexane:ethyl acetate=8:1) to give the title compound (0.9 g, yield 49%).
1H-NMR (300MHz, CDCl3): 8.03(1H, s), 7.84(1H, d, J=8.7Hz), 7.42-7.22(7H, m), 7.15(1H, s), 6.95(1H, d, J=8.2Hz), 6.85(2H, d, J=8.8Hz), 6.59(1H, d, J=8.8Hz), 5.07(1H, brs), 4.91(2H, s), 3.86(3H, s), 3.85(3H, s), 3.42(1H, m), 2.15-2.00(2H, m), 1.80-1.20(8H, m)
Step 5: Production of methyl 2-{4-[2-(4-chlorophenyl)-5-methoxybenzyloxy]phenyl}-1-cyclohexyl-1H-indole-5-carboxylate
Methyl 3-[4-(4′-chloro-4-methoxybiphenyl-2-ylmethoxy)phenyl-ethynyl]-4-cyclohexylaminobenzoate (0.5 g) obtained in the previous step was dissolved in N,N-dimethylformamide (5 ml), and copper(I) iodide (0.17 g) was added. The mixture was refluxed for 3 hr at 180° C. The insoluble materials were removed by filtration. Water (10 ml) was added and the mixture was extracted with ethyl acetate (30 ml). The organic layer was washed with water (10 ml) and saturated brine (10 ml), and dried over sodium sulfate. After filtration, the solvent was evaporated under reduced pressure and the residue was purified by silica gel flash chromatography (developing solvent, n-hexane:ethyl acetate=8:1) to give the title compound (0.27 g, yield 55%).
1H-NMR (300MHz, CDCl3): 8.34(1H, s), 7.85(1H, d, J=8.8Hz), 7.62(1H, d, J=8.8Hz), 7.40-7.18(8H, m), 7.00-6.94(3H, m), 6.48(1H, s), 4.95(2H, m), 4.18(1H, m), 3.93(3H, s), 3.88(3H, s), 2.45-2.25(2H, m), 1.95-1.20(8H, m)
Example 502
Production of 2-{4-[2-(4-chlorophenyl)-5-methoxybenzyloxy]phenyl}-1-cyclohexyl-1H-indole-5-carboxylic acid
Methyl 2-{4-[2-(4-chlorophenyl)-5-methoxybenzyloxy]phenyl}-1-cyclohexyl-1H-indole-5-carboxylate (0.27 g) obtained in Example 501 was treated in the same manner as in Example 2 to give the title compound (0.19 g, yield 71%).
APCI-Ms: 566(MH+)
1H-NMR (300MHz, DMSO-d6): 12.43(1H, brs), 8.20(1H, s), 7.79(1H, d, J=9.3Hz), 7.72(1H, d, J=9.0Hz), 7.50-7.20(8H, m), 7.07-7.03(3H, m), 6.53(1H, s), 5.01(2H, s), 4.13(1H, m), 3.83(3H, m), 2.35-2.25(2H, m), 1.85-1.10(8H, m)
In the same manner as in Examples 501 and 502, and optionally using other conventional methods where necessary, the compound of Example 503 was obtained. The chemical structure and properties are shown in Table 207.
Example 601
Production of ethyl 2-(4-benzyloxyphenyl)-3-cyclohexylimidazo-[1,2-a]pyridine-7-carboxylate
Step 1: Production of 4-benzyloxy-N-methoxy-N-methylbenzamide
4-Benzyloxybenzoic acid (5.0 g) and N,O-dimethyl-hydroxylamine hydrochloride (2.5 g) were suspended in dimethylformamide (50 ml), and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (5.0 g), 1-hydroxybenzotriazole (3.5 g) and triethylamine (3.6 ml) were added. The mixture was stirred overnight at room temperature. Water was added to the reaction mixture and the mixture was extracted with ethyl acetate. The organic layer was washed successively with water, saturated aqueous sodium hydrogencarbonate, water and saturated brine, and dried over anhydrous magnesium sulfate. The solvent was evaporated under reduced pressure to give the title compound (5.6 g, yield 94%).
1H-NMR (300MHz, CDCl3): 7.22, 2H, d, J=8.8Hz), 7.28-7.46(5H, m), 6.97(2H, d, J=8.8Hz), 5.10(2H, s), 3.56(3H, s), 3.35(3H, s)
Step 2: Production of 1-(4-benzyloxyphenyl)-2-cyclohexylethanone
Magnesium (470 mg) was suspended in tetrahydrofuran (2 ml) and cyclohexylmethyl bromide (3.4 g) was added dropwise at room temperature. After the addition, the reaction mixture was stirred for 30 min at 60° C. The reaction mixture was allowed to cool and diluted with tetrahydrofuran (5 ml). Separately, 4-benzyloxy-N-methoxy-N-methylbenzamide (3.4 g) obtained in the previous step was dissolved in tetrahydrofuran (10 ml) and the solution was added dropwise to the reaction mixture at room temperature. The mixture was stirred for 2 hr and saturated aqueous ammonium chloride solution was added to the reaction mixture. The mixture was extracted with diethyl ether. The organic layer was washed with saturated brine and dried over anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel flash chromatography (developing solvent, n-hexane:ethyl acetate=9:1) to give the title compound (3.8 g, yield 66%).
1H-NMR (300MHz, CDCl3): 7.93(2H, d, J=8.8Hz), 7.28-7.46(5H, m), 7.00(2H, d, J=8.8Hz), 5.13(2H, s), 2.76(2H, d, J=6.8Hz), 1.95(1H, m), 0.78-1.82(10H, m)
Step 3: Production of 1-(4-benzyloxyphenyl)-2-bromo-2-cyclohexylethanone
1-(4-Benzyloxyphenyl)-2-cyclohexylethanone (1.0 g) obtained in the previous step was dissolved in 1,4-dioxane (10 ml) and bromine (0.17 ml) was added. The mixture was stirred for 10 min at room temperature. Saturated aqueous sodium hydrogencarbonate was added to the reaction mixture and the mixture was extracted with diethyl ether. The organic layer was washed with water and saturated brine and dried over anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel flash chromatography (developing solvent, n-hexane:ethyl acetate=9:1) to give the title compound (696 mg, yield 55%).
1H-NMR (300MHz, CDCl3): 7.98(2H, d, J=8.9Hz), 7.28-7.48(5H, m), 7.02(2H, d, J=8.9Hz), 5.14(2H, s), 4.89(1H, d, J=9.3Hz), 0.86-3.30(11H, m)
Step 4: Production of ethyl 2-(4-benzyloxyphenyl)-3-cyclohexylimidazo[1,2-a]pyridine-7-carboxylate
Ethyl 2-aminopyridine-4-carboxylate (214 mg) prepared according to JP-A-8-48651, 1-(4-benzyloxyphenyl)-2-bromo-2-cyclohexylethanone (500 mg) obtained in the previous step and potassium carbonate (356 mg) were stirred for 5 hr with heating at 140° C. The reaction mixture was allowed to cool and chloroform was added. The insoluble materials were filtered off and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel flash chromatography (developing solvent, n-hexane:ethyl acetate=1:1) to give the title compound (95 mg, yield 16%).
APCI-MS: 455(MH+)
1H-NMR (300MHz, CDCl3): 8.33(1H, s), 8.21(1H, d, J=7.5Hz), 7.55(2H, d, J=8.7Hz), 7.25-7.50(6H, m), 5.13(2H, s), 4.41(2H, q, J=7.1Hz), 3.25(1H, m), 1.41(3H, t, J=7.1Hz), 1.15-2.00(10H, m)
Example 602
Production of 2-(4-benzyloxyphenyl)-3-cyclohexylimidazo[1,2-a]pyridine-7-carboxylic acid
Ethyl 2-(4-benzyloxyphenyl)-3-cyclohexylimidazo[1,2-a]pyridine-7-carboxylate (95 mg) obtained in the previous step was treated in the same manner as in Example 2 to give the title compound (33 mg, 37%).
APCI-MS: 427(MH+)
1H-NMR (300MHz, DMSO-d6): 8.67(1H, d, J=7.3Hz), 8.08(1H, s), 7.25-7.58(8H, m), 7.13(2H, d, J=8.7Hz), 5.17(2H, s), 3.23(1H, m), 1.25-2.10(10H, m)
The compounds shown in Tables 213 to 218 can be further obtained in the same manner as in Examples 1 to 703 or by other conventional method employed as necessary.
The evaluation of the HCV polymerase inhibitory activity of the compound of the present invention is explained in the following. This polymerase is an enzyme coded for by the non-structural protein region called NS5B on the RNA gene of HCV (EMBO J., 15:12-22, 1996).
Experimental Example [I]
i) Preparation of enzyme (HCV polymerase)
Using, as a template, a cDNA clone corresponding to the full length RNA gene of HCV BK strain obtained from the blood of a patient with hepatitis C, a region encoding NS5B (591 amino acids; J Virol 1991 Mar, 65(3), 1105-13) was amplified by PCR. The objective gene was prepared by adding a 6 His tag {base pair encoding 6 continuous histidine (His)} to the 5′ end thereof and transformed to Escherichia coli. The Escherichia coli capable of producing the objective protein was cultured. The obtained cells were suspended in a buffer solution containing a surfactant and crushed in a microfluidizer. The supernatant was obtained by centrifugation and applied to various column chromatographys {poly[U]-Sepharose, Sephacryl S-200, mono-S (Pharmacia)}, inclusive of metal chelate chromatography, to give a standard enzyme product.
ii) Synthesis of substrate RNA
Using a synthetic primer designed based on the sequence of HCV genomic 3′ untranslated region, a DNA fragment (148 bp) containing polyU and 3′X sequence was entirely synthesized and cloned into plasmid pBluescript SK II(+) (Stratagene). The cDNA encoding full length NSSB, which was prepared in i) above, was digested with restriction enzyme KpnI to give a cDNA fragment containing the nucleotide sequence of from the restriction enzyme cleavage site to the termination codon. This cDNA fragment was inserted into the upstream of 3′ untranslated region of the DNA in pBluescript SK II(+) and ligated. The about 450 bp inserted DNA sequence was used as a template in the preparation of substrate RNA. This plasmid was cleaved immediately after the 3′X sequence, linearized and purified by phenol-chloroform treatment and ethanol precipitation to give DNA.
RNA was synthesized (37° C., 3 hr) by run-off method using this purified DNA as a template, a promoter of pBluescript SK II(+), MEGAscript RNA synthesis kit (Ambion) and T7 RNA polymerase. DNaseI was added and the mixture was incubated for 1 hr. The template DNA was removed by decomposition to give a crude RNA product. This product was treated with phenol-chloroform and purified by ethanol precipitation to give the objective substrate RNA.
This RNA was applied to formaldehyde denaturation agarose gel electrophoresis to confirm the quality thereof and preserved at −80° C.
iii) Assay of enzyme (HCV polymerase) inhibitory activity
A test substance (compound of the present invention) and a reaction mixture (30 μl) having the following composition were reacted at 25° C. for 90 min.
10% Trichloroacetic acid at 4° C. and 1% sodium pyrophosphate solution (150 μl) were added to this reaction mixture to stop the reaction. The reaction mixture was left standing in ice for 15 min to insolubilize RNA. This RNA was trapped on a glass filter (Whatman GF/C and the like) upon filtration by suction. This filter was washed with a solution containing 1% trichloroacetic acid and 0.1% sodium pyrophosphate, washed with 90% ethanol and is dried. A liquid scintillation cocktail (Packard) was added and the radioactivity of RNA synthesized by the enzyme reaction was measured on a liquid scintillation counter.
The HCV polymerase inhibitory activity (IC50) of the compound of the present invention was calculated from the values of radioactivity of the enzyme reaction with and without the test substance.
The results are shown in Tables 178-184 and 222-224.
Reaction mixture : HCV polymerase (5 μg/ml) obtained in i), substrate RNA (10 μg/ml) obtained in ii), ATP (50 μM), GTP (50 μM), CTP (50 μM), UTP (2 μM), [5,6-3H]UTP (46 Ci/mmol (Amersham), 1.5 CCi) 20 mM Tris-HCl (pH 7.5), EDTA (1 mM), MgCl2 (5 mM), NaCl (50 mM), DTT (1 mM), BSA (0.01%)
Formulation Example is given in the following. This example is merely for the purpose of exemplification and does not limit the invention.










Formulation Example


















(a) compound of Example 1
10 g



(b) lactose
50 g



(c) corn starch
15 g



(d) sodium carboxymethylcellulose
44 g



(e) magnesium stearate
 1 g










 

The entire amounts of (a), (b) and (c) and 30 g of (d) are kneaded with water, dried in vacuo and granulated. The obtained granules are mixed with 14 g of (d) and 1 g of (e) and processed into tablets with a tableting machine to give 1000 tablets each containing 10 mg of (a).








TABLE 1







Example No. 31
1H NMR(δ)ppm







300MHz, CDCl3 7.81(2H, d, J=6.6Hz), 7.60(2H, d, J=8.8Hz), 7.51- 7.21(8H, m), 7.11(2H, d, J=8.8Hz), 5.15(2H, s), 4.93(1H, quint, J= 8.8Hz), 2.36-2.32(2H, m), 2.09-2.04(3H, m), 1.75-1.68(3H, m).


Purity >90%(NMR)


MS 369(M+1)


Example No. 32
1H NMR(δ)ppm







300MHz, CDCl3 8.51(1H, d, J=1.5Hz), 7.98(1H, d, J=8.4Hz), 7.61(2H, d, J=8.7Hz), 7.56-7.10(6H, m), 7.12(2H, d, J=8.7Hz), 5.15(2H, s), 4.94(1H, quint, J=9.3Hz), 4.41(2H, q, J=7.5Hz), 2.40-1.50(8H, m), 1.41(3H, t, J=7.5Hz)


Purity >90%(NMR)


MS 441(M+1)


Example No.33
1H NMR(δ)ppm







300MHz, CDCl3 7.84(1H, s), 7.61(2H, d, J=9.0Hz), 7.58-7.30(7H, m), 7.12(2H, d, J=9.0Hz), 5.15(2H, s), 4.94(1H, quint, J=8.7Hz), 3.10(6H, brs), 2.40-1.50(8H, m)


Purity >90%(NMR)


MS 440(M+1)









 









TABLE 2







Example No. 34
1H NMR(δ)ppm







300MHz, CDCl3 8.20(1H, s), 7.50-7.31(9H, m), 7.12(2H, d, J=8.7Hz), 5.15(2H, s), 4.94(1H, quint, J=8.7Hz), 3.61(3H, s), 3.40(3H, s), 2.41-1.42(8H, m)


Purity >90%(NMR)


MS 456(M+1)


Example No. 35
1H NMR(δ)ppm







300MHz, CDCl3 7.91(1H, s), 7.59(2H, d, J=8.7Hz), 7.49-7.30(7H, m), 7.11(2H, d, J=8.8Hz), 5.15(2H, s), 4.19(1H, quint, J=8.8Hz), 2.41- 2.22(2H, m), 2.13-1.49(14H, m)


Purity >90%(NMR)


MS 427(M+1)


Example No. 36
1H NMR(δ)ppm







300MHz, CDCl3 8.40(1H, d, J=1.4Hz), 7.95(1H, dd, J=8.6, 1.4Hz), 7.61(2H, d, J=8.7Hz), 7.57-7.30(6H, m), 7.13(2H, d, J=8.7Hz), 5.16(2H, s), 4.95(1H, quint, J=8.8Hz), 2.64(3H, s), 2.40-1.54(8H, m)


Purity >90%(NMR)


MS 411(M+1)









 









TABLE 3







Example No. 37
1H NMR(δ)ppm







300MHz, DMSO-d6 10.47(1H, brs,), 9.15(1H, brs), 8.40(1H, s), 8.07(1H, d, J=9.0Hz), 7.93(1H, d, J=8.7Hz), 7.77(2H, d, J=8.7Hz), 7.55-7.29(7H, m), 5.26(2H, s), 4.93(1H, quint, J= 9.0Hz), 3.77-3.63(2H, m), 3.39-3.23(2H, m), 2.84(6H, d, J= 4.8Hz), 2.32-1.60(8H, m)


Purity >90%(NMR)


MS 483(M+1)


Example No. 38
1H NMR(δ)ppm







300MHz, CDCl3 8.69(1H, s), 8.19(1H, d, J=9.0Hz), 7.62(2H, d, J=8.7Hz), 7.54(1H, d J=9.0Hz), 7.48-7.36(5H, m), 7.15(2H, d, J=8.7Hz), 5.17(2H, s), 4.98(1H, quint, J=9.0Hz), 2.27-2.07(6H, m), 1.82-1.78(2H, m)


Purity >90%(NMR)


MS 414(M+1)


Example No. 39
1H NMR(δ)ppm







300MHz, DMSO-d6 7.84(1H, d, J=9.0Hz), 7.79(2H, d, J= 8.7Hz), 7.52-7.33(8H, m), 7.26(1H, d, J=9.0Hz), 5.27(2H, s), 4.92(1H, quint, J=9.3Hz), 2.19-1.70(8H, m).


Purity >90%(NMR)


MS 384(M+1)









 









TABLE 4







Example No. 40
1H NMR(δ)ppm







300MHz, CDCl3 7.72(1H, s), 7.60-7.35(10H, m), 7.10(2H, d, J=8.7Hz), 5.14(2H, s), 4.90(1H, quint, J=8.8Hz), 2.29-2.19(2H, m), 2.19(3H, s), 2.19- 1.74(6H, m).


Purity >90%(NMR)


MS 426(M+1)


Example No. 41
1H NMR(δ)ppm







300MHz, CDCl3 7.66(1H, s), 7.61(2H, d, J=8.8Hz), 7.50-7.28(7H, m), 7.12(2H, d, J=8.8Hz), 6.86(1H, brs), 5.15(2H, s), 4.94(1H, quint, J= 8.8Hz), 2.97(3H, s), 2.29-1.76(8H, m).


Purity >90%(NMR)


MS 462(M+1)


Example No. 42
1H NMR(δ)ppm







300MHz, DMSO 8.11(1H, s), 7.81(1H, d, J=8.4Hz), 7.72(1H, d, J= 8.4Hz), 7.65(2H, d, J=8.4Hz), 7.51(2H, m), 7.43(2H, m), 7.37(1H, m), 7.29(2H, s), 7.23(2H, d, J=8.4Hz), 5.22(2H, s), 4.89(1H, quintet, J= 9.2Hz), 2.2-2.0(6H, m), 1.7(2H, m).


Purity >90%(NMR)


MS 448 (M+)









 









TABLE 5







Example No. 43
1H NMR(δ)ppm







300MHz, DMSO-d6 8.33(1H, s), 8.08(1H, d, J=9.0Hz), 7.99(1H, d, J=9.0Hz), 7.47-7.41(4H, m), 7.33(2H, d, J=8.4Hz), 5.22(2H, s), 4.96(1H, quint, J=9.0Hz), 2.25-1.60(8H, m), 1.30(9H, s).


Purity >90%(NMR)


MS 469(M+1)


Example No. 44
1H NMR(δ)ppm







300MHz, DMSO-d6 12.9(2H, brs), 8.25(1H, s), 8.00(2H, d, J= 7.8Hz), 7.90(1H, d, J=8.4Hz), 7.74(1H, d, J=8.7Hz), 7.67(2H, d, J=9.0Hz), 7.62(2H, d, J=8.1Hz), 7.24(2H, d, J=8.4Hz), 5.32(2H, s), 4.88(1H, quint, J=9.0Hz, 2.25-1.60(8H, m).


Purity >90%(NMR)


MS 457(M+1)


Example No. 45
1H NMR(δ)ppm







300MHz, DMSO-d6 13.4(1H, brs), 8.32(1H, s), 8.06(1H, d, J= 8.7Hz), 7.97(1H, d, J=8.7Hz), 7.79(2H, d, J=8.8Hz), 7.56- 7.48(4H, m), 7.33(2H, d, J=8.8Hz), 5.27(2H, s), 4.95(1H, quint, J=8.9Hz), 2.30-1.60(8H, m).


Purity >90%(NMR)


MS 447(M+1)









 









TABLE 6







Example No. 46
1H NMR(δ)ppm







300MHz, DMSO-d6 8.33(1H, s), 8.07(1H, d, J=8.7Hz), 7.98(1H, d, J=8.7Hz), 7.80.(2H, d, J=8.4Hz), 7.34(2H, d, 8.4Hz), 7.19(1H, d, J=3.6Hz), 7.09(1H, d, J=3.6Hz), 5.41(2H, s), 4.95(1H, quint, J=8.7Hz), 2.30-1.60(8H, m).


Purity > 90%(NMR)


MS 453 (M+1)


Example No. 47
1H NMR(δ)ppm







300MHz, DMSO-d6 8.33(1H, s), 8.07(1H, d, J=8.4Hz), 7.98(1H, d, J=9.0Hz), 7.82-7.72(6H, m), 7.35(2H, d, J=9.0Hz), 5.40(2H, s), 4.95(1H, quint, J=8.7Hz), 2.35-1.60(8H, m).


Purity > 90%(NMR)


MS 481 (M+1)


Example No. 48
1H NMR(δ)ppm







300MHz, DMSO-d6 8.23(1H, s), 7.88(1H, d, J=8.4Hz), 7.70(1H, d, J=8.4Hz), 7.64(2H, d, J=8.4Hz), 7.43(2H, d, J=8.4Hz), 7.20(2H, d, J=8.4Hz), 6.98(2H, d, J=8.4Hz), 5.13(2H, s), 4.88(1H, quint, J=8.7Hz), 3.77(3H, s), 2.35-1.60(8H, m).


Purity > 90%(NMR)


MS 443 (M+1)









 









TABLE 7







Example No. 49
1H NMR(δ)ppm







300MHz, DMSO-d6 8.93(2H, d, J=6.6Hz), 8.35(1H, s), 8.06-8.04(3H, m), 7.97(1H, d, J=8.7Hz), 7.83(2H, d, J=8.7Hz), 7.38(2H, d, J=8.7Hz), 5.61(2H, s) , 4.94(1H, quint, J=8.7Hz), 2.40-1.60(8H, m).


Purity > 90%(NMR)


MS 414 (M+1)


Example No. 50
1H NMR(δ)ppm







300MHz, DMSO-d6 8.33(1H, s), 8.08(1H, d, J=8.7Hz), 7.99(1H, d, J=9.0Hz), 7.78(2H, d, J=8.4Hz), 7.39(2H, d, J=8.1Hz), 7.32(2H, d, J= 8.7Hz), 7.23(2H, d, J=7.8Hz), 5.22(2H, s), 4.96(1H, quint, J=9.0Hz), 2.32(3H, s), 2.30-1.60(8H, m).


Purity > 90%(NMR)


MS 427 (M+1)


Example No. 51
1H NMR(δ)ppm







300MHz, DMSO-d6 8.31(1H, s), 8.03(1H, d, J=9.0Hz), 7.93(1H, d, J=9.0Hz), 7.77(2H, d, J=8.4Hz), 7.31(2H, d, J=8.7Hz), 5.07(2H, s), 4.94(1H, quint, J=8.7Hz), 2.45(3H, s), 2.26(3H, s), 2.26-1.60(8H, m).


Purity > 90%(NMR)


MS 432 (M+1)









 









TABLE 8







Example No. 52
1H NMR(δ) ppm







300 MHz, DMSO-d6 12.7(1H, brs), 10.0(1H, s), 8.22(1H, s), 7.87(1H, d, J=8.6Hz), 7.69(1H, d, J=8.6Hz), 7.53(2H, d, J=8.6Hz), 6.96(2H, d, J=8.6Hz), 4.89(1H, quint, J=9.0Hz), 2.30-1.60(8H, m).


Purity >90%(NMR)


MS 323 (M+1)


Example No. 53
1H NMR(δ) ppm







300 MHz, DMSO-d6 9.18(1H, t, J=5.6Hz), 8.34(1H, s), 8.04(1H, d, J=9.6Hz), 7.98(1H, d, J=8.7Hz), 7.80(2H, d, J=8.7Hz), 7.52-7.32(7H, m), 5.27(2H, s), 4.95(1H, quint, J=9.0Hz), 3.99(2H, d, J=5.7Hz), 2.04-1.60(8H, m).


Purity >90%(NMR)


MS 470 (M+1)


Example No. 54
1H NMR(δ) ppm







300 MHz, DMSO-d6 8.32(1H, s), 8.05(1H, d, J=8.7Hz), 7.95(1H, d, J=8.7Hz), 7.80(2H, d, J=8.4Hz), 7.67(1H, t, J=4.5Hz), 7.56(1H, t, J=4.5Hz), 7.45-7.42(2H, m), 7.35(2H, d, J=8.4Hz), 5.31(2H, s), 4.96(1H, quint, J=9.0Hz), 2.30-1.60(8H, m).


Purity >90%(NMR)


MS 447 (M+1)









 









TABLE 9







Example No. 55
1H NMR(δ) ppm







300 MHz, DMSO-d6 12.78(1H, brs), 8.24(1H, s), 7.88 and 7.72(2H, ABq, J=8.6Hz), 7.66 and 7.23(4H, A′B′q, J=8.6Hz), 7.58(1H, s), 7.48-7.42(3H, m), 5.24(1H, s), 4.88(1H, quint, J=8.8Hz), 2.30-1.91(6H, m), 1.78-1.60(2H, m)


Purity >90%(NMR)


MS 447 (M+1)


Example No. 56
1H NMR(δ) ppm







300 MHz, DMSO-d6 12.89(1H, broad), 8.18(1H, s), 7.87(1H, d, J=8.4Hz), 7.74(1H, d, J=9.2Hz), 7.67(2H, d, J=8.8Hz), 7.52(2H, m), 7.45(2H, m), 7.38(1H, m), 7.23(2H, d, J=8.8Hz), 5.22(2H, s), 4.94(1H, quintet, J=8.9Hz), 2.16(4H, m), 1.98(2H, m), 1.73(2H, m).


Purity >90%(NMR)


MS 413 (M+1)


Example No. 57
1H NMR(δ) ppm







300 MHz, DMSO-d6 10.99(1H, s), 8.26(1H, s), 8.01-7.86(4H, m), 7.69-7.59(5H, m), 7.38(2H, d, J=8.7Hz), 4.86(1H, quint, J=8.7Hz), 2.12-1.90(6H, m), 1.72-1.59(2H, m).


Purity >90%(NMR)


MS 462 (M+1)









 









TABLE 10







Example No. 58
1H NMR(δ)ppm







300MHz, DMSO-d6 12.78(1H, s), 10.69(1H, s), 8.26-7.72(9H, m), 4.92(1H, quint, J=9.0Hz), 2.34-1.70(6H, m), 1.75-1.61(2H, m)


Purity > 90%(NMR)


MS 494 (M+1)


Example No. 59
1H NMR(δ)ppm







300MHz, DMSO-d6 10.82(1H, s), 8.34(1H, s), 8.14 and 7.84(4H, ABq, J=8.4Hz), 8.06 and 7.66(4H, A′B′q, J=8.6Hz), 8.06-7.98(4H, m), 5.01(1H, quint, J=9.3Hz), 2.35-2.15(4H, m), 2.11-1.96(2H, m), 1.80-1.62(2H, m)


Purity > 90%(NMR)


MS 460 (M+1)


Example No. 60
1H NMR(δ)ppm







300MHz, DMSO-d6 10.61(1H, s), 8.32(1H, s), 8.12 and 7.81(4H, ABq, J=8.9Hz), 8.03 and 7.93(2H, A′B′q, J=8.7Hz), 7.95 and 7.59(4H, A′′B′′q, J=8.4Hz), 4.99(1H, quint, J=9.0Hz), 2.33- 2.12(4H, m), 2.10-1.93(2H, m), 1.80-1.63(2H, m), 1.34(9H, m)


Purity > 90%(NMR)


MS 482 (M+1)









 









TABLE 11







Example No. 61
1H NMR(δ)ppm







300MHz, DMSO-d6 10.6(1H, s), 8.34(1H, s), 8.13(2H, d, J=8.7Hz), 8.09-7.98(4H, m), 7.82(2H,  d, J=8.7Hz), 7.50-7.35(5H, m), 7.20-7.17(2H, d, J=9.0Hz), 5.24(2H, s), 5.01(1H, quint, J=9.3Hz), 2.40-1.60(8H, m).


Purity > 90%(NMR)


MS 532 (M+1)


Example No. 62
1H NMR(δ)ppm







300MHz, DMSO-d6 8.32(1H, s), 8.26(1H, d, J= 8.7Hz), 8.04(1H, d, J=8.7Hz), 7.77(2H, d, J= 8.4Hz), 7.52(2H, d, J=6.9Hz), 7.46-7.39(5H, m), 5.28(2H, s), 4.38(1H, m), 3.71(1H, m), 2.60- 2.15(2H, m), 2.04-1.96(4H, m), 1.30-1.20(2H, m).


Purity > 90%(NMR)


MS 443 (m+1)


Example No. 63
1H NMR(δ)ppm







300MHz, DMSO-d6 8.27(1H, s), 8.14(1H, d, J= 8.7Hz), 7.96(1H, d, J=8.4Hz), 7.71(2H, d, J= 9.0Hz), 7.51(2H, d, J=6.9Hz), 7.46-7.37(3H, m), 7.30(2H, d, J=8.4Hz), 5.25(3H, s), 4.39(1H m), 3.44(1H, m), 3.27(3H, s), 2.60-1.95(6H, m), 1.25-1.05(2H, m).


Purity > 90%(NMR)


MS 457 (M+1)









 









TABLE 12







Example No. 64
1H NMR(δ)ppm







300MHz, DMSO-d6 12.25(1H, brs), 7.70-7.30(9H, m), 7.20(2H, d, J=8.7Hz), 7.14(1H, d, J=8.4Hz), 5.20(2H, s), 4.84(1H, quint, J=6.0Hz), 3.66(2H, s), 2.30-1.51(8H, m)


Purity > 90%(NMR)


MS 427 (M+1)


Example No. 65
1H NMR(δ)ppm







300MHz, DMSO-d6 12.64(1H, brs), 8.13(1H, s), 7.80(1H, d, J=7.2Hz), 7.59(1H, d J=8.7Hz), 7.48-7.30(5H, m), 5.11(2H, s), 5.03(1H, quint, J=8.7Hz), 4.20-4.05(2H, m), 3.45- 3.90(3H, m), 2.15-1.60(12H, m)


Purity > 90%(NMR)


MS 448 (M+1)


Example No. 66
1H NMR(δ)ppm







300MHz, DMSO-d6 10.59(1H, s), 8.31(1H, s), 8.10(2H, d, J=8.6Hz), 8.03(1H, d, J=8.7Hz), 8.00-7.85(3H, m), 7.80(2H, d, J=8.6Hz), 7.41(2H, d, J=8.2Hz), 4.98(1H, quint, J=8.8Hz), 2.71-1.10(19H, m)


Purity > 90%(NMR)


MS 508 (M+1)









 









TABLE 13







Example No. 67
1H NMR(δ)ppm







300MHz, DMSO-d6 12.81(1H, brs), 8.42(1H, s), 7.90(1H, d, J=8.5Hz), 7.80-7.52(6H, m), 7.44(2H, d, J=8.6Hz), 5.25(2H, s), 4.88(1H, quint, J=8.8Hz), 2.30-1.52(8H, m)


Purity >90% (NMR)


MS 481 (M+1)


Example No. 68
1H NMR(δ)ppm







300MHz, DMSO-d6 8.31(1H, d, J=1.4Hz), 8.05(1H, d, J=8.6Hz), 7.96(1H, d, J=8.6Hz), 8.86-8.61(4H, m), 7.51(1H, d, J=6.3Hz), 7.33(2H, d, J=8.8Hz), 5.28(2H, s), 4.94(1H, quint, J=8.8Hz), 2.31-1.60(8H, m)


Purity >90% (NMR)


MS 481 (M+1)


Example No. 69
1H NMR(δ)ppm







300MHz, DMSO-d6 9.88(1H, s), 9.42(1H, s), 8.32(1H, s), 8.09 and 8.02(2H, ABq, J=9.0Hz), 7.81 and 7.78(4H, A′B′q, J=9.2Hz), 7.50(2H, d, J=7.8Hz), 7.31(2H, t, J=7.8Hz), 7.00(1H, t, J=7.8Hz), 5.03(1H, quint, J=8.7Hz), 2.34-2.17(4H, m), 2.13-1.96(2H, m), 1.83-1.64(2H, m)


Purity >90% (NMR)


MS 441 (M+1)









 









TABLE 14







Example No. 70
1H NMR(δ)ppm







300MHz, DMSO-d6 8.27(1H, d, J=1.2Hz), 8.04(1H, d, J=8.7Hz), 7.94(1H, d, J=8.7Hz), 7.72(2H, d, J=8.7Hz), 7.60-7.20(12H, m) 6.74(1H, s), 4.92(1H, quint, J=8.9Hz), 2.30-1.58(8H, m)


Purity >90% (NMR)


MS 489 (M+1)


Example No. 71
1H NMR(δ)ppm







300MHz, DMSO-d6 8.31(1H, s), 8.05(1H, d, J=8.7Hz), 7.97(1H, d, J=8.7Hz), 7.76(2H, d, J=8.6Hz), 7.44-7.19(7H, m), 4.94(1H, quint, J=8.8Hz), 4.35(2H, t, J=6.7Hz), 3.10(2H, t, J=6.7Hz), 2.32-1.60(8H, m)


Purity >90% (NMR)


MS 427 (M+1)


Example No. 72
1H NMR(δ)ppm







300MHz, DMSO-d6 8.30(1H, s), 8.25(1H, d, J=8.7Hz), 8.03(1H, d, J=9.0Hz), 7.75(2H, d, J=8.7Hz), 7.51(2H, d, J=7.2Hz), 7.46-7.33(5H, m), 5.27(2H, s), 4.36(1H, m), 2.50-2.25(2H, m), 2.15-2.00(2H, m), 1.95-1.85(2H, m), 1.35(1H, m), 1.20-1.10(2H, m), 0.87(9H, s).


Purity >90% (NMR)


MS 483 (M+1)









 









TABLE 15







Example No.73
1H NMR(δ)ppm







300MHz, DMSO-d6 7.59(2H, d, J=8.4Hz), 7.52-7.35(6H, m), 7.20(2H, d, J=8.7Hz), 7.14(1H, d, J=2.1Hz), 6.90(1H, dd, J=9.0, 2.4Hz), 5.21(2H, s), 4.83(1H, quint, J=8.7Hz), 4.70(2H, s), 2.30- 1.90(6H, m), 1.75-1.55(2H, m).


Purity >90% (NMR)


MS 443 (M+1)


Example No. 74
1H NMR(δ)ppm







300MHz, DMSO-d6 8.27(1H, s), 8.06 and 7.97(2H, ABq, J=8.7Hz), 7.57 and 6.86(4H, A′B′q, J=8.9Hz), 7.42-7.26(5H, m), 5.04(1H, quint, J=9.0Hz), 4.42(2H, s), 2.32-1.94(6H, m), 1.80-1.62(2H, m)


Purity >90% (NMR)


MS 412 (M+1)


Example No. 75
1H NMR(δ)ppm







300MHz, DMSO-d6 12.80(1H, s), 8.26(1H, s), 7.90(1H, d, J=9.2Hz), 7.76-7.60(8H, m), 7.35(2H, d, J=8.4Hz), 4.84(1H, quint, J=8.8Hz), 3.23(3H, s), 2.32-1.90(6H, m), 1.78-1.61(2H, m)


Purity >90% (NMR)


MS 476 (M+1)









 









TABLE 16







Example No. 76
1H NMR(δ)ppm







300MHz, DMSO-d6 8.29(1H, s), 8.07 and 7.49(2H, ABq, J=8.7Hz), 7.66 and 7.00(4H, A′B′q, J=7.7Hz), 7.39-7.24(5H, m), 5.05(1H, quint, J=8.8Hz), 4.76(2H, s), 3.21(3H, s), 2.35-1.92(6H, m), 1.81-1.62(2H, m)


Purity >90% (NMR)


MS 426 (M+1)


Example No. 77
1H NMR(δ)ppm







300MHz, DMSO-d6 8.21(1H, s), 7.87(1H, s), 7.56 and 7.43(4H, ABq, J= 8.1Hz), 7.34-7.16(5H, m), 4.25(1h, brt, J=12.5Hz), 3.06-2.92(4H, m), 2.41- 2.17(2H, m), 1.96-1.77(4H, m), 1.72-1.58(1H, m), 1.48-1.15(3H, m)


Purity >90% (NMR)


MS 425 (M+1)


Example No. 78
1H NMR(δ)ppm







300MHz, DMSO-d6 8.14(1H, s), 7.79(1H, d, J=9.0Hz), 7.57(1H, d, J=8.7Hz), 7.40-7.20(5H, m), 4.89(1H, quint, J=8.7Hz), 3.54(2H, s), 3.19-2.90(3H, m), 2.23-1.69(14H, m)


Purity >90% (NMR)


MS 404 (M+1)









 









TABLE 17







Example No. 79
1H NMR(δ)ppm







300MHz, DMSO-d6 8.15(1H, s), 7.81(1H, d, J=8.4Hz), 7.59(1H, d, J= 9.0Hz), 7.50-7.38(5H, m), 5.05(1H, quint, J=9.0Hz), 3.85-2.95(3H, m), 2.20-1.65(14H, m)


Purity >90% (NMR)


MS 418 (M+1)


Example No. 80
1H NMR(δ)ppm







300MHz, DMSO-d6 8.17(1H, m), 7.84(1H, d, J=8.4Hz), 7.78-7.62(3H, m), 7.49(2H, d, J=8.1Hz), 5.05-4.91(1H, m), 3.80-3.70(2H, m), 3.30-3.12(1H, m), 2.48-2.31(5H, m), 2.15-1.60(12H, m)


Purity >90% (NMR)


MS 468 (M+1)


Example No. 81
1H NMR(δ)ppm







300MHz, DMSO-d6 12.75(1H, brs), 8.21(1H, d, J=1.4Hz), 7.49(1H, d, J= 8.6Hz), 7.85(1H, dd, J=8.6, 1.4Hz), 7.70-7.55(5H, m), 7.23(2H, d, J= 8.7Hz), 5.25(2H, s), 4.36-4.15(1H, m), 2.39-2.18(2H, m), 2.00-1.78(4H, m), 1.70-1.57(1H, m), 1.48-1.15(3H, m)


Purity >90% (NMR)


MS 495 (M+1)









 









TABLE 18







Example No. 82
1H NMR(δ)ppm







300MHz, DMSO-d6 8.27(1H, s), 8.22(1H, d, J=8.7Hz) , 8.02(1H, d, J=8.7Hz), 7.69(2H, d, J=8.7Hz), 7.60-7.50(4H, m), 7.45-7.25(8H, m), 6.75(1H, s), 4.21-4.23(1H, m), 2.39-2.18(2H, m), 2.10-1.78(4H, m), 1.70-1.15(4H, m)


Purity >90%(NMR)


MS 503(M+1)


Example No. 83
1H NMR(δ)ppm







300MHz, DMSO-d6 13.2(1H, brs), 8.30(1H, s), 8.23(1H, d, J=8.8Hz), 8.02(1H, d, J=8.7Hz), 7.74(2H, d, J=8.6Hz), 7.40-7.33(5H, m), 5.22(2H, s), 4.36(1H, m), 2.50-1.40(10H, m), 1.31(18H, s).


Purity >90%(NMR)


MS 539(M+1)


Example No. 84
1H NMR(δ)ppm







mixture of isomers (cis:trans=3:1) 300MHz, DMSO-d6 8.30(1H, s), 8.20-7.95(2H, m), 7.72(2H, d, J=8.4Hz), 7.52-7.29(7H, m), 5.25(2H, s), 4.34, 3.40(1H, m), 2.50-2.20(2H, m), 2.05-1.50(6H, m), 1.14, 0.90(3H, d, J=6.9, 6.3Hz), 1.09(1H, m).


Purity >90%(NMR)


MS 441(M+1)









 









TABLE 19







Example No. 85
1H NMR(δ)ppm







300MHz, DMSO-d6 8.25(1H, s), 8.14-7.83(6H, m), 7.77-7.44(5H, m), 7.21(2H, d, J=7.8Hz), 4.44(2H, brt), 4.31(1H, brt), 3.56(2H, brt), 2.20-2.16(2H, m), 2.00-1.74(4H, m), 1.70-1.55(1H, m), 1.45- 1.14(3H, m)


Purity >90%(NMR)


MS 491(M+1)


Example No. 86
1H NMR(δ)ppm







300MHz, DMSO-d6 12.75(1H, s), 8.23(1H, s), 8.15(1H, d, J=7.6Hz), 8.02-7.53(10H, m), 7.32(2H, d, J=8.7Hz), 5.68(2H, s), 4.32(1H, brt, J=12.2Hz), 2.41-2.20(2H, m), 2.01-1.78(4H, m), 1.71-1.56(1H, m), 1.50-1.16(3H, m)


Purity >90%(NMR)


MS 477(M+1)


Example No. 87
1H NMR(δ)ppm







300MHz, DMSO-d6 12.75(1H, brs), 8.16(1H, s), 7.91 and 7.82(2H, ABq, J=8.5Hz), 7.44 and 6.86(4H, A′B′q, J=8.6Hz), 7.39-7.26(10H, m), 4.82(2H, s), 4.35(1H, brt, J=12.2Hz), 2.35-2.16(2H, m), 1.97- 1.75(4H, m), 1.69-1.56(1H, m), 1.45-1.16(3H, m)


Purity >90%(NMR)


MS 516(M+1)









 









TABLE 20







Example No. 88
1H NMR(δ) ppm







300 MHz, DMSO-d6 8.31(1H, s), 8.26 and 8.06(2H, ABq, J=8.9Hz), 7.73 and 7.22(4H, A′B′q, J=8.7hz), 7.50-7.36(8H, m), 5.10(2h, s), 4.37(1h, brt, J=12.2Hz), 2.38-2.28(2H, m), 2.10-1.80(4H, m),  1.70-1.56(1H, m), 1.50-1.20(3H, m)


Purity >90%(NMR)


MS 503(M+1)


Example No. 89
1H NMR(δ) ppm









Purity 91%(HPLC)


MS 427(M+1)


Example No. 90
1H NMR(δ) ppm







300 MHz, DMSO-d6 8.40-8.20(2H, m), 8.04(1H, d, J=8.4Hz), 7.65(2H, d, J=8.4Hz), 7.50-7.10(12H, m), 5.08(1H, m), 4.33(1H, m), 3.00(4H, m), 2.50-1.10(10H, m)


Purity >90%(NMR)


MS 531(M+1)









 









TABLE 21







Example No. 91
1H NMR(δ)ppm







300MHz, DMSO-d6 8.31(1H, s), 8.27(1H, d, J=8.7Hz), 8.08- 8.03(3H, m), 7.77-7.58(5H, m), 7.31(2H, d, J=8.7Hz), 5.81(2H, s), 4.40(1H, m), 2.50-1.20(10H, m).


Purity about 90%(NMR)


MS 455(M+1)


Example No. 92
1H NMR(δ)ppm







300MHz, DMSO-d6 11.8(1H, brs), 8.07(1H, s), 7.89(1H, d, J= 8.7Hz), 7.84(1H, d, J=8.4Hz), 7.69(2H, m), 7.48(3H, m), 4.42(2H, s), 4.11(1H, m), 3.73(4H, m), 3.40(4H, m), 2.40-1.40(10H, m)


Purity >90%(NMR)


MS 419(M+1)


Example No. 93
1H NMR(δ)ppm







300MHz, DMSO-d6 8.32(1H, s), 8.28(1H, d, J=8.9Hz), 8.05(1H, d, J=8.7Hz), 7.72(2H, d, J=8.7Hz), 7.38(4H, d, J=7.2Hz), 7.31(4H, t, J=7.3Hz), 7.21-7.17(4H, m), 4.37(1H, m), 4.26(1H, t, J=7.9Hz), 4.01(2H, t, J=6.2Hz), 2.57(2H, m), 2.50-2.20(2H, m), 2.10-2.00(2H, m), 2.00-1.75(2H, m), 1.75-1.55(1H, m), 1.55-1.20(3H, m).


Purity >90%(NMR)


MS 531(M+1)









 









TABLE 22







Example No. 94
1H NMR(δ)ppm







300MHz, DMSO-d6 8.32(1H, s), 8.27(1H, d, J=9.0Hz), 8.05(1H, d, J=8.7Hz), 7.75-7.70(3H, m), 7.56(1H, d, J=8.4Hz), 7.55-7.35(6H, m), 7.22(2H, d, J=8.7Hz), 5.11(2H, s), 4.36(1H, m), 2.40-2.15(2H, m), 2.15-1.95(2H, m), 1.95-1.75(2H, m), 1.75-1.55(1H, m), 1.55-1.20(3H, m).


Purity >90%(NMR)


MS 537(M+1)


Example No. 95
1H NMR(δ)ppm







300Hz, DMSO-d6 12.9(1H, brs), 8.02(1H, s), 7.82(2H, m), 7.40- 7.25(5H, m), 4.58(2H, s), 4.09(1H, m), 3.71(1H, m), 3.49(2H, m), 3.21(2H, m), 2.35-1.30(14H, m).


Purity >90%(NMR)


MS 434(M+1)


Example No. 96
1H NMR(δ)ppm







300MHz, DMSO-d6 8.31(1H, d, J=1.3Hz), 8.27(1H, d, J=8.8Hz), 8.05(1H, d, J=8.8Hz), 7.76(2H, d, J=8.7Hz), 7.40-7.25(4H, m), 7.06-6.90(3H, m), 4.53-4.26(5H, m), 2.40-2.18(2H, m), 2.12- 1.56(5H, m), 1.50-1.19(3H, m)


Purity >90%(NMR)


MS 457(M+1)









 









TABLE 23







Example No. 97
1H NMR(δ)ppm







300 MHz, DMSO-d6 8.32(1H, d, J=1.3Hz), 8.29(1H, d, J=8.8Hz,), 8.05(1H, dd, J=8.8, 1.3Hz), 8.42(2H, d, J=8.8Hz), 7.37-7.16(7H, m), 4.48-4.30(1H, m), 4.12(2H, t, J=6.2Hz), 2.83-2.70(2H, m), 2.40-1.50(9H, m), 1.59- 1.19(3H, m)


Purity >90%(NMR)


MS 455(M+1)


Example No. 98
1H NMR(δ) ppm







300 MHz, DMSO-d6 8.28(1H, d, J=1.3Hz), 8.21(1H, d, J=8.8Hz), 8.01(1H, d, J=10.1Hz), 7.70(2H, d, J=8.7Hz), 7.33-7.12(7H, m), 4.44-4.28(1H, m), 4.10(2H, t, J= 6.3Hz), 2.62(2H, t, J=7.4Hz), 2.39-2.15(2H, m), 2.10- 1.18(14H, m)


Purity >90%(NMR)


MS 483(M+1)


Example No. 99
1H NMR(δ) ppm







300 MHz, DMSO-d6 12.93(1H, brs), 8.30(1H, d, J=1.4Hz), 8.04(1H, d, J=8.7Hz), 7.92(1H, dd, J=8.7, 1.4Hz), 7.59-7.34(5H, m), 7.07 (1H, s), 5.38(2H, s), 4.78-4.60 (1H, m), 2.32-2.14(2H, m), 2.03-1.28(8H, m)


Purity >90%(NMR)


MS 418(M+1)









 









TABLE 24







Example No. 100
1H NMR(δ)ppm







300MHz, DMSO-d6 8.46(1H, d, J=2.1Hz), 8.16(1H, s), 8.00(1H, dd, J=8.5, 2.1Hz), 7.87(1H, d, J=8.5Hz), 7.68(1H, d, J=8.5Hz), 7.55-7.30(5H, m), 7.08(1H, d, J=8.5Hz), 5.45(2H, s), 4.25- 4.08(1H, m), 2.39-2.18(2H, m), 2.00-1.75(4H, m), 1.70-1.55(1H, m), 1.45-1.19(3H, m)


Purity >90%(NMR)


MS 427(M+1)


Example No. 101
1H NMR(δ)ppm







300MHz, DMSO-d6 8.33(1H, s), 8.31(1H, d, J=6.9Hz), 8.06(1H, d, J=8.4Hz), 7.76 and 7.29(4H, ABq, J=8.9Hz), 6.68(2H, s), 4.37(1H, m), 4.35(2H, t, J=7.0Hz), 3.79(6H, s), 3.63(3H, s), 3.04(2H, t, J=6.9Hz), 2.30(2H, m), 2.04(2H, m), 1.86(2H, m), 1.65(1H, m), 1.50-1.15(3H, m)


Purity >90%(NMR)


MS 531(M+1)


Example No. 102
1H NMR(δ)ppm







300MHz, DMSO-d6 12.88(1H, s), 8.34(1H, s), 7.86(1H, d, J= 8.5Hz), 7.73(1H, d, J=8.5Hz), 7.63 and 7.23 (4H, ABq, J=8.7Hz), 7.52-7.35(5H, m), 5.22(2H, s), 4.31(1H, m), 2.39(2H, m), 1.79(2H, m), 1.53(2H, m), 1.31(2H, m), 1.11(3H, s), 0.95(3H, s)


Purity >90%(NMR)


MS 455(M+1)









 









TABLE 25







Example No. 103
1H NMR(δ)ppm







300MHz, DMSO-d6 12.79(1H, brs), 8.22(2H, s), 8.02- 7.78(4H, m), 7.63-7.42(6H, m), 7.20-7.09(2H, m), 4.43(2H, s), 4.27(1H, brt, J=12.2Hz), 3.59(2H, s), 2.39-2.15(2H, m), 1.98-1.72(4H, m), 1.68-1.59(1H, m), 1.43-1.12(3H, m)


Purity >90%(NMR)


MS 491 (M+1)


Example No. 104
1H NMR(δ)ppm







300MHz, DMSO-d6 12.75(1H, s), 8.23(1H, s), 7.94 and 7.86(2H, ABq, J=8.6Hz), 7.64 and 7.05(4H, A′B′q, J=8.7Hz), 7.32-7.09(9H, m), 5.13(2H, s), 4.28(1H, brt, J=12.2Hz), 2.36-2.19(2H, m), 1.95-1.77(4H, m), 1.66-1.56(1H, m), 1.46-1.10(3H, m)


Purity >90%(NMR)


MS 519 (M+1)


Example No. 105
1H NMR(δ)ppm







300MHz, DMSO-d6 8.23(1H, s), 7.94 and 7.87(2H, ABq, J= 8.6Hz), 7.68 and 7.17(4H, A′B′q, J=8.7Hz), 7.46-7.33(6H, m), 6.93 and 6.75(2H, A′′B′′q, J=8.2Hz), 6.82(1H, s), 5.13(2H, s), 4.30(1H, brt, J=12.2Hz), 2.39-2.18(2H, m), 1.98-1.77(4H, m), 1.71-1.59(1H, m), 1.48-1.20(3H, m)


Purity >90%(NMR)


MS 519 (M+1)









 









TABLE 26







Example No. 106
1H NMR(δ)ppm







300MHz, DMSO-d6 12.89(1H, brs), 9.73(1H, s), 8.24(1H, s), 8.03 and 7.91(2H, ABq, J=8.7Hz), 7.66 and 7.04(4H, A′B′q, J=8.7Hz), 7.16-7.03(3H, m), 6.89(2H, t, J=9.2Hz), 4.33(1H, brt, J=12.2Hz), 2.40-2.18(2H, m), 2.00- 1.78(4H, m), 1.70-1.58(1H, m), 1.50-1.20(3H, m)


Purity >90%(NMR)


MS 429 (M+1)


Example No. 107
1H NMR(δ)ppm







300MHz, DMSO-d6 12.98(1H, brs), 9.82(1H, brs), 8.27(1H, s), 8.09 and 7.94(2H, ABq, J=8.7Hz), 7.74 and 7.22(4H, A′B′q, J=8.7Hz), 7.28-7.22(1H, m), 6.67-6.54(3H, m), 4.35(1H, brt, J=12.2Hz), 2.40-2.20(2H, m), 2.05- 1.80(4H, m), 1.72-1.59(1H, m), 1.50-1.21(3H, m)


Purity >90%(NMR)


MS 429 (M+1)


Example No. 108
1H NMR(δ)ppm







300MHz, DMSO-d6 8.24(1H, s), 8.01 and 7.90(2H, ABq, J=8.7Hz), 7.65 and 7.03(4H, A′B′q, J=8.7Hz), 7.32-7.20(3H, m), 7.08-7.03(1H, m), 4.32(1H, brt, J=12.2Hz), 3.77(3H, s), 2.36-2.20(2H, m), 2.00-1.78(4H, m), 1.71-1.59(1H, m), 1.44-1.11(3H, m)


Purity >90%(NMR)


MS 443 (M+1)









 









TABLE 27







Example No. 109
1H NMR(δ)ppm







300MHz, DMSO-d6 12.75(1H, s), 8.24(1H, s), 7.96 and 7.87(2H, ABq, J=9.0Hz), 7.69 and 7.19(4H, A′B′q, J=8.6Hz), 7.37(1H, t, J=7.1Hz), 6.84-6.70(3H, m), 4.31(1H, brt, J=12.2Hz), 3.78(3H, s), 2.39-2.20(2H, m), 1.98-1.78(4H, m), 1.76-1.60(1H, m), 1.48-1.13(3H, m)


Purity >90%(NMR)


MS 443 (M+1)


Example No. 110
1H NMR(δ)ppm







300MHz, DMSO-d6 8.31(1H, s), 8.26 and 8.04(2H, ABq, J=8.8Hz), 7.75 and 7.71(4H, A′B′q, J=8.8Hz), 7.32-7.03(4H, m), 4.34(1H, brt, J=12.2Hz), 3.94(2H, t, J=6.3Hz), 2.40-2.19(2H, m), 2.11- 1.81(4H, m), 1.72-1.16(6H, m), 0.71(3H, t, J=7.3Hz)


Purity >90%(NMR)


MS 471 (M+1)


Example No. 111
1H NMR(δ)ppm







300MHz, DMSO-d6 8.22(1H, s), 7.91 and 7.87(2H, ABq, J=8.7Hz), 7.68 and 7.18(4H, A′B′q, J=8.7Hz), 7.35(1H, t, J=8.5Hz), 6.80(1H, d, J=9.0Hz), 6.72-6.68(2H, m), 4.30(1H, brt, J=12.2Hz), 3.94(2H, t, J=6.5Hz), 2.39-2.18(2H, m), 1.97-1.58(7H, m), 1.45-1.20(3H, m), 0.97(3H, t, J=7.4Hz)


Purity >90%(NMR)


MS 471 (M+1)









 









TABLE 28







Example No. 112
1H NMR(δ)ppm







300MHz, DMSO-d6 12.73(1H, s), 8.22(1H, s), 7.94 and 7.85(2H, ABq, J=9.3Hz), 7.61 and 7.01(4H, A′B′q, J=8.6Hz), 7.25-7.00(4H, m), 5.25(2H, brs), 4.55(2H, d, J=6.6Hz), 4.29(1H, brt, J=12.2Hz), 2.38-2.18(2H, m), 1.96-1.78(4H, m), 1.70-1.56(1H, m), 1.67(3H, s), 1.60(3H, s), 1.48-1.15(3H, m)


Purity >90%(NMR)


MS 497 (M+1)


Example No. 113
1H NMR(δ)ppm







300MHz, DMSO-d6 12.75(1H, s), 8.23(1H, s), 7.95 and 7.86(2H, ABq, J=8.9Hz), 7.69 and 7.18(4H, A′B′q, J=8.9Hz), 7.35(1H, t, J=8.3Hz), 6.81-6.69(3H, m), 5.41(2H, brs), 4.54(2H, d, J=6.6Hz), 4.31(1H, brt, J=12.2Hz), 2.41-2.18(2H, m), 1.98-1.76(4H, m), 1.73(3H, s), 1.70-1.58(1H, m), 1.68(3H, s), 1.45-1.17(3H, m)


Purity >90%(NMR)


MS 497 (M+1)


Example No. 114
1H NMR(δ)ppm







300MHz, DMSO-d6 12.73(1H, s), 8.22(1H, s), 7.94 and 7.85(2H, ABq, J=8.4Hz), 7.60 and 6.99(4H, A′B′q, J=8.6Hz), 7.29-7.00(4H, m), 4.29(1H, brt, J=12.2Hz), 3.99(2H, t, J= 6.3Hz), 2.41-2.20(2H, m), 1.95-1.76(4H, m), 1.70-1.14(7H, m), 0.76(3H, d, J=6.6Hz)


Purity >90%(NMR)


MS 499 (M+1)









 









TABLE 29







Example No. 115
1H NMR(δ)ppm







300MHz, DMSO-d6 8.23(1H, s), 7.93 and 7.87(2H, ABq, J= 8.6Hz), 7.69 and 7.19(4H, A′B′q, J=8.6Hz), 7.35(1H, t, J= 7.8Hz), 6.82-6.69(3H, m), 4.30(1H, brt, J=12.2Hz), 4.00(2H, t, J=6.9Hz), 2.38-2.20(2H, m), 1.97-1.54(8H, m), 1.47-1.20(3H, m), 0.93(6H, d, J=6.6Hz)


Purity >90%(NMR)


MS 499 (M+1)


Example No. 116
1H NMR(δ)ppm







300MHz, DMSO-d6 8.30(1H, s), 8.25(1H, d, J=8.9Hz), 8.03(1H, d, J=8.8Hz), 7.68(2H, d, J=8.8Hz), 7.24(2H, d, J= 7.2Hz), 7.19-7.10(6H, m), 6.94(2H, t, J=7.2Hz), 4.34(1H, m), 4.19(4H, brs), 3.10(4H, brs), 2.40-2.15(2H, m), 2.10-1.95(2H, m), 1.95-1.75(2H, m), 1.75-1.55(1H, m), 1.55-1.20(3H, m).


Purity >90%(NMR)


MS 557 (M+1)


Example No. 117
1H NMR(δ)ppm







300MHz, DMSO-d6 12.8(1H, brs), 8.22(1H, s), 7.98(1H, d, J= 8.7Hz), 7.87(1H, d, J=8.6Hz), 7.80(2H, d, J=8.2Hz), 7.72- 7.67(3H, m), 7.59(2H, d, J=8.7Hz), 7.54-7.51(2H, m), 7.42- 7.41(1H, m), 7.11(2H, d, J=8.8Hz), 5.09(2H, s), 4.27(1H, m), 2.40-2.15(2H, m), 2.00-1.75(4H, m), 1.75-1.55(1H, m), 1.55-1.15(3H, m).


Purity >90%(NMR)


MS 571 (M+1)









 









TABLE 30







Example No. 118
1H NMR(δ)ppm







300MHz, DMSO-d6 13.3(1H, brs), 8.30(1H, s), 8.25(1H, d, J=8.9Hz), 8.04 (1H, d, J=8.7Hz), 7.72(2H, d, J=8.8Hz), 7.57(4H, d, J=8.6Hz), 7.47(4H, d, J=8.6Hz), 7.33(2H, d, J=8.9Hz), 6.84 (1H, s), 4.33(1H, m), 2.45-2.10 (2H, m), 2.10-1.95(2H, m), 1.95-1.70(2H, m), 1.70-1.55 (1H, m), 1.55-1.15(3H, m).


Purity >90% (NMR)


MS 571(M+1)


Example No. 119
1H NMR(δ)ppm







300MHz, DMSO-d6 8.32-8.30(2H, m), 8.07-8.03 (1H, m), 7.74 and 6.90(4H, ABq, J=8.7Hz), 4.37(1H, m), 4.31(2H, t, J-6.8Hz,), 3.74 (3H, s), 3.04(2H, t, J=6.7Hz), 2.30(2H, m), 2.02(2H, m), 1.86(2H, m), 1.63(1H, m), 1.55- 1.15(3H, m)


Purity >90% (NMR)


MS 471(M+1)


Example No. 120
1H NMR(δ)ppm







300MHz, DMSO-d6 8.23(1H, s), 7.99(1H, d, J= 8.7Hz), 7.88(1H, d, J=8.4Hz), 7.61 and 7.16(4H, ABq, J= 8.6Hz), 7.30-7.22(2H, m), 7.01 (2H, d, J=8.1Hz), 6.92(1H, t, J=7.5Hz), 4.28(1H, m), 4.25(2H, t, J=7.2Hz), 3.83(3H, s), 3.07(2H, t, J=7.1Hz), 2.28(2H, m)2.00-1.75(4H, m), 1.70-1.55(1H, m), 1.50- 1.15(3H, m)


Purity >90% (NMR)


MS 471(M+1)









 









TABLE 31







Example No. 121
1H NMR(δ)ppm







300MHz, DMSO-d6 12.85(1H, brs), 8.24(1H, s), 8.01(1H, d, J=8.7Hz), 7.90 (1H, d, J=8.6Hz), 7.62 and 7.17(4H, Abq, J=8.7Hz), 7.24 (1H, m), 6.94(2H, m), 6.82 (1H, m), 4.32(2H, t, J=6.7Hz), 3.76(3H, s), 3.07(2H, t, J= 6.7Hz), 2.29(2H, m), 2.00- 1.75(4H, m), 1.70-1.55(1H, m), 1.50-1.15(3H, m)


Purity >90% (NMR)


MS 471(M+1)


Example No. 122
1H NMR(δ)ppm







300MHz, DMSO-d6 12.8(1H, brs), 8.22(1H, s), 7.87(2H, m), 7.62(2H, d, J= 8.1Hz), 7.60-7.20(7H, m), 5.23(2H, s), 4.46(1H, m), 2.50- 2.30(2H, m), 1.70-1.40 (10H, m).


Purity >90% (NMR)


MS 441(M+1)


Example 123
1H NMR(δ)ppm







300MHz, DMSO-d6 8.24(1H, s), 7.97(1H, d, J= 9.0Hz), 7.87(1H, d, J=8.4Hz), 7.65(2H, d, J=8.7Hz), 7.40- 7.05(9H, m), 7.03(2H, d, J= 8.4Hz), 4.31(1H, m), 4.18 (2H, t, J=6.6Hz), 2.81(2H, t, J=6.3Hz), 2.40-2.20(2H, m), 2.00-1.70(4H, m), 1.70- 1.50(1H, m), 1.50-1.05(3H, m).


Purity >90% (NMR)


MS 533(M+1)









 









TABLE 32







Example No. 124
1H NMR(δ)ppm







300MHz, DMSO-d6 13.1(1H, brs), 8.29(1H, s), 8.17(1H, d, J=8.7Hz), 7.99 (1H, d, J=8.7Hz), 7.77(2H, d, J=8.7Hz), 7.40-7.20(8H, m), 6.84(1H, d, J=9.3Hz), 6.75- 6.72(2H, m), 4.36(1H, m), 4.22(2H, t, J=6.8Hz), 3.04 (2H, t, J=6.7Hz), 2.40-2.15 (2H, m), 2.15-1.95(2H, m), 1.95- 1.75(2H, m), 


#1.75-1.55 (1H, m), 1.55-1.15(3H, m).


Purity >90% (NMR)


MS 533(M+1)


Example No. 125
1H NMR(δ)ppm







300MHz, DMSO-d6 8.32(1H, s), 8.28(1H, d, J= 8.7Hz), 8.05(1H, d, J=9.0Hz), 7.73(2H, d, J=9.0Hz), 7.43 (4H, d, J=7.2Hz), 7.36-7.20 (8H, m), 4.74(2H, d, J=7.5Hz), 4.57(1H, t, J=7.5Hz), 4.38 (1H, m), 2.40-2.15(2H, m), 2.15-1.95(2H, m), 1.95-1.85 (2H, m), 1.85-1.55(1H, m), 1.55-1.20(3H, m).


Purity >90% (NMR)


MS 517(M+1)


Example No. 126
1H NMR(δ)ppm







300MHz, DMSO-d6 8.32(1H, s), 8.14(1H, d, J= 8.7Hz), 8.03(1H, d, J=8.7Hz), 7.77(2H, d, J=9.0Hz), 7.52- 7.31(7H, m), 5.74(2H, m), 5.26(2H, s), 4.61(1H, m), 2.96 (1H, m), 2.60-2.10(5H, m).


Purity >90% (NMR)


MS 425(M+1)









 









TABLE 33







Example No. 127
1H NMR(δ)ppm







300MHz, DMSO-d6 13.2(1H, brs), 8.33(1H, s), 8.12(1H, d, J=8.7Hz), 7.96 (1H, d, J=8.8Hz), 7.79(2H, d, J=8.7Hz), 7.52-7.32(7H, m), 5.26(2H, s), 4.92(1H, d, J= 49.4Hz), 4.57(1H, m), 2.65- 2.35(2H, m), 2.25-1.50(6H, m).


Purity >90% (NMR)


MS 445(M+1)


Example No. 128
1H NMR(δ)ppm







300MHz, DMSO-d6 8.21(1H, s), 7.92 and 7.85 (2H, ABq, J=8.6Hz), 7.61 and 7.06(4H, A′B′q, J=8.6Hz), 7.36- 6.91(9H, m), 4.24(1H, brt, J=12.2Hz), 2.35-2.15(2H, m), 1.95-1.75(4H, m), 1.70- 1.58(1H, m), 1.48-1.14(3H, m)


Purity >90% (NMR)


MS 505(M+1)


Example No. 129
1H NMR(δ)ppm







300MHz, DMSO-d6 8.21(1H, s), 7.92 and 7.86 (2H, ABq, J=8.6Hz), 7.69 and 7.22(4H, A′B′q, J=8.6Hz), 7.52- 7.39(1H, m), 7.47 and 7.41 (2H, A′′B′′q, J=8.1Hz), 6.91 (1H, d, J=8.0Hz), 6.89(1H, d, J=8.2Hz), 6.75(1H, s), 4.36- 4.18(1H, m), 2.38-2.17(2H, m), 1.95-1.76(4H, m), 1.70- 1.59(1H, m), 1.44-1.19(3H, m)


Purity >90% (NMR)


MS 505(M+1)









 









TABLE 34







Example No. 130
1H NMR(δ)ppm







300MHz, DMSO-d6 8.27(1H, s), 7.69(2H, d, J= 8.6Hz), 7.49-7.21(11H, m), 5.08 and 5.03(2H, ABq, J=12.6Hz), 5.07-4.99(1H, m), 4.26 (2H, d, J=6.6Hz), 2.40-2.18 (2H, m), 2.04-1.77(4H, m), 1.70-1.58(1H, m), 1.48-1.15 (3H, m)


Purity >90% (NMR)


MS 590(M+1)


Example No. 131
1H NMR(δ)ppm







300MHz, DMSO-d6 8.29(1H, s), 8.11(1H, d, J= 9.0Hz), 7.96(1H, d, J=8.4Hz), 7.80(2H, d, J=8.1Hz), 7.72- 7.41(7H, m), 7.12(1H, d, J= 12.6Hz), 7.01(1H, d, J=8.4Hz), 5.12(2H, s), 4.06(1H, m), 2.35-2.10(2H, m), 2.00-1.75 (4H, m), 1.75-1.55(1H, m), 1.60-1.20(3H, m).


Purity >90% (NMR)


MS 589(M+1)


Example No. 132
1H NMR(δ)ppm







300MHz, DMSO-d6 12.8(1H, brs), 8.23(1H, s), 7.97(1H, d, J=8.7Hz), 7.87 (1H, d, J=8.6Hz), 7.66(2H, d, J=8.6Hz), 7.49-7.33(5H, m), 7.17-7.05(6H, m), 5.12(2H, s), 4.31(1H, m), 2.40-2.15 (2H, m), 2.05-1.20(8H, m).


Purity >90% (NMR)


MS 519(M+1)









 









TABLE 35







Example No. 133
1H NMR(δ)ppm







300MHz, DMSO-d6 8.57(1H, s), 8.01(1H, d, J=8.7Hz), 7.66(1H, d, J=8.7Hz), 7.51(2H, d, J=8.7Hz), 7.31 (4H, d, J=8.0Hz), 7.16(4H, d, J=8.0Hz), 7.09(2H, d, J=8.7Hz), 6.26(1H, s), 4.37(1H, m), 2.41-2.28(2H, m), 2.33 (6H, s), 2.03-1.84(4H, m), 1.77(1H, m), 1.45-1.20(3H, m).


Purity >90%(NMR)


MS 531(M+1)


Example No. 134
1H NMR(δ)ppm







8.59(1H, d, J=1.5Hz), 8.02 (1H, dd, J=8.7, 1.5Hz), 7.68 (1H, d, J=8.7Hz), 7.54(2H, d, J=8.8Hz), 7.39(4H, dd, J=8.7, 5.3Hz), 7.08(4H, d, J=8.7Hz), 7.05(2H, d, J=8.8Hz), 6.29(1H, s), 4.36(1H, m), 2.43- 2.19(2H, m), 2.04-1.85 (4H, m), 1.78(1H, m), 1.45-1.23 (3H, m).


Purity >90%(NMR)


MS 539(M+1)


Example No. 135
1H NMR(δ)ppm







300MHz, DMSO-d6 12.34(1H, brs), 7.39(1H, s), 7.55(1H, d, J=8.6Hz), 7.33- 7.15(6H, m), 7.11(2H, d, J= 8.6Hz), 4.30-4.20(1H, m), 4.07(2H, t, J=6.3Hz), 3.93 (3H, s), 2.78(2H, t, J=7.4Hz), 2.35-2.19(2H, m), 2.12-2.00 (2H, m), 1.91-1.79(4H, m), 1.69-1.60(1H, m), 1.47-1.20 (3H, m)


Purity >90%(NMR)


MS 485(M+1)









 









TABLE 36







Example No. 136
1H NMR(δ)ppm







300MHz, DMSO-d6 8.13(1H, s), 7.65(2H, d, J= 8.7Hz), 7.63(1H, s), 7.35-7.12 (7H, m), 4.35-4.20(1H, m), 4.10(1H, t, J=6.3Hz), 2.78 (2H, t, J=7.5Hz), 2.33-1.78 (8H, m), 1.70-1.16(4H, m)


Purity >90%(NMR)


MS 471(M+1)


Example No. 137
1H NMR(δ)ppm







300MHz, DMSO-d6 8.24(1H, s), 8.11(1H, s), 7.76(2H, d, J=9.0Hz), 7.37- 7.16(7H, m), 4.43-4.30(1H, m), 4.13(2H, t, J=6.3Hz), 2.84- 2.68(5H, m), 2.42-2.22(2H, m), 2.18-1.80(6H, m), 1.70- 1.20(4H, m)


Purity >90%(NMR)


MS 469(M+1)


Example No. 138
1H NMR(δ)ppm







300MHz, DMSO-d6 12.73(1H, brs), 8.22(1H, s), 7.76(1H, d, J=8.7Hz), 7.85 (1H, d, J=8.7Hz), 7.54-7.49 (4H, m), 7.42-7.21(5H, m), 7.11-7.09(3H, m), 6.93(1H, m), 5.17(2H, s), 4.29(3H, m), 3.11(2H, m), 2.40-2.20(2H, m), 1.99-1.23(8H, m)


Purity >90%(NMR)


MS 547(M+1)









 









TABLE 37







Example No. 139
1H NMR(δ)ppm







300MHz, DMSO-d6 12.73(1H, brs), 8.22(1H, s), 7.93(1H, d, J=8.7Hz), 7.73 (1H, m), 7.60-7.57(2H, m), 7.47-6.90(1H, m), 5.11(2H, s), 4.33-4.28(3H, m), 3.09- 3.04(2H, t, J=6.7Hz), 2.35- 2.20(2H, m), 1.95-1.10(8H, m)


Purity >90%(NMR)


MS 547(M+1)


Example No. 140
1H NMR(δ)ppm







300MHz, DMSO-d6 12.83(2H, brs), 8.22(1H, s), 7.94(1H, d, J=8.7Hz), 7.85 (1H, d, J=8.4Hz), 7.63-7.60 (2H, m), 7.26-7.03(6H, m), 4.73(2H, s), 4.30(1H, m), 2.40- 2.15(2H, m), 2.00-1.20(8H, m)


Purity >90%(NMR)


MS 487(M+1)


Example No. 141
1H NMR(δ)ppm







300MHz, DMSO-d6 12.87(1H, brs), 8.24(1H, s), 7.97(1H, d, J=9.0Hz), 7.87 (1H, d, J=8.7Hz), 7.69 and 7.19(4H, ABq, J=8.7Hz), 7.36 (1H, t, J=8.7Hz), 6.80-6.72 (3H, m), 4.71(2H, s), 4.32(1H, m), 2.29(2H, m), 1.95-1.25 (8H, m)


Purity >90%(NMR)


MS 487(M+1)









 









TABLE 38







Example No. 142
1H NMR(δ)ppm







300MHz, DMSO-d6 8.32(1H, s), 8.27(1H, d, J= 8.7Hz), 8.05(1H, d, J=9.0Hz), 7.76-7.72(3H, m), 7.54(1H, d, J=8.4Hz), 7.39-7.22(7H, m), 5.11(1H, s), 4.36(1H, m), 2.35(3H, s), 2.35-2.15 (2H, m), 2.15-1.95(2H, m), 1.95- 1.75(2H, m), 1.75-1.55 (1H, m), 1.55-1.15(3H, m).


Purity >90%(NMR)


MS 551(M+1)


Example No. 143
1H NMR(δ)ppm







300MHz, DMSO-d6 13.1(1H, brs), 8.30(1H, s), 8.24(1H, d, J=8.8Hz), 8.03 (1H, d, J=8.7Hz), 7.74-7.71 (3H, m), 7.52(1H, d, J=8.3Hz), 7.40-7.36(3H, m), 7.23(2H, d, J=8.8Hz), 7.01(2H, d, J= 8.7Hz), 5.11(2H, s), 4.35 (1H, m), 3.79(3H, s), 2.45-2.15 (2H, m), 2.15-1.95(2H, 


#m), 1.95-1.75(2H, m), 1.75-1.55 (1H, m), 1.55-1.15(3H, m).


Purity >90%(NMR)


MS 567(M+1)


Example No. 144
1H NMR(δ)ppm







300MHz, DMSO-d6 13.0(1H, brs), 8.31(1H, s), 8.23(1H, d, J=8.7Hz), 8.04 (1H, d, J=8.7Hz), 7.80(2H, d, J=8.3Hz), 7.70-7.66(3H, m), 7.55-7.40(4H, m), 7.03- 6.95(2H, m), 5.08(2H, s), 4.03 (1H, m), 2.40-2.15(2H, m), 2.18(3H, s), 2.05-1.70(4H, m), 1.70-1.50(1H, m), 1.50- 1.10(3H, m).


Purity >90%(NMR)


MS 585(M+1)









 









TABLE 39







Example No. 145
1H NMR(δ)ppm







300MHz, DMSO-d6 8.31(1H, s), 8.23(1H, d, J= 8.8Hz), 8.02(1H, d, J=8.7Hz), 7.73-7.71(3H, m), 7.54(1H, d, J=8.3Hz), 7.48(2H, d, J= 8.4Hz), 7.41-7.37(3H, m), 7.22(2H, d, J=8.7Hz), 5.13 (2H, s), 4.34(1H, m), 2.40-2.20 (2H, m), 2.15-1.95(2H, m), 1.95-1.75(2H, m), 1.70- 1.55(1H, m), 1.50-1.15(3H, m), 1.31(9H, s).


Purity >90%(NMR)


MS 593(M+1)


Example No. 146
1H NMR(δ)ppm







300MHz, DMSO-d6 8.29(1H, s), 8.13(1H, d, J= 8.7Hz), 7.97(1H, d, J=8.6Hz), 7.76(1H, d, J=2.1Hz), 7.63 (1H, t, J=8.5Hz), 7.57(1H, dd, J=8.2, 2.2Hz), 7.55-7.35 (6H, m), 7.15(1H, d, J=12.1Hz), 7.02(1H, d, J=8.6Hz), 5.10(2H, s), 4.07(1H, m), 2.35- 2.10(2H, m), 2.00-1.70(4H, m), 1.70-1.55(1H, m), 1.50- 1.15(3H, m).


Purity >90%(NMR)


MS 555(M+1)


Example No. 147
1H NMR(δ)ppm







300MHz, CDCl3 8.61(1H, s), 8.04(1H, d, J= 8.7Hz), 7.69(1H, d, J=8.7Hz), 7.66(1H, d, J=2.4Hz), 7.59 (2H, d, J=8.7Hz), 7.42(1H, dd, J=8.0, 2.4Hz), 7.38(1H, t, J=1.8Hz), 7.28(2H, d, J= 1.8Hz), 7.26(1H, d, J=8.0Hz), 7.03(2H, d, J=8.7Hz), 4.94 (2H, s), 4.37(1H, m), 2.43- 2.21(2H, m), 2.17-1.86(4H, 


#m), 1.79(1H, m), 1.43-1.26(3H, m).


Purity >90%(NMR)


MS 605(M+1)









 









TABLE 40







Example No. 148
1H NMR(δ)ppm







300MHz, DMSO-d6 8.21(s, 1H), 7.89(1H, d, J= 8.7Hz), 7.87(1H, d, J=8.7Hz), 7.63-7.46(5H, m), 7.30- 7.12(5H, m), 7.08(1H, d, J= 11.0Hz), 6.81(1H, s), 3.92(1H, m), 2.15-2.06(2H, m), 1.89- 172(4H, m), 1.61(1H, m), 1.42- 1.09(3H, m).


Purity >90%(NMR)


MS 557(M+1)


Example No. 149
1H NMR(δ)ppm







300MHz, DMSO-d6 8.24(1H, d, J=1.5Hz), 7.96 (1H, d, J=9.0Hz), 7.88(1H, dd, J=9.0, 1.5Hz), 7.58(1H, d, J=8.7Hz), 7.50-7.30(5H, m), 7.22-7.00(6H, m), 5.13(2H, s), 3.98-3.80(1H, s), 2.36- 1.10(10H, m)


Purity >90%(NMR)


MS 553(M+1)


Example No. 150
1H NMR(δ)ppm







300MHz, DMSO-d6 8.23(1H, s), 8.95(1H, d, J= 8.4Hz), 7.88(1H, d, J=8.7Hz), 7.66(1H, d, J=8.4Hz), 7.52- 7.28(7H, m), 7.23(2H, d, J= 9.3Hz), 7.14(2H, d, J=8.7Hz), 5.14(2H, s), 3.90-3.72 (1H, m), 2.20-1.10(10H, m)


Purity >90%(NMR)


MS 587(M+1)









 









TABLE 41







Example No. 151
1H NMR(δ)ppm







300MHz, DMSO-d6 8.18(1H, s), 7.92-7.78(3H, m), 7.78-7.58(3H, m), 7.58- 7.44(4H, m), 7.29(1H, d, J= 8.2Hz), 7.01(2H, d, J=8.7Hz), 4.88(1H, d, J=11.8Hz), 4.80 (1H, d, J=11.8Hz), 4.22(1H, m), 2.37-2.16(2H, m), 1.95- 1.75(4H, m), 1.64(1H, m), 1.48-1.14(3H, m).


Purity >90%(NMR)


MS 605(M+1)


Example No. 152
1H NMR(δ)ppm







300MHz, DMSO-d6 8.21(2H, m), 7.99-7.80(2H, m), 7.63-7.08(9H, m), 4.20- 3.98(4H, m), 2.20-2.15(2H, m), 1.95-1.74(4H, m), 1.70- 1.54(1H, m), 1.44-1.14(3H, m)


Purity >90%(NMR)


MS 456(M+1)


Example No. 153
1H NMR(δ)ppm







300MHz, DMSO-d6 8.20(1H, s), 8.93 and 7.83 (2H, ABq, J=8.7Hz), 7.86-7.21 (11H, m), 7.03(2H, d, J=8.7Hz), 4.20(1H, brt, J=12.2Hz), 2.32-2.13(2H, m), 1.92- 1.74(4H, m), 1.69-1.58(1H, m) 1.45-1.15(3H, m)


Purity >90%(NMR)


MS 489(M+1)









 









TABLE 42







Example No. 154
1H NMR(δ)ppm







300MHz, DMSO-d6 8.23(1H, s), 7.94 and 7.86 (2H, ABq, J=8.6Hz), 7.72-7.16 (13H, m), 5.25(2H, brs), 4.55 (2H, d, J=6.6Hz), 4.31(1H, brt, J=12.2Hz), 2.37-2.18 (2H, m), 1.98-1.77(4H, m), 1.70-1.58(1H, m), 1.48-1.20 (3H, m)


Purity >90%(NMR)


MS 489(M+1)


Example No. 155
1H NMR(δ)ppm







300MHz, DMSO-d6 8.21(1H, s), 7.85 and 7.61 (2H, ABq, J=8.7Hz), 7.61 and 6.99(4H, A′B′q, J=8.7Hz), 7.28- 7.18(1H, m), 7.25(2H, d, J= 7.5Hz), 7.07-6.99(1Hm), 4.30(1H, brt, J=12.2Hz), 3.83 (2H, d, J=6.0Hz), 3.82-3.72 (1H, m), 2.68-2.49(2H, m), 2.39-2.21(2H, m), 1.95-1.80 (4H, m), 


#1.79-1.60(2H, m), 1.46-1.22(5H, m), 1.30(9H, s), 1.00-0.82(2H, m)


Purity >90%(NMR)


MS 626(M+1)


Example No. 156
1H NMR(δ)ppm







300MHz, DMSO-d6 8.22(1H, s), 7.92 and 7.86 (2H, ABq, J=8.7Hz), 7.68 and  7.18(4H, A′B′q, J=8.7Hz), 7.35 (1H, t, J=8.5Hz), 6.80(1H, d, J=8.3Hz), 6.72-6.70(2H, m)4.30(1H, brt, J=12.2Hz), 3.99(2H, brd, J=12.0Hz), 3.85(2H, d, J=6.3Hz), 2.82- 2.62(2H, m), 2.38-2.20(2H, m), 1.99-1.59(8H, 


# m), 1.42- 1.03(5H, m), 1.39(9H, s)


Purity >90%(NMR)


MS 626(M+1)









 









TABLE 43







Example No. 157
1H NMR(δ)ppm







300MHz, DMSO-d6 12.78(1H, brs), 8.22(1H, s), 7.96(1H, d, J=8.6Hz), 7.86 (1H, d, J=8.6Hz), 7.75(1H, d, J=2.2Hz), 7.60(2H, d, J= 8.4Hz), 7.55(1H, dd, J=8.3, 2.2Hz), 7.48(1H, d, J=8.3Hz), 7.18(2H, d, J=8.4Hz), 6.73 (2H, s), 5.08(2H, s), 4.23(1H, m), 3.68(9H, s), 2.37-2.17 (2H, m), 1.99-1.79(4H, 


# m), 1.65(1H, s), 1.49-1.15(3H, m).


Purity >90%(NMR)


MS 627(M+1)


Example No. 158
1H NMR(δ)ppm







300MHz, DMSO-d6 12.75(1H, brs), 8.22(1H, s), 7.93(2H, d, J=8.7Hz), 7.85 (2H, d, J=8.5Hz), 7.53-7.21 (10H, m), 6.94(2H, d, J=8.7Hz), 4.30-4.12(3H, m), 3.05 (2H, m), 2.35-2.15(2H, m), 1.95-1.75(4H, m), 1.75-1.55 (1H, m), 1.50-1.10(3H, m)


Purity >90%(NMR)


MS 517(M+1)


Example No. 159
1H NMR(δ)ppm







300MHz, DMSO-d6 12.77(1H, brs), 8.22(1H, s), 7.95(1H, d, 8.6Hz), 7.86 (1H, d, 8.6Hz), 7.80(1H, s), 7.70-7.35(10H, m), 7.27(2H, d, J=8.7Hz), 5.30(2H, s), 4.28 (1H, m), 2.35-2.15(2H, m), 1.95-1.75(4H, m), 1.70-1.55 (1H, m), 1.50-1.15(3H, m)


Purity >90%(NMR)


MS 503(M+1)









 









TABLE 44







Example No. 160
1H NMR(δ)ppm







300MHz, DMSO-d6 8.90(1H, brs), 8.59(1h, brs), 8.33(1H, s), 8.18 and 8.00 (2H, ABq, J=8.5Hz), 7.73 and 7.10(4H, A′B′q, J=8.5Hz), 7.32-7.05(4H, m), 4.35(1H, brt, J=12.2Hz), 3.86(2H, d, J=6.3Hz), 3.25-3.08(2H, m), 2.85-2.66(2H, m), 2.40-2.28 (2H, m), 2.07-1.14(15H, m)


Purity >90%(NMR)


MS 526(M+1)


Example No. 161
1H NMR(δ)ppm







300MHz, DMSO-d6 9.05(1H, brs), 8.76(1h, brs), 8.31(1H, s), 8.19 and 8.00 (2H, ABq, J=8.3Hz), 7.79 and 7.25(4H, A′B′q, J=8.3Hz), 7.39(1H, brs), 6.86-6.74(4H, m), 4.37(1H, brt, J=12.2Hz), 3.89(2H, d, J=5.0Hz), 3.35- 3.18(2H, m), 2.98-2.75(2H, m), 2.38-2.17(2H, m), 2.16- 1.15(15H, m)


Purity >90%(NMR)


MS 526(M+1)


Example No. 162
1H NMR(δ)ppm







300MHz, DMSO-d6 12.87(1H, brs), 8.58(1H, d, J=6.0Hz), 8.23(1H, s), 7.99 and 7.80(2H, ABq, J=8.6Hz), 7.61 and 7.18(4H, A′B′q, J= 8.0Hz), 7.45-7.30(5H, m), 5.29(1H, brs), 4.26(1H, brt, J=12.2Hz), 2.37-2.11(2H, m), 2.00-1.71(4H, m), 1.92(3H, s), 1.70-1.52(1H, m), 1.45- 1.11(3H, m)


Purity >90%(NMR)


MS 498(M+1)









 









TABLE 45







Example No. 163
1H NMR(δ)ppm







300MHz, DMSO-d6 8.23(1H, s), 7.95 and 7.86 (2H, ABq, J=8.6Hz), 7.69 and 7.18 (4H, A′B′q, J=8.6Hz), 7.35 (1H, t, J=8.6Hz), 6.80(1H, d, J=7.5Hz), 6.72-6.69(2H, m), 5.20(1H, t, J=3.7Hz), 4.31(1H, brt, J=12.2Hz), 3.95 (2H, t, J=6.8Hz), 2.49-2.19 (4H, m), 1.97-1.76(4H, m), 1.68(3H, 


# s), 1.67-1.54(1H, m), 1.61(3H, s), 1.45-1.20 (3H, m)


Purity >90%(NMR)


MS 511(M+1)


Example No. 164
1H NMR(δ)ppm







300MHz, DMSO-d6 8.20(1H, s), 7.87(2H, s), 7.68 and 7.18(4H, ABq, J=8.7Hz), 7.35(1H, t, J=7.9Hz), 6.81 (1H, d, J=9.4Hz), 6.72(1Hs), 6.71(1H, d, J=6.8Hz), 4.80 (2H, s), 4.29(1H, brt, J= 12.2Hz), 4.10(1H, t, J=6.7Hz), 2.43(1H, t, J=6.7Hz), 2.39- 2.19(2H, m), 1.97-1.78(4H, m), 1.76(3H, s), 


# 1.70-1.56 (1H, m), 1.43-1.19(3H, m)


Purity >90%(NMR)


MS 497(M+1)


Example No. 165
1H NMR(δ)ppm







300MHz, DMSO-d6 11.21(1H, brs), 8.33(1H, s), 8.25(1H, d, J=8.6Hz), 8.04 (1H, d, J=8.6Hz), 7.78(2H, d, J=8.7Hz), 7.70-7.67(2H, m), 7.55-7.42(3H, m), 7.27 (2H, d, J=8.7Hz), 4.73-4.30 (5H, m), 4.20-3.97(1H, m), 3.42-3.10(2H, m), 2.45-1.23 (14H, m)


Purity >90%(NMR)


MS









 









TABLE 46







Example No. 166
1H NMR(δ)ppm







300MHz, DMSO-d6 8.27(1H, s), 8.13(1H, d, J= 8.4Hz), 7.97(1H, d, J=9.0Hz), 7.73(1H, d, J=1.8Hz), 7.68 (2H, d, J=8.4Hz), 7.54(1H, dd, J=8.4, 2.1Hz), 7.41-7.31 (5H, m), 7.19(2H, d, J=8.4Hz), 5.10(2H, s), 4.32(1H, m), 2.50(3H, s), 2.40-2.15(2H, m), 2.10-1.75(4H, m), 1.75- 1.55(1H, m), 1.55-1.10(3H, m).


Purity >90%(NMR)


MS 583(M+1)


Example No. 167
1H NMR(δ)ppm







300MHz, DMSO-d6 8.25(1H, s), 8.09(1H, d, J= 8.4Hz), 8.00(2H, d, J=8.4Hz), 7.94(1H, d, J=8.7Hz), 7.80 (1H, d, J=2.1Hz), 7.73(2H, d, J=8.1Hz), 7.65(2H, d, J= 8.7Hz), 7.60(1H, dd, J=8.1, 2.1Hz), 7.44(1H, d, J=8.1Hz), 7.16(2H, d, J=8.7Hz), 5.13 (2H, s), 4.30(1H, m), 3.26(3H, s), 


# 2.40-1.15(2H, m), 2.05- 1.75(4H, m), 1.75-1.55(1H, m), 1.55-1.15(3H, m).


Purity >90%(NMR)


MS 615(M+1)


Example No. 168
1H NMR(δ)ppm







300MHz, DMSO-d6 13.1(1H, brs), 8.32(1H, s), 8.28(1H, d, J=8.8Hz), 8.05 (1H, d, J=8.7Hz), 7.80-7.75 (3H, m), 7.69(1H, d, J=4.1Hz), 7.57(2H, m), 7.34-7.29(3H, m), 7.20-7.15(1H, m), 5.24 (2H, s), 4.39(1H, m), 2.45- 2.20(2H, m), 2.20-1.95(2H, m), 1.95-1.75(2H, m), 1.75- 1.55(1H, m), 1.55-1.15(3H, m).


Purity >90%(NMR)


MS 543(M+1)









 









TABLE 47







Example No. 169
1H NMR(δ)ppm







300MHz, DMSO-d6 8.31(1H, s), 8.26(1H, d, J= 8.7Hz), 8.05(1H, d, J=8.7Hz), 7.78-7.71(3H, m), 7.59- 7.41(6H, m), 7.23(2H, d, J=9.0Hz), 5.11(2H, s), 4.35(1H, m), 2.40-2.15(2H, m), 2.15- 1.95(2H, m), 1.95-1.75(2H, m), 1.75-1.55(1H, m), 1.55- 1.15(3H, m).


Purity >90%(NMR)


MS 571(M+1)


Example No. 170
1H NMR(δ)ppm







300MHz, DMSO-d6 12.7(1H, brs), 8.66(1H, s), 8.61(1H, m), 8.21(1H, s), 7.92-7.79(4H, m), 7.61-7.56 (3H, m), 7.50-7.43(2H, m), 7.10(2H, d, J=8.7Hz), 5.09(2H, s), 4.26(1H, m), 2.40-2.15 (2H, m), 2.00-1.75(4H, m), 1.75-1.55(1H, m), 1.50-1.15 (3H, m).


Purity >90%(NMR)


MS 538(M+1)


Example No. 171
1H NMR(δ)ppm







300MHz, DMSO-d6 8.31(1H, s), 8.25(1H, d, J= 8.7Hz), 8.04(1H, d, J=8.7Hz), 7.74-7.71(3H, m), 7.57- 7.46(3H, m), 7.39(1H, d, J=8.1Hz), 7.31-7.21(4H, m), 5.11 (2H, s), 4.35(1H, m), 2.40- 2.15(2H, m), 2.15-1.95(2H, m), 1.95-1.75(2H, m), 1.75- 1.55(1H, m), 1.55-1.15(3H, m).


Purity >90%(NMR)


MS 555(M+1)









 









TABLE 48







Example No. 172
1H NMR(δ)ppm







300MHz, DMSO-d6 8.24(1H, s), 7.99(1H, d, J= 8.7Hz), 7.88(1H, d, J=10.5Hz), 7.70(1H, dd, J=11.4, 1.8Hz), 7.48-7.32(6H, m), 7.17- 7.09(5H, m), 5.12(2H, s), 4.30(1H, m), 2.40-2.15(2H, m), 2.05-1.75(4H, m), 1.75- 1.55(1H, m), 1.55-1.20(3H, m).


Purity >90%(NMR)


MS 537(M+1)


Example No. 173
1H NMR(δ)ppm







300MHz, DMSO-d6 8.33(1H, s), 8.29(1H, d, J= 8.7Hz), 8.06(1H, d, J=8.7Hz), 7.82-7.74(4H, m), 7.45(1H, dd, J=8.4, 3.0Hz), 7.39(2H, d, J=8.7Hz), 5.28(2H, s), 4.40(1H, m), 2.40-2.15(2H, m), 2.15-1.95(2H, m), 1.95- 1.75(2H, m), 1.75-1.55(1H, m), 1.55-1.15(3H, m).


Purity >90%(NMR)


MS 540(M+1)


Example No. 174
1H NMR(δ)ppm







300MHz, DMSO-d6 12.80(1H, brs), 8.26(1H, s), 8.01(1H, d, J=8.7Hz), 7.85 (1H, d, J=8.7Hz), 7.80-7.70 (1H, m), 7.60-7.36(7H, m), 7.18-6.91(2H, m), 5.09(2H, s), 4.11-3.90(1H, m), 2.32- 1.18(14H, m)


Purity >90%(NMR)


MS 590(M+1)









 









TABLE 49







Example No. 175
1H NMR(δ)ppm







300MHz, DMSO-d6 12.75(1H, s), 8.21(1H, s), 7.94 and 7.85(2H, ABq, J=8.7Hz), 7.61 and 7.00(4H, A′B′q, J=8.5Hz), 7.31-6.91(2H, m), 7.25(2H, d, J=7.7Hz), 5.41 (2H, brs), 4.54(2H, d, J=6.6Hz), 4.35-4.14(2H, m), 2.49- 2.15(3H, m), 1.95-1.55(5H, m), 1.50-1.13(5H, m), 1.10- 0.77(2H, m)


Purity >90%(NMR)


MS 568(M+1)


Example No. 176
1H NMR(δ)ppm







300MHz, DMSO-d6 8.24(1H, s), 7.97 and 7.87 (2H, ABq, J=8.6Hz), 7.69 and  7.19(4H, A′B′q, J=8,6Hz), 7.35 (1H, t, J=8.1Hz), 6.81(1H, d, J=9.2Hz), 6.72(1H, s), 6.71(1H, d, J=6.5Hz), 4.48- 4.20(2H, m), 3.95-3.75(3H, m), 3.03(1H, t, J=12.3Hz), 2.60- 2.40(1H, m), 2.39-2.15 (2H, 


# m), 2.07-1.58(6H, m), 1.99 (3H, s), 1.50-1.00(5H, m)


Purity >90%(NMR)


MS 568(M+1)


Example No. 177
1H NMR(δ)ppm







300MHz, DMSO-d6 12.76(1H, s), 8.23(1H, s), 7.96 and 7.86(2H, ABq, J=8.6Hz), 7.69 and 7.20(4H, A′B′q, J=8.6Hz), 7.39(1H, t, J=8.2Hz), 6.86(1H, d, J=8.3Hz), 6.81(1H, s), 6.76(1h, d, J=8.0Hz), 4.83(2H, s), 4.31(1H, brt, J=12.2Hz), 2.39-2.19 (2H, m), 1.99-1.79(4H, m), 1.70-1.58(1H, m), 1.48-1.20 (3H, m)


Purity >90%(NMR)


MS 467(M+1)









 









TABLE 50







Example No. 178
1H NMR(δ)ppm







300MHz, DMSO-d6 12.85(1H, s), 8.75(1H, s), 8.63(2H, d, J=3.8Hz), 8.25(1H, s), 8.04-8.01(2H, m), 8.02 and 7.90(2H, ABq, J=8.6Hz), 7.72 and 7.20(4H, A′B′q, J=8.6Hz), 7.57(2H, dd, J=7.8, 5.0Hz), 7.40(1H, t, J=8.2Hz), 6.93(1H, d, J= 8.2Hz), 6.87(1H, s), 6.77(1H, d, J=8.2Hz), 5.23(2H, s), 4.33(1H, brt, J=12.2Hz), 2.40-2.18(2H, m), 2.00-1.55(5H, m), 1.50-1.15(3H, m)


Purity >90%(NMR)


MS 520(M+1)


Example No. 179
1H NMR(δ)ppm







300MHz, DMSO-d6 8.32(1H, s), 8.29(1H, d, J=9.0Hz), 8.06(1H, d, J=8.7Hz), 7.61(1H, d, J=8.4Hz), 7.58-7.32(5H, m), 6.98(1H, d, J=2.1Hz), 6.93(1H, dd, J=8.7, 2.1Hz), 5.27(2H, s), 4.16-4.00(1H, m), 3.87(3H, s), 2.20-2.12(2H, m), 2.02-1.98(4H, m), 1.70-1.60(1H, m), 1.52-1.10(3H, m)


Purity >90%(NMR)


MS 457(M+1)


Example No. 180
1H NMR(δ)ppm







300MHz, DMSO-d6 8.21(1H, s), 7.91(1H, d, J=8.6Hz), 7.85(1H, d, J=8.6Hz), 7.63(2H, d, J=8.4Hz), 7.60(1H, d, J= 9.0Hz), 7.25(2H, d, J=8.4Hz), 7.23(1H, d, J=3.0Hz), 6.95(1H, dd, J=9.0, 3.0Hz), 5.19(2H, s), 4.30(1H, m), 3.78(3H, s), 2.40-2.19(2H, m), 2.00-1.87(4H, m), 1.66(1H, m), 1.49-1.18(3H, m).


Purity >90%(NMR)


MS 536(M+1)









 









TABLE 51







Example No. 181
1H NMR(δ)ppm







300MHz, DMSO-d6 8.19(1H, s), 7.95(1H, d, J=8.7Hz), 7.86(1H, d, J=8.7Hz), 7.65(4H, d, J=7.4Hz), 7.47(2H, d, J=8.7Hz), 7.44- 7.27(6H, m), 6.99(2H, d, J=8.7Hz), 4.20(1H, m), 2.34- 2.12(2H, m), 1.98-1.75(4H, m), 1.64(1H, m), 1.46-1.13(3H, m).


Purity >90%(NMR)


MS 547(M+1)


Example No. 182
1H NMR(δ)ppm







300MHz, DMSO-d6 8.55(1H, d, J=2.1Hz), 8.32(1H, m), 8.21(1H, s), 7.95(1H, d, J=8.4Hz), 7.86(1H, d, J=7.8Hz), 7.68-7.56(7H, m), 7.14(2H, d, J=8.7Hz), 5.21(1H, s), 4.26(1H, m), 2.35- 2.15(2H, m), 2.00-1.75(4H, m), 1.74-1.55(1H, m), 1.50-1.15(3H, m)


Purity >90%(NMR)


MS 582 (M+)


Example No. 183
1H NMR(δ)ppm







300MHz, DMSO-d6 10.16(1H, s), 8.25(1H, s), 8.07(1H, d, J= 8.7Hz), 7.94-7.87(2H, m), 7.71-7.62(3H, m), 7.50-7.42(4H, m), 7.30(1H, d, J=8.4Hz), 7.14(2H, d, J=8.4Hz), 5.06(2H, s), 4.31(1H, m), 2.35-2.15(2H, m), 2.05-1.75(4H, m), 1.75-1.55(1H, m), 1.50-1.15(3H, m)


Purity >90%(NMR)


MS 594 (M+)









 









TABLE 52







Example No. 184
1H NMR(δ)ppm







300MHz, DMSO-d6 13.2(2H, brs), 8.30(1H, s), 8.26(LH, d, J=8.8Hz), 8.04(1H, d, J=8.8Hz), 8.00(2H, d, J=8.2Hz), 7.79(1H, s), 7.73(2H, d, J=8.7Hz), 7.61-7.56(3H, m), 7.44(1H, d, J=8.3Hz), 7.23(2H, d, J=8.8Hz), 5.13(2H, s), 4.35(1H, m), 2.45-2.15(2H, m), 2.15-1.95(2H, m), 1.95- 1.75(1H, m), 1.75-1.15(3H, m).


Purity >90%(NMR)


MS 581(M+1)


Example No. 185
1H NMR(δ)ppm







300MHz, DMSO-d6 8.30(1H, m), 8.24(1H, d, J=9.0Hz), 8.03(1H, d, J=9.0Hz), 7.79-7.10(9H, m), 5.20-5.07(2H, m), 4.43-4.04(4H, m), 3.50-3.36(2H, m), 2.40-1.19(14H, m)


Purity >90%(NMR)


MS 554(M+1)


Example No. 186
1H NMR(δ)ppm







(DMSO-d6) δ:8.29(1H, brs), 8.10(1H, d, J=8.4Hz), 7.97(1H, d, J=8.4Hz), 7.79(2H, d, J=8.4Hz), 7.74-7.67(1H, m), 7.68(2H, d, J=8.4Hz), 7.61(1H, d, J=8.4Hz), 7.57-7.50(2H, m), 7.46-7.39(1H, m), 7.29(1H, d, J=2.4Hz), 7.11(1H, dd, J= 2.4, 8.4Hz), 5.12(2H, s), 3.99-3.84(1H, m), 2.35-1.72(6H, m), 1.68-1.55(1H, m), 1.42-1.10(3H, m)


Purity >90%(NMR)


MS 605(M+1)









 









TABLE 53







Example No. 187
1H NMR(δ)ppm







300MHz, DMSO-d6 12.76(1H, s), 8.57(1H, d, J=4.4Hz), 8.23(1H, s), 7.96 and 7.86(2H, ABq, J=8.2Hz), 7.87- 7.82(1H, m), 7.68 and 7.12(4H, A′B′q, J=8.6Hz), 7.53(2H, d, J=7.8Hz), 7.37(1H, t, J=8.3Hz), 7.36-7.33(1H, m), 6.90(1H, d, J=8.3Hz), 6.83(1H, s), 6.74(1H, d, J=8.0Hz), 5.20(2H, s), 4.31(1H, brt, J=12.2Hz), 2.35-2.19(2H, m), 1.99-1.57(5H, m), 1.45-1.20(3H, m)


Purity >90%(NMR)


MS 520(M+1)


Example No. 188
1H NMR(δ)ppm







300MHz, DMSO-d6 12.77(1H, brs), 8.21(1H, d, J=1, 4Hz), 7.92(1H, d, J=8.7Hz), 7.88(1H, dd, J=8.7, 1.4Hz), 7.57(2H, d, J=8.7Hz), 7.57-7.27(7H, m), 7.11(2H, d, J=8.7Hz), 5.07(2H, s), 4.26(1H, m), 2.36-2.16(2H, m), 1.98-1.75(4H, m), 1.64(1H, m), 1.49-1.17(3H, m).


Purity >90%(NMR)


MS 555(M+1)


Example No. 189
1H NMR(δ)ppm







300MHz, DMSO-d6 8.32(1H, s), 8.30-8.20(2H, m), 8.10- 7.98(2H, m), 7.74(2H, d, J=9.0Hz), 7.60-7.46(5H, m), 7.24(2H, d, J=9.0Hz), 5.19(2H, s), 4.44-4.30(1H, m), 2.40- 2.20(2H, m), 2.12-1.78(4H, m), 1.72-1.58(4H, m)


Purity >90%(NMR)


MS 581(M+1)









 









TABLE 54







Example No. 190
1H NMR(δ)ppm







300MHz, DMSO-d6 8.36-7.90(5H, m), 7.74(2H, d, J=8.6Hz), 7.60-7.40(5H, m), 7.25(2H, d, J=8.7Hz), 5.14(2H, s), 4.45- 4.28(1H, m), 2.40-2.15(4H, m), 1.75-1.55(1H, m), 1.55-1.20(3H, m)


Purity >90%(NMR)


MS 580(M+1)


Example No. 191
1H NMR(δ)ppm







300MHz, DMSO-d6 8.22(1H, s), 7.94(1H, d, J=8.4Hz), 7.85(1H, d, J=8.7Hz), 7.61(2H, d, J=8.7Hz), 7.25-7.00(6H, m), 4.86(2H, s), 4.30(1H, m), 2.89(3H, s), 2.80(3H, s), 2.29(2H, m), 2.00-1.75(4H, m), 1.70-1.55(1H, m), 1.50-1.15(3H, m)


Purity >90%(NMR)


MS 514(M+1)


Example No. 192
1H NMR(δ)ppm







300MHz, DMSO-d6 8.22(1H, s), 7.94(1H, d, J=8.4Hz), 7.85(1H, d, J=8.7Hz), 7.61(2H, d, J=8.7Hz), 7.26-7.01(6H, m), 4.84(2H, s), 4.31(1H, m), 3.36(4H, m), 2.29(2H, m), 2.00-1.75(4H, m), 1.75-1.15(10H, m)


Purity >90%(NMR)


MS 554(M+1)









 









TABLE 55







Example No. 193
1H NMR(δ)ppm







300MHz, DMSO-d6 13.00(1H, brs), 8.29(1H, d, J=1.4Hz), 8.15(1H, d, J=8.8Hz), 7.97(1H, dd, J=1.4Hz, 8.8Hz), 7.89(2H, d, J=8.8Hz), 7.80-7.60(5H, m) 7.25(2H, d, J=8.8Hz), 4.47-3.90(4H, m), 3.20- 3.10(2H, m), 2.41-1.22(14H, m)


Purity > 90%(NMR)


MS 560 (M+1)


Example No. 194
1H NMR(δ)ppm







300MHz, DMSO-d6 12.80(1H, brs), 8.23(1H, s), 7.97(1H, d, J=8.5Hz), 7.87(1H, d, J=8.5Hz), 7.70-7.17(9H, m), 4.60-4.13(4H, m), 3.72- 3.40(2H, m), 2.40-1.15(14H, m)


Purity > 90%(NMR)


MS 524 (M+1)


Example No. 195
1H NMR(δ)ppm







300MHz, DMSO-d6 8.25(1H, s), 8.09-7.92(5H, m), 7.77(1H, s), 7.65(2H, d, J=8.4Hz), 7.59-7.51(3H, m), 7.43(2H, d, J=8.4Hz), 7.17(2H, d, J=8.7Hz), 5.10(2H, s), 4.30(1H, m), 2.40-2.15(2H, m), 2.10-1.75(4H, m), 1.75-1.55(1H, m), 1.55-1.10(3H, m).


Purity > 90%(NMR)


MS 580 (M+1)









 









TABLE 56







Example No. 196
1H NMR(δ)ppm







300MHz, DMSO-d6 8.22(1H, s), 7.95(1H, d, J=8.4Hz), 7.86(1H, d, J=8.4Hz), 7.69 and 7.18(4H, ABq, J=8.7Hz), 7.34(1H, t, J=8.0Hz), 6.80-6.69(3H, m), 4.83(2H, s), 4.31(1H, m), 2.98(3H, s), 2.84(3H, s), 2.29(2H, m), 2.00- 1.75(4H, m), 1.70-1.55(1H, m), 1.50-1.15(3H, m)


Purity > 90%(NMR)


MS 514 (M+1)


Example No. 197
1H NMR(δ)ppm







300MHz, DMSO-d6 8.23(1H, s), 7.95(1H, d, J=8.4Hz), 7.86(1H, d, J=8.7Hz), 7.69 and 7.18(4H, ABq, J=8.7Hz), 7.35(1H, t, J=8.4Hz), 6.80-6.70(3H, m), 4.82(2H, s), 4.31(1H, m), 3.40(4H, m), 2.29(2H, m), 2.00-1.75(4H, m), 1.70-1.15(10H, m)


Purity > 90%(NMR)


MS 554 (M+1)


Example No. 198
1H NMR(δ)ppm







300MHz, DMSO-d6 12.75(1H, s), 8.23(1H, d, J=4.4Hz), 7.95 and 7.86(2H, ABq, J= 8.6Hz), 7.69 and 7.19(4H, A′B′q, J=8.6Hz), 7.36(1H, t, J=7.8Hz) , 6.82(1H, d, J=9.3Hz), 6.73(1H, s), 6.71(1H, d, J=7.2Hz), 4.30(1H, brt, J=12.2Hz), 3.89(2H, d, J=6.0Hz), 3.59(2H, d, J=11.7Hz), 2.85(3H, s) 2.73(2H, t, J= 10.5Hz), 2.41-2.20(2H, m), 


#1.98-1.59(8H, m), 1.46-1.18(5H, m)


Purity > 90%(NMR)


MS 604 (M+1)









 









TABLE 57







Example No. 199
1H NMR(δ)ppm







300MHz, DMSO-d6 8.33(1H, s), 8.30(1H, d, J= 8.9Hz), 8.06(1H, d, J=8.7Hz), 7.79(2H, d, J=8.7Hz), 7.70(2H, d, J=8.7Hz), 7.61(2H, d, J=8.7Hz), 7.39(2H, d, J=8.8Hz), 5.28(2H, s), 4.39(1H, m), 2.50-2.15(2H, m), 2.15-1.95(2H, m), 1.95-1.75(2H, m), 1.75- 1.55(1H, m), 1.55-1.15(3H, m).


Purity > 90%(NMR)


MS 542 (M+1)


Example No. 200
1H NMR(δ)ppm







(DMSO-d6) δ:8.23(1H, s), 7.96(1H, d, J=8.6Hz), 7.86(1H, d, J=8.6Hz), 7.69(2H, d, J=8.4Hz), 7.52(1H, s), 7.50-7.30(4H, m), 7.18(2H, d, J=8.4Hz), 6.90(1H, d, J=8.3Hz), 6.84(1H, s), 6.74(1H, d, J=8.3Hz), 5.15(2H, s), 4.39-4.21(1H, m), 2.39-2.18(2H, m), 1.99-1.80(4H, m), 1.71-1.59(1H, m), 1.50-1.20(3H, m)


Purity > 90%(NMR)


MS 553 (M+1)


Example No. 201
1H NMR(δ)ppm







(DMSO-d6) δ:8.26(1H, s), 8.06(1H, d, J=8.7Hz), 7.92(1H, d, J=8.7Hz), 7.72(2H, d, J=8.7Hz), 7.47(4H, s), 7.38(1H, t, J=8.2Hz), 7.20(2H, d, J=8.7Hz), 6.90(1H, d, J=8.2Hz), 6.83(1H, s), 6.74(1H, d, J= 8.2Hz), 5.14(2H, s), 2.40-2.19(2H, m), 2.04-1.78(4H, m), 1.71-1.60(1H, m), 1.50-1.21(3H, m)


Purity > 90%(NMR)


MS 553 (M+1)









 









TABLE 58







Example No. 202
1H NMR(δ)ppm







(DMSO-d6) δ:12.81(1H, brs), 8.24(1H, s), 7.99(1H, d, J=8.7Hz), 7.87(1H, d, J=8.7Hz), 7.69(2H, d, J= 8.6Hz), 7.53-7.47(2H, m), 7.38(1H, t, J=8.2Hz), 7.26-7.16(4H, m), 6.89(1H, d, J=8.2Hz), 6.82(1H, s), 6.73(1H, d, J=8.2Hz), 5.11(2H, s), 4.40-4.21(1H, m), 2.40-2.17(2H, m), 2.01-1.77(4H, m), 1.71- 1.59(1H, m), 1.50-1.20(3H, m)


Purity > 90%(NMR)


MS 537 (M+1)


Example No. 203
1H NMR(δ)ppm







300MHz, DMSO-d6 12.74(1H, brs), 8.21(1H, s), 8.08(2H, d, J=9.0Hz), 7.93(1H, d, J=8.7Hz), 7.85(2h, d, J=8.7Hz), 7.58(2H, d, J=8.7Hz), 7.13(2H, d, J= 8.7Hz), 6.83(2H, d, J=9.0Hz), 4.50-4.08(4H, m), 3.68-3.30(2H, m), 2.40-1.23(14H, m)


Purity > 90%(NMR)


MS 541 (M+1)


Example No. 204
1H NMR(δ)ppm







300MHz, DMSO-d6 8.39-8.28(2H, m), 8.08(1H, d, J=8.8Hz), 7.76(2H, d, J=8.7Hz), 7.29(2H, d, J= 8.7Hz), 7.25-7.13(2H, m), 6.80-6.60(3H, m), 4.46- 3.98(4H, m), 3.51-3.42(1H, m), 3.20-3.04(1H, m), 2.39-1.20(14H, m)


Purity > 90%(NMR)


MS









 









TABLE 59







Example No. 205
1H NMR(δ)ppm







300MHz, DMSO-d6 9.59(1H, brs), 8.23(1H, s), 8.04(1H, d, J=8.4Hz), 7.90(1H, d, J=8.4Hz), 7.62(2H, d, J=8.7Hz), 7.39(2H, 2H, d, J=8.7Hz) 7.18(2H, d, J=8.7Hz), 6.63(2H, d, J=8.7Hz), 3.95-3.37(4H, m), 3.51- 3.40(1H, m), 3.17-3.02(1H, m), 2.39-1.18(17H, m)


Purity > 90%(NMR)


MS 553 (M+1)


Example No. 206
1H NMR(δ)ppm







300MHz, DMSO-d6 13.1(1H, brs), 8.33(1H, s), 8.29(1H, d, J=8.8Hz), 8.06(1H, d, J=8.7Hz), 7.77(2H, d, J=8.7Hz), 7.59-7.52(4H, m), 7.35(2H, d, J=8.8Hz), 5.19(2H, s), 4.39(1H, m), 2.71(3H, s), 2.45-2.20(2H, m), 2.20- 1.95(2H, m), 1.95-1.75(2H, m), 1.75-1.55(1H, m), 1.55-1.15(3H, m).


Purity > 90%(NMR)


MS 558 (M+1)


Example No. 207
1H NMR(δ)ppm







300MHz, DMSO-d6 8.29(1H, s), 8.26(1H, d, J=8.8Hz), 8.04(1H, d, J= 8.7Hz), 7.73(2H, d, J=8.8Hz), 7.50-7.41(6H, m), 7.36(2H, d, J=8.8Hz), 7.18-7.13(2H, m), 6.84(1H, s), 4.33(1H, m), 2.40-2.15(2H, m), 2.15- 1.95(2H, m), 1.95-1.75(2H, m), 1.75-1.55(1H, m), 1.55-1.15(3H, m).


Purity > 90%(NMR)


MS 539 (M+1)









 









TABLE 60







Example No. 208
1H NMR(δ)ppm







300MHz, DMSO-d6 8.32(1H, s), 8.27(1H, d, J= 9.0Hz), 8.07-8.00(3H, m), 7.79-7.70(3H, m), 7.51(2H, d, J=8.1Hz), 7.40(2H, d, J=8.4Hz), 7.18(2H, d, J=8.7Hz), 4.99(2H, s), 4.34(1H, m), 2.40-2.15(2H, m), 2.15-1.95(2H, m), 1.95- 1.75(2H, m), 1.75-1.55(1H, m), 1.55-1.15(3H, m).


Purity >90% (NMR)


MS 582 (M+1)


Example No. 209
1H NMR(δ)ppm







300MHz, DMSO-d6 8.24(1H, d, J=4.4Hz), 7.98 and 7.88(2H, ABq, J=8.6Hz), 7.70 and 7.19(4H, A′B′q, J=8.4Hz), 7.35(1H, t, J=8.4Hz), 6.86(1H, d, J= 8.1Hz), 6.79(1H, s), 6.71(1H, d, J=8.1Hz), 4.65- 4.53(1H, m), 4.31(1H, brt, J=12.2Hz), 3.88- 3.78(2H, m), 3.48(2H, t, J=9.0Hz), 2.39-2.19(2H, m), 1.02-1.71(6H, m), 1.70-1.50(3H, m), 1.46-1.19(3H, m)


Purity >90% (NMR)


MS 513 (M+1)


Example No. 210
1H NMR(δ)ppm







300MHz, DMSO-d6 12.75(1H, s), 8.23(1H, s), 7.96 and 7.87(2H, ABq, J=8.7Hz), 7.84-7.66(6H, m), 7.38(1H, t, J=8.4Hz), 7.18(2H, d, J=8.4Hz), 6.91(1H, d, J=9.0Hz), 6.84(1H, s), 6.74(1H, d, J= 8.1Hz), 5.26(2H, s), 4.31(1H, brt, J=12.2Hz), 2.40- 2.20(2H, m), 1.99-1.76(4H, m), 1.69-1.58(1H, m), 1.45-1.20(3H, m)


Purity >90% (NMR)


MS 587 (M+1)









 









TABLE 61







Example No. 211
1H NMR(δ)ppm







300MHz, DMSO-d6 8.29(1H, s), 8.15 and 7.47(2H, ABq, J=9.0Hz), 7.77 and 7.24(4H, ABq, J=8.9Hz), 7.39(1H, t, J=7.8Hz), 6.84(1H, d, J=9.3Hz), 6.76(1H, s), 6.75(1H, d, J=9.5Hz), 4.36(1H, brt, J=12.2Hz), 3.89(2H, d, J=6.0Hz), 3.42(2H, d, J=10.8Hz), 3.04-2.88(2H, m), 2.78- 2.60(1H, m), 2.71(2H, d, J=4.8Hz), 2.38- 2.20(2H, m), 


# 2.07-1.80(7H, m), 1.70-1.20(5H, m)


Purity >90% (NMR)


MS 540 (M+1)


Example No. 212
1H NMR(δ)ppm







300MHz, DMSO-d6 8.22(1H, s), 7.93 and 7.87(2H, ABq, J=8.6Hz), 7.68 and 7.17(4H, A′B′q, J=8.7Hz), 7.43-7.33(5H, m), 6.87(1H, d, J=8.1Hz), 7.18(2H, d, J=8.4Hz), 6.91(1H, d, J=9.0Hz), 6.81(1H, s), 6.72(1H, d, J=8.0Hz), 5.08(2H, s), 4.36(1H, brt, J=12.2Hz), 2.37- 2.20(2H, m), 1.98-1.78(4H, m), 1.69-1.60(1H, m), 1.41-1.21(3H, m), 1.28(9H, s)


Purity >90% (NMR)


MS 575 (M+1)


Example No. 213
1H NMR(δ)ppm







300MHz, DMSO-d6 8.23(1H, s), 7.95 and 7.86(2H, ABq, J=8.4Hz), 7.69 and 7.19(4H, A′B′q, J=8.7Hz), 7.62-7.36(5H, m), 6.90(1H, d, J=8.1Hz), 6.84(1H, s), 6.76(1H, d, J=8.1Hz), 5.19(2H, s), 4.31(1H, brt, J=12.2Hz), 2.40- 2.19(2H, m), 1.99-1.76(4H, m), 1.68-1.55(1H, m), 1.50-1.18(3H, m)


Purity >90% (NMR)


MS 553 (M+1)









 









TABLE 62







Example No. 214
1H NMR(δ)ppm







300MHz, DMSO-d6 8.94(1H, d, J=2.1Hz), 8.60(1H, dd, J= 4.8, 1.5Hz), 8.23(1H, d, J=1.5Hz), 8.12(1H, dt, J=8.1, 2.1Hz), 7.93(1H, d, J=8.7Hz), 7.87(1H, dd, J=8.7, 1.5Hz), 7.70(1H, d, J=8.7Hz), 7.67-7.54(3H, m), 7.50(1H, dd, J= 8.1, 4.8Hz), 7.25(2H, d, J=8.7Hz), 7.21(1H, m), 4.31(1H, m), 2.38-2.19(2H, m), 2.00-1.78(4H, m), 1.65(1H, m), 1.48-1.22(3H, m).


Purity >90% (NMR)


MS 490 (M+1)


Example No. 215
1H NMR(δ)ppm







300MHz, DMSO-d6 12.75(1H, brs), 8.23(1H, s), 7.95(1H, d, J=8.7Hz), 7.86(1H, d, J=8.7Hz), 7.73(2H, d, J=8.4Hz), 7.71(2H, d, J=8.4Hz), 7.63-7.39(2H, m), 7.52(2H, d, J= 8.4Hz), 7.24(2H, d, J=8.4Hz), 7.18(1H, m), 4.31(1H, m), 2.39-2.20(2H, m), 2.00-1.76(4H, m), 1.65(1H, m), 1.49-1.18(3H, m).


Purity >90% (NMR)


MS 523 (M+1)


Example No. 216
1H NMR(δ)ppm







300MHz, DMSO-d6 12.77(1H, s), 8.23(1H, d, J=1.4Hz), 7.95(1H, d, J=8.6Hz), 7.86(1H, dd, J=8.6, 1.4Hz), 7.70(2H, d, J=8.7Hz), 7.64(2H, d, J=8.8Hz), 7.56-7.48(2H, m), 7.40(1H, s), 7.23(2H, d, J=8.7Hz), 7.10(1H, m), 7.03(2H, d, J=8.8Hz), 4.31(1H, m), 3.80(3H, s), 2.48-2.20(2H, m), 2.00- 1.88(4H, m), 1.66(1H, m), 1.50-1.21(3H, m).


Purity >90% (NMR)


MS 519 (M+1)









 









TABLE 63







Example No. 217
1H NMR(δ)ppm







(DMSO-d6) δ:12.80(1H, brs), 8.23(1H, s), 8.04(1H, d, J=8.6Hz), 7.96(3H, d, J=8.6Hz), 7.86(1H, d, J=8.7Hz), 7.63(2H, d, J=8.6Hz), 7.25(2H, d, J=8.6Hz), 5.50(2H, s), 4.36-4.21(1H, m), 3.27(3H, s), 2.74(3H, s), 2.40-2.19(2H, m), 1.99-1.79(4H, m), 1.71-1.60(1H, m), 1.49-1.19(3H, m)


Purity >90% (NMR)


MS 602 (M+1)


Example No. 218
1H NMR(δ)ppm







300MHz, DMSO-d6 12.9(1H, brs), 8.25(1H, s), 8.04(1H, d, J= 8.7Hz), 7.91(1H, d, J=8.6Hz), 7.72(2H, d, J=8.5Hz), 7.67(2H, d, J= 8.7Hz), 7.56(2H, d, J=8.5Hz), 7.26(2H, d, J=8.7Hz), 5.45(2H, s), 4.31(1H, m), 2.71(3H, s), 2.40-2.15(2H, m), 2.05-1.80(4H, m), 1.75-1.55(1H, m), 1.55-1.15(3H, m).


Purity >90% (NMR)


MS 558 (M+1)


Example No. 219
1H NMR(δ)ppm







300MHz, DMSO-d6 8.21(1H, d, J=1.5Hz), 7.93(1H, d, J=9.0Hz), 7.84(1H, dd, J=9.0, 1.5Hz), 7.56(2H, d, J=8.7Hz), 7.42-7.30(4H, m), 7.12(2H, d, J=8.7Hz), 4.53(1H, brs), 4.36-4.20(1H, m), 3.55(2H, brs), 3.00-2.90(1H, m), 2.70-2.58(1H, m), 2.40-1.10(18H, m)


Purity >90% (NMR)


MS 544 (M+1)









 









TABLE 64







Example No. 220
1H NMR(δ)ppm







300MHz, DMSO-d6 12.76(1H, s), 8.23(1H, s), 7.96 and 7.87(2H, ABq, J=8.9Hz), 7.69 and 7.19(4H, A′B′q, J= 8.6Hz), 7.55(1H, s), 7.37(1H, t, J=8.1Hz), 6.91(1H, d, J= 7.8Hz), 6.85(1H, s), 6.74(1H, d, J=7.5Hz), 5.13(2H, s), 4.31(1H, brt, J=12.2Hz), 2.65(3H, s), 2.41-2.20(2H, m), 2.00-1.74(4H, m), 1.70-1.59(1H, m), 1.58-1.20(3H, m)


Purity >90% (NMR)


MS 540 (M+1)


Example No. 221
1H NMR(δ)ppm







300MHz, DMSO-d6 8.23(1H, s), 7.96 and 7.86(2H, ABq, J=8.6Hz), 7.69 and 7.18(4H, A′B′q, J=8.7Hz), 7.37(1H, t, J=8.2Hz), 6.87(1H, d, J=8.2Hz), 6.82(1H, s), 6.75(1H, d, J=8.0Hz), 5.24(2H, s), 4.32(1H, brt, J=12.2Hz), 2.58(3H, s), 2.38-2.20(2H, m), 2.30(3H, s), 2.00-1.79(4H, m), 1.70- 1.59(1H, m), 1.44-1.20(3H, m)


Purity >90% (NMR)


MS 554 (M+1)


Example No. 222
1H NMR(δ)ppm







300MHz, DMSO-d6 12.88(1H, brs), 8.25(s, 1H), 8.07- 7.57(11H, m), 7.26(2H, d, J=8.7Hz), 7.24(1H, m), 4.34(1H, m), 2.30-2.20(2H, m), 2.03-1.78(4H, m), 1.64(1H, m), 1.49-1.19(3H, m).


Purity >90% (NMR)


MS 557 (M+1)









 









TABLE 65







Example No. 223
1H NMR(δ)ppm







300MHz, DMSO-d6 10.96(1H, brs), 8.21(1H, d, J=1.4Hz), 7.93(1H, d, J=8.7Hz), 7.84(1H, dd, J=8.7, 1.4Hz), 7.76- 7.40(7H, m), 7.18(2H, d, J=8.0Hz), 4.24-4.16(2H, m), 2.40- 1.12(18H, m)


Purity >90%(NMR)


MS 544(M+1)


Example No. 224
1H NMR(δ)ppm







(DMSO-d6) δ:8.22(1H, s), 8.07(1H, d, J=8.4Hz), 7.92(1H, d, J=8.4Hz), 7.54(2H, d, J=8.7Hz), 7.40(2H, d, J=8.4Hz), 7.30(2H, d, J=8.4Hz), 7.14(2H, d, J=8.7Hz), 4.61(2H, s), 4.48-4.32(1H, m), 3.82(1H, brd, J=12.3Hz), 3.65-3.47(2H, m), 3.10(brdd, J=8.4, 12.3Hz), 2.40-2.20(2H, m), 2.09- 1.76(6H, m), 1.71-1.16(6H, m)


Purity >90%(NMR)


MS 544(M+1)


Example No. 225
1H NMR(δ)ppm







(DMSO-d6) δ:12.83(1H, brs), 8.21(1H, s), 8.10(1H, brs), 7.01-7.91(2H, m), 7.89-7.82(2H, m), 7.75(1H, d, J=8.0Hz), 7.59(2H, d, J=8.7Hz), 7.53(4H, s), 7.46(1H, brs), 7.12(2H, d, J=8.7Hz), 7.23(2H, s), 4.35-4.17(1H, m), 2.38-2.20(2H, m), 1.99-1.79(4H, m), 1.71-1.59(1H, m), 1.48-1.18(3H, m)


Purity >90%(NMR)


MS 580(M+1)









 









TABLE 66







Example No. 226
1H NMR(δ)ppm







300MHz, DMSO-d6 8.33 and 8.08(2H, ABq, J= 8.7Hz), 8.31(1H, m), 7.66 and 7.26(4H, A′B′q, J= 9.2Hz), 7.42 and 7.39(4H, A′′B′′q, J=8.7Hz), 4.57(2H, s), 4.50(1H, brt, J=12.2Hz), 3.85-3.62(3H, m), 3.28- 3.16(2H, m), 2.42-2.23(2H, m), 2.14-1.81(6H, m), 1.72-1.25(6H, m)


Purity >90%(NMR)


MS 544(M+1)


Example No. 227
IH NMR(δ)ppm







300MHz, DMSO-d6 8.43(1H, d, J=5.0Hz), 8.23(1H, s), 7.96 and 7.86(2H, ABq, J=8.6Hz), 7.69 and 7.18(4H, A′B′q, J=8.6Hz), 7.57(1H, s), 7.47(1H, d, J=5.0Hz), 7.40(2H, t, J=8.2Hz), 6.91(1H, d, J=8.3Hz), 6.85(1H, s), 6.77(1H, d, J=7.9Hz), 5.25(2H, s), 4.31(1H, brt, J=12.2Hz), 2.40-2.19(2H, m), 1.99- 1.75(4H, m), 1.73-1.57(1H, m), 1.49-1.19(3H, m)


Purity >90%(NMR)


MS 554(M+1)


Example No. 228
1H NMR(δ)ppm







300MHz, DMSO-d6 12.80(1H, brs), 8.22(1H, s), 7.94(1H, d, J=8.6Hz), 7.87(1H, d, J=8.6Hz), 7.60(2H, d, J=8.7Hz), 7.32(2H, d, J=8.7Hz)7.17(2H, d, J= 8.7Hz), 6.70(2H, d, J=8.7Hz), 4.35-3.97(4H, m), 3.62-3.11(2H, m), 2.96(6H, s), 2.39-1.12(14H, m)


Purity >90%(NMR)


MS 567(M+1)









 









TABLE 67







Example No. 229
1H NMR(δ)ppm







300MHz, DMSO-d6 8.25(1H, s), 8.20(1H, s), 8.04(1H, dd, J= 8.1, 1.8Hz), 7.92(1H, d, J=8.1Hz), 7.84(1H, d, J=9.9Hz), 7.62- 7.50(7H, m), 7.12(2H, d, J=8.7Hz), 5.14(2H, s), 4.36(2H, q, J= 6.9Hz), 4.30-4.20(1H, m), 2.38-2.18(2H, m), 1.98-1.18(8H, m), 1.35(3H, t, J=6.9Hz)


Purity >90%(NMR)


MS 608(M+1)


Example No. 230
1H NMR(δ)ppm







300MHz, DMSO-d6 8.35(1H, s), 8.27(1H, d, J=8.7Hz), 8.05(1H, d, J=9.0Hz), 7.87(2H, d, J=8.7Hz), 7.74(1H, t, J= 8.1Hz), 7.64(1H, d, J=7.8Hz), 7.59-7.50(2H, m), 7.36(2H, d, J= 8.7Hz), 4.39(1H, m), 2.40-2.15(2H, m), 2.15-1.95(2H, m), 1.95-1.75(2H, m), 1.75-1.55(1H, m), 1.55-1.20(3H, m).


Purity about 90%(NMR)


MS 481(M+1)


Example No. 231
1H NMR(δ)ppm







300MHz DMSO-d6 12.78(1H, brs), 8.23(1H, d, J=1.5Hz), 7.96(1H, d, J=8.7Hz), 7.87(1H, dd, J=8.7, 1.5Hz), 7.75(2H, d, J=8.4Hz), 7.63(2H, d, J=8.4Hz), 7.52(2H, d, J=8.4Hz), 7.24(2H, d, J=8.4Hz), 5.47(2H, s), 4.29(1H, m), 2.97(6H, brs), 2.72(3H, s), 2.39-2.16(2H, m), 2.00-1.78(4H, m), 1.71-1.59(1H, m), 1.49-1.17(3H, m).


Purity about 90%(NMR)


MS 595(M+1)









 









TABLE 68







Example No. 232
1H NMR(δ)ppm







300MHz, DMSO-d6 12.8(1H, brs), 8.22(1H, s), 7.96(1H, d, J= 8.7Hz), 7.86(1H, d, J=8.6Hz), 7.70(1H, s), 7.59(2H, d, J=8.7Hz), 7.53-7.50(5H, m), 7.42(1H, d, J=7.9Hz), 7.12(2H, d, J=8.7Hz), 5.11(2H, s), 4.27(1H, m), 3.01(3H, brs), 2.97(3H, brs), 2.40- 2.15(2H, m), 2.00-1.75(4H, m), 1.75-1.55(1H, m), 1.50- 1.15(3H, m).


Purity >90%(NMR)


MS 608(M+1)


Example No. 233
1H NMR(δ)ppm







DMSO-d6 13.20(1H, brs), 8.99(1H, s), 8.32(1H, s), 8.25(1H, d, J= 8.8Hz), 8.04(1H, d, J=8.6Hz), 7.79-7.74(4H, m), 7.60(2H, d, J= 8.5Hz), 7.30(2H, d, J=8.7Hz), 5.26(2H, s), 4.36(1H, m), 2.72(3H, s), 2.50-2.15(2H, m), 2.15-1.95(2H, m), 1.95-1.75(2H, m), 1.75- 1.55(1H, m), 1.55-1.15(3H, m).


Purity >90%(NMR)


MS 553(M+1 − HCl)


Example No. 234
1H NMR(δ)ppm







DMSO-d6 8.77(1H, d, J=3.6Hz), 8.36-8.26(3H, m), 8.08(1H, d, J= 8.8Hz), 7.79(2H, d, J=8.7Hz), 7.72-7.64(3H, m), 7.58(2H, d, J= 8.4Hz), 7.30(2H, d, J=8.7Hz), 5.26(2H, s), 4.38(1H, m), 2.50- 2.15(2H, m), 2.15-1.95(2H, m), 1.95-1.75(2H, m), 1.75-1.55(1H, m), 1.55-1.15(3H, m).


Purity >90%(NMR)


MS 538(M+1− 2HCl)









 









TABLE 69







Example No. 235
1H NMR(δ)ppm







300MHz, DMSO-d6 12.74(1H, brs), 8.67(1H, dd, J=3.1, 1.6Hz), 8.21(1H, d, J=1.6Hz), 7.93(1H, dJ=8.6Hz), 7.90- 7.80(2H, m), 7.60-7.50(7H, m), 7.09(2H, d, J=8.7Hz), 5.16(2H, s), 4.26(1H, m), 2.40-2.20(2H, m), 2.00-1.60(5H, m), 1.50-1.20(3H, m)


Purity >90%(NMR)


MS APCI-Ms 538(M+1)


Example No. 236
1H NMR(δ)ppm







300MHz, DMSO-d-6 8.40-7.40(11H, m), 2.95, 2.81(3H, each d, J=4.7Hz), 2.40-2.20(2H, m), 2.10-1.80(4H, m), 1.70- 1.60(1H, m), 1.50-1.20(3H, m)


Purity >90%(NMR)


MS APCI-Ms 555(M+1)


Example No. 237
1H NMR(δ)ppm







300MHz, DMSO-d6 8.21(1H, s), 8.15(1H, d, J=9.5Hz), 8.02(1H, s), 8.00-7.80(3H, m), 7.70-7.50(6H, m), 7.12(2H, d, J=8.7Hz), 5.16(2H, s), 4.28(1H, m), 2.40-2.20(2H, m), 2.00-1.80(4H, m), 1.65(1H, m), 1.50-1.20(3H, m)


Purity >90%(NMR)


MS FAB-Ms 605(M+1)









 









TABLE 70







Example No. 238
1H NMR(δ)ppm







300MHz, DMSO-d6 12.80(1H, brs), 8.54(1H, s), 8.25(1H, s), 7.98 and 7.88(2H, Abq, J=8.6Hz), 7.76(2H, d, J= 8.6Hz), 7.53-7.31(3H, m), 6.61(1H, s), 5.46(2H, s), 4.32(1H, brt), 2.40-2.20(2H, m), 2.02-1.79(4H, m), 1.69- 1.59(1H, m), 1.48-1.19(3H, m)


Purity >90%(NMR)


MS APCI-Ms 521 (M+1)


Example No. 239
1H NMR(δ)ppm







300MHz, DMSO-d6 12.79(1H, brs), 8.60(2H, d, J=1.5Hz), 8.53(1H, s), 8.25(1H, s), 7.98 and 7.85(2H, ABq, J= 9.4Hz), 7.76(2H, d, J=9.0Hz), 7.44(4H, d, J=6.5Hz), 6.69(1H, s), 5.53(2H, s), 4.32(1H, brt), 2.40-2.19(2H, m), 2.03-1.82(4H, m), 1.72-1.61(1H, m), 1.42-1.22(3H, m)


Purity >90%(NMR)


MS APCI-Ms 522 (M+1)


Example No. 240
1H NMR(δ)ppm







300MHz, DMSO-d6 8.90(1H, s), 8.32(1H, s), 8.28(1H, s), 8.25(1H, d, J=8.3Hz), 8.05(1H, d, J=8.8Hz), 7.96(1H, s), 7.93(1H, d, J=8.8Hz), 7.83(1H, d, J=8.4Hz), 7.68-7.59(2H, m), 7.54(2H, d, J=8.8Hz), 4.37(1H, brt), 2.30(2H, m), 2.00(2H, m), 1.88(2H, m), 1.67(1H, m), 1.5-1.2(3H, m)


Purity >90%(NMR)


MS APCI-Ms 525 (M+1)









 










TABLE 71





Ex. No.
Formula
MS







1001





364 (M+H)


1002





454 (M+H)


1003





398( M+H)


1004





357 (M+H)


1005





322 (M+H)


1006





385 (M+H)









 










TABLE 72





Ex. No.
Formula
MS







1007





357 (M+H)


1008





416 (M+H)


1009





310 (M+H)


1010





390 (M+H)


1011





395 (M+H)


1012





366 (M+H)









 










TABLE 73





Ex. No.
Formula
MS







1013





374 (M+H)


1014





382 (M+H)


1015





350 (M+H)


1016





402 (M+H)


1017





414 (M+H)


1018





340 (M+H)









 










TABLE 74





Ex. No.
Formula
MS







1019





350 (M+H)


1020





380 (M+H)


1021





366 (M+H)


1022





378 (M+H)


1023





402 (M+H)









 










TABLE 75





Ex. No.
Formula
MS







1024





518(M+H)


1025





408(M+H)


1026





336(M+H)


1027





408(M+H)


1028





366(M+H)


1029





362(M+H)









 










TABLE 76





Ex. No.
Formula
MS







1030





473(M+H)


1031





338(M+H)


1032





307(M+H)


1033





406(M+H)


1034





466(M+H)


1035





412(M+H)









 










TABLE 77





Ex. No.
Formula
MS







1036





412(M+H)


1037





428(M+H)


1038





466(M+H)


1039





406(M+H)


1040





417(M+H)


1041





440(M+H)









 










TABLE 78





Ex. No.
Formula
MS

















1042





417(M+H)


1043





440(M+H)


1044





312(M+H)


1045





423(M+H)


1046





352(M+H)


1047





307(M+H)









 










TABLE 79





Ex. No.
Formula
MS







1048





374(M+H)


1049





398(M+H)


1050





326(M+H)


1051





442(M+H)


1052





518(M+H)









 










TABLE 80





Ex. No.
Formula
MS







1053





442(M+H)


1054





376(M+H)


1055





442(M+H)


1056





352(M+H)


1057





367(M+H)


1058





367(M+H)









 










TABLE 81





Ex. No.
Formula
MS







1059





364(M+H)


1060





324(M+H)


1061





352(M+H)


1062





357(M+H)


1063





360(M+H)


1064





351(M+H)









 










TABLE 82





Ex. No.
Formula
MS







1065





351(M+H)


1066





366(M+H)


1067





367(M+H)


1068





364(M+H)


1069





350(M+H)


1070





306(M+H)









 










TABLE 83





Ex. No.
Formula
MS







1071





365(M+H)


1072





455(M+H)


1073





399(M+H)


1074





358(M+H)


1075





337(M+H)


1076





386(M+H)









 










TABLE 84





Ex. No.
Formula
MS







1077





358(M+H)


1078





417(M+H)


1079





311(M+H)


1080





391(M+H)


1081





396(M+H)


1082





367(M+H)









 










TABLE 85





Ex. No.
Formula
MS







1083





375(M+H)


1084





351(M+H)


1085





383(M+H)


1086





403(M+H)


1087





415(M+H)


1088





341(M+H)









 










TABLE 86





Ex. No.
Formula
MS







1089





351(M+H)


1090





381(M+H)


1091





367(M+H)


1092





379(M+H)


1093





403(M+H)









 










TABLE 87





Ex. No.
Formula
MS







1094





519(M+H)


1095





409(M+H)


1096





337(M+H)


1097





409(M+H)


1098





367(M+H)


1099





363(M+H)









 










TABLE 88





Ex. No.
Formula
MS







1100





474(M+H)


1101





339(M+H)


1102





308(M+H)


1103





467(M+H)


1104





413(M+H)


1105





413(M+H)









 










TABLE 89





Ex. No.
Formula
MS







1106





429(M+H)


1107





467(M+H)


1108







1109







1110





441(M+H)


1111





418(M+H)









 










TABLE 90





Ex. No.
Formula
MS







1112





313(M+H)


1113





308(M+H)


1114





375(M+H)


1115





399(M+H)


1116





327(M+H)


1117





443(M+H)









 










TABLE 91





Ex. No.
Formula
MS







1118





519(M+H)


1119





443(M+H)


1120





377(M+H)


1121





443(M+H)


1122





353(M+H)









 










TABLE 92





Ex. No.
Formula
MS







1123





368(M+H)


1124





368(M+H)


1125





365(M+H)


1126





325(M+H)


1127





353(M+H)


1128





358(M+H)









 










TABLE 93





Ex. No.
Formula
MS







1129





361(M+H)


1130





352(M+H)


1131





352(M+H)


1132





367(M+H)


1133





368(M+H)


1134





365(M+H)









 










TABLE 94





Ex. No.
Formula
MS







1135





351(M+H)


1136





307(M+H)


1137





385(M+H)


1138





365(M+H)


1139





467(M+H)


1140





387(M+H)









 










TABLE 95





Ex. No.
Formula
MS







1141





322(M+H)


1142





364(M+H)


1143





323(M+H)


1144





363(M+H)


1145





484(M+H)


1146





385(M+H)









 










TABLE 96





Ex. No.
Formula
MS







1147





427(M+H)


1148





420(M+H)


1149





508(M+H)


1150





458(M+H)


1151





458(M+H)









 










TABLE 97





Ex. No.
Formula
MS







1152





474(M+H)


1153





458(M+H)


1154





508(M+H)


1155





454(M+H)









 










TABLE 98





Ex. No.
Formula
MS







1156





470(M+H)


1157





496(M+H)


1158





482(M+H)


1159





448(M+H)


1160





488(M+H)









 










TABLE 99





Ex. No.
Formula
MS







1161





468(M+H)


1162





447(M+H)


1163





466(M+H)


1164





526(M+H)


1165





420(M+H)









 










TABLE 100





Ex. No.
Formula
MS







1166





490(M+H)


1167





435(M+H)


1168





436(M+H)


1169





436(M+H)


1170





404(M+H)


1171





406(M+H)









 










TABLE 101





Ex. No.
Formula
MS







1172





392(M+H)


1173





420(M+H)


1174





406(M+H)


1175





420(M+H)


1176





523(M+H)


1177





406(M+H)









 










TABLE 102





Ex. No.
Formula
MS







1178





447(M+H)


1179





433(M+H)


1180





509(M+H)


1181





513(M+H)









 










TABLE 103





Ex. No.
Formula
MS







1182





497(M+H)


1183





496(M+H)


1184





418(M+H)


1185





508(M+H)


1186





490(M+H)









 










TABLE 104





Ex. No.
Formula
MS







1187





441(M+H)


1188





455(M+H)


1189





455(M+H)


1190





513(M+H)


1191





504(M+H)


1192





494(M+H)









 










TABLE 105





Ex. No.
Formula
MS







1193





512(M+H)


1194





504(M+H)


1195





516(M+H)


1196





497(M+H)


1197





456(M+H)


1198





509(M+H)









 










TABLE 106





Ex. No.
Formula
MS







1199





483 (M+H)


1200





427 (M+H)


1201





427 (M+H)


1202





477 (M+H)


1203





519 (M+H)


1204





440 (M+H)









 










TABLE 107





Ex. No.
Formula
MS







1205





454 (M+H)


1206





325 (M+H)


1207





341 (M+H)


1208





385 (M+H)


1209





363 (M+H)


1210





332 (M+H)









 










TABLE 108





Ex. No.
Formula
MS







1211





351 (M+H)


1212





335 (M+H)


1213





349 (M+H)


1214





321 (M+H)


1215





375 (M+H)


1216





367 (M+H)









 










TABLE 109





Ex. No.
Formula
MS







1217





433 (M+H)


1218





391 (M+H)


1219





337 (M+H)


1220





385 (M+H)


1221





341 (M+H)


1222





332 (M+H)









 










TABLE 110





Ex. No.
Formula
MS







1223





395 (M+H)


1224





375 (M+H)


1225





351 (M+H)


1226





321 (M+H)


1227





426 (M+H)


1228





460 (M+H)









 










TABLE 111





Ex. No.
Formula
MS







1229





442 (M+H)


1230





468 (M+H)


1231





456 (M+H)


1232





494 (M+H)


1233





451 (M+H)


1234





468 (M+H)









 










TABLE 112





Ex. No.
Formula
MS







1235





498 (M+H)


1236





476 (M+H)


1237





502 (M+H)


1238





505 (M+H)


1239





469 (M+H)









 










TABLE 113





Ex. No.
Formula
MS







1240





483 (M+H)


1241





408 (M+H)


1242





460 (M+H)


1243





468 (M+H)


1244





494 (M+H)


1245





454 (M+H)









 










TABLE 114





Ex. No.
Formula
MS







1246





468 (M+H)


1247





498 (M+H)


1248





482 (M+H)


1249





468 (M+H)


1250





460 (M+H)









 










TABLE 115





Ex. No.
Formula
MS







1251





442 (M+H)


1252





468 (M+H)


1253





456 (M+H)


1254





494 (M+H)









 










TABLE 116





Ex. No.
Formula
MS







1255





451 (M+H)


1256





468 (M+H)


1257





498 (M+H)


1258





470 (M+H)









 










TABLE 117





Ex. No.
Formula
MS







1259





476 (M+H)


1260





502 (M+H)


1261





505 (M+H)


1262





469 (M+H)









 










TABLE 118





Ex. No.
Formula
MS







1263





483 (M+H)


1264





408 (M+H)


1265





460 (M+H)


1266





468 (M+H)









 










TABLE 119





Ex. No.
Formula
MS







1267





494 (M+H)


1268





454 (M+H)


1269





468 (M+H)


1270





498 (M+H)









 










TABLE 120





Ex. No.
Formula
MS







1271





482 (M+H)


1272





468 (M+H)


1273





494 (M+H)


1274





484 (M+H)









 










TABLE 121





Ex. No.
Formula
MS







1275





519 (M+H)


1276





427 (M+H)


1277





456 (M+H)


1278





516 (M+H)









 










TABLE 122





Ex. No.
Formula
MS







1279





436 (M+H)


1280





426 (M+H)


1281





440 (M+H)


1282





454 (M+H)


1283





468 (M+H)









 










TABLE 123





Ex. No.
Formula
MS







1284





482 (M+H)


1285





406 (M+H)


1286





420 (M+H)


1287





508 (M+H)


1288





508 (M+H)









 










TABLE 124





Ex. No.
Formula
MS







1289





509 (M+H)


1290





455 (M+H)


1291





494 (M+H)


1292





418 (M+H)









 










TABLE 125





Ex. No.
Formula
MS







1293





490 (M+H)


1294





496 (M+H)


1295





477 (M+H)


1296





508 (M+H)


1297





470 (M+H)









 










TABLE 126





Ex. No.
Formula
MS







1298





435 (M+H)


1299





488 (M+H)


1300





454 (M+H)


1301





504 (M+H)









 










TABLE 127





Ex. No.
Formula
MS







1302





513 (M+H)


1303





399 (M+H)


1304





530 (M+H)


1305





504 (M+H)


1306





440 (M+H)









 










TABLE 128





Ex. No.
Formula
MS







1307





494 (M+H)


1308





508 (M+H)


1309





518 (M+H)


1310





532 (M+H)


1311





522 (M+H)









 










TABLE 129





Ex. No.
Formula
MS







1312





546 (M+H)


1313





484 (M+H)


1314





517 (M+H)


1315





488 (M+H)


1316





481 (M+H)









 










TABLE 130





Ex. No.
Formula
MS







1317





413 (M+H)


1318





423 (M+H)


1319





504 (M+H)


1320





510 (M+H)


1321





522 (M+H)


1322





522 (M+H)









 










TABLE 131





Ex. No.
Formula
MS







1323





484 (M+H)


1324





449 (M+H)


1325





502 (M+H)


1326





491 (M+H)


1327





496 (M+H)









 










TABLE 132





Ex. No.
Formula
MS







1328





497 (M+H)


1329





470 (M+H)


1330





530 (M+H)


1331





502 (M+H)


1332





522 (M+H)









 










TABLE 133





Ex. No.
Formula
MS







1333





491 (M+H)


1334





536 (M+H)


1335





547 (M+H)


1336





484 (M+H)


1337





484 (M+H)


1338





498 (M+H)









 










TABLE 134





Ex. No.
Formula
MS







1339





528 (M+H)


1340





498 (M+H)


1341





514 (M+H)


1342





513 (M+H)


1343





488 (M+H)


1344





502 (M+H)









 










TABLE 135





Ex. No.
Formula
MS







1345





488 (M+H)


1346





502 (M+H)


1347





499 (M+H)


1348





480 (M+H)


1349





522 (M+H)


1350





546 (M+H)









 










TABLE 136





Ex. No.
Formula
MS







1351





482 (M+H)


1352





484 (M+H)


1353





609 (M+H)


1354





532 (M+H)


1355





480 (M+H)


1356





566 (M+H)









 










TABLE 137





Ex. No.
Formula
MS







1357





602 (M+H)


1358





596 (M+H)


1359





491 (M+H)


1360





491 (M+H)


1361





491 (M+H)


1362





496 (M+H)









 










TABLE 138





Ex. No.
Formula
MS







1363





512 (M+H)


1364





494 (M+H)


1365





488 (M+H)


1366





481 (M+H)


1367





524 (M+H)


1368





497 (M+H)









 










TABLE 139





Ex. No.
Formula
MS







1369





472 (M+H)


1370





469 (M+H)


1371





470 (M+H)


1372





469 (M+H)


1373





494 (M+H)


1374





458 (M+H)









 










TABLE 140





Ex. No.
Formula
MS







1375





612 (M+H)


1376





554 (M+H)


1377





542 (M+H)


1378





526 (M+H)


1379





496 (M+H)


1380





510 (M+H)









 










TABLE 141





Ex. No.
Formula
MS







1381





540 (M+H)


1382





525 (M+H)


1383





558 (M+H)


1384





523 (M+H)


1385





539 (M+H)









 










TABLE 142





Ex. No.
Formula
MS







1386





533 (M+H)


1387





500 (M+H)


1388





485 (M+H)


1389





523 (M+H)


1390





512 (M+H)









 










TABLE 143





Ex. No.
Formula
MS







1391





540 (M+H)


1392





527 (M+H)


1393





525 (M+H)


1394





507 (M+H)


1395





491 (M+H)


1396





506 (M+H)









 










TABLE 144





Ex. No.
Formula
MS







1397





522 (M+H)


1398





538 (M+H)


1399





522 (M+H)


1400





530 (M+H)


1401





600 (M+H)


1402





504 (M+H)









 










TABLE 145





Ex. No.
Formula
MS







1403





534 (M+H)


1404





475 (M+H)


1405





472 (M+H)


1406





455 (M+H)


1407





469 (M+H)


1408





547 (M+H)









 










TABLE 146





Ex. No.
Formula
MS







1409





529 (M+H)


1410





435 (M+H)


1411





504 (M+H)


1412





469 (M+H)


1413





522 (M+H)


1414





488 (M+H)









 










TABLE 147





Ex. No.
Formula
MS







1415





502 (M+H)


1416





488 (M+H)


1417





502 (M+H)


1418





455 (M+H)


1419





455 (M+H)


1420





522 (M+H)









 










TABLE 148





Ex. No.
Formula
MS







1421





469 (M+H)


1422





536 (M+H)


1423





510 (M+H)


1424





494 (M+H)


1425





458 (M+H)









 










TABLE 149





Ex. No.
Formula
MS







1426





612 (M+H)


1427





526 (M+H)


1428





480 (M+H)


1429





441 (M+H)


1430





511 (M+H)









 










TABLE 150





Ex. No.
Formula
MS







1431





530 (M+H)


1432





497 (M+H)


1433





441 (M+H)


1434





491 (M+H)


1435





491 (M+H)


1436





491 (M+H)









 










TABLE 151





Ex. No.
Formula
MS







1437





524 (M+H)


1438





508 (M+H)


1439





474 (M+H)


1440





490 (M+H)


1441





508 (M+H)


1442





474 (M+H)









 










TABLE 152





Ex. No.
Formula
MS







1443





516 (M+H)


1444





600 (M+H)


1445





504 (M+H)


1446





534 (M+H)


1447





475 (M+H)









 










TABLE 153





Ex. No.
Formula
MS







1448





530 (M+H)


1449





440 (M+H)


1450





490 (M+H)


1451





474 (M+H)


1452





441 (M+H)


1453





508 (M+H)









 










TABLE 154





Ex. No.
Formula
MS







1454





455 (M+H)


1455





522 (M+H)


1456





496 (M+H)


1457





516 (M+H)


1458





426 (M+H)


1459





482 (M+H)









 










TABLE 155





Ex. No.
Formula
MS







1460





486 (M+H)


1461





516 (M+H)


1462





427 (M+H)


1463





476 (M+H)


1464





460 (M+H)


1465





502 (M+H)









 










TABLE 156





Ex. No.
Formula
MS







1466





586 (M + H)


1467





518 (M + H)


1468





530 (M + H)


1469





598 (M + H)


1470





512 (M + H)


1471





544 (M + H)









 










TABLE 157





Ex. No.
Formula
MS







1472





440 (M + H)


1473





490 (M + H)


1474





474 (M + H)


1475





441 (M + H)


1476





508 (M + H)


1477





455 (M + H)









 










TABLE 158





Ex. No.
Formula
MS







1478





522 (M + H)


1479





496 (M + H)


1480





516 (M + H)


1481





426 (M + H)


1482





482 (M + H)









 










TABLE 159





Ex. No.
Formula
MS







1483





486 (M + H)


1484





516 (M + H)


1485





427 (M + H)


1486





476 (M + H)









 










TABLE 160





Ex. No.
Formula
MS







1487





460 (M + H)


1488





502 (M + H)


1489





586 (M + H)


1490





518 (M + H)









 










TABLE 161





Ex. No.
Formula
MS







1491





530 (M + H)


1492





598 (M + H)


1493





512 (M + H)


1494





544 (M + H)









 










TABLE 162





Ex. No.
Formula
MS







1495





580 (M + H)


1496





550 (M + H)


1497





606 (M + H)


1498





580 (M + H)


1499





550 (M + H)









 










TABLE 163





Ex. No.
Formula
MS







1500





606 (M + H)


1501





630 (M + H)


1502





600 (M + H)


1503





656 (M + H)









 










TABLE 164





Ex. No.
Formula
MS







1504





630 (M + H)


1505





600 (M + H)


1506





656 (M + H)


1507





580 (M + H)









 










TABLE 165





Ex. No.
Formula
MS







1508





550 (M + H)


1509





606 (M + H)


1510





580 (M + H)


1511





550 (M + H)


1512





546 (M + H)









 










TABLE 166





Ex. No.
Formula
MS







1513





516 (M + H)


1514





572 (M + H)


1515





546 (M + H)


1516





516 (M + H)


1517





572 (M + H)









 










TABLE 167





Ex. No.
Formula
MS







1518





602 (M + H)


1519





572 (M + H)


1520





628 (M + H)


1521





606 (M + H)









 










TABLE 168





Ex. No.
Formula
MS







1522





573 (M + H)


1523





606 (M + H)


1524





602 (M + H)


1525





572 (M + H)









 










TABLE 169





Ex. No.
Formula
MS







1526





628 (M + H)


1527





606 (M + H)


1528





606 (M + H)


1529





614 (M + H)









 










TABLE 170





Ex. No.
Formula
MS







1530





584 (M + H)


1531





640 (M + H)


1532





618 (M + H)


1533





614 (M + H)


1534





584 (M + H)









 










TABLE 171





Ex. No.
Formula
MS







1535





640 (M + H)


1536





627 (M + H)


1537





627 (M + H)









 










TABLE 172





Ex. No.
Formula
MS







1538





560 (M + H)


1539





634 (M + H)


1540





593 (M + H)


1541





627 (M + H)









 










TABLE 173





Ex. No.
Formula
MS







1542





627 (M + H)


1543





560 (M + H)


1544





634 (M + H)


1545





593 (M + H)









 










TABLE 174





Ex. No.
Formula
MS







1546





627 (M + H)


1547





627 (M + H)


1548





560 (M + H)


1549





634 (M + H)









 










TABLE 175





Ex. No.
Formula
MS







1550





627 (M + H)


1551





560 (M + H)


1552





532 (M + H)


1553





565 (M + H)









 










TABLE 176





Ex. No.
Formula
MS







1554





599 (M+H)


1555





599 (M+H)


1556





532 (M+H)


1557





532 (M+H)









 










TABLE 177





Ex. No.
Formula
MS







1558





584 (M+H)


1559





570 (M+H)









 











TABLE 178








HCV polymerase



Ex.
inhibitory activity



No.
IC50 [μM]



















2
0.079



6
0.034



9
0.019



11
0.53



12
0.60



17
0.047



20
0.042



26
0.033



30
0.052



43
0.58



44
0.95



45
0.40



46
0.47



47
0.54



48
0.44



49
0.94



50
0.54



51
1.0



54
0.56



55
0.36



67
0.26



68
0.28



70
0.19



71
0.62



77
0.51



81
0.18



82
0.097



83
0.52



85
0.17



86
0.13



87
0.80



88
0.092



89
0.34



90
0.20



91
0.53



93
0.16



94
0.084



96
0.25



97
0.16



98
0.30










 











TABLE 179








HCV polymerase



Ex.
inhibitory activity



No.
IC50 [μM]



















 99
0.53



100
0.78



101
0.14



103
0.17



104
0.073



105
0.076



106
0.40



107
0.11



108
0.21



109
0.11



110
0.24



111
0.14



112
0.11



113
0.071



114
0.56



115
0.17



116
0.37



117
0.075



118
0.14



119
0.13



120
0.16



121
0.19



122
0.51



123
0.10



124
0.091



125
0.12



128
0.14



129
0.12



130
0.16



131
0.046



132
0.055



133
0.12



134
0.071



139
0.26



140
0.11



141
0.43



142
0.055



143
0.053



144
0.19



145
0.088










 











TABLE 180








HCV polymerase



Ex.
inhibitory activity



No.
IC50 [μM]



















146
0.043



147
0.31



148
0.038



149
0.15



150
0.24



151
0.20



153
0.19



154
0.076



155
0.53



156
0.23



157
0.16



158
0.11



159
0.13



160
0.24



161
0.062



162
0.43



163
0.15



164
0.16



165
0.58



166
0.055



167
0.033



168
0.078



169
0.15



170
0.048



171
0.050



172
0.10



173
0.14



174
0.030



175
0.29



176
0.053



177
0.077



178
0.052



179
0.63



180
0.11



181
0.71



182
0.021



183
0.017



184
0.018



185
0.11



186
0.37










 











TABLE 181








HCV polymerase



Ex.
inhibitory activity



No.
IC50 [μM]



















187
0.056



188
0.038



189
0.017



190
0.020



191
0.43



192
0.22



193
0.13



194
0.52



195
0.023



196
0.20



197
0.11



198
0.044



199
0.11



200
0.10



201
0.14



202
0.095



203
0.063



204
0.16



205
0.077



206
0.05



207
0.081



208
0.039



209
0.12



210
0.31



211
0.059



212
0.23



213
0.10



214
0.059



215
0.078



216
0.084



217
0.058



218
0.033



219
0.13



220
0.073



221
0.058



222
0.041



223
0.21



225
0.014



227
0.045



228
0.18










 











TABLE 182








HCV polymerase



Ex.
inhibitory activity



No.
IC50 [μM]



















229
0.022



230
0.17



231
0.073



232
0.015



233
0.028



234
0.022



235
0.036



236
0.075



237
0.015



238
0.19



239
0.17



240
0.055



248
0.012



249
0.022



250
0.018



252
0.32



253
0.65



254
0.038



255
0.038



256
0.079



257
0.074



259
0.10



260
0.27



262
0.013



263
0.035



264
<0.01



265
0.014



266
0.018



267
0.014



268
0.012



269
0.013



270
0.012



271
0.024



272
0.066



273
0.041



276
0.023



279
0.017



280
0.016



281
0.052



282
0.019










 











TABLE 183








HCV polymerase



Ex.
inhibitory activity



No.
IC50 [μM]



















283
0.014



284
0.014



285
0.012



286
0.014



287
0.012



288
0.013



289
<0.01



290
0.012



291
0.016



292
0.015



293
0.034



294
0.032



295
0.045



296
0.034



297
0.022



298
0.011



299
0.018



300
0.045



301
0.017



303
0.10



304
0.017



305
0.01



306
0.013



307
0.022



308
0.023



311
0.16



312
0.023



313
0.025



314
0.097



315
0.028



316
0.022



317
0.032



318
0.012



319
0.030










 











TABLE 184








HCV polymerase



Ex.
inhibitory activity



No.
IC50 [μM]



















320
0.036



321
0.015



322
0.016



323
0.018



324
0.027



325
0.019



326
0.018



327
0.019



328
0.015



329
0.047



330
0.011



331
0.017



332
0.023



333
0.016



334
0.016



335
0.013










 









TABLE 185







Example No. 249
1H NMR(δ)ppm







300MHz, DMSO-d6 8.02(1H, d, J=1.5Hz), 8.11(1H, d, J=1.8Hz), 7.96-7.81(3H, m), 7.67(1H, s), 7.61-7.49(6H, m), 7.08(2H, d, J=8.6Hz), 5.19(2H, s), 4.25(1H, m), 2.38-2.17(2H, m), 1.96-1.78(4H, m), 1.70- 1.56(1H, m), 1.46-1.16(3H, m), 1.11(9H, s)









Purity
>90% (NMR)



MS
672(M+1)








Example No. 250
1H NMR(δ)ppm







300MHz, DMSO-d6 8.25(1H, d, J=1.5Hz), 8.16-8.08(2H, m), 7.99-7.88(2H, m), 7.66(2H, d, J=8.6Hz), 7.60-7.48(5H, m), 7.19(2H, d, J=8.6Hz), 5.17(2H, s), 4.31(1H, m), 2.39-2.20(2H, m), 2.04-1.79(4H, m), 1.72-1.60(1H, m), 1.50-1.18(3H, m)









Purity
>90% (NMR)



MS
616 (M+1)








Example No. 251
1H NMR(δ)ppm







300MHz, DMSO-d6 cis and trans mixture 8.13 and 8.11 (total 1H, each s), 7.90-7.42 (2H, m), 7.42-7.22(5H, m), 4.56 and 4.52(total 2H, each s), 4.42(1H, brs), 3.78-3.06(2H, m)2.33-1.33(18H, m)









Purity
>90% (NMR)



MS
433 (M+1)









 









TABLE 186







Example No. 252
1H NMR(δ)ppm







300MHz, DMSO-d6 8.20(1H, d, J=1.5Hz), 7.96(1H, d, J=8.6Hz), 7.84(1H, dd, J=8.6, 1.5Hz), 7.54(2H, d, J=6.9Hz), 7.48-7.26(8H, m), 7.09(1H, t, J= 7.3Hz), 5.43(2H, s), 4.06(1H, m), 2.40-2.20(2H, m), 2.01-1.80(4H, m), 1.75-1.64(1H, m), 1.51-1.28(3H, m)









Purity
>90% (NMR)



MS
509 (M+1)








Example No. 253
1H NMR(δ)ppm







300MHz, DMSO-d6 8.21(1H, d, J=1.5Hz), 7.93(1H, d, J=8.7Hz), 7.85(1H, dd, J=8.4, 1.5Hz), 7.54-7.47(2H, m), 7.40-7.24(6H, m), 7.15(1H, d, J=3.6Hz), 7.11-7.05(1H, m), 6.81(1H, d, J=3.6Hz), 5.26(2H, s), 4.96(1H, m), 2.32-2.13(2H, m), 1.95-1.72(4H, m), 1.68-1.55(1H, m), 1.43- 1.18(3H, m)









Purity
>90% (NMR)



MS
493 (M+1)








Example No. 254
1H NMR(δ)ppm







300MHz, DMSO-d6 8.25(1H, s), 8.02(1H, d, J=8.7Hz), 7.90(1H, dd, J=8.4, 1.4Hz), 7.80- 7.71(2H, m), 7.67(2H, d, J=8.7Hz), 7.33(2H, t, J=8.7Hz), 7.26(2H, d, J=8.7Hz), 5.46(2H, s), 4.78(2H, s), 4.31(1H, m), 2.39-2.19(2H, m), 2.03-1.79(4H, m), 1.71-1.59(1H, m), 1.50-1.17(3H, m)









Purity
>90% (NMR)



MS
558 (M+1)









 









TABLE 187







Example No. 255
1H NMR(δ)ppm







300MHz, DMSO-d6 8.34(1H, s), 8.32(1H, d, J=8.8Hz), 8.09-8.03(3H, m), 7.83(2H, d, J= 8.3Hz), 7.79(2H, d, J=8.8Hz), 7.36(2H, d, J=8.8Hz), 5.54(2H, s), 4.38 (1H, m), 2.74(3H, s), 2.40-2.18(2H, m), 2.13-1.96(2H, m), 1.93-1.78 (2H, m), 1.73-1.57(1H, m), 1.55-1.15(3H, m)









Purity
>90% (NMR)



MS
568 (M+1)








Example No. 256
1H NMR(δ)ppm







300MHz, DMSO-d6 12.67(1H, brs), 8.23(1H, s), 7.94 and 7.87(2H, ABq, J=8.6Hz), 7.79 (1H, dd, J=8.7, 5.4Hz), 7.62-7.41(7H, m), 6.80(1H, dd, J=11.9, 2.3Hz), 6.69(1H, dd, J=8.1, 2.1Hz), 5.20(2H, s), 3.93(1H, brt, J=15.3Hz), 2.30- 2.11(2H, brm)1.88-1.74(4H, brm), 1.64-1.58(1H, brm), 1.41-1.14(3H, brm)









Purity
>90% (NMR)



MS
585 (M+1)








Example No. 257
1H NMR(δ)ppm







300MHz, DMSO-d6 8.19(1H, d, J=8.7Hz), 7.93(1H, s), 7.83-7.71(3H, m), 7.50-7.39(4H, m), 7.34-7.10(4H, m), 7.06(1H, dd, J=8.4, 2.9Hz), 5.09(2H, s), 4.34 (1H, m), 3.82(3H, s), 2.39-2.19(2H, m), 2.11-1.98(2H, m), 1.94- 1.79(2H, m), 1.74-1.58(1H, m), 1.52-1.21(3H, m)









Purity
>90% (NMR)



MS
603 (M+1)









 









TABLE 188







Example No. 258
1H NMR(δ)ppm







300MHz, DMSO-d6 7.79(1H, d, J=6.7Hz), 7.56(1H, d, J=7.5Hz), 7.49(2H, d, J=8.6Hz), 7.42(4H, s), 7.32-7.23(3H, m), 7.09-7.03(3H, m), 5.02(2H, s), 4.46(1H, m), 3.82(3H, s), 1.95-1.83(2H, m), 1.75-1.44(5H, m), 1.30-1.10(2H, m), 0.89-0.71(1H, m)









Purity
>90% (NMR)



MS
567 (M+1)








Example No. 259
1H NMR(δ)ppm







300MHz, DMSO-d6 8.93(2H, d, J=6.6Hz), 8.36(1H, s), 8.28(1H, d, J=8.7Hz), 8.10-8.03(3H, m), 7.85(2H, d, J=8.7Hz), 7.33(2H, d, J= 8.7Hz), 7.23(1H, s), 7.23(1H, s), 6.81(1H, s), 5.56(2H, s), 4.39(1H, m), 2.97, 2.92(6H, s), 2.40-2.18(2H, m), 2.16- 1.95(2H, m), 1.90-1.75(2H, m), 1.70-1.55(1H, m), 1.50- 1.15(3H, m)









Purity
>90% (NMR)



MS
591 (M+1)








Example No. 260
1H NMR(δ)ppm







300MHz, DMSO-d6 8.93(2H, d, J=6.3Hz), 8.35(1H, s), 8.26(1H, d, J=8.7Hz), 8.09-8.02(3H, m), 7.86(2H, d, J=8.7Hz), 7.50(1H, s), 7.35 (2H, d, J=8.4Hz), 7.24(2H, d, J=7.8Hz), 5.60(2H, s), 4.39 (1H, m), 2.50-2.18(2H, m), 2.15-1.95(2H, m), 1.90-1.75 (2H, m), 1.70-1.55(1H, m), 1.50-1.10(3H, m)









Purity
>90% (NMR)



MS
564 (M+1)









 









TABLE 189







Example No. 261
1H NMR(δ)ppm







300MHz, DMSO-d6 8.22(1H, d, J=7.8Hz), 7.85(1H, d, J=6.7Hz), 7.63(2H, d, J=9.0H), 7.51-7.38(5H, m), 7.29(1H, d, J=8.3Hz), 7.23(1H, d, J=3.0Hz), 7.06(2H, d, J=9.0Hz), 7.06(1H, dd, J=8.6, 3.0Hz), 5.05(2H, s), 4.41-4.25(1H, m), 3.83(3H, s), 2.40-2.20(2H, m), 2.03-1.78(4H, m), 1.72-1.57(1H, m), 1.50-1.18(3H, m)









Purity
>90% (NMR)



MS
567 (M+1)








Example No. 262
1H NMR(δ)ppm







300MHz, DMSO-d6 8.29(1H, d, J=1.5Hz), 8.26(1H, d, J=9.0Hz), 8.19(1H, d, J=1.8Hz), 8.13(1H, brs), 8.08-7.96(2H, m), 7.73(2H, d, J=9.0Hz), 7.57-7.43 (6H, m), 7.24(2H, d, J=9.0Hz), 5.14(2H, s), 4.36(1H, m), 2.38- 2.18(2H, m), 2.12-1.97(2H, m), 1.93-1.80(2H, m), 1.73-1.58(1H, m), 1.52-1.20(3H, m)









Purity
>90% (NMR)



MS
580 (M+1)








Example No. 263
1H NMR(δ)ppm







300MHz, DMSO-d6 12.85(1H, brs), 8.72(1H, d, J=4.8Hz), 8.22(1H, s), 8.14(1H, d, J= 6.3Hz), 8.03 and 7.76(4H, ABq, J=8.6Hz), 7.93 and 7.85(2H, A′B′q, J=8.6Hz), 7.60 and 7.15(4H, A′′B′′q, J=8.7Hz), 7.55(1H, dd, J=6.3, 4.8Hz), 5.19(2H, s), 4.26(1H, brt, J=12.6Hz), 2.35-2.18 (2H, brm), 1.95-1.77(4H, brm), 1.70-1.60(1H, brm), 1.45-1.15(3H, brm)









Purity
>90% (NMR)



MS
548 (M+1)









 









TABLE 190







Example No. 264
1H NMR(δ)ppm







300MHz, DMSO-d6 8.23(1H, d, J=1.0Hz), 7.92(1H, dd, J=8.7, 1.0Hz), 7.87(1H, d, J= 8.7Hz), 7.60(2H, d, J=8.6Hz), 7.47(2H, d, J=8.7Hz), 7.30(1H, d, J= 8.3Hz), 7.23(1H, d, J=2.6Hz), 7.11(2H, d, J=8.7Hz), 7.06(1H, dd, J= 8.7, 2.6Hz), 5.04(2H, s), 4.36(1H, m), 3.83(3H, s), 2.80-2.70(4H, m), 2.60-2.40(2H, m), 2.30-2.20(2H, m)









Purity
>90% (NMR)



MS
586, 588 (M+1)








Example No. 265
1H NMR(δ)ppm







300MHz, DMSO-d6 8.30(1H, d, J=1.5Hz), 8.25(1H, d, J=9.1Hz), 8.03(1H, dd, J=8.7, 1.5Hz), 7.76-7.96(3H, m), 7.55-7.49(5H, m), 7.42(1H, d, J=7.6Hz), 7.23(2H, d, J=8.7Hz), 5.15(2H, s), 4.35(1H, m), 3.01(3H, s), 2.97 (3H, s), 2.37-2.20(2H, m), 2.09-1.97(2H, m), 1.94-1.81(2H, m), 1.72-1.60(1H, m), 1.50-1.21(3H, m)









Purity
>90% (NMR)



MS
608 (M+1)








Example No. 266
1H NMR(δ)ppm







300MHz, DMSO-d6 8.27(1H, d, J=1.5Hz), 8.20(1H, d, J=9.0Hz), 8.00(1H, dd, J=8.6, 1.5Hz), 7.82(2H, d, J=8.2Hz), 7.76-7.65(5H, m), 7.56(1H, dd, J=7.9, 1.8Hz), 7.47(1H, d, J=7.5Hz), 7.20(2H, d, J=8.6Hz), 5.16(2H, s), 4.32(1H, m), 3.02(3H, s), 2.98(3H, s), 2.38-2.19(2H, m), 2.07-1.95 (2H, m), 1.93-1.80(2H, m), 1.72-1.58(1H, m), 1.52-1.18(3H, m)









Purity
>90% (NMR)



MS
642 (M+1)









 









TABLE 191







Example No. 267
1H NMR(δ)ppm







300MHz, DMSO-d6 8.34(2H, m), 8.03(1H, d, J=8.3Hz) 7.77-7.68(3H, m), 7.54-7.40(4H, m), 7.33(2H, d, J=8.6Hz), 7.24(2H, d, J=9.0Hz), 5.16(2H, s), 4.36 (1H, m), 3.01(3H, s), 2.97(3H, s), 2.40-2.20(2H, m), 2.11-1.97(2H, m), 1.93-1.81(2H, m), 1.71-1.60(1H, m), 1.50-1.21(3H, m)









Purity
>90% (NMR)



MS
620 (M+1)








Example No. 268
1H NMR(δ)ppm







300MHz, DMSO-d6 8.67-8.59(1H, m), 8.30(1H, s), 8.13-8.20(2H, m), 8.02-7.92(2H, m), 7.65(1H, t, J=8.3Hz), 7.56-7.45(5H, m), 7.18(1H, dd, J=12.0, 2.2Hz), 7.05(1H, dd, J=8.6, 2.2Hz), 5.14(2H, s), 4.09(1H, m), 2.82 (3H, d, J=4.5Hz), 2.34-2.12(2H, m), 1.99-1.79(4H, m), 1.71-1.59 (1H, m), 1.49-1.21(3H, m)









Purity
>90% (NMR)



MS
612 (M+1)








Example No. 269
1H NMR(δ)ppm







300MHz, DMSO-d6 8.29(1H, s), 8.13(1H, d, J=9.0Hz), 7.97(1H, dd, J=8.6, 1.5Hz), 7.71(1H, d, J=1.8Hz), 7.63(1H, t, J=8.2Hz), 7.56-7.41(6H, m), 7.17(1H, dd, J=12.0, 2.2Hz), 7.03(1H, dd, J=8.2, 1.8Hz), 5.14(2H, s), 4.15-4.00(1H, m), 3.01(3H, s), 2.98(3H, s), 2.32-2.13(2H, m), 1.95-1.79(4H, m), 1.72-1.59(1H, m), 1.45-1.21(3H, m)









Purity
>90% (NMR)



MS
626 (M+1)









 









TABLE 192







Example No. 270
1H NMR(δ)ppm







300MHz, DMSO-d6 8.24(1H, d, J=1.4Hz), 8.19(1H, d, J=1.8Hz), 8.11(1H, brs), 8.02- 7.85(3H, m), 7.60-7.44(7H, m), 7.10(1H, dd, J=12.0, 2.1Hz), 6.98 (1H, dd, J=8.4, 2.1Hz), 5.11(2H, s), 3.98(1H, m), 2.30-2.12(2H, m), 1.91-1.73(4H, m), 1.71-1.58(1H, m), 1.45-1.15(3H, m)









Purity
>90% (NMR)



MS
598 (M+1)








Example No. 271
1H NMR(δ)ppm







300MHz, DMSO-d6 8.29(1H, d, J=1.5Hz), 8.24(1H, d, J=8.7Hz), 8.07-7.98(3H, m), 7.80-7.68(5H, m), 7.56(1H, dd, J=8.0, 1.8Hz), 7.47(1H, d, J=8.0Hz), 7.21(2H, d, J=8.4Hz), 5.18(2H, s), 4.34(1H, m), 3.27(3H, s), 3.02 (3H, s), 2.98(3H, s), 2.38-2.18(2H, m), 2.10-1.95(2H, m), 1.93- 1.79(2H, m), 1.72-1.59(1H, m), 1.50-1.19(3H, m)









Purity
>90% (NMR)



MS
652 (M+1)








Example No. 272
1H NMR(δ)ppm







300MHz, DMSO-d6 8.97(1H, d, J=1.8Hz), 8.85(1H, d, J=4.7Hz), 8.46(1H, d, J=8.0Hz), 8.39-8.26(2H, m), 8.06(1H, d, J=8.7Hz), 7.99-7.64(6H, m), 7.24 (2H, d, J=8.7Hz), 5.25(2H, s), 4.36(1H, m), 3.03(3H, s), 2.97(3H, s), 2.39-2.19(2H, m), 2.14-1.96(2H, m), 1.94-1.78(2H, m), 1.73- 1.60(1H, m), 1.21-1.55(3H, m)









Purity
>90% (NMR)



MS
575 (M+1)









 









TABLE 193







Example No. 273
1H NMR(δ)ppm







300MHz, DMSO-d6 8.30(1H, s), 8.27(1H, d, J=8.7Hz), 8.05(1H, d, J=8.7Hz), 7.77-7.67(3H, m), 7.58-7.48(6H, m), 7.22(2H, d, J=8.4Hz), 5.18(2H, s), 4.35(1H, brt, J=9.8Hz), 3.06-2.88(12H, brm), 2.38-2.20(2H, brm), 2.08-1.96(2H, brm), 1.90-1.80(2H, brm), 1.70-1.60(1H, brm), 1.49-1.22(3H, brm)


Purity >90%(NMR)


MS 645 (M+1)


Example No. 274
1H NMR(δ)ppm







300MHz, DMSO-d6 mixture of cis and trans 8.35, 8.34(1H, s), 8.15-8.10(2H, m), 7.79-7.70(3H, m), 7.49(2H, d, J=8.7Hz), 7.44(2H, d, J=8.7Hz), 7.31(1H, d, J=8.4Hz), 7.25-7.19(2H, m), 7.07(1H, d, J=8.5Hz), 5.08(2H, s), 4.75(1H, m), 3.83(3H, s), 3.70-1.90(8H, m)


Purity about 80%(NMR)


MS 601 (M+1)


Example No. 275
1H NMR(δ)ppm







300MHz, DMSO-d6 8.33(1H, s), 8.13(1H, d, J=7.5Hz), 7.93(1H, d, J=8.8Hz), 7.74(2H, d, J=8.7Hz), 7.49(2H, d, J=8.6Hz), 7.44(2H, d, J=8.6Hz), 7.31(1H, d, J=8.5Hz), 7.25-7.15(3H, m), 7.07(1H, d, J=8.5Hz), 5.08(2H, s), 4.98(1H, m), 3.83(3H, s), 3.65-3.45(2H, m), 3.30-3.10(2H, m), 3.00-2.75(2H, m), 2.60-2.30(2H, m)


Purity >90%(NMR)


MS 617 (M+1)









 









TABLE 194







Example No. 276
1H NMR(δ)ppm







300MHz, DMSO-d6 8.25(1H, s), 7.93 and 7.87(2H, ABq, J=9.1Hz), 7.55(1H, t, J=8.6Hz), 7.48 and 7.42(4H, A′B′q, J=8.6Hz), 7.31(1H, d, J=8.5Hz), 7.24(1H, d, J=2.6Hz), 7.09-6.95(3H, m), 5.05(2H, s), 4.11(1H, brt, J=14.0Hz), 3.84(3H, s), 2.83-2.67(4H, brm), 2.50-2.32(2H, brm), 2.21-2.10(2H, brm)


Purity >90%(NMR)


MS 603 (M+1)


Example No. 277
1H NMR(δ)ppm







300MHz, DMSO-d6 cis and trans mixture 8.28 and 8.24(total 1H, each s), 7.94-7.87(1H, m), 7.60-7.41(5H, m), 7.31(1H, d, J=8.5Hz), 7.23-7.21(1H, m), 7.12-7.05(2H, m), 7.00-6.95(1H, m), 5.06 and 5.05(total 2H, each s), 4.47 and 4.34 (total 1H, each brs), 3.83(3H, s), 3.12-1.76(8H, m)


Purity >90%(NMR)


MS 619 (M+1)


Example No. 278
1H NMR(δ)ppm







300MHz, DMSO-d6 12.9(1H, brs), 8.27(1H, s), 7.97 and 7.74(2H, ABq, J=8.6Hz), 7.58(1H, t, J=8.6Hz), 7.49 and 7.43(4H, A′B′q, J=8.5Hz), 7.31(1H, d, J=8.5Hz), 7.22(1H, d, J=2.6Hz), 7.13-6.92(3H, m), 5.05(2H, s), 4.67(1H, brt, J=14.2Hz), 3.57-3.40(2H, brm), 3.20-3.05(2H, brm), 2.91-2.70(2H, brm), 2.28-2.11(2H, brm)


Purity >90%(NMR)


MS 635 (M+1)









 









TABLE 195







Example No. 279
1H NMR(δ)ppm







300MHz, DMSO-d6 8.30(1H, s), 8.23(1H, d, J=8.7Hz), 8.06- 8.00(2H, m), 7.83(1H, dd, J=8.0, 1.8Hz), 7.71(2H, d, J=8.4Hz), 7.64(1H, d, J=8.0Hz), 7.59-7.54(4H, m), 7.22(2H, d, J=8.4Hz), 5.25(2H, s), 4.33(1H, m), 2.66(3H, s), 2.66(3H, s), 2.37-2.19(2H, m), 1.93-1.80(2H, m), 1.70-1.59(1H, m), 1.47-1.21(3H, m)


Purity >90%(NMR)


MS 644 (M+1)


Example No. 280
1H NMR(δ)ppm







300MHz, DMSO-d6 8.32-8.23(3H, m), 8.08-8.01(2H, m), 7.73(2H, d, J=8.6Hz), 7.65(1H, d, J=8.2Hz), 7.59-7.51(4H, m), 7.25(2H, d, J=8.6Hz), 5.21(2H, s), 4.34(1H, m), 3.32(3H, s), 2.37- 2.19(2H, m), 2.10-1.98(2H, m), 1.93-1.80(2H, m), 1.71-1.60(1H, m), 1.51-1.21(3H, m)


Purity >90%(NMR)


MS 615 (M+1)


Example No. 281
1H NMR(δ)ppm







300MHz, DMSO-d6 8.30(1H, d, J=1.5Hz), 8.24(1H, s), 8.14(1H, d, J=8.6Hz), 8.07-7.95(2H, m), 7.63(1H, t, J=8.6Hz), 7.57- 7.47(5H, m), 7.16(1H, dd, J=12.0, 2.2Hz), 7.03(1H, dd, J=8.6, 2.2Hz), 5.17(2H, s), 4.06(1H, m), 3.90(3H, s), 2.31-2.11(2H, m), 1.97-1.78(4H, m), 1.71-1.59(1H, m), 1.43-1.22(3H, m)


Purity >90%(NMR)


MS 315









 









TABLE 196







Example No. 282
1H NMR(δ)ppm







300MHz, DMSO-d6 8.36(1H, s), 8.35(1H, d, J=9.3Hz), 8.09(1H, d, J=9.3Hz), 7.78(2H, d, J=8.7Hz), 7.48-7.25(9H, m), 5.09(2H, s), 4.39(1H, m), 3.04(6H, s), 2.40-2.15(2H, m), 2.10-1.95(2H, m), 1.90-1.75(2H, m), 1.70-1.55(1H, m), 1.50- 1.20(3H, m)


Purity >90%(NMR)


MS 580 (M+1)


Example No. 283
1H NMR(δ)ppm







300MHz, DMSO-d6 10.03(1H, s), 8.33(1H, s), 8.29(1H, d, J=8.7Hz), 8.06(1H, d, J=9.0Hz), 7.74(2H, d, J=9.0Hz), 7.51- 7.42(5H, m), 7.37-7.30(2H, m), 7.22(2H, d, J=8.7Hz), 5.10(2H, s), 4.37(1H, m), 3.06(3H, s), 2.40-2.18(2H, m), 2.15-1.95(2H, m), 1.90-1.80(2H, m), 1.75-1.55(1H, m), 1.50-1.20(3H, m)


Purity >90%(NMR)


MS 630 (M+1)


Example No. 284
1H NMR(δ)ppm







300MHz, DMSO-d6 8.30(1H, s), 8.14(1H, d, J=8.7Hz), 7.97(1H, d, J=8.7Hz), 7.96-7.41(8H, m), 7.16(1H, dd, J=12.4, 2.2Hz), 7.03(1H, dd, J=8.4, 2.2Hz), 5.15(2H, s), 4.15(1H, m), 3.54-3.16(4H, m), 2.33-2.13(2H, m), 1.97-1.79(4H, m), 1.70- 1.02(9H, m)


Purity >90%(NMR)


MS 654 (M+1)









 









TABLE 197







Example No. 285
1H NMR(δ)ppm







300MHz, DMSO-d6 8.37(1H, d, J=7.3Hz), 8.30(1H, s), 8.19- 8.12(2H, m), 8.02-7.95(2H, m), 7.65(1H, t, J=8.4Hz), 7.56- 7.43(5H, m), 7.18(1H, dd, J=12.0, 1.8Hz), 7.06(1H, dd, J=8.4, 2.1Hz), 5.13(2H, s), 4.22-4.03(2H, m), 2.34-2.13(2H, m), 1.99-1.78(4H, m), 1.72-1.57(1H, m), 1.44-1.14(3H, m), 1.20, 1.18(6H, each s)


Purity >90%(NMR)


MS 640 (M+1)


Example No. 286
1H NMR(δ)ppm







300MHz, DMSO-d6 8.29(1H, s), 8.13(1H, d, J=8.7Hz), 7.97(1H, dd, J=8.7, 1.4Hz), 7.69-7.40(8H, m), 7.16(1H, dd, J=12.0, 2.2Hz), 7.02(1H, dd, J=8.4, 2.2Hz), 5.15(2H, s), 4.07(1H, m), 3.71-3.23(2H, m), 1.98-1.71(4H, m), 1.71- 1.18(10H, m)


Purity >90%(NMR)


MS 666 (M+1)


Example No. 287
1H NMR(δ)ppm







300MHz, DMSO-d6 8.29(1H, s), 8.13(1H, d, J=8.0Hz), 7.97(1H, d, J=8.4Hz), 7.83(1H, s), 7.68-7.41(7H, m), 7.17(1H, d, J=12.0Hz), 7.03(1H, d, J=8.4Hz), 5.15(2H, s), 4.07(1H, m), 3.58-3.41(4H, m), 2.34-2.13(2H, m), 1.97- 1.77(8H, m), 1.71-1.58(1H, m), 1.49-1.18(3H, m)


Purity >90%(NMR)


MS 652 (M+1)









 









TABLE 198







Example No. 288
1H NMR(δ)ppm







300MHz, DMSO-d6 8.62(1N, m), 8.31(1H, s), 8.22-8.14(2H, m), 8.99(2H, d, J=8.7Hz), 7.66(1H, t, J=7.7Hz), 7.58-7.44(5H, m), 7.19(1H, dd, J=8.7, 2.2Hz), 5.14(2H, s), 4.11(1H, m), 3.67-3.49(2H, m), 3.45-3.30(2H, m), 2.37-2.12(2H, m), 2.00- 1.76(4H, m), 1.70-1.58(1H, m), 1.48-1.17(3H, m)


Purity >90%(NMR)


MS 642 (M+1)


Example No. 289
1H NMR(δ)ppm







400MHz, DMSO-d6 8.28(1H, s), 8.11(1H, d, J= 8.9Hz), 7.96(1H, d, J=8.9Hz), 7.68(1H, s), 7.62(1H, t, J=8.2Hz), 7.55-7.41(6H, m), 7.15(1H, d, J= 11.7Hz), 7.02(1H, d, J=8.4Hz), 5.14(2H, s), 4.12- 3.13(6H, m), 2.30-1.19(13H, m)


Purity >90%(NMR)


MS 682 (M+1)


Example No. 290
1H NMR(δ)ppm







400MHz, DMSO-d6 8.29(1H, s), 8.15(1H, d, J= 8.6Hz), 7.98(1H, d, J=8.8Hz), 7.72(1H, s), 7.64(1H, t, J=8.8Hz), 7.57-7.43(6H, m), 7.18(1H, dd, J=12.1, 2.1Hz), 7.03(1H, d, J=10.7Hz), 5.12(2H, s), 4.15- 4.01(1H, m), 3.75-3.33(8H, m), 2.31-2.14(2H, m), 1.96-1.78(4H, m), 1.70-1.58(1H, m), 1.47- 1.21(3H, m)


Purity >90%(NMR)


MS 668 (M+1)









 









TABLE 199







Example No. 291
1H NMR(δ)ppm







400MHz, DMSO-d6 8.29(1H, s), 8.14(1H, d, J=8.9Hz), 7.97(1H, d, J=8.6Hz), 7.71(1H, s), 7.63(1H, t, J=8.2Hz), 7.56-7.42(6H, m), 7.17(1H, d, J=12.3Hz), 7.03(1H, d, J=10.7Hz), 5.14(2H, s), 4.07(1H, m), 3.96-3.52(4H, m), 2.79-2.56(4H, m), 2.32-2.14(2H, m), 1.97-1.79(4H, m), 1.71-1.58(1H, m), 1.51-1.19(3H, m)


Purity >90%(NMR)


MS 684 (M+1)


Example No. 292
1H NMR(δ)ppm







300MHz, DMSO-d6 9.07-8.99(1H, m), 8.30(1H, s), 8.23- 8.12(2H, m), 8.04-7.95(2H, m), 7.65(1H, t, J=8.2Hz), 7.60-7.45(5H, m), 7.19(1H, dd, J=12.0, 2.6Hz), 7.06(1H, dd, J=8.6, 2.2Hz), 5.16(2H, s), 4.18-4.02(1H, m), 3.97(2H, d, J=6.0Hz), 2.33-2.14(2H, m), 1.99-1.79(4H, m), 1.72- 1.59(1H, m), 1.45-1.19(3H, m)


Purity >90%(NMR)


MS 656 (M+1)


Example No. 293
1H NMR(δ)ppm







300MHz, DMSO-d6:8.21(1H, s), 7.94 and 7.86(2H, ABq, J=8.6Hz), 7.72(1H, d, J=2.4Hz), 7.59 and 7.11(4H, A′B′q, J=8.9Hz), 7.53(1H, dd, J=8.4, 2.4Hz), 7.38(1H, d, J= 8.4Hz), 7.36 and 7.32(4H, A′′B′′q, J=8.1Hz), 5.07(2H, s), 4.27(1H, brt, J=13.8Hz), 2.87(2H, t, J=7.8Hz), 2.57(2H, t, J=7.8Hz), 2.35-2.20(2H, brm), 1.96-1.79(4H, brm), 1.68- 1.59(1H, brm), 


#1.47-1.18(3H, brm)


Purity >90%(NMR)


MS 637 (M+1)









 









TABLE 200







Example No. 294
1H NMR(δ)ppm







300MHz, DMSO-d6 8.30(1H, s), 8.25 and 8.03(2H, ABq, J=8.9Hz), 7.73(1H, s), 7.73(2H, d, J=8.6Hz), 7.55(1H, dd, J=8.0, 2.3Hz), 7.40(4H, s), 7.39(1H, d, J=8.0Hz), 7.23(2H, d, J=8.6Hz), 5.11(2H, s), 4.55(2H, s), 4.36(1H, brt, J=14.8Hz), 2.37-2.19(2H, brm), 2.09-1.96(2H, brm), 1.91-1.79(2H, brm), 1.71-1.59(1H, brm), 1.50-1.20(3H, brm)


Purity >90%(NMR)


MS 567 (M+1)


Example No. 295
1H NMR(δ)ppm







300MHz, DMSO-d6 8.30(1H, s), 8.25 and 8.04(2H, ABq, J=8.7hz), 7.74(1H, s), 7.72(2H, d, J=8.7Hz), 7.56(1H, d, J=8.7Hz), 7.48-7.35(5H, m), 7.22(2H, d, J=8.7Hz), 5.11(2H, s), 4.46(2H, s), 4.35(1H, brt, J=14.8Hz), 3.31(3H, s), 2.37-2.17(2H, brm), 2.07-1.95(2H, brm), 1.92-1.79(2H, brm), 1.73-1.56(1H, brm), 1.52-1.20(3H, brm)


Purity >90%(NMR)


MS 581 (M+1)


Example No. 296
1H NMR(δ)ppm







300MHz, DMSO-d6 8.21(1H, d, J=1.5Hz), 7.98(1H, d, J=1.2Hz), 7.97- 7.91(2H, m), 7.84(1H, dd, J=8.7, 1.5Hz), 7.77(1H, d, J=2.1Hz), 7.70(1H, d, J=7.5Hz), 7.60-7.54(4H, m), 7.43(1H, d, J=8.4Hz), 7.09(2H, d, J=8.7Hz), 5.05(2H, s), 4.25(1H, brt, J=14.8Hz), 2.36-2.18(2H, brm), 1.95-1.79(4H, brm), 1.71-1.6(1H, brm), 1.43-1.18(3H, brm)


Purity >90%(NMR)


MS 581 (M+1)









 









TABLE 201







Example No. 297
1H NMR(δ)ppm







300MHz, DMSO-d6 12.7(1H, brs), 8.21(1H, s), 7.94 and 7.85(2H, ABq, J=8.6Hz), 7.60-7.55(3H, m), 7.49 and 7.45(4H, A′B′q, J=8.3Hz), 7.12(2H, d, J=8.7Hz), 5.05(2H, s), 4.26(1H, brt, J=13.0Hz), 2.54(3H, s), 2.38-2.20(2H, brm), 1.97-1.80(4H, brm), 1.71-1.59(1H, brm), 1.47-1.20(3H, brm)


Purity >90%(NMR)


MS 583 (M+1)


Example No. 298
1H NMR(δ)ppm







300MHz, DMSO-d6 8.22(1H, s), 8.01(1H, s), 7.95 and 7.86(2H, ABq, J=8.6Hz), 7.79(1H, d, J=7.8Hz), 7.58(3H, t, J=7.5Hz), 7.53(4H, s), 7.13(2H, d, 8.7Hz), 5.15(2H, s), 4.26(1H, brt, J=13.8Hz), 2.83(3H, s), 2.37-2.18(2H, brm), 1.95-1.78(4H, brm), 1.70-1.59(1H, brm), 1.47- 1.17(3H, brm)


Purity >90%(NMR)


MS 599 (M+1)


Example No. 299
1H NMR(δ)ppm







300MHz, DMSO-d6 8.43-8.16(3H, m), 8.07-7.94(2H, m), 7.72(2H, d, J=8.6Hz), 7.62-7.49(5H, m), 7.23(2H, d, J=8.6Hz), 5.16(2H, s), 4.34(1H, m), 2.39-2.20(2H, m), 2.10-1.96(2H, m), 1.93-1.80(2H, m), 1.71-1.58(1H, m), 1.49-1.19(3H, m)


Purity >90%(NMR)


MS 562 (M+1)









 









TABLE 202







Example No. 300
1H NMR(δ)ppm







300MHz, DMSO-d6:2.77(1H, brs), 8.83(2H, d, J=1.9Hz), 8.56(2H, dd, J=4.9, 1.9Hz), 8.22(1H, d, J=1.5Hz), 7.97(2H, dt, J=7.9, 1.9Hz), 7.95(1H, d, J=8.6Hz), 7.87(1H, dd, J=8.6, 1.5Hz), 7.57(1H, t, J=8.7Hz), 7.46(2H, dd, J=7.9, 4.9Hz), 7.26(1H, dd, J=12.0, 4.9Hz), 7.14(1H, dd, J=8.8, 2.3Hz), 6.99(2H, s), 3.94(1H, brt), 2.26-2.09(2H, m), 1.87-1.73(4H, m), 


#1.67-1.57(1H, m), 1.42-1.12(3H, m)


Purity >90%(NMR)


MS 523 (M+1)


Example No. 301
1H NMR(δ)ppm







300MHz, DMSO-d6 8.22(1H, s), 7.95(1H, d, J=8.7Hz), 7.87(1H, dd, J=1.5Hz, 9.0Hz), 7.62(4H, d, J=8.4Hz), 7.55(1H, t, J=9.0Hz), 7.44(4H, d, J=8.1Hz), 7.20(1H, dd, J=2.1Hz, 12.0Hz), 7.11(1H, dd, J=2.1Hz, 8.7Hz), 6.86(1H, s), 3.94(1H, m), 2.96, 2.88(12H, s), 2.35-2.00(2H, m), 1.95-1.70(4H, m), 1.65-1.50(1H, m), 1.45-1.10(3H, m)


Purity >90%(NMR)


MS 663 (M+1)


Example No. 302
1H NMR(δ)ppm







300MHz, DMSO-d6 8.14(1H, s), 7.88(1H, d, J=8.4Hz), 7.68(1H, d, J=8.7Hz), 7.64-7.55(3H, m), 7.50(1H, t, J= 8.7Hz), 7.22-7.17(3H, m), 7.11(1H, s), 7.08-7.00(2H, m), 3.90(1H, m), 2.15-2.00(2H, m), 1.95-1.50(5H, m), 1.45- 1.00(3H, m)


Purity >90%(NMR)


MS 532 (M+1)









 









TABLE 203







Example No. 303
1H NMR(δ)ppm







300MHz, CDCl3 8.49(1H, s), 7.98(1H, dd, J=8.6, 1.5Hz), 7.71(1H, d, J=1.8Hz), 7.66(1H, d, J=8.6Hz), 7.55-7.29(7H, m), 6.80(1H, dd, J=8.2, 2.2Hz), 6.69(1H, dd, J=11.2, 2.2Hz), 4.99(2H, s), 4.10-3.92(1H, m), 3.95(3H, s), 3.15(3H, s), 3.06(3H, s), 2.31- 2.14(2H, m), 2.04-1.86(4H, m), 1.81-1.71(1H, m), 1.41-1.21(3H, m)


Purity >90%(NMR)


MS 640 (M+1)


Example No. 304
1H NMR(δ)ppm







300MHz, DMSO-d6 8.21(1H, s), 7.94(1H, d, J=8.7Hz), 7.84(1H, d, J=9.1Hz), 7.70(1H, s), 7.26-7.39(9H, m), 7.11(2H, d, J=8.4Hz), 5.11(2H, s), 4.26(1H, m), 3.01(3H, s), 2.97(3H, s), 2.38-2.19(2H, m), 1.97-1.78(4H, m), 1.72-1.57(1H, m), 1.48-1.17(3H, m)


Purity >90%(NMR)


MS 608 (M+1)


Example No. 305
1H NMR(δ)ppm







300MHz, DMSO-d6 8.24(2H, s), 8.03(1H, d, J=8.0Hz), 7.96(1H, d, J=8.8Hz), 7.87(1H, d, J=9.1Hz), 7.60-7.46(6H, m), 7.09(1H, dd, J=12.0, 1.8Hz), 6.97(1H, dd, J=8.4, 1.8Hz), 5.16(2H, s), 3.97(1H, m), 2.31-2.11(2H, m), 1.92-1.73(4H, m), 1.70-1.57(1H, m), 1.46-1.13(3H, m)


Purity >90%(NMR)


MS 599 (M+1)









 









TABLE 204







Example No. 306
1H NMR(δ)ppm







300MHz, DMSO-d6 12.84(1H, brs), 8.21(1H, s), 7.98-7.84(5H, m), 7.58(2H, d, J=8.7Hz), 7.54(2H, d, J=7.8Hz), 7.34(1H, d, J=8.7Hz), 7.26(1H, d, J=2.4Hz), 7.13-7.06(3H, m), 5.06(2H, s), 4.26(1H, brt, J=12.7Hz), 3.84(3H, s), 2.36-2.17(2H, brm), 1.99-1.80(4H, brm), 1.73-1.59(1H, brm), 1.47-1.17(3H, brm)


Purity >90%(NMR)


MS 577 (M+1)


Example No. 307
1H NMR(δ)ppm







300MHz, DMSO-d6 8.22(1H, s), 8.04(1H, s), 7.96(2H, d, J=8.1Hz), 7.87(2H, s), 7.72(1H, d, J=1.2Hz), 7.59-7.41(7H, m), 5.12(2H, s), 4.25(1H, brt, J=11.8Hz), 3.02(3H, brs), 2.98(3H, brs), 2.38-2.15(2H, brm), 1.93-1.76(4H, brm), 1.71-1.59(1H, brm), 1.46-1.16(3H, brm)


Purity >90%(NMR)


MS 617 (M+1)


Example No. 308
1H NMR(δ)ppm







300MHz, DMSO-d6 8.27(1H, s), 8.08(1H, d, J=9.0Hz), 7.93(1H, d, J=8.7Hz), 7.65(2H, d, J=8.7Hz), 7.46(2H, d, J=8.1Hz), 7.42(2H, d, J=8.4Hz), 7.30-7.04(5H, m), 5.03(2H, s), 4.32(1H, m), 2.40- 2.10(2H, m), 2.05-1.10(8H, m)


Purity >90%(NMR)


MS 552 (M+1)









 









TABLE 205







Example No. 309
1H NMR(δ)ppm







300MHz, DMSO-d6 8.33(1H, s), 8.15 and 7.99(2H, ABq, J=8.9Hz), 7.84 and 7.59(4H, A′B′q, J=8.3Hz), 7.46(2H, d, J=8.4Hz), 7.22- 7.16(3H, m), 7.01-6.98(2H, m), 4.27 and 4.23(2H, A′′′ B′′′ q, J= 12.9Hz), 3.78(3H, s), 2.39-2.21(2H, brm), 2.07-1.95(2H, brm), 1.91-1.80(2H, brm), 1.72-1.59(1H, brm), 1.49-1.17(3H, brm)


Purity >90%(NMR)


MS


Example No. 310
1H NMR(δ)ppm







300MHz, DMSO-d6 8.33(1H, s), 8.09 and 7.95(2H, ABq, J=8.7Hz), 7.87 and 7.71(4H, A′B′q, J=8.0Hz), 7.43(2H, d, J=7.8Hz), 7.15(1H, d, J=8.7Hz), 7.07-7.02(4H, m), 4.66(2H, s), 4.23(1H, brt, J=11.8Hz), 3.76(3H, s), 2.38-2.20(2H, brm), 2.04-1.93(2H, brm), 1.89-1.79(2H, brm), 1.70-1.59(1H, brm), 1.49-1.18(3H, brm)


Purity >90%(NMR)


MS 615 (M+1)


Example No. 311
1H NMR(δ)ppm







300MHz, DMSO-d6 8.30(1H, s), 8.21 and 8.01(2H, ABq, J=8.7Hz), 7.65(2H, d, J=8.4Hz), 7.52-7.41(6H, m), 7.20(1H, d, J=8.4Hz), 7.14(1H, d, J=2.7Hz), 6.97(1H, dd, J=8.4, 2.4Hz), 4.31(1H, brt, J= 9.8Hz), 4.28(2H, s), 3.78(3H, s), 2.37-2.20(2H, brm), 2.07-1.95(2H, brm), 1.92-1.80(2H, brm), 1.71-1.60(1H, brm), 1.50-1.19(3H, brm)


Purity >90%(NMR)


MS 583 (M+1)









 









TABLE 206







Example No. 312
1H NMR(δ)ppm







300MHz DMSO-d6 8.22(1H, s), 8.12(1H, d, J=8.4Hz), 8.00- 7.84(5H, m), 7.70(4H, d, J=8.4Hz), 7.56(1H, t, J=8.6Hz), 7.23(1H, d, J=12.0Hz), 7.13(1H, d, J=8.6Hz), 6.97(1H, s), 3.92(1H, m), 2.35-2.00(2H, m), 1.95-1.70(4H, m), 1.65-1.55(1H, m), 1.50- 1.05(3H, m)


Purity >90%(NMR)


MS 609 (M+1)


Example No. 313
1H NMR(δ)ppm







300MHz, DMSO-d6 8.89(1H, brs), 8.63(1H, brs), 8.24(1H, s), 8.11(1H, d, J=7.8Hz), 7.99(1H, d, J=8.8Hz), 7.89(1H, d, J=9.9Hz), 7.61-7.55(4H, m), 7.43(2H, t, J=7.7Hz), 7.34(1H, t, J=7.2Hz), 7.24(1H, d, J=12.0Hz), 7.14(1H, d, J=8.6Hz), 6.95(1H, s), 3.96(1H, m), 2.35-2.05(2H, m), 2.00-1.50(5H, m), 1.45-1.10(3H, m)


Purity >90%(NMR)


MS 522 (M+1)


Example No. 314
1H NMR(δ)ppm







300MHz, CDCl3 8.48(1H, d, J=1.4Hz), 8.05(1H, d, J=1.8Hz), 8.98(1H, d, J=8.6Hz), 7.82(1H, d, J=7.9Hz), 7.66(1H, d, J=8.6Hz), 7.55-7.24(6H, m), 6.78(1H, dd, J=8.6, 2.6Hz), 6.69(1H, dd, J= 11.6Hz), 2.2Hz), 6.40-6.30(1H, m), 4.99(2H, s), 4.02(1H, m), 3.95(3H, s), 3.05(3H, d, J=4.8Hz), 2.32-2.13(2H, m), 2.03- 1.87(4H, m), 1.81-1.71(1H, m), 1.46-1.23(3H, m)


Purity >90%(NMR)


MS 626 (M+1)









 









TABLE 207







Example No. 503
1H NMR(δ) ppm







300 MHz, DMSO-d6 8.23(1H, s), 7.76(1H, d, J=8.7Hz), 7.58(1H, d, J=8.8Hz), 7.51-7.32(7H, m), 7.17(2H, d, J=8.7Hz), 6.55(1H, s), 5.18 (2H, s), 4.75(1H, m), 2.35- 2.12(2H, m), 2.10-1.85(4H, m), 1.80-1.50(2H, m)


Purity >90%(NMR)


MS 412(M+1)


Example No. 701
1H NMR(δ) ppm







300 MHz, DMSO-d6 8.96(1H, s), 8.50(1H, s), 7.77 (2H, d, J=8.7Hz), 7.50-7.40 (4H, m), 7.30(1H, d, J=8.4 Hz), 7.24(1H, d, J=2.4Hz), 7.16(2H, d, J=8.4Hz), 7.06(1H, dd, J=2.4Hz, 8.1Hz), 5.06 (2H, s), 4.31(1H, s), 3.83(3 H, s), 2.80-2.55(2H, m), 2.00- 1.80(4H, m), 1.70-1.55(1H, m), 1.40-1.15(3H, m)


Purity >90%(NMR)


MS 568(M+1)









 









TABLE 208







Example No. 315
1H NMR(δ)ppm







300MHz, DMSO-d6 8.84(2H, d, J=6.3Hz), 8.28(1H, s), 8.17 and 7.99(2H, ABq, J=8.7Hz), 7.87-7.85(3H, m), 7.70-7.50(3H, m), 7.52(1H, d, J=8.3Hz), 7.18(2H, d, J=8.7Hz), 5.22(2H, s) 4.31(1H, brt, J=12.5Hz), 2.36-2.18(2H, m), 2.03- 1.78(4H, m), 1.70-1.58(1H, m), 1.50-1.23(3H, m)


Purity >90%(NMR)


MS 538 (M+1)


Example No. 316
1H NMR(δ)ppm







300MHz, DMSO-d6 9.23(1H, t, J=6.3Hz), 8.29(1H, s), 8.25-8.22(2H, m), 8.03(2H, d, J=7.9Hz), 7.55- 7.48(5H, m) 7.34(4H, d, J=4.4Hz), 7.28-7.22,(3H, m), 5.15(2H, s), 4.52(2H, d, J=5.9Hz), 4.35(1H, brt, J=12.1Hz), 2.37-2.18(2H, m), 2.08-1.95(2H, m), 1.91-1.79(2H, m), 


# 1.72-1.59(1H, m), 1.47-1.19(3H, m)


Purity >90%(NMR)


MS 670 (M+1)


Example No. 317
1H NMR(δ)ppm







300MHz, DMSO-d6 8.59(1H, t, J=5.5Hz), 8.28(1H, s), 8.21 and 8.01(2H, ABq, J=8.8Hz), 8.16(1H, s), 7.97 and 7.46(2H, A′B′q, J=8.0Hz), 7.71 and 7.23(4H, A′′B′′q, J=8.7Hz), 7.53 and 7.49(4H, A′′′ B′′′q, J=9.2Hz), 5.14(2H, s), 4.34(1H, brt, J= 12.8Hz), 3.14(2H, t, J=6.3Hz), 


# 2.38-2.18(2H, m), 2.07-1.78(4H, m), 1.78-1.47(7H, m), 1.47- 1.07(6H, m), 1.03-0.83(2H, m)


Purity >90%(NMR)


MS 676 (M+1)









 









TABLE 209







Example No. 318
1H NMR(δ)ppm







300MHz, DMSO-d6 9.63(1H, t, J=4.8Hz), 8.86 and 7.97(4H, ABq, J=6.6Hz), 8.30(1H, s), 8.27(1H, s), 8.23 and 8.03(2H, A′B′q, J=8.8Hz), 8.09 and 7.54(2H, A′′B′′q, J=8.1Hz), 7.73 and 7.24(4H, A′′′B′′′q, J=8.8Hz), 7.54 and 7.52(4H, A′′′′B′′′′q, J=8.8Hz), 5.16(2H, s) 4.78(2H, d, J=5.6Hz), 4.35(1H, brt, J=11.0Hz), 


# 2.39-2.19(2H, m), 2.07- 1.96(2H, m), 1.91-1.78(2H, m), 1.70-1.57(1H, m) 1.50-1.19(3H, m)


Purity >90%(NMR)


MS 671 (M+1)


Example No. 319
1H NMR(δ)ppm







300MHz, DMSO-d6 8.28(1H, s), 8.24 and 8.03(2H, ABq, J=9.0Hz), 7.77(1H, s), 7.70(2H, d, J=8.4Hz), 7.64-7.10(13H, m), 5.16(2H, s), 4.74 and 4.57(total 2H, each brs), 4.34(1H, brt, J=11.7Hz), 2.90(3H, s), 2.35-2.17(2H, m), 2.07-1.93(2H, m), 1.93- 1.78(2H, m), 1.71-1.57(1H, m), 1.51-1.19(3H, m)


Purity >90%(NMR)


MS 684 (M+1)


Example No. 320
1H NMR(δ)ppm







300MHz, DMSO-d6 8.94 and 8.06(4H, ABq, J= 6.8Hz), 8.33(1H, s), 8.28 and 8.05(2H, A′B′q, J=8.7Hz), 7.80(1H, s), 7.73 and 7.22(4H, A′′B′′q, J=8.7Hz), 7.63 and 7.57(2H, A′′′B′′′q, J=7.9Hz), 5.30(2H, s), 4.34(1H, brt, J=12.1Hz), 3.04(3H, s), 2.97(3H, s), 2.38-2.18(2H, m), 2.10-1.96(2H, m), 1.93-1.80(2H, m), 1.72-1.58(1H, m), 1.52-1.08(3H, m)


Purity >90%(NMR)


MS 575 (M+1)









 









TABLE 210







Example No. 321
1H NMR(δ)ppm







300MHz, DMSO-d6 11.19(1H, brs), 8.31(1H, s), 8.23 and 8.02(2H, ABq, J=9.0Hz), 7.77(1H, s), 7.72 and 7.23(4H, A′B′q, J=8.7Hz), 7.59 and 7.48(2H, A′′B′′q, J=7.9Hz), 7.53 and 7.51(4H, A′′′B′′′q, J=9.0Hz), 5.16(2H, s), 4.72-2.97(8H, br m), 4.34(1H, brt, J= 12.1Hz), 2.79(3H, s), 2.38-2.17(2H, m), 2.07- 1.93(2H, m), 1.93-1.78(2H, m), 


# 1.69-1.58(1H, m), 1.50-1.10(3H, m)


Purity >90%(NMR)


MS 663 (M+1)


Example No. 322
1H NMR(δ)ppm







300MHz, DMSO-d6 9.54(1H, t, J=5.7Hz), 8.91(1H, s), 8.81(1H, d, J=4.9Hz), 8.48(1H, d, J=7.9Hz), 8.32(1H, s), 8.27(1H, d, J=9.0Hz), 8.25(1H, s), 8.07-7.97(3H, m), 7.74 and 7.25(4H, ABq, J= 8.9Hz), 7.56-7.49(5H, m), 5.16(2H, s), 4.69(2H, d, J=5.6Hz), 4.36(1H, brt, J=12.4Hz), 2.37-2.20(2H, m), 2.09-1.97(2H, m), 1.91-1.78(2H, m), 


# 1.70- 1.57(1H, m), 1.50-1.17(3H, m)


Purity >90%(NMR)


MS 671 (M+1)


Example No. 323
1H NMR(δ)ppm







300MHz, DMSO-d6 9.52(1H, t, J=6.0Hz), 8.72(1H, d, J=5.3Hz), 8.30-8.19(4H, m), 8.08(1H, d, J= 7.9Hz), 8.02(1H, d, J=7.6Hz), 7.77-7.64(4H, m), 7.57-7.49(5H, m), 7.24(2H, d, J=8.7Hz), 5.16(2H, s), 4.77(2H, d, J=5.6Hz), 4.34(1H, t, J=12.8Hz), 2.36-2.19(2H, m), 2.07-1.95(2H, m), 1.91- 1.78(2H, m), 1.69-1.59(1H, m), 1.45-1.20(3H, m)


Purity >90%(NMR)


MS 671 (M+1)









 









TABLE 211







Example No. 324
1H NMR(δ)ppm







300MHz, DMSO-d6 8.36(1H, d, J=7.9Hz), 8.30(1H, s), 8.28 and 8.05(2H, ABq, J=8.8Hz), 8.16(1H, s), 7.79 and 7.46(2H, A′B′q, J=8.3Hz), 7.74 and 7.25(4H, A′′′ B′′′ q, J=8.9Hz), 7.52 and 7.50(4H, A′′′B′′′q, J=8.7Hz), 5.14(2H, s), 4.36(1H, brt, J=12.1Hz), 3.80(1H, brs), 2.39-2.18(2H, m), 2.10-1.98(2H, m), 1.93-1.57(8H, m), 1.49-1.04(8H, m)


Purity >90%(NMR)


MS 662 (M+1)


Example No. 325
1H NMR(δ)ppm







300MHz, DMSO-d6 8.86(1H, t, J=6.0Hz), 8.84 and 8.00(4H, ABq, J=6.6Hz), 8.33(1H, s), 8.27 and 8.04(2H, A′B′q, J=9.0Hz), 8.12(1H, s), 7.92 and 7.46(2H, A′′B′′q, J=7.9Hz), 7.74 and 7.23(4H, A′′′B′′′q, J=9.0Hz), 7.53 and 7.49(4H, A′′′′B′′′′q, J=9.1Hz), 5.13(2H, s), 4.36(1H, brt, J=12.8Hz), 3.70(2H, td, J=6.8, 6.0Hz), 


# 3.21(2H, t, J=6.8Hz), 2.38-2.20(2H, m), 2.09-1.95(2H, m), 1.91- 1.77(2H, m), 1.70-1.59(1H, m), 1.49-1.20(3H, m)


Purity >90%(NMR)


MS 685 (M+1)


Example No. 326
1H NMR(δ)ppm







300MHz, DMSO-d6 12.80(1H, brs), 8.23(1H, s), 7.90(1H, d, J=8.7Hz), 7.83(1H, d, J=8.7Hz), 7.60- 7.50(5H, m), 7.39(2H, d, J=7.8Hz), 7.23-7.10(3H, m), 7.05(1H, d, J=7.8Hz), 6.85(1H, s), 3.94(1H, s), 2.97, 2.88(6H, s), 2.30-2.10(2H, m), 1.90- 1.50(5H, m), 1.40-1.00(3H, m)


Purity >90%(NMR)


MS 610 (M+1)









 









TABLE 212







Example No. 327
1H NMR(δ)ppm







300MHz, DMSO-d6 13.20-12.60(2H, brs), 8.23(1H, s), 7.98(2H, d, J=6.6Hz), 7.95(1H, d, J=8.7Hz), 7.87(1H, d, J=8.7Hz), 7.70- 7.50(5H, m), 7.27-7.20(3H, m), 7.08(1H, d, J=7.8Hz), 6.90(1H, s), 3.93(1H, s), 2.51-2.05(2H, m), 1.90-1.70(4H, m), 1.65- 1.55(1H, m), 1.40-1.10(3H, m)


Purity >90%(NMR)


MS 583 (M+1)









 








TABLE 213





















Ex.




No.
R
R′





2001
—H
4-(—Me)


2002
—H
3-(—CF3)


2003
5-(—F)
—H


2004
3-(—F)
2-(—F)


2005
3-(—F)
3-(—F)


2006
3-(—F)
4-(—F)


2007
4-(—F)
4-(—F)


2008
5-(—F)
4-(—F)


2009
6-(—F)
4-(—F)


2010
4-(—F)
4-(—Cl)


2011
5-(—F)
4-(—Me)


2012
5-(—F)
4-(—CF3)


2013
5-(—F)
4-(—CO2H)


2014
5-(—F)
4-(—CO2Me)


2015
5-(—F)







2016
5-(—F)
4-(—CONH2)


2017
5-(—F)
4-{—CON(Me)2}


2018
5-(—F)
4-(—OMe)


2019
5-(—F)
4-(—SMe)


2020
5-(—F)







2021
5-(—F)







2022
4-(—Cl)
—H


2023
4-(—Cl)
4-(—F)


2024
4-(—Cl)
4-(—Cl)


2025
4-(—Cl)
4-(—Me)


2026
5-(—Cl)
4-(—CF3)


2027
4-(—Cl)
4-(—CO2H)


2028
5-(—Cl)
4-(—CO2Me)


2029
5-(—Cl)







2030
4-(—Cl)
4-(—CONH2)


2031
5-(—Cl)
4-{—CON(Me)2}


2032
5-(—Cl)
3-(—OMe)


2033
4-(—Cl)
4-(—SMe)


2034
5-(—Cl)







2035
4-(—Cl)







2036
5-(—CN)
4-(—F)


2037
4-(—CN)
4-(—Cl)


2038
5-(—NO2)
4-(—F)


2039
4-(—NO2)
4-(—Cl)


2040
5-(—Me)
4-(—CO2H)


2041
5-(—Me)
4-(—CO2Me)


2042
5-(—Me)







2043
5-(—CF3)
4-(—CO2H)


2044
5-(—CF3)
4-(—CO2Me)


2045
5-(—CF3)







2046
5-(—CO2H)
4-(—F)


2047
4-(—CO2H)
4-(—Cl)


2048
5-(—CO2Me)
4-(—F)


2049
5-(—CO2Me)
4-(—Cl)


2050
5-(—Ac)
4-(—F)


2051
5-(—Ac)
4-(—Cl)


2052





—H


2053





4-(—F)


2054





4-(—Cl)


2055





4-(—CN)


2056





4-(—NO2)


2057





4-(—Me)


2058





4-(—CF3)


2059





4-(—Ac)


2060





4-(—CO2H)


2061





4-(—CO2Me)


2062












2063





4-(—CONH2)


2064





4-{—CON(Me)2}


2065





4-{—C(═NH)NH2}


2066





4-(—OMe)


2067












2068





4-(—NHMe)


2069





4-(—NHAc)


2070












2071





4-(—SMe)


2072












2073












2074












2075












2076
5-(—CONH2)
—H


2077
5-(—CONH2)
4-(—F)


2078
5-(—CONH2)
2,3,4,5,6-penta-(—F)


2079
5-(—CONH2)
2-(—Cl)


2080
5-(—CONH2)
3-(—Cl)


2081
3-(—CONH2)
2-(—Cl)


2082
3-(—CONH2)
3-(—Cl)


2083
3-(—CONH2)
4-(—Cl)


2084
4-(—CONH2)
2-(—Cl)


2085
4-(—CONH2)
3-(—Cl)


2086
4-(—CONH2)
4-(—Cl)


2087
6-(—CONH2)
2-(—Cl)


2088
6-(—CONH2)
3-(—Cl)


2089
6-(—CONH2)
4-(—Cl)


2090
5-(—CONH2)
3,5-di-(—Cl)


2091
5-(—CCNH2)
4-(—CN)


2092
5-(—CONH2)
4-(—NO2)


2093
5-(—CONH2)
4-(—Me)


2094
5-(—CONH2)
2,6-di-(—Me)


2095
5-(—CONH2)
4-(—CF3)


2096
5-(—CONH2)
4-(—Ac)


2097
5-(—CONH2)
4-(—CO2H)


2098
5-(—CONH2)
4-(—CO2Me)


2099
5-(—CONH2)







2100
5-(—CONH2)
4-(—CONH2)


2101
5-(—CONH2)
3,5-di-(—CONH2)


2102
5-(—CONH2)
4-{—CON(Me)2}


2103
5-(—CONH2)
4-{—C(═NH)NH2}


2104
5-(—CONH2)
4-(—OMe)


2105
5-(—CONH2)
3,4,5-tri-(—OMe)


2106
5-(—CONH2)







2107
5-(—CONH2)
4-(—NHMe)


2108
5-(—CONH2)
4-(—NHAc)


2109
5-(—CONH2)







2110
5-(—CONH2)
4-(—SMe)


2111
5-(—CONH2)







2112
5-(—CONH2)







2113
5-(—CONH2)







2114
5-(—CONH2)







2115
5-{—CON(Me)2}
—H


2116
5-{—CON(Me)2}
4-(—F)


2117
4-{—CON(Me)2}
4-(—Cl)


2118
5-{—CON(Me)2}
4-(—CN)


2119
5-{—CON(Me)2}
4-(—NO2)


2120
5-{—CON(Me)2}
4-(—Me)


2121
4-{—CON(Me)2}
4-(—CF3)


2122
5-{—CON(Me)2}
4-(—Ac)


2123
5-{—CON(Me)2}
4-(—CO2H)


2124
5-{—CON(Me)2}
4-(—CO2Me)


2125
5-{—CON(Me)2}







2126
5-{—CON(Me)2}
3-(—CONH2)


2127
4-{—CON(Me)2}
4-{—CON(Me)2}


2128
5-{—CON(Me)2}
4-{—C(═NH)NH2}


2129
5-{—CON(Me)2}
4-(—OMe)


2130
5-{—CON(Me)2}







2131
5-{—CON(Me)2}
4-(—NHMe)


2132
5-{—CON(Me)2}
4-(—NHAc)


2133
5-{—CON(Me)2}







2134
4-{—CON(Me)2}
4-(—SMe)


2135
5-{—CON(Me)2}







2136
4-{—CON(Me)2}







2137
5-{—CON(Me)2}







2138
5-{—CON(Me)2}







2139
5-(—OMe)
—H


2140
5-(—OMe)
4-(—F)


2141
3-(—OMe)
4-(—Cl)


2142
4-(—OMe)
4-(—Cl)


2143
5-(—OMe)
2-(—Cl)


2144
5-(—OMe)
3-(—Cl)


2145
6-(—OMe)
4-(—Cl)


2146
5-(—OMe)
4-(—CN)


2147
5-(—OMe)
4-(—NO2)


2148
5-(—OMe)
4-(—Me)


2149
5-(—OMe)
4-(—CF3)


2150
5-(—CMe)
4-(—Ac)


2151
4-(—OMe)
4-(—CO2H)


2152
4,5-di-(—OMe)
4-(—CO2H)


2153
5-(—OMe)
4-(—CO2Me)


2154
5-(—OMe)







2155
5-(—OMe)
4-(—CONH2)


2156
5-(—OMe)
4-{—CON(Me)2}


2157
5-(—OMe)
4-{—CON(═NH)NH2}


2158
5-(—OMe)
4-(—OMe)


2159
5-(—OMe)







2160
5-(—OMe)
4-(—NHMe)


2161
5-(—OMe)
4-(—NHAc)


2162
5-(—OMe)







2163
5-(—OMe)
4-(—SMe)


2164
5-(—OMe)







2165
5-(—OMe)







2166
5-(—OMe)







2167
5-(—OMe)







2168
5-(—NHMe)
4-(—F)


2169
5-(—NHMe)
4-(—Cl)


2170
5-(—NHAc)
4-(—F)


2171
5-(—NHAc)
4-(—Cl)


2172
5-(—NHAc)
4-(—Ac


2173
5-(—NHAc)
4-(—CONH2)


2174
5-(—NHAc)
4-{—CON(Me)2}


2175





4-(—F)


2176





4-(—Cl)


2177





4-(—Me)


2178





4-(—CF3)


2179





4-(—CO2H)


2180





4-(—CO2Me)


2181












2182





4-(—SMe)


2183












2184












2185
5-(—SMe)
4-(—F)


2186
4-(—SMe)
4-(—Cl)


2187
5-(—SMe)
4-(—Me)


2188
5-(—SMe)
4-(—CF3)


2189
5-(—SMe)
4-(—Ac)


2190
5-(—SMe)
4-(—CONH2)


2191
5-(—SMe)
4-{—CON(Me)2}


2192





4-(—F)


2193





4-(—Cl)


2194





4-(—Me)


2195





4-(—CF3)


2196





4-(—Ac)


2197





4-(—CONH2)


2198





4-{—CON(Me)2}


2199





4-(—F)


2200





4-(—Cl)


2201





4-(—Me)


2202





4-(—CF3)


2203





4-(—Ac)


2204





4-(—CONH2)


2205





4-{—CON(Me)2}


2206





4-(—F)


2207





4-(—Cl)


2208





2,4-di-(—Cl)


2209





4-(—Me)


2210





3-(—CF3)


2211





4-(—CF3)


2212





4-(—CONH2)


2213





4-{—CON(Me)2}


2214





4-(—SMe)


2215












2216












2217





4-(—F)


2218





4-(—Cl)


2219





4-(—Me)


2220





4-(—CF3)


2221





4-(—CONH2)


2222





4-{—CON(Me)2}


2223





4-(—SMe)


2224












2225












2226
5-{—O—(CH2)2—OH}
4-(—Cl)


2227
5-{—O—(CH2)3—OH}
4-(—Cl)


2228





4-(—Cl)


2229





4-(—Cl)


2230





4-(—Cl)


2231





4-(—Cl)


2232





4-(—Cl)


2233





4-(—Cl)


2234





4-(—Cl)


2235





4-(—Cl)


2236





4-(—Cl)


2237





4-(—Cl)


2238





4-(—Cl)


2239





4-(—Cl)


2240





4-(—Cl)


2241





4-(—Cl)


2242





4-(—Cl)


2243





4-(—Cl)


2244





4-(—Cl)


2245





4-(—Cl)


2246





4-(—Cl)


2247





4-(—Cl)


2248





4-(—Cl)


2249





4-(—Cl)


2250





4-(—Cl)


2251





4-(—Cl)


2252





4-(—Cl)


2253





4-(—Cl)


2254





4-(—Cl)









 








TABLE 214





















Ex.




No.
R
R′





2255
—H
—H


2256
—H
4-(-Me)


2257
—H
3-(-CF3)


2258
5-(-F)
—H


2259
5-(-F)
4-(-F)


2260
5-(-F)
4-(-Cl)


2261
5-(-F)
4-(-Me)


2262
5-(-F)
4-(-CF3)


2263
5-(-F)
4-(-CO2H)


2264
5-(-F)
4-(-CO2Me)


2265
5-(-F)







2266
5-(-F)
4-(-CONH2)


2267
5-(-F)
4-{-CON(Me)2}


2268
5-(-F)
4-(-OMe)


2269
5-(-F)
4-(-SMe)


2270
5-(-F)







2271
5-(-F)







2272
4-(-Cl)
—H


2273
5-(-Cl)
4-(-F)


2274
4-(-Cl)
4-(-Cl)


2275
5-(-Cl)
4-(-Me)


2276
5-(-Cl)
4-(-CF3)


2277
5-(-Cl)
4-(-CO2H)


2278
5-(-Cl)
4-(-CO2Me)


2279
5-(-Cl)







2280
5-(-Cl)
4-(-CONH2)


2281
5-(-Cl)
4-{-CON(Me)2}


2282
5-(-Cl)
4-(-OMe)


2283
5-(-Cl)
4-(-SMe)


2284
5-(-Cl)







2285
5-(-Cl)







2286
5-(-CN)
4-(-F)


2287
5-(-CN)
4-(-Cl)


2288
5-(-NO2)
4-(-F)


2289
5-(-NO2)
4-(-Cl)


2290
5-(-Me)
4-(-CO2H)


2291
5-(-Me)
4-(-CO2Me)


2292
5-(-Me)







2293
5-(-CF3)
4-(-CO2H)


2294
5-(-CF3)
4-(-CO2Me)


2295
5-(-CF3)







2296
5-(-CO2H)
4-(-F)


2297
4-(-CO2H)
4-(-Cl)


2298
5-(-CO2Me)
4-(-F)


2299
5-(-CO2Me)
4-(-Cl)


2300
5-(-Ac)
4-(-F)


2301
5-(-Ac)
4-(-Cl)


2302





—H


2303





4-(-F)


2304





4-(-Cl)


2305





4-(-CN)


2306





4-(-NO2)


2307





4-(-Me)


2308





4-(-CF3)


2309





4-(-Ac)


2310





4-(-CO2H)


2311





4-(-CO2Me)


2312












2313





4-(-CONH2)


2314





4-{-CON(Me)2}


2315





4-{-C(═NH)NH2}


2316





4-(-OMe)


2317












2318





4-(-NHMe)


2319





4-(-NHAc)


2320












2321





4-(-SMe)


2322












2323












2324












2325












2326
5-(-CONH2)
—H


2327
5-(-CONH2)
4-(-F)


2328
4-(-CONH2)
4-(-Cl)


2329
5-(-CONH2)
4-(-CN)


2330
5-(-CONH2)
4-(-NO2)


2331
5-(-CONH2)
4-(-Me)


2332
5-(-CONH2)
4-(-CF3)


2333
5-(-CONH2)
4-(-Ac)


2334
5-(-CONH2)
4-(-CO2H)


2335
5-(-CONH2)
4-(-CO2Me)


2336
5-(-CONH2)







2337
5-(-CONH2)
4-(-CONH2)


2338
5-(-CONH2)
4-{-CON(Me)2}


2339
5-(-CONH2)
4-{-C(═NH)NH2}


2340
5-(-CONH2)
4-(-OMe)


2341
5-(-CONH2)







2342
5-(-CONH2)
4-(-NHMe)


2343
5-(-CONH2)
4-(-NHAc)


2344
5-(-CONH2)







2345
5-(-CONH2)
4-(-SMe)


2346
5-(-CONH2)







2347
5-(-CONH2)







2348
5-(-CONH2)







2349
5-(-CONH2)







2350
5-{-CON(Me)2}
—H


2351
5-{-CON(Me)2}
4-(-F)


2352
4-{-CON(Me)2}
4-(-Cl)


2353
5-{-CON(Me)2}
4-(-CN)


2354
5-{-CON(Me)2}
4-(-NO2)


2355
5-{-CON(Me)2}
4-(-Me)


2356
5-{-CON(Me)2}
4-(-CF3)


2357
5-{-CON(Me)2}
4-(-Ac)


2358
5-{-CON(Me)2}
4-(-CO2H)


2359
5-{-CON(Me)2}
4-(-CO2Me)


2360
5-{-CON(Me)2}







2361
5-{-CON(Me)2}
4-(-CONH2)


2362
5-{-CON(Me)2}
4-{-CON(Me)2}


2363
5-{-CON(Me)2}
4-{-C(═NH)NH2}


2364
5-{-CON(Me)2}
4-(-OMe)


2365
5-{-CON(Me)2}







2366
5-{-CON(Me)2}
4-(-NHMe)


2367
5-{-CON(Me)2}
4-(-NHAc)


2368
5-{-CON(Me)2}







2369
5-{-CON(Me)2}
4-(-SMe)


2370
5-{-CON(Me)2}







2371
5-{-CON(Me)2}







2372
5-{-CON(Me)2}







2373
5-{-CON(Me)2}







2374
5-(-OMe)
—H


2375
5-(-OMe)
4-(-F)


2376
5-(-OMe)
4-(-Cl)


2377
5-(-OMe)
4-(-CN)


2378
5-(-OMe)
4-(-NO2)


2379
5-(-OMe)
4-(-Me)


2380
5-(-OMe)
4-(-CF3)


2381
5-(-OMe)
4-(-Ac)


2382
5-(-OMe)
4-(-CO2H)


2383
5-(-OMe)
4-(-CO2Me)


2384
5-(-OMe)







2385
5-(-OMe)
4-(-CONH2)


2386
5-(-OMe)
4-{-CON(Me)2}


2387
5-(-OMe)
4-{-C(═NH)NH2}


2388
5-(-OMe)
4-(-OMe)


2389
5-(-OMe)







2390
5-(-OMe)
4-(-NHMe)


2391
5-(-OMe)
4-(-NHAc)


2392
5-(-OMe)







2393
5-(-OMe)
4-(-SMe)


2394
5-(-OMe)







2395
5-(-OMe)







2396
5-(-OMe)







2397
5-(-OMe)







2398
5-(-NHMe)
4-(-F)


2399
5-(-NHMe)
4-(-Cl)


2400
5-(-NHAc)
4-(-F)


2401
5-(-NHAc)
4-(-Cl)


2402
5-(-NHAc)
4-(-Ac)


2403
5-(-NHAc)
4-(-CONH2)


2404
5-(-NHAc)
4-{-CON(Me)2}


2405





4-(-F)


2406





4-(-Cl)


2407





4-(-Me)


2408





4-(-CF3)


2409





4-(-CO2H)


2410





4-(-CO2Me)


2411












2412





4-(-SMe)


2413












2414












2415
5-(-SMe)
4-(-F)


2416
5-(-SMe)
4-(-Cl)


2417
5-(-SMe)
4-(-Me)


2418
5-(-SMe)
4-(-CF3)


2419
5-(-SMe)
4-(-Ac)


2420
5-(-SMe)
4-(-CONH2)


2421
5-(-SMe)
4-{-CON(Me)2}


2422





4-(-F)


2423





4-(-Cl)


2424





4-(-Me)


2425





4-(-CF3)


2426





4-(-Ac)


2427





4-(-CONH2)


2428





4-{-CON(Me)2}


2429





4-(-F)


2430





4-(-Cl)


2431





4-(-Me)


2432





4-(-CF3)


2433





4-(-Ac)


2434





4-(-CONH2)


2435





4-{-CON(Me)2}


2436





4-(-F)


2437





4-(-Cl)


2438





4-(-Me)


2439





4-(-CF3)


2440





4-(-CONH2)


2441





4-{-CON(Me)2}


2442





4-(-SMe)


2443












2444












2445





4-(-F)


2446





4-(-Cl)


2447





4-(-Me)


2448





4-(-CF3)


2449





4-(-CONH2)


2450





4-{-CON(Me)2}


2451





4-(-SMe)


2452












2453



















 








TABLE 215





















Ex.




No.
R
R′





2454
2-(—F)
2-(—F)


2455
2-(—F)
3-(—F)


2456
2-(—F)
4-(—F)


2457
3-(—Cl)
3-(—Cl)


2458
3,5-di-(—Cl)
3,5-di-(—Cl)


2459
3-(—CN)
3-(—CN)


2460
3-(—NO2)
3-(—NO2)


2461
3-(—Me)
3-(—Me)


2462
3-(—CF3)
3-(—CF3)


2463
3-(—Ac)
3-(—Ac)


2464
3-(—CO2H)
3-(—CO2H)


2465
3-(—CO2Me)
3-(—CO2Me)


2466












2467
3-(—CONH2)
3-(—CONH2)


2468
3-(—CONH2)
3-(—F)


2469
3-(—CONH2)
3-(—Cl)


2470
3-{—CON(Me)2}
3-{—CON(Me)2}


2471
3-{—CON(Me)2}
3-(—F)


2472
3-{—CON(Me)2}
3-(—Cl)


2473
3-{—C(═NH)NH2}
3-{—C(═NH)NH2}


2474
3-(—OMe)
3-(—OMe)


2475












2476
3-(—NHMe)
3-(—NHMe)


2477
3-(—NHAc)
3-(—NHAc)


2478












2479
3-(—SMe)
3-(—SMe)


2480












2481












2482












2483












2484
3-(—F)
4-(—F)


2485
3-(—Cl)
4-(—Cl)


2486
4-(—CN)
4-(—CN)


2487
4-(—NO2)
4-(—NO2)


2488
3-(—Me)
4-(—Me)


2489
4-(—Me)
2,6-di-(—Me)


2490
4-(—CF3)
4-(—CF3)


2491
4-(—Ac)
4-(—Ac)


2492
4-(—CO2H)
4-(—CO2H)


2493
4-(—CO2Me)
4-(—CO2Me)


2494












2495
4-(—CONH2)
4-(—CONH2)


2496
4-(—CONH2)
4-(—F)


2497
4-(—CONH2)
2,3,4,5,6-penta-(—F)


2498
4-(—CONH2)
4-(—Cl)


2499
4-{—CON(Me)2}
4-{—CON(Me)2}


2500
4-{—CON(Me)2}
4-(—F)


2501
4-{—CON(Me)2}
4-(—Cl)


2502
4-{—CON(Me)2}
3,5-di-(—Cl)


2503
4-{—C(=NH)NH2}
4-{—C(=NH)NH2}


2504
4-(—OMe)
4-(—OMe)


2505
4-(—OMe)
3,4,5-tri-(—OMe)


2506












2507
4-(—NHMe)
4-(—NHMe)


2508
4-(—NHAC)
4-(—NHAc)


2509












2510
4-(—SMe)
4-(—SMe)


2511












2512












2513












2514



















 








TABLE 216





















Ex.




No.
R
R′





2515
—H
—H


2516
2-(—F)
3-(—F)


2517
3-(—Cl)
3-(—Cl)


2518
3-(—CN)
3-(—CN)


2519
3-(—NO2)
3-(—NO2)


2520
3-(—Me)
3-(—Me)


2521
3-(—CF3)
3-(—CF3)


2522
3-(—Ac)
3-(—Ac)


2523
3-(—CO2H)
3-(—CO2H)


2524
3-(—CO2Me)
3-(—CO2Me)


2525












2526
3-(—CONH2)
3-(—CONH2)


2527
3-(—CONH2)
3-(—F)


2528
3-(—CONH2)
3-(—Cl)


2529
3-{—CON(Me)2}
3-{—CON(Me)2}


2530
3-{—CON(Me)2}
3-(—F)


2531
3-{—CON(Me)2}
3-(—Cl)


2532
3-{—C(═NH)NH2}
3-{—C(═NH)NH2}


2533
3-(—OMe)
3-(—OMe)


2534












2535
3-(—NHMe)
3-(—NHMe)


2536
3-(—NHAc)
3-(—NHAc)


2537












2538
3-(—SMe)
3-(—SMe)


2539












2540












2541












2542












2543
3-(—F)
4-(—F)


2544
4-(—Cl)
4-(—Cl)


2545
4-(—CN)
4-(—CN)


2546
4-(—NO2)
4-(—NO2)


2547
4-(—Me)
4-(—Me)


2548
4-(—CF3)
4-(—CF3)


2549
4-(—Ac)
4-(—Ac)


2550
3-(—CO2H)
4-(—CO2H)


2551
4-(—CO2Me)
4-(—CO2Me)


2552












2553
4-(—CONH2)
4-(—CONH2)


2554
4-(—CONH2)
4-(—F)


2555
4-(—CONH2)
4-(—C#)


2556
3-{—CON(Me)2}
4-{—CON(Me)2}


2557
3-{—CON(Me)2}
4-(—F)


2558
4-{—CON(Me)2}
4-(—CI)


2559
4-{—C(═NH)NH2}
4-{—C(═NH)NH2}


2560
4-(—OMe)
4-(—OMe)


2561












2562
4-(—NHMe)
4-(—NHMe)


2563
4-(—N#IAc)
4-(—NHAc)


2564












2565
4-(—SMe)
4-(—SMe)


2566












2567












2568












2569



















 








TABLE 217





















Ex.




No.
Py
R′





2570
3-Py
—H


2571
3-Py
3-(—F)


2572
3-Py
3-(—Cl)


2573
3-Py
3-(—Me)


2574
3-Py
3-(—CF3)


2575
3-Py
3-(—Ac)


2576
3-Py
3-(—CO2H)


2577
3-Py
3-(—CO2Me)


2578
3-Py







2579
3-Py
3-(—CONH2)


2580
3-Py
3-{—CON(Me)2}


2581
3-Py
4-(—F)


2582
3-Py
4-(—Cl)


2583
3-Py
4-(—Me)


2584
3-Py
4-(—CF3)


2585
3-Py
4-(—Ac)


2586
2-Py
4-(—CO2H)


2587
3-Py
4-(—CO2Me)


2588
3-Py







2589
4-Py
4-(—CONH2)


2590
3-Py
4-{—CON(Me)2}









 








TABLE 218





















Ex.




No.
Py
R′





2591
3-Py
—H


2592
3-Py
3-(—F)


2593
3-Py
3-(—Cl)


2594
3-Py
3-(—Me)


2595
3-Py
3-(—CF3)


2596
3-Py
3-(—Ac)


2597
3-Py
3-(—CO2H)


2598
3-Py
3-(—CO2Me)


2599
3-Py







2600
3-Py
3-(—CONH2)


2601
3-Py
3-{—CON(Me)2}


2602
3-Py
4-(—F)


2603
3-Py
4-(—Cl)


2604
3-Py
4-(—Me)


2605
3-Py
4-(—CF3)


2606
3-Py
4-(—Ac)


2607
3-Py
4-(—CO2H)


2608
3-Py
4-(—CO2Me)


2609
3-Py







2610
3-Py
4-(—CONH2)


2611
3-Py
4-{—CON(Me)2}









 









TABLE 219







Example No. 328
1H NMR (δ) ppm







300MHz, DMSO-d6 8.29(1H, s), 8.23(1H, d, J= 9.0Hz), 8.02(1H, d, J=8.4Hz), 7.80(1H, s), 7.71(2H, d, J=8.4Hz), 7.61(1H, d, J=9.3Hz), 7.55-7.45(3H, m), 7.46(2H, d, J=8.1Hz), 7.22(2H, d, J=8.7Hz), 5.16(2H, s,), 4.34(1H, m), 4.20-3.40(4H, m), 2.60- 2.15(6H, m), 2.10-1.90(2H, m), 1.85-1.70(2H, m), 1.65-1.55(1H, m), 1.50-1.10(3H, m)


Purity > 90% (NMR)


MS 662 (M + 1)


Example No. 329
1H NMR (δ) ppm







400MHz, DMSO-d6 9.80(1H, brs), 8.32(1H, s), 8.30(1H, d, J=8.8Hz), 8.06(1H, d, J=8.8Hz), 7.74(2H, d, J=8.6Hz), 7.48-7.37(4H, m), 7.22(1H, d, J=8.6Hz), 7.17(1H, d, J=8.2Hz), 7.05(1H, d, J=2.3Hz), 6.88(1H, dd, J=8.3, 2.5Hz), 5.04(2H, s), 4.37(1H, m), 2.37- 2.22(2H, m), 2.11-1.98(2H, m), 1.93-1.81(2H, m), 1.70-1.58(1H, m), 1.56-1.22(3H, m)


Purity > 90% (NMR)


MS 553 (M + 1)


Example No. 330
1H NMR (p67 ) ppm







300MHz, DMSO-d6 8.38(1H, d, J=7.5Hz), 8.32(1H, s), 8.29(1H, d, J=9.0Hz), 8.16(1H, s), 8.05(1H, d, J= 9.0Hz), 7.96(1H, d, J=7.5Hz), 7.75(2H, d, J=8.4Hz), 7.53-7.43(5H, m), 7.25(2H, d, J=8.4Hz), 5.13(2H, s), 4.36(1H, m), 4.12(1H, sept, J=6.9Hz), 2.40-2.15(2H, m), 2.10-1.95(2H, m), 1.90-1.75(2H, m), 1.70- 1.55(1H, m), 1.50-1.20(3H, m), 1.18(6H, d, J=6.6Hz)


Purity > 90% (NMR)


MS 622 (M + 1)









 









TABLE 220







Example No. 331
1H NMR (δ) ppm







300MHz, DMSO-d6 8.31(1H, s), 8.27(1H, d, J= 8.7Hz), 8.05(1H, d, J=8.7Hz), 7.75-7.41(9H, m), 7.23(2H, d, J=8.7Hz), 4.36(1H, m), 4.00-3.90(1H, m), 2.84(3H, brs), 2.40-2.15(2H, m), 2.10-2.00(2H, m), 1.95-1.75(2H, m), 1.70-1.55(1H, m), 1.50-1.00(7H, m)


Purity > 90% (NMR)


MS 636 (M + 1)


Example No. 332
1H NMR (δ) ppm







300MHz, DMSO-d6 10.42(1H, s), 8.29(1H, s), 8.27(1H, s), 8.10(1H, d, J=7.9Hz), 8.03(1H, d, J= 8.6Hz), 7.82(2H, d, J=7.5Hz), 7.73(2H, d, J= 8.7Hz), 7.56-7.52(5H, m), 7.38(2H, t, J=7.9Hz), 7.26(2H, d, J=8.7Hz), 7.13(1H, t, J=7.5Hz), 5.20(2H, s), 4.35(1H, brt, J=11.7Hz), 2.37-2.19(2H, m), 2.07-1.96(2H, m), 1.92-1.79(2H, m), 


#1.69- 1.58(1H, m), 1.50-1.20(3H, m)


Purity > 90% (NMR)


MS 656 (M + 1)


Example No. 333
1H NMR (δ) ppm







300MHz, DMSO-d6 8.30(1H, s), 8.24 and 8.03(2H, ABq, J=8.8Hz), 7.71 and 7.22(4H, A′B′q, J=8.8Hz), 7.69(1H, s), 7.52(4H, s), 7.50 and 7.43(2H, A′′B′′q, J=7.7Hz), 5.15(2H, s) 4.35(1H, brt, J=12.1Hz), 4.05-3.15(5H, brm), 3.27(3H, s), 2.39-2.20(2H, m), 2.07-1.75(6H, m), 1.70-1.58(1H, m) 1.55-1.20(5H, m)


Purity > 90% (NMR)


MS 678 (M + 1)









 









TABLE 221







Example No. 334
1H NMR (δ) ppm







300MHz, DMSO-d6 8.22(1H, d, J=1.5Hz), 8.01(1H, d, J=9.0Hz), 7.89(1H, dd, J=8.6, 1.5Hz), 7.61(2H, d, J= 8.6Hz), 7.50-7.39(4H, m), 7.27(1H, d, J=8.6Hz), 7.22(1H, d, J=2.6Hz), 7.13(2H, d, J=8.6Hz), 7.04(1H, dd, J=8.2, 2.6Hz), 5.04(2H, s), 4.28(1H, m), 4.11(2H, t, J=6.3Hz), 3.57(2H, t, J=6.3Hz), 2.38-2.17(2H, m), 


#2.00-1.79(6H, m), 1.70-1.59(1H, m), 1.52-1.16(3H, m)


Purity > 90% (NMR)


MS 611 (M + 1)


Example No. 335
1H NMR (δ) ppm







300MHz, DMSO-d6 8.30(1H, d, J=1.5Hz), 8.27(1H, d, J=9.0Hz), 8.04(1H, dd, J=8.6, 1.5Hz), 7.72(2H, d, J= 9.0Hz), 7.60-7.40(4H, m), 7.32-7.19(4H, m), 7.06(1H, dd, J=8.6, 3.0Hz), 5.08(2H, s), 4.36(1H, m), 4.06(2H, t, J= 4.8Hz), 3.74(2H, t, J=4.8Hz), 2.38-2.19(2H, m), 2.13- 1.97(2H, m), 1.94-1.78(2H, m), 1.72-1.59(1H, m), 1.52-1.20(3H, m)


Purity > 90% (NMR)


MS 597 (M + 1)









 











TABLE 222








HCV polymerase



Ex.
inhibitory activity



No.
IC50 [μM]



















340
0.017



341
0.025



342
0.015



343
0.017



344
0.016



345
0.012



346
0.025



347
0.022



348
0.013



349
0.021



350
0.020



351
0.019



352
0.013



353
0.023



354
0.013



355
0.015



356
0.016



357
0.019



358
0.017



359
0.015



360
0.014



361
0.028



362
0.020



363
0.11



364
0.12



365
0.020



366
0.024



367
0.011



368
0.024



369
0.022



370
0.017



371
0.015



372
0.033



373
0.013



374
0.013



375
0.012



376
0.014



377
0.012



378
0.018



379
0.021










 











TABLE 223








HCV polymerase



Ex.
inhibitory activity



No.
IC50 [μM]



















380
0.023



381
0.011



382
0.015



383
0.013



384
0.016



385
0.019



386
0.018



387
0.025



388
0.020



389
0.012



390
0.014



391
0.017



392
0.014



393
0.011



394
0.019



395
0.016



396
0.025



397
0.037



398
0.077



399
0.032



409
0.020



410
0.018



411
0.015



412
0.019



413
0.026



414
0.024



415
0.019



416
0.024



417
0.029



418
0.016



419
0.021



420
0.015



421
0.017



422
0.017



423
0.017



424
0.020



425
0.026



426
0.053



427
0.020



428
0.026










 











TABEL 224








HCV polymerase



Ex.
inhibitory activity



No.
IC50 [μM]



















429
0.017



430
0.017



431
0.015



432
0.022



433
0.014



434
0.011



435
0.012



436
0.026



440
0.070



442
0.024



443
0.030



445
0.33



446
0.016



447
0.12



448
0.20



449
0.025



450
0.040



451
0.031



452
0.028



454
0.013



455
0.015



456
0.017



457
0.015



458
0.015



459
0.014



460
0.017



461
0.021



462
0.028



463
0.026



464
0.030



465
0.033



466
0.023



467
0.032



468
0.028



469
0.024



502
0.024



503
0.196



601
0.32



701
0.052










 









TABLE 225







Example No. 341
1H NMR (δ) ppm







300MHz, DMSO-d6 8.29(1H, d, J=1.5Hz), 8.25(1H, d, J=8.7Hz), 8.03(1H, dd, J= 8.7Hz), 7.72 and 7.22(4H, Abq, J=8.8Hz), 7.67(1H, d, J=1.5Hz), 7.52(4H, s), 7.49(1H, dd, J=7.9, 1.5Hz), 7.43(1H, d, J=7.9Hz), 4.46(1H, brs), 4.35(1H, brt, J=12.4Hz), 3.62(1H, brs), 3.06(1H, brs), 2.79(1H, brs), 2.38-2.20(2H, brm), 


#2.08-1.81(4H, brm), 1.77-1.52(4H, brm), 1.46-1.20(3H, brm), 1.19-1.00(2H, brm), 0.94 and 0.92(total 3H, each s)


Purity > 90% (NMR)


MS 662 (M + 1)


Example No. 342
1H NMR (δ) ppm







300Mz, DMSO-d6 8.28(1H, d, J=1.5Hz), 8.26(1H, d, J=1.8Hz), 8.19(1H, d, J=8.8Hz), 8.07(1H, dd, J=7.7, 1.8Hz), 8.00(1H, dd, J= 8.8, 1.5Hz), 7.70 and 7.22(4H, Abq, J= 8.8Hz), 7.56-7.50(1H, m), 7.56(4H, s), 5.17(2H, s), 4.33(1H, brt, J=12.5Hz), 2.05(3H, s), 2.37-2.20(2H, brm), 2.06- 1.80(4H, brm), 1.70-1.60(1H, brm), 1.50- 1.20(3H, brm)


Purity > 90% (NMR)


MS 679 (M + 1)


Example No. 343
1H NMR (δ) ppm







300MHz, DMSO-d6 8.20(1H, d, J=1.5Hz), 7.93(1H, d, J=8.6Hz), 7.84(1H, dd, J= 8.3Hz, 1.5Hz), 7.57(2H, d, J=8.6Hz), 7.50- 7.40(4H, m), 7.27(1H, d, J=8.2Hz), 7.22(1H, d, J=2.6Hz), 7.10(2H, d, J=8.6Hz) 7.01(1H, dd, J=8.6Hz, 2.6Hz), 5.02(2H, s), 4.89(2H, s), 4.78(1H, d, J=4.1Hz), 4.38-4.18(1H, m), 3.96-3.81(1H, m), 


#3.78-3.62(2H, m), 3.27- 2.99(2H, m), 2.35-1.15(14H, m)


Purity > 90% (NMR)


MS 694 (M + 1)









 









TABLE 226







Example No. 344
1H NMR (δ) ppm







300MHz, DMSO-d6 8.30(1H, s), 8.23(1H, d, J=8.7Hz), 8.02(1H, d, J=8.4Hz), 7.71(2H, d, J=8.7Hz), 7.55-7.15(8H, m), 7.07(1H, dd, J= 8.4Hz, 3.0Hz), 5.07(2H, s), 4.35(1H, m), 4.17(2H, t, J=4.5Hz), 3.69(2H, t, J=4.5Hz), 3.32(3H, s), 2.40-2.15(2H, m), 2.10-1.80(4H, m), 1.75-1.60(1H, m), 1.50-1.20(3H, m)


Purity > 90% (NMR)


MS 611 (M + 1)


Example No. 345
1H NMR (δ) ppm







300MHz, DMSO-d6 8.29(1H, d, J=1.5Hz), 8.22(1H, d, J=8.7Hz), 8.01(1H, d, J=8.7Hz), 7.70(1H, d, J=8.7Hz), 7.50-7.15(8H, m), 7.07(1H, dd, J=8.4Hz, 2.4Hz), 5.07(2H, s), 4.35(1H, m), 4.17(2H, t, J=4.2Hz), 3.76(2H, t, J=4.5Hz), 3.65-3.40(4H, m), 3.25(3H, s), 2.40-2.20(2H, m), 2.10-1.80(4H, m), 1.75- 1.65(1H, m), 1.65-1.20(3H, m)


Purity > 90% (NMR)


MS 655 (M + 1)


Example No. 346
1H NMR (δ) ppm







300Mz, DMSO-d6 8.26(1H, d, J=1.9Hz), 8.23(1H, d, J=1.5Hz), 8.08-8.02(2H, m), 7.91(1H, dd, J=8.7, 1.5Hz), 7.63 and 7.16(4H, Abq, J=8.9Hz), 7.56-7.51(5H, m), 5.15(2H, s), 4.29(1H, brt, J=11.7Hz), 2.96(2H, d, J=6.9Hz), 2.37-2.12(3H, m), 2.00-1.79(4H, brm), 1.71- 1.60(1H, brm) 1.49-1.19(3H, brm), 0.97 and 0.95(total 6H, each s)


Purity > 90% (NMR)


MS 621 (M + 1)









 









TABLE 227







Example No. 347
1H NMR (δ) ppm







300Mz, DMSO-d6 8.26(1H, s) , 8.22(1H, s), 8.06(1H, s), 8.05(1H, d, J=8.0Hz), 7.94 and 7.85(2H, ABq, J=8.8Hz), 7.59 and 7.15(4H, A′B′q, J=8.6Hz), 7.52(4H, s), 7.44(1H, d, J=8.0Hz), 5.12(2H, s), 4.27(1H, brt, J=11.4Hz), 2.38- 2.18(2H, brm), 1.97-1.77(4H, brm), 1.70-1.59(1H, brm), 1.49-1.17(3H, brm)


Purity > 90% (NMR)


MS 634 (M + 1)


Example No. 348
1H NMR (δ) ppm







300MHz, DMSO-d6 8.32(1H, s), 8.29(1H, d, J= 9.0Hz), 8.06(1H, d, J=8.7Hz), 7.74(2H, d, J= 9.0Hz), 7.72(1H, brs), 7.60-7.45(5H, m), 7.42(1H, d, J=7.8Hz), 7.24(2H, d, J=8.7Hz), 5.15(2H, s), 4.37(1H, m), 4.00-3.10(6H, m), 2.40-2.18(2H, m), 2.15-1.95(2H, m), 1.90-1.80(2H, m), 1.75-1.20(6H, m)


Purity > 90% (NMR)


MS 680 (M + 1)


Example No. 349
1H NMR (δ) ppm







300MHz, DMSO-d6 8.41(1H, d, J=1.5Hz), 8.33(1H, d, J=1.5Hz), 8.26(1H, d, J=8.7Hz), 8.18(1H, dd, J=2.0Hz, 8.0Hz), 8.04(1H, dd, J= 1.5Hz, 9.0Hz), 7.75(2H, d, J=8.7Hz), 7.63(1H, d, J=8.1Hz), 7.62-7.45(4H, m), 7.26(2H, d, J=8.7Hz), 5.25(2H, s), 4.35(1H, m), 2.45(3H, s), 2.40- 2.18(2H, m), 


#2.15-1.95(2H, m), 1.90-1.80(2H, m), 1.75-1.55(1H, m), 1.50-1.20(3H, m)


Purity > 90% (NMR)


MS 619 (M + 1)









 









TABLE 228







Example No. 350
1H NMR (δ) ppm







300MHz, DMSO-d6 8.36(1H, d, J=7.7Hz), 8.29(1H, s), 8.23(1H, d, J=8.8Hz), 8.02(1H, d, J=8.6Hz), 7.94(1H, d, J=7.9Hz), 7.84(1H, d, J=1.6Hz), 7.80-7.65(3H, m), 7.53(4H, s), 5.15(2H, s), 4.34(1H, m), 4.12(1H, m), 2.35- 2.20(2H, m), 2.10-1.60(5H, m), 1.50-1.20(3H, m), 1.17(6H, d, J=6.5Hz)


Purity > 90% (NMR)


MS 622 (M + 1)


Example No. 351
1H NMR (δ) ppm







300MHz, DMSO-d6 8.29(1H, s), 8.24(1H, d, J=8.8Hz), 8.02(1H, d, J=8.6Hz), 7.80-7.65(3H, m), 7.55-7.45(5H, m), 7.32(1H, d, J=1.5Hz), 7.22(2H, d, J=8.8Hz), 5.13(2H, s), 4.35(1H, m), 3.60(2H, m), 3.33(2H, m), 2.40-2.15(2H, m), 2.10-1.15(14H, m)


Purity > 90% (NMR)


MS 648 (M + 1)


Example No. 352
1H NMR (δ) ppm







300MHz, DMSO-d6 13.20(1H, brs), 8.30-8.24(2H, m), 8.13(1H, s), 8.04(1H, d, J=8.7Hz), 7.94(1H, d, J=8.0Hz), 7.75-7.70(3H, m), 7.55-7.43(5H, m), 7.25(2H, d, J= 8.7Hz), 5.13(2H, s), 4.36(1H, m), 3.53(2H, s), 2.40- 2.18(2H, m), 2.15-1.95(2H, m), 1.90-1.80(2H, m), 1.75- 1.55(1H, m), 1.50-1.20(9H, m)


Purity > 90% (NMR)


MS 652 (M + 1)









 









TABLE 229







Example No. 353
1H NMR(δ)ppm







300MHz, DMSO-d6 8.41(1H, s), B, 8.33-8.29(2H, m), 8.16(1H, d, J=8.2Hz), 8.07(1H, d, J=8.6Hz), 7.77(2H, d, J=8.7Hz), 7.62(1H, d, J=8.0Hz), 7.59- 7.51(4H, m), 7.28(2H, d, J=8.8Hz), 5.21(2H, s), 4.56(2H, s), 4.37(1H, m), 2.40-2.18(2H, m), 2.15- 1.95(2H,m), 1.90-1.80(2H, m), 1.75-1.55(1H, m), 1.50-1.20(9H, m)


Purity about 90%(NMR)


MS 634 (M+1)


Example No. 354
1H NMR(δ)ppm







300MHz, DMSO-d6 8.31(1H, s), 8.25(1H, d, J= 9.0Hz), 8.03(1H, d, J=8.7Hz), 7.76-7.71(3H, m), 7.51-7.47(5H, m), 7.33(1H, s), 7.23(2H, d, J= 9.0Hz), 5.14(2H, s), 4.36(1H, m), 4.02(1H, m), 3.75(1H, m), 3.56(1H, m), 3.22(2H, m), 2.40- 2.18(2H, m), 2.15-1.95(2H, m), 1.90-1.55(5H, m), 1.50-1.20(5H, m)


Purity >90%(NMR)


MS 664 (M+1)


Example No. 355
1H NMR(δ)ppm







300MHz, DMSO-d6 8.62(1H, t, J=5.7Hz), 8.32- 8.30(2H, m), 8.25(1H, d, J=8.7Hz), 8.03(1H, d, J= 8.7Hz), 7.96(1H, d, J=8.1Hz), 7.86(1H, s), 7.75(1H, d, J=9.0Hz), 7.72(2H, d, J=9.0Hz), 7.55-7.50(4H, m), 7.22(2H, d, J=9.0Hz), 5.17(2H, s), 4.35(1H, m), 3.52(2H, t, J=6.0Hz), 3.36(2H, t, J=6.0Hz), 2.40- 2.18(2H, m), 


# 2.15-1.95(2H, m), 1.90-1.80(2H, m), 1.75-1.55(1H, m), 1.50-1.20(3H, m)


Purity >90%(NMR)


MS 624 (M+1)









 









TABLE 230







Example No. 356
1H NMR(δ)ppm







300Mz, DMSO-d6 9.30(1H, t, J=5.9Hz), 8.54(2H, d, J= 5.9Hz), 8.22(1H, s), 8.02-7.79(5H, m), 7.59 and 7.12(4H, ABq, J=8.6Hz), 7.55(4H, s), 7.37(2H, d, J=5.9Hz), 5.15(2H, s), 4.54(2H, d, J=5.7Hz), 4.26(1H, brt, J=12.8Hz), 2.36- 2.18(2H, brm), 1.97-1.78(4H, brm), 1.70-1.60(1H, brm), 1.47-1.17(3H, brm)


Purity >90%(NMR)


MS 671 (M+1)


Example No. 357
1H NMR(δ)ppm







300Mz, DMSO-d6 8.31(1H, d, J=1.5Hz), 8.43(1H, d, J= 8.4Hz), 8.03(1H, dd, J=8.4, 1.5Hz), 7.74(1H, d, J=8.1Hz), 7.73 and 7.23(4H, ABq, J=9.0Hz), 7.54-7.51(5H, m), 7.37(1H, d, J=1.8Hz), 5.14(2H, s), 4.36(1H, brt, J=12.1Hz), 2.98(6H, brs), 2.37-2.20(2H, brm), 2.08-1.81(4H, brm), 1.70-1.60(1H, brm), 1.50-1.21(3H, brm)


Purity >90%(NMR)


MS 608 (M+1)


Example No. 358
1H NMR(δ)ppm







300MHz, DMSO-d6 8.33(1H, s), 8.31(1H, d, J=8.7Hz), 8.14(1H, s), 8.07(1H, d, J=8.7Hz), 7.92(1H, d, J=8.0Hz), 7.76(2H, d, J=8.7Hz), 7.52-7.40(5H, m), 7.31-7.26(3H, m), 5.15(2H, s), 4.37(1H, m), 2.40-2.18(2H, m), 2.15-1.95(2H, m), 1.90-1.80(2H, m), 1.75-1.55(1H, m), 1.50-1.20(3H, m)


Purity about 90%(NMR)


MS 635 (M+1)









 









TABLE 231







Example No. 359
1H NMR(δ)ppm







300MHz, DMSO-d6 8.31(1H, s), 8.25(1H, d, J= 8.7Hz), 8.10-7.90(2H, m), 7.82(1H, dd, J=7.8Hz, 1.8Hz), 7.72(2H, d, J=9.0Hz), 7.63(1H, d, J= 8.1Hz), 7.23(2H, d, J=9.0Hz), 5.25(2H, s), 4.34(1H, m), 3.65-3.50(1H, m), 3.20-3.05(2H, m), 2.90- 2.75(2H, m), 2.40-2.15(2H, m), 2.10-1.10(12H, m)


Purity >90%(NMR)


MS 700 (M+1)


Example No. 360
1H NMR(δ)ppm







300MHz, DMSO-d6 8.33(1H, s), 8.30(1H, d, J= 8.5Hz), 8.06(1H, d, J=10.1Hz), 8.80-8.65(3H, m), 8.60-8.45(3H, m), 7.42(1H, d, J=7.8Hz), 7.35- 7.15(4H, m), 5.15(2H, s), 4.36(1H, m), 3.01, 2.97(6H, s), 2.40-2.15(2H, m), 2.10-1.75(4H, m), 1.70-1.55(1H, m), 1.50-1.20(3H, m)


Purity >90%(NMR)


MS 592 (M+1)


Example No. 361
1H NMR(δ)ppm







300MHz, DMSO-d6 8.35-8.20(2H, m), 8.05(1H, d, J=8.7Hz), 8.80-8.65(3H, m), 7.60-7.40(3H, m), 7.40-7.30(5H, m), 5.17(2H, s), 4.35(1H, m), 3.01, 2.97(6H, s), 2.40-2.15(2H, m), 2.10-1.80(4H, m), 1.70-1.20(4H, m)


Purity >90%(NMR)


MS 592 (M+1)









 









TABLE 232







Example No. 362
1H NMR(δ)ppm







300MHz, DMSO-d6 8.33(1H, s), 8.29(1H, d, J=8.7Hz), 8.06(1H, d, J=8.7Hz), 7.79(2H, d, J=9.0Hz), 7.76(1H, d, J=9.0Hz), 7.60(1H, d, J=8.1Hz), 7.53(1H, dd, J=1.7Hz, 8.0Hz), 7.35(2H, d, J=8.7Hz), 6.85-6.80(2H, m), 5.29(2H, s), 4.38(1H, m), 3.01, 2.96(6H, s), 2.40-2.18(2H, m), 2.15-1.95(2H, m), 1.90-1.80(2H, m), 1.75- 1.55(1H, m), 1.50-1.20(3H, m)


Purity >90%(NMR)


MS 614 (M+1)


Example No. 363
1H NMR(δ)ppm







300MHz, DMSO-d6 8.28(1H, d, J=1.3Hz), 8.20-8.10(2H, m), 8.98(1H, d, J=8.6Hz), 7.90-7.80(2H, m), 7.75(2H, d, J=8.7Hz), 7.36(2H, d, J=8.7Hz), 7.04(1H, d, J=1.3Hz), 5.35(2H, s), 4.36(1H, m), 2.39(3H, s), 2.35-2.15(2H, m), 2.05-1.75(4H, m), 1.70-1.60(1H, m), 1.50-1.20(3H, m)


Purity >90%(NMR)


MS 586 (M+1)


Example No. 364
1H NMR(δ)ppm







300MHz, DMSO-d6 8.31(1H, s), 8.26(1H, d, J=8.7Hz), 8.13(1H, s), 8.04(1H, d, J=9.0Hz), 7.90-7.70(4H, m), 7.65(1H, s), 7.39(2H, d, J=9.0Hz), 5.37(2H, s), 4.38(1H, m), 2.40-2.20(2H, m), 2.15- 2.00(2H, m), 1.95-1.80(2H, m), 1.75-1.60(1H, m), 1.50-1.20(3H, m)


Purity >90%(NMR)


MS 604 (M+1)









 









TABLE 233







Example No. 365
1H NMR(δ)ppm







300MHz, DMSO-d6 8.28(1H, s), 8.23(1H, s), 8.17(1H, d, J= 8.7Hz), 8.00(2H, t, J=6.9Hz), 7.69(2H, d, J=8.4Hz), 7.60- 7.45(5H, m), 7.21(2H, d, J=8.4Hz), 7.05(1H, s), 5.19(2H, s), 4.33(1H, m), 2.41(3H, s), 2.40-2.20(2H, m), 2.10-1.80(4H, m), 1.70-1.60(1H, m), 1.50-1.20(3H, m)


Purity >90%(NMR)


MS 618 (M+1)


Example No. 366
1H NMR(δ)ppm







300MHz, DMSO-d6 8.26(1H, s), 8.17(1H, s), 8.11(1H, d, J= 8.7Hz), 7.95(2H, d, J=9.6Hz), 7.70-7.40(8H, m), 7.19(2H, d, J= 8.4Hz), 5.18(2H, s), 4.30(1H, m), 2.51(3H, s), 2.40-2.15(2H, m), 2.05-1.80(4H, m), 1.75-1.60(1H, m), 1.50-1.20(3H, m)


Purity >90%(NMR)


MS 634 (M+1)


Example No. 367
1H NMR(δ)ppm







300Mz, DMSO-d6 8.42(1H, d, J=1.9Hz), 8.30(1H, J=1.5Hz), 8.27(1H, d, J=8.7Hz), 8.18(1H, dd, J=7.9, 1.9Hz), 8.04(1H, dd, J=8.7, 1.5Hz), 7.75 and 7.29(4H, ABq, J=8.9Hz) 7.63(1H, d, J= 7.9Hz), 5.23(2H, s), 4.36(1H, brt, J=12.3Hz) 2.37-2.20(2H, brm), 2.08-1.80(4H, brm), 1.71-1.60(1H, brm), 1.51-1.21(3H, brm)


Purity >90%(NMR)


MS 605 (M+1)









 









TABLE 234







Example No. 368
1H NMR(δ) ppm







300 MHz, DMSO-d6 8.30(1H, d,  J=1.5Hz), 8.25(1H, d, J=8.6Hz), 8.04(1H, dd, J=8.6, 1.5Hz), 7.93 and 7.67(4H, ABq, J=8.1Hz), 7.80(1H, d, J=2.2Hz), 7.72 and 7.21(4H, A′B′q, J=8.6Hz), 7.60(1H, dd, J=8.1, 2.2Hz), 7.44(1H, d, J=8.1Hz), 5.13(2H, s), 4.34(1H, brt, J=11.7Hz), 2.37- 2.19(2H, brm), 2.09-1.80(4H, brm), 1.72- 1.60(1H, brm), 1.50- 1.21(3H, brm)


Purity >90%(NMR)


MS 562(M+1)


Example No. 369
1H NMR(δ) ppm







300 MHz, DMSO-d6 8.30(1H, d, J=1.5Hz), 8.25(1H, d, J=8.6Hz), 8.16 and 7.72(4H, ABq, J=8.4Hz), 8.13(1H, dd, J=8.6, 1.5Hz), 7.80(1H, d, J=2.2Hz), 7.70 and 7.24(4H, A′B′q, J=8.8Hz), 7.61(1H, dd, J=8.1, 2.2Hz), 7.48(1H, d, J=8.1Hz), 5.17(2H, s), 4.33(1H, brt, J=12.1Hz), 2.36- 2.18(2H, brm), 2.08-1.77(4H, brm), 1.69- 1.57(1H, brm), 1.49- 1.17(3H, brm)


Purity >90%(NMR)


MS 605(M+1)


Example No. 370
1H NMR(δ) ppm







300 MHz, DMSO-d6 10.94(1H, brs), 8.33(1H, s), 8.27 (1H, d, J=8.7Hz), 8.04(1H, d, J=8.7Hz), 7.74(2H, d, J=8.4Hz), 7.56-7.29(6H, m), 7.23(2H, d, J=8.7Hz), 7.13(1H, d, J=8.7Hz), 5.08(2H, s), 4.51(2H, brs), 4.36 (1H, m), 3.94(1H, brs), 3.75- 3.00(6H, m), 3.20-1.20(14H, m)


Purity >90%(NMR)


MS 680(M+1)









 









TABLE 235







Example No. 371
1H NMR(δ)ppm







300MHz, DMSO-d6 8.31(1H, d, J=1.5Hz), 8.17(1H, d, J=9.0Hz) 7.99(1H, dd, J=8.7Hz, 1.4Hz), 7.70-7.55(2H, m), 7.50-7.30(6H, m), 7.19(1H, dd, J=12.0Hz, 2.2Hz), 7.06(1H, dd, J=8.6Hz, 2.2Hz), 5.08(2H, 4.10(1H, m), 3.68(2H, brt, J=5.2), 2.50(2H, brt, J=1.8Hz), 2.30-2.10(2H, m), 2.00-1.75(8H, m), 1.70-1.55(1H, m), 1.50- 1.20(3H, m)


Purity >90%(NMR)


MS 652 (M+1)


Example No. 372
1H NMR(δ)ppm







300Mz, DMSO-d6 8.29(1H, d, J=1.5Hz), 8.11(1H, d, J=8.6Hz), 7.96(1H, dd, J=8.6, 1.5Hz), 7.89(1H, s), 7.78 and 7.56(4H, ABq, J= 8.4Hz), 7.69(1H, s), 7.66(1H, t, J=8.5Hz), 7.31(1H, dd, J=12.1, 2.2Hz), 7.18(1H, dd, J=8.8, 2.2Hz), 5.37(2H, s), 4.08(1H, brt, J= 11.0Hz), 3.02(3H, s), 2.96(3H, s), 2.31-2.14(2H, brm), 1.95- 1.77(4H, brm,) 1.69-1.59(31H, brm), 1.46-1.18(3H, brm)


Purity >90%(NMR)


MS 626 (M+1)


Example No. 373
1H NMR(δ)ppm







300MHz, DMSO-d6 11.40(1H, brs), 9.25(2H, brs), 8.29(1H, d, J= 1.3Hz), 8.12-8.09(2H, m), 7.96(1H, d, J=8.7Hz), 7.88(1H, dd, J= 1.8Hz, 8.1Hz), 7.67-7.63(2H, m), 7.56(2H, d, J=8.7Hz), 7.51(2H, d, J=8.7Hz), 7.17(1H, d, J=12.0Hz), 7.05(1H, d, J=8.6Hz), 5.16(2H, s), 4.05(1H, m), 2.40-2.10(2H, m), 2.00-1.75(4H, m), 1.70- 1.55(1H, m), 1.50-1.20(3H, m)


Purity >90%(NMR)


MS 613 (M+1)









 









TABLE 236







Example No. 374
1H NMR(δ)ppm







300MHz, DMSO-d6 13.21(1H, brs), 8.31(1H, d, J=1.4Hz), 8.18-8.15(2H, m), 7.99(1H, d, J=8.7Hz), 7.94(1H, dd, J=1.8Hz, 8.0Hz), 7.70-7.53(6H, m), 7.17(1H, d, J=12.0Hz), 7.05(1H, d, J=8.6Hz), 5.20(2H, s), 4.09(1H, m), 2.40-2.10(2H, m), 2.00- 1.75(4H, m), 1.70-1.55(1H, m), 1.50-1.20(3H, m)


Purity >90%(NMR)


MS 639 (M+1)


Example No. 375
1H NMR(δ)ppm







300MHz, DMSO-d6 8.32(1H, d, J=1.5Hz), 8.23(1H, d, J= 1.5Hz), 8.19(1H, d, J=9.0Hz), 8.03-7.98(2H, m), 7.68(1H, t, J=8.4Hz), 7.60(1H, d, J=8.1Hz), 7.56(2H, d, J=9.3Hz), 7.53(2H, d, J=9.0Hz), 7.22(1H, dd, J=2.1Hz, 12.0Hz), 7.09(1H, dd, J= 2.1Hz, 8.4Hz), 5.21(2H, s), 4.12(1H, m), 2.40-2.10(2H, m), 2.00-1.75(4H, m), 1.70-1.55(1H, m), 1.50-1.20(3H, m)


Purity >90 (NMR)


MS 658 (M+1)


Example No. 376
1H NMR(δ)ppm







300MHz, DMSO-d6 13.61(1H, brs), 8.34-8.30(2H, m), 8.21(1H, d, J=8.7Hz), 8.07(1H, dd, J=1.8Hz, 8.1Hz), 8.02(1H, dd, J=1.5Hz, 8.7Hz), 7.69(1H, t, J=8.4Hz), 7.57-7.49(5H, m), 7.22(1H, dd, J=2.7Hz, 12.0Hz), 7.09(1H, dd, J=2.4Hz, 9.0Hz), 5.19(2H, s), 4.12(1H, m), 2.40-2.10(2H, m), 2.00-1.75(4H, m), 1.70-1.55(1H, m), 1.50-1.20(3H, m)


Purity >90%(NMR)


MS 655 (M+1)









 









TABLE 237







Example No. 377
1H NMR(δ)ppm







300Mz, DMSO-d6 8.60(1H, d, J=4.5Hz), 8.29(1H, d, J=1.5Hz), 8.14(1H, d, J=8.9Hz), 8.13(1H, d, J=1.5Hz), 7.98(1H, dd, J= 8.9, 1.5Hz), 7.94(1H, dd, J=8.1, 1.5Hz), 7.64(1H, t, J=8.7Hz), 7.52 and 7.49(4H, ABq, J=9.0Hz), 7.46(1H, d, J=8.1Hz), 7.18(1H, dd, J=12.1, 2.3Hz), 7.05(1H, dd, J=8.7, 2.3Hz), 5.13(2H, s), 4.08(1H, brt, 


# J=12.1H), 2.95-2.84(1H, m), 2.31- 2.14(2H, brm), 1.97-1.78(4H, brm), 1.72-1.59(1H, brm), 1.47- 1.21(3H, brm), 0.76-0.58(4H, m)


Purity >90%(NMR)


MS 638 (M+1)


Example No. 378
1H NMR(δ)ppm







300Mz, DMSO-d6 8.77(1H, d, J=1.4Hz), 8.30(1H, d, J=1.4Hz), 8.16(1H, d, J=1.8Hz), 8.13(1H, d, J=8.4Hz), 7.98(2H, dd, J=8.4, 1.8Hz), 7.65(1H, t, J=8.4Hz), 7.53 and 7.49(4H, ABq, J= 8.8Hz), 7.47(1H, d, J=7.7Hz), 7.18(1H, dd, J=12.1, 2.2Hz), 7.05(1H, dd, J=8.4, 2.2Hz), 5.13(2H, s), 4.53-4.40(1H, m), 4.09(1H, brt, 


# J=12.8Hz), 2.31-2.02(6H, brm,), 1.96-1.80(4H, brm), 1.78-1.60(3H, brm), 1.47-1.21(3H, brm)


Purity >90%(NMR)


MS 652 (M+1)


Example No. 379
1H NMR(δ)ppm







300Mz, DMSO-d6 8.29(1H, d, J=1.1Hz), 8.11(1H, d, J=1.5Hz), 8.11(1H, d, J=8.8Hz), 7.98-7.91(2H, m), 7.89(1H, s), 7.63(1H, t, J=8.8Hz), 7.52 and 7.48(4H, ABq, J=8.6Hz), 7.44(1H, d, J= 8.1Hz), 7.17(1H, dd, J=12.1, 2.2Hz), 7.04(1H, dd, J=8.8, 2.2Hz), 5.12(2H, s), 4.07(1H, brt, J=12.4Hz), 2.33-2.14(2H, brm), 


# 1.96-1.79(4H, brm), 1.70-1.60(1H, brm), 1.48-1.21(3H, brm), 1.41(9H, s)


Purity >90%(NMR)


MS 654 (M+1)









 









TABLE 238







Example No. 380
1H NMR(δ)ppm







300Mz, DMSO-d6 8.62(1H, t, J=5.5Hz), 8.30(1H, d, J= 1.5Hz), 8.17(1H, d, J=1.8Hz), 8.14(1H, d, J=8.8Hz), 7.98(1H, dd, J=8.1, 1.8Hz), 7.64(1H, t, J=8.8Hz), 7.52 and 7.50(4H, ABq, J=8.8Hz), 7.48(1H, d, J=8.1Hz), 7.18(1H, dd, J=12.1, 2.2Hz), 7.05(1H, dd, J=8.8, 2.2Hz), 5.14(2H, s), 4.08(1H, brt, J=12.1Hz), 3.13(1H, t, J=6.2Hz), 2.31- 2.14(2H, brm), 


# 1.97-1.78(5H, brm), 1.70-1.60(1H, brm), 1.47-1.21(3H, brm), 0.92(3H, s), 0.90(3H,s)


Purity >90%(NMR)


MS 654 (M+1)


Example No. 381
1H NMR(δ)ppm







300Mz, DMSO-d6 8.29(1H, d, J=1.5Hz), 8.27(1H, d, J= 8.3Hz), 8.18(1H, d, J=1.9Hz), 8.13(1H, d, J=8.7Hz), 8.01- 7.96(2H, m), 7.64(1H, t, J=8.7Hz), 7.52 and 7.49(1H, ABq, J=8.8Hz), 7.49(1H, d, J=7.9Hz), 7.18(1H, dd, J=12.1, 2.3Hz), 7.05(1H, dd, J=8.7, 2.3Hz), 5.13(2H, s), 4.12- 4.00(2H, m), 3.52-3.34(2H, m), 2.31-2.14(2H, brm), 1.97- 1.79(4H, brm), 


# 1.71-1.60(1H, brm), 1.48-1.21(3H, m), 1.17 and 1.15(total 3H, each s)


Purity >90%(NMR)


MS 656 (M+1)


Example No. 382
1H NMR(δ)ppm







300Mz, DMSO-d6 8.30(1H, d, J=1.5Hz), 8.13(1H, d, J= 8.8Hz), 8.09(1H, d, J=1.5Hz), 7.98(1H, dd, J=8.8, 1.5Hz), 7.86(1H, dd, J=8.1, 1.5Hz), 7.64(1H, J=8.8Hz), 7.55- 7.47(5H, m), 7.17(1H, dd, J=12.1, 2.2Hz), 7.05(1H, dd, J= 8.8, 2.2Hz), 5.14(2H, s), 4.08(1H, brt, J=12.8Hz), 3.75(3H, s), 2.32-2.14(2H, brm), 1.96-1.78(4H, brm), 1.70-1.59(1H, brm), 1.47-1.21(3H, brm)


Purity >90%(NMR)


MS 628 (M+1)









 









TABLE 239







Example No. 383
1H NMR(δ)ppm







300Mz, DMSO-d6 8.57(1H, t, J=5.5Hz), 8.29(1H, d, J=1.4Hz), 8.19(1H, d, J=1.5Hz), 8.12(1H, d, J= 9.2Hz), 8.01-7.95(2H, m), 7.64(1H, t, J=8.8Hz), 7.53 and 7.50(4H, ABq, J=8.8Hz), 7.48(1H, d, J= 7.7Hz), 7.17(1H, dd, J=12.1, 2.2Hz), 7.04(1H, dd, J=8.8, 2.2Hz), 5.14(2H, s), 4.08(1H, brt, J=13.9Hz), 3.70-3.66(1H, m), 


# 3.48-3.36(3H, m), 3.28- 3.20(1H, m), 2.32-2.13(2H, brm), 1.96-1.79(4H, brm), 1.71-1.60(1H, brm), 1.47-1.19(3H, brm)


Purity >90%(NMR)


MS 672 (M+1)


Example No. 384
1H NMR(δ)ppm







300Mz, DMSO-d6 8.30(1H, d, J=1.5Hz), 8.14(1H, d, J=8.4Hz), 7.98(1H, dd, J=8.4, 1.5Hz), 7.68(1H, brs), 7.63(1H, t, J=8.4Hz), 7.51(5H, s), 7.43(1H, d, J=8.1Hz), 7.17(1H, dd, J=12.5, 1.8Hz), 7.03(1H, dd, J=8.4, 1.8Hz), 4.08(1H, brt, J=11.4Hz), 3.50 and 3.30(total 2H, each brs), 2.97(3H, brs), 2.33- 2.13(2H, 


# brm), 1.96-1.79(4H, brm), 1.70-1.59(1H, brm), 1.47-1.03(6H, brm)


Purity >90%(NMR)


MS 640 (M+1)


Example No. 385
1H NMR(δ)ppm







300Mz, DMSO-d6 8.29(1H, d, J=1.5Hz), 8.12(1H, d, J=8.8Hz), 7.97(1H, dd, J=8.8, 1.5Hz), 7.72- 7.60(2H, m), 7.55-7.42(6H, m), 7.16(1H, d, J= 11.7Hz), 7.03(1H, d, J=8.4Hz), 5.15(2H, s), 4.07(1H, brt, J=12.5Hz), 3.44 and 3.22(total 2H, each s), 2.97(3H, brs), 2.32-2.13(2H, brm), 1.72- 1.50(3H, brm), 1.47-1.23(3H, brm), 


# 0.93 and 0.72(total 3H, each brs)


Purity >90%(NMR)


MS 654 (M+1)









 









TABLE 240







Example No. 386
1H NMR(δ)ppm







300Mz, DMSO-d6 8.29(1H, d, J=1.5Hz), 8.12(1H, d, J=8.7Hz), 7.97(1H, dd, J=8.7, 1.5Hz) 7.74-7.60(2H, m), 7.54-7.42(6H, m), 7.17(1H, dd, J=12.1, 2.2Hz), 7.02(1H, dd, J=8.3, 2.2Hz), 5.15(2H, s), 4.06(1H, brt, J=12.8Hz), 3.92(1H, brs), 2.85(3H, brs), 2.32- 2.14(2H, brm), 1.96-1.79(4H, brm), 1.70-1.59(1H, brm), 1.46-1.07(3H, brm), 1.15(6H, brs)


Purity >90%(NMR)


MS 654 (M+1)


Example No. 387
1H NMR(δ)ppm







300Mz, DMSO-d6 8.29(1H, s), 8.14 and 7.97(2H, ABq, J=8.7Hz), 7.63(1H, s), 7.63(1H, t, J=8.7Hz), 7.51-7.41(6H, m), 7.16(1H, dd, J=12.1, 1.9Hz), 7.02(1H, dd, J=8.7, 1.9Hz), 5.16(2H, s), 4.26(2H, brs), 4.07(1H, brt, J=12.1Hz), 2.32-2.14(2H, brm), 1.97-1.78(5H, brm) 1.70-1.15(9H, brm), 1.24(3H, s), 1.21(3H, s)


Purity >90%(NMR)


MS 694 (M+1)


Example No. 388
1H NMR(δ)ppm







300MHz, DMSO-d6 8.58(1H, m), 8.29(1H, s), 8.20- 8.10(2H, m), 8.05-7.90(2H, m), 7.64(1H<t, J=8.4Hz), 7.60-7.40(5H, m), 7.15(1H, d, J=12.3Hz), 7.04(1H, d, J=8.4Hz), 5.13(2H, s), 4.08(1H, m), 3.40-3.20(2H, m), 2.35-2.10(2H, m), 2.00-1.20(12H, m), 0.91(3H, t, J=6.9Hz)


Purity >90%(NMR)


MS 654 (M+1)









 









TABLE 241







Example No. 389
1H NMR(δ)ppm







300MHz, DMSO-d6 8.60(1H, m), 8.29(1H, s), 8.20-7.90(4H, m), 7.64(1H, t, J=9.0Hz), 7.60-7.40(5H, m), 7.17(1H, d, J= 12.0Hz), 7.04(1H, d, J=8.7Hz), 5.13(2H, s), 4.80(1H, m), 3.35-3.15(2H, m), 2.30-2.05(2H, m), 2.00-1.10(10H, m), 0.91(3H, t, J=7.5Hz)


Purity >90%(NMR)


MS 640 (M+1)


Example No. 390
1H NMR(δ)ppm







300MHz, DMSO-d6 8.62(1H, m), 8.30(1H, s), 8.20-8.10(2H, m), 8.05-7.90(2H, m), 7.65(1H, t, J=8.4Hz), 7.60-7.40(5H, m), 7.18(1H, d, J=12.0Hz), 7.05(1H, d, J=8.4Hz), 5.14(2H, s), 4.09(1H, m), 3.40-3.20(2H, m), 2.35-2.10(2H, m), 2.00- 1.80(4H, m), 1.75-1.60(1H, m), 1.45-1.20(3H, m), 1.15(3H, t, J=7.2Hz)


Purity >90%(NMR)


MS 626 (M+1)


Example No. 391
1H NMR(δ)ppm







400NHz, DMSO-d6 8.54(1H, s), 8.31(1H, s), 8.19(1H, d, J= 8.6Hz), 8.01(1H, d, J=8.6Hz), 7.81(1H, d, J=2.1Hz), 7.64(1H, t, J=8.4Hz), 7.61(1H, dd, J=2.3Hz, 8.4Hz), 7.47(2H, d, J= 8.6Hz), 7.43(2H, d, J=8.8Hz), 7.25(1H, d, J=8.4Hz), 7.17(1H, dd, J=2.3Hz, 12.1Hz), 7.05(1H, dd, J=2.3Hz, 8.6Hz), 5.05(2H, s), 4.12(1H, m), 2.96(6H, 


# s), 2.40-2.10(2H, m), 2.00-1.75(4H, m), 1.70-1.55(1H, m), 1.50-1.20(3H, m)


Purity >90%(NMR)


MS 641 (M+1)









 









TABLE 242







Example No. 392
1H NMR(δ)ppm







300Mz, DMSO-d6 8.79(1H, s), 8.29(1H, d, J=1.5Hz), 8.13(1H, d, J=8.8Hz), 7.98(1H, dd, J=8.8, 1.5Hz), 7.80(1H, d, J=2.2Hz), 7.63(1H, t, J=8.4Hz), 7.61(1H, dd, J=8.2, 2.2Hz), 7.47 and 7.43(4H, ABq, J=8.8Hz), 7.26(1H, d, J= 8.2Hz), 7.14(1H, dd, J=12.1, 2.2Hz), 7.02(1H, dd, J=8.4, 2.2Hz), 5.05(2H, s), 4.08(1H, 


# brt, J=12.1Hz), 3.64-3.61(2H, m), 3.48-3.45(2H, m), 2.32-2.13(2H, brm), 1.96-1.78(4H, brm), 1.70-1.66(1H, brm), 1.44-1.19(3H, brm)


Purity >90%(NMR)


MS 683 (M+1)


Example No. 393
1H NMR(δ)ppm







400MHz, DMSO-d6 8.94(1H, s), 8.31(1H, d, J=1.0Hz), 8.18(1H, d, J=8.6Hz), 8.00(1H, dd, J=1.4Hz, 8.8Hz), 7.71(1H, d, J=2.2Hz), 7.66(1H, t, J=8.6Hz), 7.52(1H, dd, J= 2.4Hz, 8.6Hz), 7.46(2H, d, J=8.6Hz), 7.42(2H, d, J=8.2Hz), 7.24(1H, d, J=8.4Hz), 7.16(1H, d, J=12.1Hz), 7.04(1H, dd, J= 2.4Hz, 8.8Hz), 5.05(2H, s), 


# 4.13(1H, m), 2.40-2.10(2H, m), 2.00-1.75(4H, m), 1.70-1.55(1H, m), 1.50-1.20(3H, m)


Purity >90%(NMR)


MS 613 (M+1)


Example No. 394
1H NMR(δ)ppm







300MHz, DMSO-d6 8.93(1H, s), 8.31(1H, d, J=1.4Hz), 8.19(1H, d, J=8.8Hz), 8.01(1H, d, J=8.7Hz), 7.71(1H, d, J= 2.2Hz), 7.66(1H, t, J=8.5Hz), 7.51(1H, dd, J=2.2Hz, 8.4Hz), 7.46(2H, d, J=8.6Hz), 7.41(2H, d, J=8.7Hz), 7.23(1H, d, J= 8.4Hz), 7.16(1H, d, J=12.2Hz), 7.05(1H, d, J=8.7Hz), 5.05(2H, s), 4.13(1H, m), 3.12(2H, q, 


# J=7.2Hz), 2.40- 2.10(2H, m), 2.00-1.75(4H, m), 1.70-1.60(1H, m), 1.55- 1.20(3H, m), 1.06(3H, t, J=7.2Hz)


Purity >90%(NMR)


MS 641 (M+1)









 









TABLE 243







Example No. 395
1H NMR(δ)ppm







300MHz, DMSO-d6 8.83(1H, s), 8.32(1H, d, J=1.4Hz), 8.21(1H, d, J=8.8Hz), 8.02(1H, dd, J=1.4Hz, 8.7Hz), 7.71(1H, d, J=2.1Hz), 7.68(1H, t, J=8.6Hz), 7.49(1H, dd, J= 2.2Hz, 8.4Hz), 7.46(2H, d, J=8.4Hz), 7.41(2H, d, J=8.6Hz), 7.23(1H, d, J=8.4Hz), 7.17(1H, d, J=12.2Hz), 7.06(1H, d, J= 8.7Hz), 6.30(1H, brs), 


# 5.05(2H, s), 4.14(1H, m), 3.77(1H, sept, J=6.5Hz), 2.40-2.10(2H, m), 2.00-1.75(4H, m), 1.70- 1.55(1H, m), 1.50-1.20(3H, m), 1.11(6H, d, J=6.5Hz)


Purity >90%(NMR)


MS 655 (M+1)


Example No. 396
1H NMR(δ)ppm







300MHz, DMSO-d6 8.37(1H, d, J=7.3Hz), 8.25(1H, s), 8.15(1H, s), 7.97(2H, d, J=8.8Hz), 7.88(1H, d, J=8.8Hz), 7.58-7.47(4H, m), 7.31(1H, m), 7.11(1H, dd, J=8.4, 2.2Hz), 6.98(1H, dd, J=8.4, 2.2), 5.13(2H, s), 4.13(1H, q, J=6.6Hz), 3.98(1H, m), 2.19(2H, m), 1.86(4H, m) 1.62(1H, m) 1.31(3H, m), 1.20(6H, d, J=6.6Hz)


Purity >90%(NMR)


MS 642 (M+1)


Example No. 397
1H NMR(δ)ppm







300MHz, DMSO-d6 8.40(1H, d, J=7.9Hz), 8.28(1H, d, J= 1.9Hz), 8.15(1H, d, J=1.9Hz), 8.11(1H, d, J=8.7Hz), 7.96(2H, m), 7.56(1H, t, J=8.7Hz), 7.45(3H, m), 7.18(1H, m), 7.08(1H, dd, J=12.1, 1.9Hz), 6.96(1H, dd, J=8.3, 2.3Hz), 5.09(2H, s), 4.14(1H, m), 4.04(1H, m), 2.23(2H, m), 1.86(3H, m), 1.62(1H, m), 1.33(3H, m), 1.20(6H, d, J=6.4Hz)


Purity >90%(NMR)


MS 642 (M+1)









 









TABLE 244







Example No. 398
1H NMR(δ)ppm







8.41(1H, d, J=8.1Hz), 8.29(1H, d, J=1.5Hz), 8.17(1H, d, J= 1.8Hz), 8.12(1H, d, J=8.4Hz), 8.01-7.95(2H, m), 7.67-7.62(2H, m), 7.55-7.51(3H, m), 7.19(1H, dd, J=12.1, 2.2Hz), 7.05(1H, dd, J=8.8, 2.2Hz), 5.13(2H, s), 4.10-4.00(2H, m), 2.32- 2.13(4H, m), 1.71-1.60(1H, m), 1.49-1.14(3H, m), 1.21(3H, s), 1.19(3H, s)


Purity >90%(NMR)


MS 674 (M+1)


Example No. 399
1H NMR(δ)ppm







300Mz, DMSO-d6 8.39(1H, d, J=7.7Hz), 8.29(1H, d, J=1.5Hz), 8.16(1H, d, J=1.8Hz), 8.11(1H, d, J=8.8Hz), 8.00-7.95(2H, m), 7.69-7.61(2H, m), 7.54-7.46(3H, m), 7.18(1H, dd, J=12.1, 2.2Hz), 7.04(1H, dd, J=8.8, 2.2Hz), 5.13(2H, s), 4.20-4.02(2H, m), 2.33-2.13(2H, brm), 1.97-1.80(4H, m), 1.72-1.61(1H, m), 1.44-1.13(3H, m), 1.21(3H, s), 1.19(3H, s)


Purity >90%(NMR)


MS 658 (M+1)


Example No. 400
1H NMR(δ)ppm







300MHz, DMSO-d6 8.39(1H, d, J=7.7Hz), 8.29(1H, s), 8.17(1H, d, J=1.5Hz), 8.11(1H, d, J=8.8Hz), 7.98(2H, m), 7.73(2H, m), 7.64(1H, t, J=8.4Hz), 7.52(1H, d, J=8.0Hz), 7.46(1H, dd, J=8.4, 1.8Hz), 7.18(1H, dd, J=11.9, 2.0Hz), 7.05(1H, dd, J=8.6, 2.4Hz), 5.14(2H, s), 4.13(2H, m), 2.22(2H, m), 1.88(4H, m) 1.64(1H, m), 1.34(3H, m), 1.20(6H, d, J=6.6Hz)


Purity >90%(NMR)


MS 642 (M+1)









 









TABLE 245







Example No. 401
1H NMR(δ)ppm







300MHz, DMSO-d6 8.38(1H, d, J=7.8Hz), 8.28(1H, s), 8.20- 8.05(2H, m), 8.00-7.90(2H, m), 7.65-7.30(5H, m), 7.09(1H, d, J=12.3Hz), 6.97(1H, d, J=10.2Hz), 5.09(2H, s), 4.20-4.00(2H, m), 2.30-2.10(2H, m), 2.00-1.80(4H, m), 1.70-1.60(1H, m), 1.40-1.10(3H, m), 1.19(6H, d, J=6.6Hz)


Purity >90%(NMR)


MS 658 (M+1)


Example No. 402
1H NMR(δ)ppm







300MHz, DMSO-d6 8.25(1H, s), 8.03(1H, d, J=8.7Hz), 7.91(1H, d, J=8.7Hz), 7.83(1H, s), 7.70-7.35(6H, m), 7.04(1H, d, J=12.0Hz), 6.93(1H, d, J=8.4Hz), 5.09(2H, s), 4.00(1H, m), 3.60-3.40(4H, m), 2.30-2.10(2H, m), 1.45-1.15(3H, m)


Purity >90%(NMR)


MS 670 (M+1)


Example No. 403
1H NMR(δ)ppm







400MHz, DMSO-d6 8.25(1H, s), 8.08(1H, d, J=8.4Hz), 7.92(1H, d, J=9.2Hz), 7.79(1H, s), 7.66-7.49(4H, m), 7.42(1H, d, J=7.6Hz), 7.31-7.28(1H, m), 7.14(1H, d, J=11.3Hz), 6.99(1H, d, J=8.8Hz), 5.13(2H, s), 4.02(1H, m), 3.54-3.33(4H, m), 2.29-2.08(2H, m), 1.93-1.73(8H, m), 1.67-1.52(1H, m), 1.48-1.11(3H, m)


Purity >90%(NMR)


MS 670 (M+1)









 









TABLE 246







Example No. 404
1H NMR(δ)ppm







400MHz, DMSO-d6 8.41(1H, d, J=7.6Hz), 8.32(1H, d, J= 1.5Hz), 8.20(1H, d J=8.6Hz), 8.17(1H, d, J=1.7H), 8.00(1H, dt, J=8.8Hz, 1.5Hz), 7.71-7.64(2H, m), 7.54(1H, dd, J=10.3Hz, 1.9Hz), 7.32(1H, dd, J=8.2Hz, 1.9Hz), 7.22(1H, dd, J=12.1Hz, 2.3Hz), 7.08(1H, dd, J=8.6Hz), 2.3Hz), 5.17(2H, s), 4.15(1H, m), 2.31-2.14(2H, m), 


# 1.99-1.70(4H, m), 1.70-1.60(1H, m), 1.46-1.20(3H, m), 1.19(6H, d, J=6.6Hz)


Purity >90%(NMR)


MS 658 (M+1)


Example No. 405
1H NMR(δ)ppm







300MHz, DMSO-d6 8.32(1H, s), 8.19(1H, d, J=9.0Hz), 8.03- 7.98(2H, m), 7.75(1H, dd, J=2.1Hz, 8.4Hz), 7.67(1H, t, J= 8.6Hz), 7.40-7.36(3H, m), 7.32(2H, d, J=8.4Hz), 7.19(1H, dd, J=2.1Hz, 12.3Hz), 7.07(1H, dd, J=2.1Hz, 8.7Hz), 5.11(2H, s), 4.12(1H, m), 4.12(1H, m), 3.90(2H, t, J=6.9Hz), 2.54(2H, t, J= 8.1Hz), 2.50(3H, s), 2.40-2.05(4H, 


# m), 2.00-1.75(4H, m), 1.70-1.55(1H, m), 1.50-1.20(3H, m)


Purity >90%(NMR)


MS 650 (M+1)


Example No. 406
1H NMR(δ)ppm







300MHz, DMSO-d6 8.34(1H, d, J=7.7Hz), 8.29(1H, s), 8.15(1H, s), 8.11(1H, d, J=8.8Hz), 7.97(2H, d, J=9.2Hz), 7.63(1H, t, J=8.8Hz), 7.47-7.31(5H, m), 7.18(1H, dd, J=12.4, 2.2Hz), 7.06(1H, dd, J=12.4, 2.2Hz), 5.13(2H, s), 4.13(2H, m), 1.96(2H, m), 1.87(4H, m), 1.62(1H, m), 1.34(3H, m), 1.20(6H, d, J=6.2Hz)


Purity >90%(NMR)


MS 652 (M+1)









 









TABLE 247







Example No. 407
1H NMR(δ)ppm







400MHz, DMSO-d6 8.32(1H, d, J=1.4Hz), 8.20(1H, d, J= 8.8Hz), 8.01(1H, dd, J=1.6Hz, 8.8Hz), 7.90(1H, s), 7.67(1H, t, J=8.4Hz), 7.61(1H, s), 7.55-7.50(4H, m), 7.21(1H, dd, J= 2.3Hz, 12.0Hz), 7.06(1H, dd, J=2.2Hz, 8.7Hz), 5.10(2H, s), 4.11(1H, m), 3.78(2H, t, J=6.7Hz), 3.47(2H, t, J=7.4Hz), 2.54- 2.48(2H, m), 2.40-2.10(2H, m), 


# 2.00-1.80(4H, m), 1.75- 1.55(1H, m), 1.50-1.20(3H, m)


Purity >90%(NMR)


MS 708 (M+1)


Example No. 408
1H NMR(δ)ppm







400MHz, DMSO-d6 8.32(1H, d, J=1.6Hz), 8.21(1H, d, J= 8.8Hz), 8.02(1H, dd, J=1.6Hz, 8.8Hz), 7.76(1H, s), 7.68(1H, t, J=8.5Hz), 7.59(1H, s), 7.54-7.51(4H, m), 7.21(1H, dd, J=2.4Hz, 12.1Hz), 7.07(1H, dd, J=2.4Hz, 8.8Hz), 5.08(2H, s), 4.11(1H, m), 3.77(2H, t, J=6.9Hz), 2.47(2H, t, J=8.0Hz), 2.40-2.10(4H, m), 2.00-1.80(4H, m), 1.70-1.60(1H, m), 1.45-1.20(3H, m)


Purity >90%(NMR)


MS 672 (M+1)


Example No. 409
1H NMR(δ)ppm







300MHz, DMSO-d6 8.28(1H, d, J=1.5Hz), 8.20-8.85(4H, m), 7.75(1H, d, J=6.9Hz), 7.70-7.45(6H, m), 7.13(1H, dd, J= 12.0Hz, 2.1Hz), 7.00(1H, dd, J=8.7Hz), 2.1Hz), 5.22(2H s), 4.05(1H, m), 3.40-3.20(1H, m), 2.30-2.10(2H, m), 2.00- 1.55(5H, m), 1.45-1.10(3H, m), 1.00(6H, d, J=6.6Hz)


Purity >90%(NMR)


MS 676 (M+1)









 









TABLE 248







Example No. 410
1H NMR(δ)ppm







300MHz, DMSO-d6 8.31(1H, s), 8.00(1H, d, J= 8.7Hz), 7.88(1H, d, J=8.7Hz), 7.70(1H, s), 7.65(1H, t, J=8.4Hz), 7.53(2H, d, J=8.4Hz), 7.49(2H, d, J= 8.7Hz), 7.45-7.41(2H, m), 7.16(1H, d, J=12.0Hz), 7.04(1H, d, J=8.7Hz), 5.14(2H, s), 4.68(1H, quint, J=8.4Hz), 3.02, 2.98(6H, s), 2.30-1.85(6H, m), 1.80-1.50(2H, m)


Purity >90%(NMR)


MS 612 (M+1)


Example No. 411
1H NMR(δ)ppm







300MHz, DMSO-d6 8.30(1H, s), 7.99(1H, d, J= 9.0Hz), 7.87(1H, d, J=8.7Hz), 7.67(1H, s), 7.64(1H, t, J=8.7Hz), 7.53(2H, d, J=8.7Hz), 7.49(2H, d, J= 7.5Hz), 7.45-7.41(2H, m), 7.15(1H, d, J=12.3Hz), 7.02(1H, d, J=8.4Hz), 5.15(2H, s), 4.67(1H, quint, J=8.7Hz), 4.02(1H, m), 3.76(1H, m), 3.55(1H, m), 3.22(2H, m), 2.40-1.20(12H, m)


Purity >90%(NMR)


MS 668 (M+1)


Example No. 412
1H NMR(δ)ppm







300MHz, DMSO-d6 8.38(1H, d, J=7.5Hz), 8.33(1H, s), 8.16(1H, s), 8.02(1H, d, J=8.7Hz), 7.98(1H, d, J=9.0Hz), 7.91(1H, d, J=8.4Hz), 7.67(1H, t, J=8.4Hz), 7.53(2H, d, J=8.7Hz), 7.48(2H, d, J=8.7Hz), 7.46(1H, d, J=8.1Hz), 7.18(1H, d, J=11.7Hz), 7.06(1H, d, J=8.7Hz), 5.13(2H, s), 4.70(1H, quint, J=8.4Hz), 4.13(1H, sept, J=6.6Hz), 


# 2.30-1.85(6H, m), 1.80-1.50(2H, m), 1.16(6H, d, J=6.3Hz)


Purity >90%(NMR)


MS 626 (M+1)









 









TABLE 249







Example No. 413
1H NMR(δ)ppm







300Mz, DMSO-d6 8.39(1H, d, J=7.5Hz), 8.31(1H, d, J=1.5Hz), 8.16(1H, d, J=1.9Hz), 8.06(1H, dd, J=8.8, 1.5Hz), 7.99-7.95(2H, m), 7.76 and 7.24(4H, ABq, J=8.9Hz), 7.53 and 7.50(4H, A′B′q, J=9.1Hz), 7.46(1H, d, J=8.3Hz), 5.14(2H, s), 4.94(1H, quint, J=9.0Hz), 4.19-4.08(1H, m), 2.32-2.11(4H, brm), 2.10-1.95(2H, brm), 1.78-1.62(2H, 


# brm), 1.26(3H, s), 1.18(3H, s)


Purity >90%(NMR)


MS 608 (M+1)


Example No. 414
1H NMR(δ)ppm







300Mz, DMSO-d6 8.31(1H, d, J=1.5Hz), 8.06(1H, dd, J=8.7, 1.5Hz), 7.97(1H, d, J=8.7Hz), 7.75 and 7.22(4H, ABq, J=8.9Hz), 7.70(1H, d, J=1.9Hz), 7.53(1H, dd, J=7.9, 1.9Hz), 7.52(4H, s), 7.43(1H, d, J=7.9Hz), 5.15(2H, s), 4.93(1H, quint, J=8.9Hz), 3.01(3H, s), 2.97(3H, s), 2.32-2.11(4H, brm), 2.09- 1.94(2H, 


# brm), 1.77-1.62(2H, brm)


Purity >90%(NMR)


MS 594 (M+1)


Example No. 415
1H NMR(δ)ppm







300Mz, DMSO-d6 8.31(1H, d, J=1.5Hz), 8.06(1H, dd, J=8.7, 1.5Hz), 7.98(1H, d, J=8.7Hz), 7.75 and 7.22(4H, ABq, J=8.9Hz), 7.67(1H, d, J=1.5Hz), 7.52(4H, s), 7.49(1H, dd, J=7.9, 1.5Hz), 7.43(1H, d, J=8.9Hz), 5.16(2H, s), 4.93(1H, quint, J=8.9Hz), 3.76(1H, brs), 3.55(2H, brs), 3.22(2H, brs), 2.31- 2.11(4H, brm), 2.16-1.95(2H, brm), 


# 1.88-1.62(4H, brm), 1.48-1.28(2H, brm)


Purity >90%(NMR)


MS 650 (M+1)









 









TABLE 250







Example No. 416
1H NMR(δ)ppm







300MHz, DMSO-d6 8.38(1H, d, J=7.7Hz), 8.30(1H, s), 8.20- 7.90(4H, m), 7.72(2H, d, J=8.7Hz), 7.60-7.40(5H, m), 7.22(2H, d, J=8.7Hz), 5.13(2H, s), 4.47(1H, m), 4.15(1H, m), 2.90- 2.70(4H, m), 2.60-2.30(4H, m), 1.19(6H, d, J=6.5Hz)


Purity >90%(NMR)


MS 640 (M+1)


Example No. 417
1H NMR(δ)ppm







400MHz, DMSO-d6 8.33(1H, s), 8.17(1H, d, J=8.6Hz), 8.10(1H, d, J=8.6Hz), 7.82(1H, d, J=1.4Hz), 7.74(2H, d, J= 8.7Hz), 7.64(1H, dd, J=8.0Hz, 1.7Hz), 7.55-7.50(4H, m), 7.43(1H, d, J=7.8Hz), 7.24(1H, d, J=8.7Hz), 5.16(2H, s), 4.49(1H, m), 3.60-3.40(4H, m), 2.90-2.70(4H, m), 2.60- 2.30(4H, m), 2.20-1.80(4H, m)


Purity >90%(NMR)


MS 652 (M+1)


Example No. 418
1H NMR(δ)ppm







400MHz, DMSO-d6 8.34(1H, d, J=7.6Hz), 8.25(1H, s), 8.11(1H, d, J=1.3Hz), 7.90-8.00(3H, m), 7.59(1H, t, J=8.6Hz), 7.40-7.55(5H, m), 7.12(1H, d, J=11.9Hz), 7.00(1H, d, J= 8.6Hz), 5.08(2H, s), 4.30-4.10(2H, m), 2.80-2.65(4H, m), 2.45-2.30(2H, m), 1.15(6H, d, J=4.8Hz)


Purity >90%(NMR)


MS 658 (M+1)









 









TABLE 251







Example No. 419
1H NMR(δ)ppm







400MHz, DMSO-d6 8.30(1H, s), 8.05-7.95(3H, m), 7.80- 7.75(1H, m), 7.63(1H, t, J=8.6Hz), 7.55-7.35(5H, m), 7.15(1H, dd, J=12.1Hz, 2.1Hz), 7.03(1H, dd, J=8.7Hz, 2.3Hz), 5.10(2H, s), 4.23(1H, m), 3.90(2H, t, J=7.0Hz), 2.95-2.70(4H, m), 2.60- 2.35(4H, m), 2.30-2.00(4H, m)


Purity >90%(NMR)


MS 656 (M+1)


Example No. 420
1H NMR(δ)ppm







300Mz, DMSO-d6 8.37(1H, d, J=7.5Hz), 8.28(1H, d, J=1.5Hz), 8.17(1H, d, J=1.5Hz), 8.13(1H, d, J=8.7Hz), 7.97(1H, dd, J=8.1, 1.5Hz), 7.94(1H, dd, J=8.7, 1.5Hz), 7.61(1H, t, J=8.7Hz), 7.51 and 7.49(4H, ABq, J=8.9Hz), 7.46(1H, d, J=8.1Hz), 7.08(1H, dd, J=12.4, 2.3Hz), 6.97(1H, dd, J=8.7, 2.3Hz), 5.10(2H, s), 4.20-4.08(1H, m), 3.62-3.56(2H, brm), 3.13-3.10(2H, brm), 


# 1.79-1.60(3H, brm), 1.54-1.34(3H, brm), 1.21(3H, s), 1.18(3H, s)


Purity >90%(NMR)


MS 641 (M+1)


Example No. 421
1H NMR(δ)ppm







300Mz, DMSO-d6 8.24(1H, d, J=1.5Hz), 8.02(1H, d, J=8.7Hz), 7.88(1H, dd, J=8.7, 1.5Hz), 7.82(1H, d, J=1.9Hz), 7.63(1H, dd, J=7.9, 1.9Hz), 7.54(1H, t, J=8.7Hz), 7.50(4H, s), 7.42(1H, d, J=7.9Hz), 7.01(1H, dd, J=12.0, 2.3Hz), 6.91(1H, dd, J=8.7, 2.3Hz), 5.11(2H, s), 3.63-3.41(6H, m), 3.07-3.04(2H, brm), 1.95-1.79(4H, brm), 1.77-1.57(3H, brm), 1.50-1.32(3H, brm)


Purity >90%(NMR)


MS 653 (M+1)









 









TABLE 252







Example No. 422
1H NMR(δ)ppm







300MHz, DMSO-d6 10.99(2H, s), 8.44(1H, s), 8.30(1H, s), 8.18(1H, d, J=8.7Hz), 8.14(1H, d, J=8.7Hz), 7.98(1H, d, J=9.0Hz), 7.70- 7.66(2H, m), 7.57(2H, d, J=8.7Hz), 7.54(2H, d, J=8.7Hz), 7.21(1H, d, J=12.0Hz), 7.09(1H, d, J=8.4Hz), 5.19(2H, s), 4.05(4H, s), 2.40- 2.18(2H, m), 2.15-1.80(4H, m), 1.75-1.55(1H, m), 1.50-1.20(3H, m)


Purity >90%(NMR)


MS 623 (M+1)


Example No. 423
1H NMR(δ)ppm







300MHz, DMSO-d6 8.27(1H, s), 8.05(1H, d, J=8.7Hz), 7.93(1H, d, J=8.7Hz), 7.90(1H, s), 7.70(1H, d, J=8.4Hz), 7.59(1H, t, J=8.4Hz), 7.50(2H, d, J=9.0Hz), 7.45(2H, d, J=8.7Hz), 7.41(1H, d, J=8.4Hz), 7.12(1H, d, J=12.0Hz), 7.00(1H, d, J=8.7Hz), 5.10(2H, s), 4.49(2H, t, J=7.8Hz), 4.14(2H, t, J=8.0Hz), 4.04(1H, m), 2.40-2.10(2H, m), 2.00-1.50(5H, m), 1.45-1.20(3H, m)


Purity >90%(NMR)


MS 640 (M+1)


Example No. 424
1H NMR(δ)ppm







300MHz, DMSO-d6 8.30(1H, s), 8.14(1H, d, J=8.4Hz), 7.98(1H, d, J=9.3Hz), 7.89(1H, s), 7.68(1H, d, J=8.4Hz), 7.62(1H, d, J=9.0Hz), 7.48(2H, d, J=8.4Hz), 7.43(2H, d, J=8.4Hz), 7.33(1H, d, J=8.4Hz), 7.16(1H, d, J=12.0Hz), 7.04(1H, d, J=9.0Hz), 5.07(2H, s), 4.10(1H, m), 3.92(2H, t, J=8.0Hz), 3.45(2H, t, J=8.0Hz), 2.40-2.10(2H, m), 2.00-1.50(5H, m), 1.45-1.20(3H, m)


Purity >90%(NMR)


MS 639 (M+1)









 









TABLE 253







Example No. 425
1H NMR(δ)ppm







300MHz, DMSO-d6 9.05(1H, s), 8.30(1H, s), 8.16(1H, d, J=8.8Hz), 7.99(1H, d, J=8.6Hz), 7.72(1H, s), 7.64(1H, t, J=8.6Hz), 7.52(1H, d, J= 8.4Hz), 7.47(2H, d, J=8.7Hz), 7.42(2H, d, J= 8.6Hz), 7.25(1H, d, J=8.4Hz), 7.15(1H, d, J= 12.2Hz), 7.04(1H, d, J=8.6Hz), 6.60(1H, brs), 5.05(2H, s), 4.10(1H, m), 3.68(2H, t, J=6.1Hz), 3.45(2H, t, 


# J=6.1Hz), 2.40-2.10(2H, m), 2.00- 1.55(5H, m), 1.50-1.20(3H, m)


Purity >90%(NMR)


MS 639 (M+1)


Example No. 426
1H NMR(δ)ppm







300MHz, DMSO-d6 8.32(1H, s), 8.24(1H, d, J=8.7Hz), 8.03(1H, d, J=8.7Hz), 7.78-7.73(4H, m), 7.38-7.32(4H, m), 5.52(2H, s), 4.88(2H, s), 4.40(2H, s), 4.37(1H, m), 2.92, 2.84(6H, s), 2.40- 2.18(2H, m), 2.15-1.95(2H, m), 1.90-1.80(2H, m), 1.75-1.55(1H, m), 1.50-1.20(3H, m)


Purity >90%(NMR)


MS 643 (M+1)


Example No. 427
1H NMR(δ)ppm







300MHz, DMSO-d6 11.26(1H, brs), 8.35(1H, s), 8.27(1H, d, J=9.0Hz), 8.05(1H, d, J=8.4Hz), 7.83- 7.78(4H, m), 7.42-7.35(4H, m), 5.57(2H, s), 4.77, 4.73(2H, s), 4.37(1H, m), 3.95(1H, s), 3.70- 3.00(4H, m), 2.40-1.00(14H, m)


Purity >90%(NMR)


MS 641 (M+1)









 









TABLE 254







Example No. 428
1H NMR(δ)ppm







300MHz, DMSO-d6 8.31(1H, s), 8.26(1H, d, J= 9.0Hz), 8.04(1H, d, J=8.7Hz), 7.79-7.73(4H, m), 7.38-7.31(6H, m), 5.53(2H, s), 4.90(2H, s), 4.37(1H, m), 4.05(2H, s), 2.40-2.18(2H, m), 2.15- 1.95(2H, m), 1.90-1.80(2H, m), 1.75-1.55(1H, m), 1.50-1.20(3H, m)


Purity >90%(NMR)


MS 615 (M+1)


Example No. 429
1H NMR(δ)ppm







300MHz, DMSO-d6 8.88(1H, q, J=4.5Hz), 8.33(1H, d, J=1.5Hz), 8.18(1H, d, J=8.7Hz), 8.01(1H, dd, J=1.5Hz, 8.7Hz), 7.89-7.83(2H, m), 7.50-7.34(3H, m), 7.20(1H, dd, J=2.1Hz, 8.4Hz), 5.61(2H, s), 4.13(1H, m), 2.84(3H, d, J=4.8Hz), 2.40-2.10(2H, m), 2.00-1.75(4H, m), 1.70- 1.55(1H, m), 1.50-1.20(3H, m)


Purity >90%(NMR)


MS 603 (M+1)


Example No. 430
1H NMR(δ)ppm







400MHz, DMSO-d6 8.79(1H, t, J=5.9Hz), 8.31(1H, s), 8.15(1H, d, J=8.7Hz), 7.99(1H, d, J=8.8Hz), 7.87(1H, d, J=8.1Hz), 7.85(1H, d, J=8.7Hz), 7.70(1H, t, J=8.4Hz), 7.42-7.33(3H, m), 7.18(1H, d, J=8.8Hz), 5.60(2H, s), 4.11(1H, m), 3.62- 3.54(4H, m), 2.40-2.10(2H, m), 2.00-1.75(4H, m), 1.70-1.55(1H, m), 1.50-1.20(3H, m)


Purity >90%(NMR)


MS 633 (M+1)









 









TABLE 255







Example No. 431
1H NMR(δ)ppm







300MHz, DMSO-d6 8.31(1H, s), 8.16(1H, d, J= 8.8Hz), 7.99(1H, d, J=8.7Hz), 7.74-7.60(4H, m), 7.37(2H, t, J=8.8Hz), 7.28(1H, dd, J=2.2Hz, 12.2Hz), 7.14(1H, dd, J=2.2Hz, 8.6Hz), 5.17(2H, s), 4.10(1H, m), 3.15(6H, brs), 2.40-2.10(2H, m), 2.00-1.75(4H, m), 1.70-1.55(1H, m), 1.50-1.15(3H, m)


Purity >90%(NMR)


MS 616 (M+1)


Example No. 432
1H NMR(δ)ppm







300MHz, DMSO-d6 8.45(1H, d, J=7.7Hz), 8.32(1H, s), 8 19(1H, d, J=8.8Hz), 8.02-7.99(2H, m), 7.70(1H, t, J=8.6Hz), 7.60(2H, dd, J=5.4Hz, 8.7Hz), 7.37(2H, t, J=8.8Hz), 7.27(1H, dd, J=2.3Hz, 12.2Hz), 7.14(1H, dd, J=2.2Hz, 8.7Hz), 5.16(2H, s), 4.20-4.00(2H, m), 2.40-2.10(2H, m), 2.00-1.75(4H, m), 1.70-1.55(1H, m), 1.50-1.20(3H, m), 1.18(6H, d, J=6.6Hz)


Purity >90%(NMR)


MS 630 (M+1)


Example No. 433
1H NMR(δ)ppm







300MHz, DMSO-d6 8.31(1H, d, J=1.4Hz), 8.15(1H, d, J=8.8Hz), 7.98(1H, dd, J=1.4Hz, 8.7Hz), 7.68- 7.60(4H, m), 7.36(2H, t, J=8.8Hz), 7.28(1H, dd, J=2.2Hz, 12.2Hz), 7.15(1H, dd, J=2.2Hz, 8.6Hz), 5.17(2H, s), 4.10(1H, m), 4.05-3.90(2H, m), 3.85- 3.70(1H, m), 3.55-3.25(2H, m), 2.40-2.10(2H, m), 2.00-1.75(6H, m), 1.70-1.55(1H, m), 1.50-1.20(5H, m)


Purity >90%(NMR)


MS 672 (M+1)









 









TABLE 256







Example No. 434
1H NMR(δ)ppm







300Mz, DMSO-d6 8.45(1H, d, J=1.5Hz), 8.26(1H, d, J= 8.8Hz), 8.10(1H, dd, J=8.8, 1.5Hz), 7.72(1H, d, J= 1.5Hz), 7.64(1H, t, J=8.6Hz), 7.56-7.48(5H, m), 7.44(1H, d, J=J=7.7Hz), 7.18(1H, dd, J=12.3, 2.4Hz), 7.04(1H, dd, J=8.6, 2.4Hz), 5.15(2H, s), 4.08(1H, brt, J= 11.7Hz), 3.02(3H, s), 2.99(3H, s), 2.34-2.17(2H, brm), 1.97-1.81(4H, brm), 


# 1.70-1.60(1H, brm), 1.49-1.21(3H, brm)


Purity >90%(NMR)


MS 650 (M+1)


Example No. 435
1H NMR(δ)ppm







300Mz, DMSO-d6 8.42(1H, d, J=1.5Hz), 8.24(1H, d, J=8.8Hz), 8.08(1H, dd, J=8.8, 1.5Hz), 8.00(2H, d, J= 8.8Hz), 7.79(1H, d, J=7.8Hz), 7.62(1H, t, J=8.4Hz), 7.61-7.55(3H, m), 7.44(1H, d, J=8.1Hz), 7.16(1H, dd, J=12.1, 2.6Hz), 7.02(1H, dd, J=8.4, 2.6Hz), 5.12(2H, s), 4.07(1H, brt, J=12.5Hz), 2.33(2H, brm), 1.96-1.79(4H, brm), 1.71-1.61(1H, brm), 1.49-1.21(3H, brm)


Purity >90%(NMR)


MS 623 (M+1)


Example No. 436
1H NMR(δ)ppm







300MHz, DMSO-d6 8.41(1H, d, J=7.7Hz), 8.30- 8.26(2H, m), 8.18(1H, d, J=1.4Hz), 7.99(1H, dd, J= 1.7Hz, 8.0Hz), 7.89(1H, d, J=10.1Hz), 7.67(1H, t, J= 8.8Hz), 7.55-7.45(5H, m), 7.20(1H, d, J=12.2Hz), 7.07(1H, dd, J=2.1Hz, 8.7Hz), 5.14(2H, s), 4.18- 4.11(2H, m), 2.40-2.10(2H, m), 2.00-1.75(4H, m), 1.70-1.55(1H, m), 1.50-1.20(3H, m), 


# 1.20(6H, d, J=6.6Hz)


Purity >90%(NMR)


MS 680 (M+1)









 









TABLE 257







Example No. 437
1H NMR(δ)ppm









Purity >90%(NMR)


MS 580 (M+1)


Example No. 438
1H NMR(δ)ppm









Purity >90%(NMR)


MS 607 (M+1)


Example No. 439
1H NMR(δ)ppm







300MHz, CDCl3 8.60(1H, d, J=1.5Hz), 8.05(1H, dd, J=1.6Hz, 8.7Hz), 7.70(1H, d, J=8.7Hz), 7.62(2H, d, J=8.2Hz), 7.49(2H, d, J=8.2Hz), 7.31(2H, d, J=8.8Hz), 7.27-7.23(2H, m), 7.06(2H, t, J=8.6Hz), 6.80(2H, d, J=8.8Hz), 5.05(2H, s), 4.38(1H, m), 3.06(6H, s), 2.45-2.20(2H, m), 2.10-1.70(5H, m), 1.50-1.20(3H, m)


Purity >90%(NMR)


MS 591 (M+1)









 









TABLE 258







Example No. 440
1H NMR(δ)ppm







300MHz, DMSO-d6 8.20(1H, s), 7.86(2H, m), 7.39(1H, d, J=7.9Hz), 7.34(1H, d, J=7.9Hz), 7.07(2H, dt, J=2.3Hz, 8.6Hz), 6.98-6.88(5H, m), 6.83(1H, d, J=8.3Hz), 5.91(1H, s), 3.96(1H, m), 2.30-1.95(2H, m), 1.90-1.50(4H, m), 1.40-1.10(3H, m)


Purity >90%(NMR)


MS 557 (M+1)


Example No. 441
1H NMR(δ)ppm







300MHz, DMSO-d6 8.24(1H, d, J=1.4Hz), 8.01(1H, d, J=8.8Hz), 7.91(1H, dd, J=1.4Hz, 8.7Hz), 7.47(1H, t, J=8.4Hz), 7.43-7.35(2H, m), 7.15-7.01(5H, m), 6.92(2H, d, J=10.4Hz), 6.11(1H, s), 3.90(1H, m), 2.30-1.95(2H, m), 1.90-1.50(4H, m), 1.40-1.10(3H, m)


Purity >90%(NMR)


MS 557 (M+1)


Example No. 442
1H NMR(δ)ppm







300Mz, DMSO-d6 8.26(1H, d, J=1.5Hz), 8.11(1H, d, J=8.9Hz), 7.96(1H, dd, J=8.9, 1.5Hz), 7.65-7.57(5H, m), 7.47(1H, t, J=7.7Hz), 7.35(1H, d, J=7.6Hz), 7.30-7.22(3H, m), 7.16(1H, dd, J=8.7, 2.3Hz), 6.88(1H, s), 4.04(1H, brt, J=11.3Hz), 2.98(3H, s) 2.84(3H, s), 2.30-2.10(2H, brm), 1.94-1.75(4H, brm), 1.68-1.57(1H, brm), 1.45-1.14(3H, brm)


Purity >90%(NMR)


MS 610 (M+1)









 









TABLE 259







Example No. 443
1H NMR(δ)ppm







300Mz, DMSO-d6 8.23(1H, s), 7.98 and 7.89(2H, ABq, J=8.8Hz), 7.62-7.06(11H, m), 6.86(1H, s), 4.12-3.77(2H, brm), 3.72(1H, brs), 3.69(1H, brs), 3.18(1H, brs), 3.05(1H, brs), 2.31-2.08(2H, brm), 1.90-1.54(7H, brm), 1.48-1.13(5H, brm)


Purity >90%(NMR)


MS 666 (M+1)


Example No. 444
1H NMR(δ)ppm







300MHz, DMSO-d6 8.36(1H, s), 8.00(1H, d, J= 8.7Hz), 7.90(1H, d, J=9.3Hz), 7.80-7.70(2H, m), 7.63(2H, d, J=8.4Hz), 7.32(2H, t, J=8.7Hz), 7.22(2H, d, J=8.4Hz), 5.62(1H, d, J=7.5Hz), 5.57(1H, brd, J=4.8Hz), 5.41(2H, s), 5.31(1H, m), 4.29(1H, m), 3.84(1H, d, J=9.0Hz), 3.50-3.20(3H, m), 2.71(3H, s), 2.40-2.20(2H, m), 1.75-1.60(1H, m), 1.50-1.20(3H, m)


Purity >90%(NMR)


MS 718 (M+1)


Example No. 445
1H NMR(δ)ppm







300MHz, DMSO-d6 8.36(1H, s), 8.00(1H, d, J= 8.7Hz), 7.92(1H, d, J=9.3Hz), 7.57(1H, t, J=8.4Hz), 7.50-7.35(6H, m), 7.25-7.05(4H, m), 6.82(1H, s), 5.62(1H, d, J=7.2Hz), 5.56(1H, m), 5.28(1H, brs), 3.95(1H, m), 3.82(1H, d, J=8.7Hz), 3.50-3.20(3H, m), 2.30-2.05(2H, m), 1.90-1.55(5H, m), 1.40-1.10(3H, m)


Purity >90%(NMR)


MS 733 (M+1)









 









TABLE 260







Example No. 446
1H NMR(δ)ppm







300MHz, DMSO-d6 8.29(1H, s), 8.13(1H, d, J=9.0Hz), 7.97(1H, d, J=9.0Hz), 7.63(1H, t, J=8.6Hz), 7.51-7.32(7H, m), 7.15 (1H, d, J=12.0Hz), 7.03(1H, d, J=9.0Hz), 5.10(2H, s), 4.09(1H, m), 3.82(2H, t, J=6.3Hz), 3.56(2H, t, J=7.4Hz), 2.45(2H, m), 2.40-2.10(2H, m), 2.00-1.55(5H, m), 1.50-1.20(3H, m)


Purity >90%(NMR)


MS 674 (M+1)


Example No. 447
1H NMR(δ)ppm







300MHz, DMSO-d6 8.36(1H, d, J=7.7Hz), 8.14(2H, d, J= 12.1Hz), 8.08(1H, d, J=8.5Hz), 7.97(1H, dd, J=1.7Hz, 8.3Hz), 7.74(1H, dd, J=1.8Hz, 8.4Hz), 7.58-7.45(6H, m), 7.31(2H, s), 7.12(1H, dd, J=2.2Hz, 12.1Hz), 7.00(1H, dd, J=2.4Hz, 8.6Hz), 5.11(2H, s), 4.16(1H, m), 4.02(1H, m), 2.20(2H, m), 1.86(4H, m), 1.62(1H, m), 1.21(9H, m)


Purity >90%(NMR)


MS 675 (M+1)


Example No. 448
1H NMR(δ)ppm







300MHz, DMSO-d6 8.29(2H, m), 8.04(1H, d, J=8.5Hz), 7.93(1H, dd, J=1.5Hz, 8.8Hz), 7.60-7.42(8H, m), 7.05(1H, dd, J=2.2Hz, 12.1Hz), 6.95(1H, dd, J=2.4Hz, 8.6Hz), 5.11(2H, s), 4.07-3.90(2H, m), 2.28-2.19(2H, m), 1.88-1.84(4H, m), 1.67- 1.62(1H, m), 1.40-1.26(3H, m), 1.04(6H, d, J=6.6Hz)


Purity >90%(NMR)


MS 640 (M+1)









 









TABLE 261







Example No. 449
1H NMR(δ)ppm







300MHz, DMSO-d6 8.31(1H, s), 8.17(1H, d, J=8.7Hz), 8.00(1H, d, J=8.7Hz), 7.78(1H, d, J=8.1Hz), 7.66(1H, t, J= 8.7Hz), 7.55-7.45(4H, m), 7.40(1H, d, J=11.7Hz), 7.19(1H, d, J=12.3Hz), 7.05(1H, d, J=8.7Hz), 5.07(2H, s), 4.10(1H, m), 3.85(2H, t, J=6.6Hz), 3.47(2H, t, J=7.5z) 


# 2.60-2.50(2H, m), 2.40-2.10(2H, m), 2.00-1.80(4H, m), 1.75-1.55(1H, m), 1.50- 1.20(3H, m)


Purity >90 %(NMR)


MS 692 (M+1)


Example No. 450
1H NMR(δ)ppm







300MHz, DMSO-d6 8.37(1H, d, J=7.8Hz), 8.15(1H, s), 7.97(1H, d, J=9.8Hz), 7.64-7.45(8H, m), 7.12(1H, d, J= 12.1Hz), 7.00(1H, d, J=8.6Hz), 5.11(2H, s), 4.21(3H, s), 4.18- 4.05(1H, m), 4.04-3.89(1H, m), 2.29-2.08(2H, m), 1.90- 1.74(4H, m), 1.68-1.58(1H, m), 1.40-1.17(3H, m), 1.20(6H, d, J=6.6Hz)


Purity >90%(NMR)


MS 670 (M+1)


Example No. 451
1H NMR(δ)ppm







300MHz, DMSO-d6 8.29(1H, s), 8.12(1H, d, J=8.8Hz), 7.97(1H, d, J=10.2Hz), 7.65-7.59(2H, m), 7.51(4H, s), 7.46(2H, s), 7.15(1H, d, J=12.2Hz), 7.01(1H, d, J=8.6Hz), 5.15(2H, s), 4.13-3.98(1H, m), 3.21(3H, s), 2.56-2.42(1H, m), 2.30- 2.15(2H, m), 1.95-1.77(4H, m), 1.69-1.59(1H, m), 1.45- 1.17(3H, m), 0.96(6H, d, J=6.5Hz)


Purity >90%(NMR)


MS 654 (M+1)









 









TABLE 262







Example No. 452
1H NMR(δ)ppm







300MHz, DMSO-d6 10.1(1H, s), 8.28(1H, s), 8.11(1H, d, J= 8.7Hz), 7.96(1H, d, J=11.4Hz), 7.95(1H, s), 7.72(1H, d, J= 8.7Hz), 7.62(1H, t, J=9.0Hz), 7.48 and 7.43(4H, ABq, J= 8.4Hz), 7.31(1H, d, J=8.4Hz), 7.13(1H, d, J=12.0Hz), 7.02(1H, d, J=9.0Hz), 5.07(2H, s), 4.14-4.00(1H, m), 2.69-2.59(1H, m), 2.30-2.12(2H, m), 


# 1.95-1.77(4H, m), 1.71-1.57(1H, m), 1.45- 1.20(3H, m), 1.12(6H, d, J=6.9Hz)


Purity >90%(NMR)


MS 640 (M+1)


Example No. 453
1H NMR(δ)ppm







300MHz, DMSO-d6 11.1(1H, brs), 8.31(1H, d, J=9.4Hz), 8.29(1H, s), 8.07(1H, d, J=10.2Hz), 7.70-7.62(3H, m), 7.31- 7.23(3H, m), 4.40-4.23(1H, m), 4.24(2H, s), 2.61(3H, s), 2.34- 2.14(2H, m), 1.99-1.72(4H, m), 1.66-1.54(1H, m), 1.46- 1.30(1H, m), 1.27-1.08(2H, m)


Purity >90%(NMR)


MS 542 (M+1)


Example No. 454
1H NMR(δ)ppm







300MHz, DMSO-d6 8.27(1H, d, J=1.4Hz), 8.05(1H, d, J= 8.7Hz), 7.92(1H, d, J=8.7Hz), 7.79(1H, d, J=7.8Hz), 7.59(1H, t, J=8.6Hz), 7.55-7.45(4H, m), 7.37(1H, d, J=11.4Hz), 7.14(1H, d, J=12.1Hz), 7.01(1H, d, J=8.6Hz), 5.04(2H, s), 4.10(1H, m), 3.84(2H, t, J=6.Hz), 2.55-2.45(2H, m), 2.40-2.10(4H, m), 2.00-1.80(4H, m), 1.75-1.55(1H, m), 1.50-1.20(3H, m)


Purity >90%(NMR)


MS 656 (M+1)









 









TABLE 263







Example No. 455
1H NMR(δ)ppm







300MHz, DMSO-d6 10.05(1H, brs), 8.32(1H, d, J=1.3Hz), 8.19(1H, d, J=8.8Hz), 8.01(1H, d, J=8.7Hz), 7.67(1H, t, J=8.6Hz), 7.50- 7.41(5H, m), 7.38-7.33(2H, m), 7.17(1H, dd, J=2.2Hz, 12.2Hz), 7.05(1H, dd, J=2.2Hz, 8.7Hz), 5.10(2H, s), 4.12(1H, m), 3.07(3H, s), 2.40-2.10(2H, m), 2.00-1.80(4H, m), 1.75-1.55(1H, m), 1.50- 1.20(3H, m)


Purity >90%(NMR)


MS 648 (M+1)


Example No. 456
1H NMR(δ)ppm







300MHz, DMSO-d6 8.31(1H, d, J=1.4Hz), 8.17(1H, d, J=8.8Hz), 8.00(1H, dd, J=1.5Hz, 8.7Hz), 7.73(1H, d, J=2.3Hz), 7.66(1H, t, J=8.6Hz), 7.56(1H, dd, J=2.3Hz, 8.3Hz), 7.50-7.47(4H, m), 7.42(1H, d, J=8.3Hz), 7.19(1H, d, J=12.2Hz), 7.06(1H, dd, J= 2.2Hz, 8.6Hz), 5.11(2H, s), 4.10(1H, m), 3.31(3H, s), 3.03(3H, s), 2.40-2.10(2H, m), 2.00-1.80(1H, m), 


# 1.75-1.55(1H, m), 1.50- 1.20(3H, m)


Purity >90%(NMR)


MS 662 (M+1)


Example No. 457
1H NMR(δ)ppm







300MHz, DMSO-d6 8.41(1H, d, J=8.8Hz), 8.28(1H, s), 8.10(1H, d, J=9.2Hz), 7.96(1H, d, J=8.8Hz), 7.87(1H, d, J=8.8Hz), 7.61(1H, dd, J=8.5Hz, 8.5Hz), 7.56-7.49(4H, m), 7.19(1H, dd, J=2.4Hz, 12.2Hz), 7.05(1H, dd, J=2.4Hz, 8.7Hz), 5.18(2H, s), 4.06-3.97(4H, m), 2.62(2H, t, J=8.1Hz), 2.28-2.15(2H, m), 2.11-2.01(4H, m), 1.91-1.87(4H, m), 1.64(1H, m), 1.43-1.23(3H, m)


Purity >90%(NMR)


MS 639 (M+1)









 









TABLE 264







Example No. 458
1H NMR(δ)ppm







(300MHz, DMSO-d6) 10.19(1H, s), 8.29(1H, s), 8.14(1H, d, J= 8.8Hz), 7.98(1H, dd, J=1.7Hz, 8.7Hz), 7.90(1H, d, J=2.2Hz), 7.69(1H, dd, J=2.2Hz, 8.4Hz), 7.64(1H, dd, J=8.5Hz, 8.5Hz), 7.50- 7.42(4H, m), 7.32(1H, d, J=8.4Hz), 7.14(1H, dd, J=2.5Hz, 12.1Hz), 7.02(1H, dd, J=2.4Hz, 8.6Hz), 5.08(2H, s), 4.17-4.02(1H, m), 2.30- 2.18(2H, m), 2.08(3H, s), 


# 1.87-1.79(4H, m), 1.68-1.59(1H, m), 1.35-1.23(3H, m)


Purity >90%(NMR)


MS 612 (M+1)


Example No. 459
1H NMR(δ)ppm







300MHz, DMSO-d6 8.29(1H, s), 8.11(1H, d, J=8.8Hz), 7.96(1H, d, J=8.6Hz), 7.64-7.58(2H, m), 7.51(4H, s), 7.44(2H, s), 7.15(1H, d, J=12.2Hz), 7.02(1H, d, J=8.5H), 5.14(2H, s), 4.12-3.95(1H, m), 3.70(2H, q, J=7.1 Hz), 2.50(3H, s) 2.31-2.12(2H, m), 1.92-1.82(4H, m), 1.69-1.57(1H, m), 1.43-1.16(3H, m), 1.05(3H, t, J=7.1Hz)


Purity >90%(NMR)


MS 640 (M+1)


Example No. 460
1H NMR(δ)ppm







300MHz, DMSO-d6 8.28(1H, s), 8.09(1H, d, J=8.8Hz), 7.95(1H, d, J=10.1Hz), 7.64-7.56(2H, m), 7.51(4H, ws), 7.44(2H, s), 7.14(1H, d, J=12.2Hz), 7.01(1H, d, J=8.6Hz), 5.14(2H, s), 4.12-3.95(1H, m), 3.64(2H, t, J=7.2Hz). 2.50(3H, s), 2.31-2.12(2H, m), 1.93-1.84(4H, m), 1.69-1.59(1H, m), 1.52-1.17(5H, m), 0.84(3H, t, J=7.3Hz)


Purity >90%(NMR)


MS 654 (M+1)









 









TABLE 265







Example No. 461
1H NMR(δ)ppm







400MHz, DMSO-d6 8.30(1H, s), 8.13(1H, d, J=8.8Hz), 7.99(1H, d, J=8.8Hz), 7.69(1H, s), 7.62(1H, t, J=8.4Hz), 7.96-7.50(4H, m), 7.45(1H, d, J=8.7Hz), 7.17(1H, dd, J=2.3Hz, 12.0Hz), 7.05(1H, dd, J=2.2Hz, 8.7Hz), 5.14(2H, s), 4.07(1H, m), 3.73(2H, q, J=7.2Hz), 3.05(3H, s), 2.40-2.10(2H, m), 2.00-1.80(4H, m), 1.75-1.55(1H, m), 1.50-1.20(3H, m), 1.06(3H, t, J=7.2Hz)


Purity >90%(NMR)


MS 676 (M+1)


Example No. 462
1H NMR(δ)ppm







300MHz, DMSO-d6 8.30(1H, s), 8.13(1H, d, J=8.7Hz), 7.98(1H, d, J=8.7Hz), 7.70(1H, d, J=1.8Hz), 7.63(1H, t, J=8.4Hz), 7.55- 7.50(5H, m), 7.43(1H, d, J=8.1Hz), 7.15(1H, d, J=12.0Hz), 7.02(1H, d, J=8.7Hz), 5.13(2H, s), 4.07(1H, m), 3.65(2H, t, J=6.6Hz), 3.03(3H, s), 2.40-2.10(2H, m), 2.00-1.75(4H, m), 1.70-1.60(1H, m), 1.50-1.20(5H, m), 0.87(3H, t, J=7.5Hz)


Purity >90%(NMR)


MS 690 (M+1)


Example No. 463
1H NMR(δ)ppm







300MHz, DMSO-d6 8.29(1H, s), 8.11(1H, d, J=8.5Hz), 7.97(1H, d, J=9.9Hz), 7.65(1H, br), 7.61(1H, d, J=8.4Hz), 7.53-7.42(6H, m), 7.16(1H, dd, J=2.2Hz, 12.1Hz), 7.03(1H, dd, J=2.0Hz, 9.0Hz), 5.12(2H, s), 4.04-4.00(1H, m), 3.24(3H, s), 2.20(2H, m), 1.87(7H, m), 1.64(1H, m), 1.41-1.28(3H, m)


Purity >90%(NMR)


MS 626 (M+1)









 









TABLE 266







Example No. 464
1H NMR(δ)ppm







300MHz, DMSO-d6 8.28(1H, s), 8.09(1H, d, J=8.8Hz), 7.95(1H, d, J=8.8Hz), 7.73(1H, d, J=2.2Hz), 7.63-7.39(7H, m), 7.15(1H, dd, J=2.2Hz, 12.1Hz), 7.01(1H, dd, J=2.0Hz, 8.6Hz), 5.10(2H, s), 4.05-3.99(1H, m), 3.34(3H, s), 3.23(2H, q, J= 7.2Hz), 2.20(2H, m), 1.87(4H, m), 1.62(1H, m), 1.33(3H, m), 1.24(3H, t, J=7.3Hz)


Purity >90%(NMR)


MS 676 (M+1)


Example No. 465
1H NMR(δ)ppm







300MHz, DMSO-d6 8.29(1H, d, J=1.5Hz), 8.11(1H, d, J= 8.8Hz), 7.98(1H, dd, J=1.4Hz, 8.4Hz), 7.69(1H, d, J=2.2Hz), 7.62(1H, dd, J=8.6Hz, 8.6Hz), 7.56-7.47(5H, m), 7.43(1H, d, J=8.1Hz), 7.16(1H, dd, J=2.2Hz, 12.1Hz), 7.02(1H, dd, J= 2.4Hz, 8.7Hz), 5.13(2H, s), 4.09-4.02(1H, m), 3.77(2H, q, J= 6.8Hz), 3.19(2H, q, 


# J=7.4Hz), 2.25-2.21(2H, m), 1.90-1.87(4H, m), 1.63(1H, m), 1.39-1.33(3H, m), 1.27(3H, t, J=7.4Hz), 1.06(3H, t, J=6.9Hz)


Purity >90%(NMR)


MS 690 (M+1)


Example No. 466
1H NMR(δ)ppm







300MHz, DMSO-d6 8.28(1H, s), 8.10(1H, d, J=8.4Hz), 7.96(1H, d, J=8.4Hz), 7.64(1H, s), 7.61(1H, d, J=8.4Hz), 7.50(4H, s), 7.44(2H, s), 7.14(1H, d, J=12.0Hz), 7.02(1H, d, J=8.4Hz), 5.12(2H, s), 4.12-3.95(1H, m), 3.23(3H, s), 2.32- 2.06(4H, m), 1.94-1.77(4H, m), 1.70-1.59(1H, m), 1.42- 1.18(3H, m), 0.96(3H, t, J=7.2Hz)


Purity >90%(NMR)


MS 640 (M+1)









 









TABLE 267







Example No. 467
1H NMR(δ)ppm







300MHz, DMSO-d6 8.28(1H, s), 8.08(1H, d, J=8.7Hz), 7.95(1H, d, J=8.4Hz), 7.60(1H, t, J=8.4Hz), 7.59(1H, s), 7.51(4H, s), 7.45 and 7.42(2H, ABq, J=8.1Hz), 7.14(1H, d, J=12.0Hz), 7.00(1H, d, J= 8.4Hz), 5.14(2H, s), 4.12-3.95(1H, m), 3.70(2H, q, J=6.9Hz), 2.30- 1.98(4H, m), 1.94-1.79(4H, m), 1.69-1.59(1H, m), 1.45-1.17(3H, m), 1.05(3H, t, J=6.9Hz), 0.94(3H, t, J=7.5Hz)


Purity >90%(NMR)


MS 654 (M+1)


Example No. 468
1H NMR(δ)ppm







400MHz, DMSO-d6 8.25(1H, s), 7.96(1H, d, J=8.8Hz), 7.90(1H, d, J=8.8Hz), 7.55(1H, t, J=8.4Hz), 7.46(2H, d, J=8.7Hz), 7.41(2H, d, J=8.7Hz), 7.10-7.00(2H, m), 6.98(1H, dd, J=2.2Hz, 8.7Hz), 5.05(2H, s), 3.98(1H, m), 3.84(3H, s), 2.30-2.10(2H, m), 1.90- 1.75(4H, m), 1.70-1.60(1H, m), 1.50-1.20(3H, m)


Purity >90%(NMR)


MS 585 (M+1)


Example No. 469
1H NMR(δ)ppm







400MHz, DMSO-d6 8.26(1H, s), 8.02(1H, d, J=8.8Hz), 7.93(1H, d, J=8.8Hz), 7.60-7.50(6H, m), 7.45(1H, d, J=8.7Hz), 7.08(1H, dd, J= 2.3Hz, 12.0Hz), 6.97(1H, dd, J=2.2Hz, 8.7Hz), 5.18(2H, s), 4.85(1H, sept, J=6.6Hz), 3.98(1H, m), 2.40-2.10(2H, m), 2.00-1.80(4H, m), 1.75-1.55(4H, m), 1.50-1.20(3H, m), 1.02(6H, d, J=6.6Hz)


Purity >90%(NMR)


MS 654 (M+1)









 









TABLE 268







Example No. 470
1H NMR(δ)ppm







300MHz, DMSO-d6 8.39(1H, d, J=1.4Hz), 8.04(1H, J=8.8Hz), 7.98(1H, d, J=2.2Hz), 7.95(1H, d, J=8.8Hz), 7.78(1H, dd, J=2.3Hz, 8.5Hz), 7.57(1H, t, J=8.6Hz), 7.50(2H, d, J= 8.8Hz), 7.45(2H, d, J=8.8Hz), 7.39(1H, d, J= 8.4Hz), 7.10(1H, d, J=12.1Hz), 6.98(1H, d, J= 8.6Hz), 5.65-5.60(2H, m), 5.35(1H, d, J=4.2Hz), 5.08(2H, s), 


# 4.00(1H, m), 3.93-3.84(3H, m), 3.50-3.30(4H, m) 2.54(2H, t, J=7.8Hz), 2.40- 2.00(4H, m), 1.95-1.75(4H, m), 1.70-1.55(1H, m), 1.45-1.15(3H, m)


Purity >90%(NMR)


MS 814 (M+1)


Example No. 471
1H NMR(δ)ppm







300MHz, DMSO-d6 12.78(1H, brs), 8.30(1H, dd, J=0.9Hz, 1.5Hz), 8.22(1H, d, J=1.5Hz), 7.95(1H, d, J=1.8Hz), 7.94(1H, d, J=8.4Hz), 7.85(1H, dd, J=1.2Hz, 8.4Hz), 6.96(1H, dd, J= 0.9Hz, 1.8Hz), 4.46(1H, m), 2.40-2.10(2H, m), 2.00-1.20(8H, m)


Purity >90%(NMR)


MS 311 (M+1)









 









TABLE 269







Example No. 702
1H NMR(δ)ppm







300MHz, DMSO-d6 8.97(1H, d, J=1.8Hz), 8.52(1H, d, J= 2.4Hz), 8.36(1H, d, J=7.8Hz), 8.16(1H, s), 7.96(1H, d, J= 8.1Hz), 7.55-7.40(5H, m), 7.14(1H, d, J=12.6Hz), 7.01(1H, dd, J=8.4Hz, 1.8Hz), 5.11(2H, s), 4.20-3.95(2H, m), 2.65-2.45(2H, m), 1.95-1.80(5H, m), 1.20-1.10(3H, m)


Purity >90%(NMR)


MS 641 (M+1)


Example No. 703
1H NMR(δ)ppm







300MHz, DMSO-d6 8.97(1H, d, J=1.8Hz), 8.52(1H, d, J= 1.8Hz), 7.82(1H, s), 7.70-7.35(7H, m), 7.13(1H, d, J=12.3Hz), 7.00(1H, d, J=11.1Hz), 5.14(2H, s), 3.60-3.35(4H, m), 2.65- 2.40(2H, m), 2.00-2.55(9H, m), 1.40-1.10(3H, m)


Purity >90%(NMR)


MS 653 (M+1)









 

INDUSTRIAL APPLICABILITY
As is evident from the above-mentioned results, the compound of the present invention shows a high inhibitory activity against HCV polymerase.
Therefore, the compound of the present invention can provide a pharmaceutical agent effective for the prophylaxis or treatment of hepatitis C, based on the anti-HCV effect afforded by the HCV polymerase inhibitory activity. When used concurrently with a different anti-HCV agent, such as interferon, and/or an anti-inflammatory agent and the like, it can provide a pharmaceutical agent more effective for the prophylaxis or treatment of hepatitis C. Its high inhibitory activity specific to HCV polymerase suggests the possibility of the compound being a pharmaceutical agent with slight side effects, which can be used safely for humans.
This application is based on patent application Nos. 369008/1999, 391904/2000, 193786/2001 and 351537/2001 filed in Japan, international application No. PCT/JP00/09181 and U.S. patent application Ser. No. 09/939,374, the contents of which are hereby incorporated by reference.

## Claims

1. A compound of the formula:





 
or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

2. The compound of claim 1, wherein the compound is





 
or a pharmaceutically acceptable salt.

3. The compound of claim 1, wherein the compound is a hydrate.

4. The compound of claim 1, wherein the compound is a solvate.

5. A composition comprising (i) a compound of the formula:





 
or a pharmaceutically acceptable salt, hydrate or solvate thereof, and (ii) a pharmaceutically acceptable carrier.

6. The composition of claim 5, wherein the compound is





 
or a pharmaceutically acceptable salt.

7. The composition of claim 5, wherein the compound is a hydrate.

8. The composition of claim 5, wherein the compound is a solvate.

9. A method of treating hepatitis C in a patient, comprising administering to the patient an effective amount of a compound of the formula:





 
or a pharmaceutically acceptable salt hydrate, or solvate thereof, whereby hepatitis C is treated in the patient.

10. The method of claim 9, wherein the compound is





 
or a pharmaceutically acceptable salt.

11. The method of claim 9, wherein the compound is a hydrate.

12. The method of claim 9, wherein the compound is a solvate.

13. A method of inhibiting hepatitis C virus polymerase in a patient, comprising administering to the patient an effective amount of a compound of the formula:





 
or a pharmaceutically acceptable salt, hydrate, or solvate thereof, whereby hepatitis C virus polymerase is inhibited in the patient.

14. The method of claim 13, wherein the compound is





 
or a pharmaceutically acceptable salt.

15. The method of claim 13, wherein the compound is a hydrate.

16. The method of claim 13, wherein the compound is a solvate.

17. A method of inhibiting RNA-dependent RNA polymerase of hepatitis C virus in a patient, comprising administering to the patient an effective amount of a compound of the formula:





 
or a pharmaceutically acceptable salt, hydrate, or solvate thereof, whereby RNA-dependent RNA polymerase of hepatitis C virus is inhibited in the patient.

18. The method of claim 17, wherein the compound is





 
or a pharmaceutically acceptable salt.

19. The method of claim 17, wherein the compound is a hydrate.

20. The method of claim 17, wherein the compound is a solvate.